Funda Meric-Bernstam, MD
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
About Dr. Funda Meric-Bernstam
Funda Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics -- the Phase I Program at MD Anderson Cancer Center, the Medical Director of the Institute for Personalized Cancer Therapy (IPCT), and The Nellie B. Connally Chair in Breast Cancer at MD Anderson Cancer Center. Dr. Meric-Bernstam has a basic and translational research program that is focused on molecular therapeutics to delineate the mechanism of action of each agent targeting this pathway and the molecular alterations useful to prospectively identify patients who will benefit most from each agent, and optimal combination therapies. Her clinical research is focused on Phase I /II trials with focus on novel mechanisms of action, novel combination therapies and biomarkers to predict and monitor drug response. As the Medical Director of the Institute for Personalized Cancer Therapy at MD Anderson, she has not only led large efforts of genomic testing within the institution, but has a) helped build a framework for rapid assessment of actionability of genomic alterations; b) established a Precision Oncology Decision Support Team who can provide point of care input for actionability; c) launched the public website “http://www.personalizedcancertherapy.org” providing access to expert curation of information on therapeutic relevance of specific genes/variants; d) created databases and clinical trial alert systems to facilitate accrual to genotype-selected trials across the institution; and e) monitors trial enrollment after genomic testing to identify approaches to obstacles to trial enrollment.
Present Title & Affiliation
Primary Appointment
Endowed Chair Nellie B. Connally Chair in Breast Cancer, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Chair, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Department of Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member (Joint appointment), Department of Cancer Biology, University of Texas Houston Graduate School of Biomedical Sciences, Houston, TX
Dual/Joint/Adjunct Appointment
Nellie B. Connally Chair in Breast Cancer, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, Department of Cancer Biology, University of Texas Houston Graduate School of Biomedical Sciences, Houston, TX
Research Interests
Funda Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics -- the Phase I Program, and the Medical Director of the Institute for Personalized Cancer Therapy at MD Anderson Cancer Center. She has a basic and translational research program that is focused on molecular therapeutics, to delineate the mechanism of action of each agent targeting this pathway and the molecular alterations useful to prospectively identify patients who will benefit most from each agent, and optimal combination therapies with targeted therapies and novel immune-modulators. She is an active clinical trialist focused on Phase I trials, and rationale combinations, biomarker-driven therapy and immune-oncology.
Education & Training
Degree-Granting Education
| 1991 | Yale University School of Medicine, New Haven, Connecticut, US, MD |
| 1987 | Hacettepe University Faculty of Medicine, Ankara, TR, Premed/Medical Program |
Postgraduate Training
| 1999-2000 | Research Fellowship, Molecular Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1998-2001 | Fellow, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1996-1998 | Resident, General Surgery, University of Michigan Medical Center, Ann Arbor, Michigan |
| 1994-1996 | Postdoc Fellow, Regulation of Gene Expression, National Institute of Health, Bethesda, Maryland |
| 1991-1994 | Resident, General Surgery, University of Michigan Medical Center, Ann Arbor, Michigan |
Licenses & Certifications
| 2015 | American Board of Preventive Medicine (ABPM); Subspecialty Clinical Informatics |
| 1999 | American Board of Surgery |
| 1999 | Texas Department of Public Safety |
| 1999 | Texas Medical Board |
| 1999 | DEA |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, 2005 - 2009
Assistant Professor, Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, 2001 - 2005
Administrative Appointments/Responsibilities
Department Chair, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Medical Director, Department of Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - Present
Other Professional Positions
Advisory Committee, Single-Cell Multi-omics Study on TROP2-ADC Response, UT MD Anderson, 2025 - Present
REJOICE-Ovarian01 Data Monitoring Committee, Clinical Trial, Daiichi Sankyo, Inc, 2025 - 2029
TAPUR Scientific Advisory Group, American Society of Clinical Oncology, 2025 - 2027
TBCRC EVOLVE Trial External Advisory Board, Lineberger Comprehensive Cancer Center, 2025 - 2031
MD Anderson Site Director, UT Health Clinical Informatics Fellowship Program, Houston, TX, 2023
Scientific Committee, 32nd EORTC-NCI-AACR Symposium, EORTC-NCI-AACR, Barcelona, 2020
Co-Chair, NCI, Special Emphasis Panel, U01 Grant Applications, Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models, Rockville, MD, 2019
Member, Targeted Agent and Profiling Utilization Registry (TAPUR) Study Steering Group, American Society of Clinical Oncology, Alexandria, VA, 2019
Member, Patient Derived Xenograft Network Clinical Translation Committee, Houston, TX, 2019 - Present
Chair, NCI ComboMATCH Steering Committee and Agents and Genes Working Group, Houston, TX, 2019 - Present
ASCO-Friends-FDA Planning Committee, ASCO, Alexandria, VA, 2018
External Reviewer, NCI National Clinical Trials Network Biospecimen Banks (NCTN Banks), NIH/NCI, Rockville, MD, 2018
Co-Chair, Expert panel charged with the development of a Somatic Genetic Panel Testing for Metastatic Disease Guideline, ASCO, Chicago, IL, 2018
Member, ESMO Translational Research and Personalized Medicine Working Group, Lugano, 2018
NCI T32 External Advisor, Johns Hopkins, Baltimore, MD, 2017 - Present
Chair, Internal Advisory Committee, NCI T32 Multidisciplinary Subspecialty Pathology, MD Anderson Cancer Center, Houston, TX, 2017 - Present
NCI T32 External Advisor, Surgical Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2016 - Present
Member, NCI-CCCT Investigational Drug Steering Committee, Bethesda, MD, 2014 - Present
NCI-MATCH Agent and Gene Selection Working Group, NIH/NCI, Bethesda, MD, 2014 - Present
NCI T32 External Advisor, Cancer Biology, University of Kentucky, Lexington, KY, 2013 - Present
Advisory Board, NCI T32 Internal Advisory Board, Medical Oncology and Hematology and GYN Oncology, MD Anderson Cancer Center, Houston, TX, 2012 - Present
Associate Member, Komen for the Cure Scientific Advisory Council, Washington, DC, 2010 - Present
Member Locoregional Disease Working Group, Translational Breast Cancer Research Consortium, Rockville, MD, 2009 - Present
Member, TCGA Breast Working Group, NCI, Bethesda, MD, 2009 - Present
Alternate Correlative Studies Working Group Liaison to the Locoregional Disease Working Group, Translational Breast Cancer Research Consortium Correlative Science Working Group, Rockville, MD, 2009 - Present
Extramural Institutional Committee Activities
Co-Chair, IDSC, National Cancer Institute/National Institutes of Health, 2025 - Present
Executive Committee Member, NCTN LAPS Grant Executive Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Neuro-Oncology Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2019
Chair, Advanced Research Module (ARM) Steering Committee, The University of Texas MD Anderson Cancer Center, 2018
Member, Lymphoma/Myeloma Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2018
Member, IND Task Force, The University of Texas MD Anderson Cancer Center, 2017
Member, NCI T32 External/Internal Advisory Boards, Cancer Biology, The University of Texas MD Anderson Cancer Center, 2017
Member, MD Anderson Physicians Network Board of Directors, The University of Texas MD Anderson Cancer Center, 2016 - 2017
Member, Advisory Committee for the Review of Events Occurring in Research under External IRB Oversight, The University of Texas MD Anderson Cancer Center, 2016 - 2017
Nominee Committee, The Charles A. LeMaistre Outstanding Achievement Award in Cancer, The University of Texas MD Anderson Cancer Center, 2015 - 2015
Member, Institutional Research Executive Committee (IREC), The University of Texas MD Anderson Cancer Center, 2015 - 2017
Member, Subcommittee for Translational Research Strategic Planning, The University of Texas MD Anderson Cancer Center, 2015 - 2016
Member, IRB Policy on Conducting Genetic Research, The University of Texas MD Anderson Cancer Center, 2014 - 2016
Member, Breast Cancer Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, T32 Steering Committee, Department of Medical Oncology and Hematology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2013
Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2013 - 2016
Member, Oversight Committee, Pharmaceutical Development Center (PDC), The University of Texas MD Anderson Cancer Center, 2013 - 2014
Member, CTS-MS/PhD Steering Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2014
Member, Moonshots Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2013
Member, Institutional Clinical Executive Committee, Clinical Research Subcommittee, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Associate Member, Institutional Review Board (IRB3), The University of Texas MD Anderson Cancer Center, 2011 - 2013
Member, Molecular Testing Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present
Chair, Tumor Bank Steering Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2011
Member, Department of Surgical Oncology Educational Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2013
Co-Chair, Breast Center Personalized Cancer Therapy Steering Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2010
Associate Member, Institutional Review Board (IRB5), The University of Texas MD Anderson Cancer Center, 2008 - Present
Co-Director - Career Development & Developmental Awards, Breast Cancer SPORE, The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, MD Anderson Physicians' Network Host Affiliates Multidisciplinary Planning Conference, The University of Texas MD Anderson Cancer Center, 2008 - 2009
Member, Planning for the future of bioinformatics at MDACC, The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, Kleberg Center for Molecular Markers Peer Review Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2010
Executive Committee Member, Enterprise Internet Strategy Steering Team (EISST), The University of Texas MD Anderson Cancer Center, 2007 - 2009
Member, Institutional Review Board (IRB1), The University of Texas MD Anderson Cancer Center, 2007 - 2010
Member, Tumor Bank Steering Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010
Member, Physician Scientist Review Committee, The University of Texas MD Anderson Cancer Center, 2007 - Present
Chair (CRC 3), Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2013
Member, Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010
Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2007
Member, Alfred G. Knudson Award Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2005
Member, Bridge Funding Oversight Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2011
Composition and Tenure Alternate member for Kelly K. Hunt, MD, Tumor Bank Steering Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2006
Member, eForm Project Steering Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2006
Member, Division of Surgery Research Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2006
Member, Nellie B. Connally Breast Center, Breast Operations Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2006
Member, Breast Center Leadership Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2007
Member, Evidence-Based Cancer Care Review Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2005
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2002 - 2009
Member, Steering Committee, Texas Cancer Genetics Consortium, The University of Texas MD Anderson Cancer Center, 2002 - 2005
General Surgery Representative, Physician’s Network Credentials Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2006
Member, Breast Center Room Utilization Team, The University of Texas MD Anderson Cancer Center, 2001 - 2004
Editorial Activities
Editorial Board, Annals of Oncology, 2024 - Present
Editorial Board Member, Annals of Oncology, 2019
Editor, www.personalizedcancertherapy.org, 2014 - Present
Editorial Board Member, Translation, 2012 - Present
Section Editor - Breast, Cancer, 2009 - 2012
International Editorial Board Member, KBCS Journal of Breast Cancer, 2008 - 2012
Editorial Board Member, Annals of Surgical Oncology, 2003 - 2019
Honors & Awards
| 2025 | Exceptional Women in Medicine, Castle Connolly |
| 2025 | Castle Connolly Top Doctor, Castle Connolly |
| 2024 | Castle Connolly Top Doctor, Castle Connolly |
| 2024 | Exceptional Women in Medicine, Castle Connolly |
| 2024 - Present | James Ewing Lecturer Award, Society of Surgical Oncology |
| 2024 | TAT Honorary Award, ESMO |
| 2023 | Exceptional Women in Medicine, Castle Connolly |
| 2023 | Flance-Karl Award, American Surgical Association |
| 2022 | Exceptional Women in Medicine, Castle Connolly |
| 2021 | Exceptional Women in Medicine, Castle Connolly |
| 2020 | Exceptional Women in Medicine, Castle Connolly |
| 2020 | Division of Cancer Medicine Faculty Recognition for Fastest Protocol Timelines, MD Anderson Cancer Center |
| 2019 - 2023 | Highly Cited Researcher, Web of Science |
| 2019 | Exceptional Women in Medicine, Castle Connolly |
| 2017 | Alcides & Rosaura Diniz (ARD) Foundation Excellence in Oncology Award, Alcides & Rosaura Diniz Foundation |
| 2017 | MD Anderson Cancer Center, Top Performer (Nationally on CAHPS Measures Related to Patient Care) |
| 2015 | American Society for Clinical Investigation |
| 2015 - 2018 | Advisor (and Komen representative, CancerLinQ (CLQ) Data Governance Oversight Committee, CancerLinQ LLC/ASCO |
| 2011 | America's Top Doctor for Cancer, Castle Connolly |
| 2009 - 2010 | Society of Surgical Oncology Clinical Investigator Award in Breast Cancer Research, Susan O. Komen |
| 2009 - 2011 | Clinical Investigator Award in Breast Cancer Research, Society of Surgical Oncology |
| 2005 | Outstanding Teaching Award for Research, M. D. Anderson Cancer Center, Department of Surgical Oncology |
| 2001 | Career Development Award (returned due to scientific overlap with K08), United States Department of Defense |
| 2000 - 2001 | Administrative Fellow, M.D. Anderson Dept. of Surgical Oncology |
| 1999 | Clinical Fellows Research Award, M.D. Anderson Associates |
| 1999 | ASCO-Kanojia Award, M. D. Anderson Associates |
| 1997 | Young Investigator Award, University of Michigan, Department of Surgery |
| 1996 | NIH Fellows Award for Research Excellence, National Institutes of Health |
| 1994 - 1996 | NIH Intramural National Research Service Award, National Institutes of Health |
| 1991 | Janet M. Glasgow Memorial Achievement Citation, Yale University School of Medicine |
| 1991 | Alpha Omega Alpha, Honor Medical Society |
| 1991 | Connecticut Society of American Board Surgeons Prize, Yale University School of Medicine |
| 1991 | Doctor of Medicine Cum Laude, Yale University School of Medicine |
| 1988 | Summer Research Fellowship, Yale University School of Medicine |
| 1984 - 1987 | Dogramaci Scholarship, Turkey |
| 1983 - 1987 | Koc Scholarship, Turkey |
| 1983 | Highest Scientific Test Score (First-Prize) - Turkish University Entrance Exams |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Evolving strategies in antibody drug conjugate therapy. Invited. 2nd Joint Symposium on Cancer Biology & Precision Oncology. Houston, Texas, US.
- 2025. Genomically informed therapy: Advances and informatics challenges. Invited. UT Health Houston, McWilliams School of Biomedical Informatics. Houston, Texas, US.
- 2025. Tumor Agnostics. Invited. 2025 Fall Conference on Advances in Oncology. Houston, Texas, US.
- 2024. Navigating the NCI’s Early Therapeutics Clinical Trials Network. Conference. Navigating the NCI’s Early Therapeutics Clinical Trials Network. Houston, TX, US.
- 2023. Panel Discussion on Targeted Delivery of Tumor Killing Agents ADCs and RLTs. Conference. Panel Discussion on Targeted Delivery of Tumor Killing Agents ADCs and RLTs. Houston, TX, US.
- 2022. Implementing Precision Oncology. Visiting. Houston Methodist Oncology Grand Rounds,. Houston, TX, US.
- 2019. Personalizing the Treatment of Cancer. Conference. Personalizing the Treatment of Cancer. Houston, TX, US.
- 2019. Decision Support for Precision Oncology. Conference. Decision Support for Precision Oncology. Houston, TX, US.
- 2019. Personalized (precision) medicine: A primer for oncology nurses. Conference. Personalized (precision) medicine: A primer for oncology nurses. Houston, TX, US.
- 2015. Genomic Resources for Clinical Trials. Conference. Genomic Resources for Clinical Trials. Houston, TX, US.
- 2014. Clinical Trials Phase 1 End of Year Summary and Vision for 2014. Conference. Clinical Trials Phase 1 End of Year Summary and Vision for 2014. Houston, TX, US.
- 2013. Cancer Genomics. Conference. Cancer Genomics. Houston, TX, US.
- 2013. Challenging cases in Breast cancer management. Conference. Challenging cases in Breast cancer management. Houston, TX, US.
- 2013. Emerging treatments and advances in metastatic breast cancer. Conference. Emerging treatments and advances in metastatic breast cancer. Houston, TX, US.
- 2013. Institute of Personalized Cancer Therapy Molecular Testing Program. Conference. Institute of Personalized Cancer Therapy Molecular Testing Program. Houston, TX, US.
- 2012. Biobanking and Tissue Based Research: Clinical and Ethical Concerns. Conference. Biobanking and Tissue Based Research: Clinical and Ethical Concerns. Houston, TX, US.
- 2012. Informatics to enable personalized cancer care. Conference. Informatics to enable personalized cancer care. Houston, TX, US.
- 2011. Best Science: Advances in Breast Cancer Treatment and Research. Conference. Best Science: Advances in Breast Cancer Treatment and Research. Houston, TX, US.
- 2010. PI3K/mTOR Signaling as a Therapeutic Target: Opportunities for Nanotechnology. Conference. PI3K/mTOR Signaling as a Therapeutic Target: Opportunities for Nanotechnology. Houston, TX, US.
- 2009. mTOR signaling as a target for cancer therapy. Conference. mTOR signaling as a target for cancer therapy. Houston, TX, US.
- 2008. Towards Personalized Breast Cancer Therapy. Conference. Towards Personalized Breast Cancer Therapy. Houston, TX, US.
- 2008. Targeting mTOR: From Bench to Bedside and Back. Conference. Targeting mTOR: From Bench to Bedside and Back. Houston, TX, US.
- 2008. Breast Cancer. Conference. Breast Cancer. Houston, TX, US.
- 2007. Pathologic Nodal Status for clinical T3NO Breast Cancer. Conference. Pathologic Nodal Status for clinical T3NO Breast Cancer. Houston, TX, US.
- 2007. The Principles of Molecular Therapeutics. Conference. The Principles of Molecular Therapeutics. Houston, TX, US.
- 2007. The Principles of Molecular Therapeutics. Conference. The Principles of Molecular Therapeutics. Houston, TX, US.
- 2007. The Successful Academic Career - Senior Faculty Share their tips on academic success. Conference. The Successful Academic Career - Senior Faculty Share their tips on academic success. Houston, TX, US.
- 2005. Introduction to Biomarkers. Conference. Introduction to Biomarkers. Houston, TX, US.
- 2005. Breast Cancer Biomarkers. Conference. Breast Cancer Biomarkers. Houston, TX, US.
- 2005. Lymphatic Mapping in Breast Cancer. Conference. Lymphatic Mapping in Breast Cancer. Houston, TX, US.
- 2002. Bioinformatics Tools and Applications (Informatics Short Course). Conference. Bioinformatics Tools and Applications (Informatics Short Course). Houston, TX, US.
- 2001. Breast Cancer Research. Conference. Breast Cancer Research. Houston, TX, US.
Regional Presentations
- 2025. Drug Discovery & Development. Conference. Texas Regional CTSA Consortium. San Antonio, TX, US.
- 2020. Genomic Tumor Board: Opportunities and Pitfalls. Conference. Genomic Tumor Board: Opportunities and Pitfalls. San Antonio, TX, US.
- 2019. Precision Oncology Decision Support Core: Update on CPRIT-funded Core Facility Research. Conference. Precision Oncology Decision Support Core: Update on CPRIT-funded Core Facility Research. Austin, TX, US.
- 2017. DEBATE: This house believes that all women diagnosed with metastatic breast cancer should undergo next generation sequencing?. Conference. DEBATE: This house believes that all women diagnosed with metastatic breast cancer should undergo next generation sequencing?. San Antonio, TX, US.
- 2017. Precision Oncology Decision Support Core: Update on CPRIT-funded Core Facility Research. Conference. Precision Oncology Decision Support Core: Update on CPRIT-funded Core Facility Research. Austin, TX, US.
- 2017. Bench to Bedside. Conference. Bench to Bedside. Galveston, TX, US.
- 2014. ConvertHER: Evolution of Genomic Alterations from Primary to Metastatic Breast Cancer. Conference. ConvertHER: Evolution of Genomic Alterations from Primary to Metastatic Breast Cancer. San Antonio, TX, US.
- 2011. Best Science. Conference. Best Science. Fort Worth, TX, US.
- 2009. Translational Research in Breast Surgical Oncology. Conference. Translational Research in Breast Surgical Oncology, US.
- 2009. Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2/neu-negative breast cancer. Conference. Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2/neu-negative breast cancer. San Antonio, TX, US.
- 2005. Progress in Breast Cancer Therapy. Conference. Progress in Breast Cancer Therapy. Austin, TX, US.
National Presentations
- 2026. Clinical Advances in HER2-Directed Therapy. Invited. ICRN/ENS-CCA Translational Science Seminar Series. Virtual, US.
- 2026. Improving triple negative breast cancer with personalised PARP inhibitor- based combination therapy. Invited. SU2C Scientific Summit 2026. Pasadena, California, US.
- 2026. Matching Novel Drug Delivery Systems to Actionable Targets. Invited. 22nd Oncology Updates: Advanced and Controversies. Steamboat Springs, Colorado, US.
- 2025. ADCs for pancreatic cancer. Invited. AACR Special Conference on Pancreatic Cancer. Boston, MA, US.
- 2025. Optimizing therapy with antibody drug conjugates. Invited. ASCI Scientific Session, US.
- 2025. Exciting New Therapies on the Horizon. Invited. PER's International Congress on the Future of Breast Cancer. San Diego, CA, US.
- 2025. Advances in Personalized Cancer Therapy. Invited. Dartmouth Cancer Center Grand Rounds. Dartmouth, MA, US.
- 2025. Bispecifics Plus Tyrosine Kinase Inhibition in Combination Strategy. Invited. ASCO Annual Meeting. Chicago, IL, US.
- 2025. Targeting HER2 for Cancer Therapy: Clinical Advances and Pathology Considerations. Invited. University of Southern California, Dept. of Pathology Grand Rounds, US.
- 2025. Clinical application of transcriptomics in precision oncology. Invited. AAADV Workshop, US.
- 2025. An open-label, multicenter, Phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2. Poster. AACR Annual Meeting, US.
- 2025. Translational Science Working Group. Conference. Cholangiocarcinoma Foundation Annual Conference. Salt Lake City, UT, US.
- 2025. Automating Patient Matching to Clinical Trials. Invited. GA4GH Connect, US.
- 2025. Advances in Treatment with Antibody-drug Conjugates. Invited. MSK Early Drug Development Service Scientific Meeting, US.
- 2025. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. Conference. ASCO Genitourinary Cancers Symposium. San Francisco, CA, US.
- 2025. HER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer. Invited. ASCO Genitourinary Cancers Symposium. San Francisco, CA, US.
- 2025. Promising Actional Target from 2024. Conference. 21 Oncology Update. Steamboat Springs, CO, US.
- 2024. Guidelines for Genomic Testing Today. Conference. NASEM Workshop - Examining Clinical Guidelines for the Adoption of Genomic Testing. Washington, DC, US.
- 2024. ADCs: Patient Selection and Novel Combinations. Invited. 2024 Ochsner Multidisciplinary Cancer Update. New Orleans, LA, US.
- 2024. Emerging ADC Clinical Data. Invited. Immunomodulation of ADCs Virtual Summit, US.
- 2024. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02). Poster. ASCO Annual Meeting. Chicago, Illinois, US.
- 2024. Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Poster. ASCO Annual Meeting. Chicago, Illinois, US.
- 2024. Implementing Precision Oncology. Visiting. 26th Annual George E. Block Memorial Lecture. Chicago, Illinois, US.
- 2024. Implementing Precision Oncology. Visiting. Masters of Surgery Grand Rounds Presentation. Bronx, New York, US.
- 2024. In Vivo Modeling and Considerations for Clinical Translation. Conference. In Vivo Modeling and Considerations for Clinical Translation. Salt Lake City, UT, US.
- 2024. TIP Poster Presentation: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress). Conference. Seagen. San Diego, CA, US.
- 2024. James Ewing Featured Lecturer. Conference. James Ewing Featured Lecturer. Atlanta, GA, US.
- 2024. Implementing Precision Oncology. Visiting. Medical Oncology Grand Rounds. St. Louis, MO, US.
- 2024. Biomarker Directed Conjugate Therapy and Promising Actional Targets. Conference. 20th Oncology Update. Steamboat Spring, CO, US.
- 2023. Optimizing Personalized Cancer Therapy. Invited. Perlmuter Cancer Center Research Seminar Series. New York, NY, US.
- 2023. Poster Presentation: TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors. Conference. AACR Annual Meeting. Orlando, FL, US.
- 2023. AACR Dinner Symposium: Therapeutics Targeting TROP-2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors. Conference. AACR Dinner Symposium: Therapeutics Targeting TROP-2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors. Orlando, FL, US.
- 2023. Management of Futibatinib-Associated Adverse Events in Patients With Advanced Cancers: Results of a Pooled Analysis. Conference. Taiho Oncology. Salt Lake City, UT, US.
- 2023. The Future of Antibody Drug Conjugates and Selective PIK3CA-Pathway Inhibitors. Conference. 19th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2022. Spotlight Poster: Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC). Conference. San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, US.
- 2022. Delving into Patient selection for HER2 targeted Basket Trials. Conference. HER2 Targeted Therapies Summit. Boston, MA, US.
- 2022. Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC). Conference. AACR Annual Meeting. New Orleans, LA, US.
- 2022. Translational Research with Patient-Derived Models: Bench to Bedside and Back. Visiting. William A Maddox Visiting Professor. Birmingham, AL, US.
- 2022. Informatics Challenges in Precision Oncology. Visiting. Biomedical Informatics Grand Rounds. Salt Lake City, Utah, US.
- 2021. Poster Presentation: Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA). Conference. ESMO Congress, US.
- 2021. Poster Presentation: A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02). Conference. ESMO Congress, US.
- 2021. Progress in Precision Oncology. Invited. Seattle, Washington, US.
- 2021. Oral Abstract: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors. Conference. AACR Annual Meeting, US.
- 2021. Poster Presentation: A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in NCI PDXNet centers. Conference. AACR Annual Meeting, US.
- 2021. Oral Abstract: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort. Conference. AACR Annual Meeting, US.
- 2021. Modeling acquired resistance and underlying mechanisms in cancer therapy. Conference. Modeling acquired resistance and underlying mechanisms in cancer therapy, US.
- 2021. Webinar: HER2-targeted therapies in CCA. Conference. Webinar: HER2-targeted therapies in CCA, US.
- 2020. Webcast: Advances in Next-Generation Sequencing-informed Precision Medicine. Conference. Webcast: Advances in Next-Generation Sequencing-informed Precision Medicine, US.
- 2020. Molecular targets/HER2-directed therapy. Conference. Molecular targets/HER2-directed therapy, US.
- 2020. Implementing Precision Oncology in Advanced and Early Stage Disease. Visiting. George H. A. Clowes Visiting Professor of Surgery. Boston, MA, US.
- 2020. Evolving Actionable Targets. Conference. 18th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2020. Advances in Precision Oncology. Visiting. New Brunswick, NJ, US.
- 2019. In-Person Special Emphasis Panel: Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models. Conference. Cancer Moonshot Initiatives. Rockville, MD, US.
- 2019. Poster discussion: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer. Conference. Poster discussion: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer. Boston, MA, US.
- 2019. Precision Oncology through Multiplex Testing for Antibody Drug Conjugate Targets. Conference. Precision Oncology through Multiplex Testing for Antibody Drug Conjugate Targets. Rockville, MD, US.
- 2019. NCI MATCH and COMBO MATCH. Conference. Individualizing Medicine Conference: Precision Cancer Care Through Immunotherapy and Genomics. Scottsdale, AZ, US.
- 2019. Precision Oncology. Visiting. Sparkman Endowed Lecture. Dallas, TX, US.
- 2019. TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study. Conference. TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study. Atlanta, GA, US.
- 2019. Precision oncology decision support. Conference. Precision oncology decision support. San Francisco, CA, US.
- 2019. Poster presentation: Single-agent activity of ZW25, a HER2 targeted bispecific antibody, in HER2-expressing gastroesophageal and other cancers. Conference. Poster presentation: Single-agent activity of ZW25, a HER2 targeted bispecific antibody, in HER2-expressing gastroesophageal and other cancers. Salt Lake, UT, US.
- 2019. Promising actionable biomarkers from phase I studies. Conference. Promising actionable biomarkers from phase I studies. Breckenridge, CO, US.
- 2018. Decision Support for Genomically Informed Therapy. Conference. Decision Support for Genomically Informed Therapy. Biddleford, ME, US.
- 2018. Moderator: Science Behind the News. Conference. Moderator: Science Behind the News. Orlando, FL, US.
- 2018. Moderator, Symposium 3: Breakthrough in Triple Negative Cancer. Conference. Moderator, Symposium 3: Breakthrough in Triple Negative Cancer, US.
- 2018. Novel Targets and Overview of Ongoing Clinical Trials. Conference. Novel Targets and Overview of Ongoing Clinical Trials.
- 2018. Opportunities for Biomarker Driven Trials in Breast Cancer. Conference. Society of Surgical Oncology. Chicago, IL, US.
- 2018. Keynote Presentation: Advances in Genomic Diagnostics and Therapeutics. Conference. Keynote Presentation: Advances in Genomic Diagnostics and Therapeutics. Steamboat Springs, CO, US.
- 2017. Precision Medicine in Surgical Oncology: What Every Surgeon Needs to Know. Conference. Precision Medicine in Surgical Oncology: What Every Surgeon Needs to Know. San Diego, CA, US.
- 2017. Developmental therapeutics in TNBC. Conference. Developmental therapeutics in TNBC. Hollywood, CA, US.
- 2017. Translational research and biomarker-driven clinical trials. Visiting. Ann Arbor Annual Student Leadership Weekend. Ann Arbor, MI, US.
- 2017. Oxidative phosphorylation as a target in triple negative breast cancer therapy. Conference. Oxidative phosphorylation as a target in triple negative breast cancer therapy. Washington, DC, US.
- 2017. Advanced Clinical Trial Design for Advanced Breast Cancer. Conference. Advanced Clinical Trial Design for Advanced Breast Cancer. Washington, DC, US.
- 2017. Precision Medicine: Hype or Hope?. Conference. Precision Medicine: Hype or Hope?. Las Vegas, NV, US.
- 2017. Emerging treatment options for metastatic breast cancer. Conference. Emerging treatment options for metastatic breast cancer. Steamboat Springs, CO, US.
- 2016. Genomically informed medicine. Conference. Genomically informed medicine. Columbia, MO, US.
- 2016. Keynote Address: Genomically informed medicine. Invited. Health Sciences Research Day,. Columbia, MO, US.
- 2016. Ductal carcinoma in situ- Risk factor lesion or cancer?. Conference. Ductal carcinoma in situ- Risk factor lesion or cancer?. Washington, DC, US.
- 2016. Clinical and applied genomics in breast cancer, in Plenary Updates: Personalized Medicine and Genetics. Conference. Clinical and applied genomics in breast cancer, in Plenary Updates: Personalized Medicine and Genetics, US.
- 2016. Informatics technology for cancer research: Identifying clinically actionable genomic alterations for cancer therapy. Conference. Informatics technology for cancer research: Identifying clinically actionable genomic alterations for cancer therapy. New Orleans, LA, US.
- 2016. Identifying clinically actionable genomic alterations for cancer therapy. Conference. Identifying clinically actionable genomic alterations for cancer therapy. New Orleans, LA, US.
- 2016. DCIS – Is it cancer? – Yes. Conference. DCIS – Is it cancer? – Yes. Dallas, TX, US.
- 2016. Setting the stage for gene expression profiling in clinical cancer management: The Breast Cancer Experience. Conference. Setting the stage for gene expression profiling in clinical cancer management: The Breast Cancer Experience. Boston, MA, US.
- 2016. Optimizing genomically informed therapy. Visiting. Holden Cancer Center Grand Rounds. Cedar Rapids, IA, US.
- 2016. Neoadjuvant breast cancer therapy. Visiting. Department of Surgery Grand Rounds. Cedar Rapids, IA, US.
- 2016. Next generation of Phase 1 drug development based on biomarker discovery. Conference. Next generation of Phase 1 drug development based on biomarker discovery. Steamboat Springs, CO, US.
- 2015. Making the transition to independence. Conference. Making the transition to independence. Boston, MA, US.
- 2015. Making the transition to independence. Conference. Making the transition to independence. Boston, MA, US.
- 2015. Education regarding the use of personalized medicine throughout the health care continuum. Conference. Education regarding the use of personalized medicine throughout the health care continuum. Washington, DC, US.
- 2015. Panel Discussion, Demonstrating the value of personalized medicine in clinical practice. Conference. Panel Discussion, Demonstrating the value of personalized medicine in clinical practice. Washington, DC, US.
- 2015. Genomically informed breast cancer therapy. Conference. Genomically informed breast cancer therapy. Chicago, IL, US.
- 2015. PMO Live: Fourth Annual Conference of the Global Biomarkers Consortium. Conference. PMO Live: Fourth Annual Conference of the Global Biomarkers Consortium. Chicago, IL, US.
- 2015. Keynote Presentation: The Impact of Molecular Biomarkers on Clinical Trials. Conference. Fourth Annual Conference of the Global Biomarkers Consortium. Seattle, WA, US.
- 2015. Keynote Speaker, The impact of molecular biomarkers on clinical trials. Conference. Keynote Speaker, The impact of molecular biomarkers on clinical trials. Seattle, WA, US.
- 2015. Moderator, Session "Adjuvant Therapies". Conference. Moderator, Session "Adjuvant Therapies". Orlando, FL, US.
- 2015. PI3 Kinase and Cancer. Conference. PI3 Kinase and Cancer. Las Vegas, NV, US.
- 2014. Somatic mutation testing and opportunities for clinical interventions. Conference. Somatic mutation testing and opportunities for clinical interventions. San Francisco, CA, US.
- 2014. Targeting PI3K/mTOR signaling for breast cancer therapy. Invited. Melodie Wilson Oldenburg Breast Cancer Symposium. Milwaukee, WI, US.
- 2014. Targeting mTOR in breast cancer. Conference. Targeting mTOR in breast cancer. Philadelphia, PA, US.
- 2014. Best of San Antonio and ASCO. Conference. Best of San Antonio and ASCO. Las Vegas, NV, US.
- 2014. Personalizing cancer therapy: From bench to bedside. Invited. Washington, DC, US.
- 2014. How to incorporate genomic analysis in the multidisciplinary assessment and management of the surgical oncology patient. Conference. How to incorporate genomic analysis in the multidisciplinary assessment and management of the surgical oncology patient. Phoenix, AZ, US.
- 2014. Selective use of adjuvant therapy: Have the new markers helped?. Conference. Selective use of adjuvant therapy: Have the new markers helped?. Steamboat Springs, CO, US.
- 2014. Keynote Presentation: Molecular prognostic and predictive markers: Is personalized therapy around the corner?. Conference. Keynote Presentation: Molecular prognostic and predictive markers: Is personalized therapy around the corner?. Steamboat Springs, CO, US.
- 2013. Personalizing Cancer Therapy: Opportunities and Challenges. Invited. Breast Service Conference. New York, NY, US.
- 2013. Targeting PI3K-mTOR signaling. Invited. Surgical Research Conference. New York, NY, US.
- 2013. Best of San Antonio and ASCO Meetings. Conference. The American Society of Breast Surgeons 14th Annual Meeting. Chicago, IL, US.
- 2013. Nodal Staging and Management for Breast Cancer. Visiting. Madison, WI, US.
- 2013. CanDrA: Cancer-specific driver missense mutation annotation with optimized features. Conference. AACR Annual Meeting. Washington, DC, US.
- 2013. mTOR inhibitor MLN0128 has antitumor efficacy in cell lines with intrinsic and acquired rapamycin resistance in vitro and in vivo. Conference. AACR Annual Meeting. Washington, DC, US.
- 2013. Epithelial to mesenchymal transition and rapamycin sensitivity in cancer cell lines. Conference. AACR Annual Meeting. Washington, DC, US.
- 2013. Personalized Medicine from the Surgeons Perspective. Conference. 66th Annual Cancer Symposium. National Harbor, MD, US.
- 2013. Incidence and consequence of close margins for ductal carcinoma in situ treated with mastectomy. Conference. 66th Annual Cancer Symposium. National Harbor, MD, US.
- 2013. Utility of sentinel lymph node dissection (SLND) in ductal carcinoma in situ (DCIS). Conference. 66th Annual Cancer Symposium. National Harbor, MD, US.
- 2013. How do I develop a research focus?. Conference. How do I develop a research focus?. New Orleans, LA, US.
- 2012. Effect of Biospecimen Variables on Proteomic Biomarker Assessment in Breast Cancer. Conference. Effect of Biospecimen Variables on Proteomic Biomarker Assessment in Breast Cancer. San Antonio, US.
- 2012. Challenges and Opportunities for Personalized Cancer Therapy. Visiting. Grand Rounds. Los Angeles, CA, US.
- 2012. Molecular Characterization of Cancer Patients to Accelerate Personalized Medicine: MD Anderson Cancer Center Case Study. Conference. 4th Molecular Diagnostics for Cancer Drug Development. Boston, MA, US.
- 2012. Personalized Cancer Therapy: Opportunities and Challenges. Visiting. The Levine Lecture. Boston, MA, US.
- 2012. Biomarker Assessment for PI3K/mTOR-Targeted Breast Cancer Therapy. Conference. 65th Annual Cancer Symposium. Orlando, FL, US.
- 2012. Prophylactic Mastectomy. Conference. Prophylactic Mastectomy. Steamboat Springs, CO, US.
- 2012. Biomarkers: Prognostic or Predictive?. Conference. 10th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2011. Re-expression of ERalpha in ER Negative Breast Cancer Cells Following Trastuzumab Treatment. Conference. Re-expression of ERalpha in ER Negative Breast Cancer Cells Following Trastuzumab Treatment. San Francisco, CA, US.
- 2011. Imatinib Modulates Tumor Associated Macrophages in Gastrointestinal Stromal Tumor (GIST). Conference. Imatinib Modulates Tumor Associated Macrophages in Gastrointestinal Stromal Tumor (GIST). San Francisco, CA, US.
- 2011. Targeting BRAFV600E using Nanoliposomal-Small Interfering RNA restores the Expression of Sodium Iodide Symporter and Increases the Uptake of Iodide in Thyroid Cancer Cells. Conference. Targeting BRAFV600E using Nanoliposomal-Small Interfering RNA restores the Expression of Sodium Iodide Symporter and Increases the Uptake of Iodide in Thyroid Cancer Cells. San Francisco, CA, US.
- 2011. The I-Domain, A Multifaceted Nanoparticle for Targeting of Poorly Differentiated Thyroid Cancer. Conference. The I-Domain, A Multifaceted Nanoparticle for Targeting of Poorly Differentiated Thyroid Cancer. San Francisco, CA, US.
- 2011. Personalized Cancer Therapy: Promises and Challenges. Conference. Personalized Cancer Therapy: Promises and Challenges. Houston, TX, US.
- 2009. Targeting the mTOR Signaling Network for Cancer Therapy. Visiting. Atlanta, GA, US.
- 2009. Inflamatory Breast Cancer. Conference. 10th Annual Meeting ASBS. San Diego, CA, US.
- 2008. Are There Patients Who Should Not Receive Pre-Operative Therapy?. Conference. 2008 Breast Cancer Symposium. Washington, DC, US.
- 2008. Fellows, Residents, Trainees, and Junior Faculty Breakfast. Conference. 2008 Breast Cancer Symposium. Washington, DC, US.
- 2008. Future Directions in Therapy. Conference. 23rd Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy. Aspen, CO, US.
- 2008. ACOSOG CRA Training - Z1041 protocol. Conference. ACOSOG Annual Meeting 2008. Chicago, IL, US.
- 2007. Targeting Translation Initiation for Cancer Therapy. Conference. American College of Surgeons. New Orleans, LA, US.
- 2007. Breast Conservation in Early and Advanced Disease. Conference. 3rd U.T. M. D. Anderson Cancer Center & M. D. Anderson Physicians Network Annual Symposium. Santa Barbara, CA, US.
- 2007. Surgical Update on Sentinel Lymph Node Assessment, Prophylactic Mastectomy and Immediate Reconstruction. Conference. 3rd U.T. M. D. Anderson Cancer Center & M. D. Anderson Physicians Network Annual Symposium. Santa Barbara, CA, US.
- 2007. Establishing a Funded and Productive Laboratory (Meet The Professor Breakfast). Conference. 60th Annual Cancer Symposium. Washington, DC, US.
- 2007. Controversies in the Surgical Management of LCIS. Conference. 7th Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2006. Lumpectomy following Neoadjuvant Therapy: Technical Issues. Conference. American Society for Breast Surgeons Annual Conference. Baltimore, MD, US.
- 2006. Profiling in Patients with Breast Cancer. Conference. 6th Annual Oncology Update: Advances and Controversies. Park City, UT, US.
- 2005. Signal Transduction and Translational Regulation. Conference. TX/UK Collaborative Research Initiative Post Receptor Events in Cell Signaling and Disease Workshop. Scotland, TX, US.
- 2005. Treatment of DCIS. Conference. The U T M. D. Anderson Cancer Center and the M. D. Anderson Physicians Network First Annual Symposium: Breast and Prostate Cancer Update. Kauai, HI, US.
- 2004. Sentinel Lymph Node Mapping: Concepts and Controversies. Conference. The Radiology Society of North America. Chicago, IL, US.
- 2004. Surgical Therapy of Breast Cancer. Conference. American College of Surgeons. Washington, DC, US.
- 2003. Surgical Therapy of Breast Cancer: Challenges and Controversies. Conference. Korea Breast Cancer Society. Seoul.
International Presentations
- 2025. Mechanisms of response and resistance to antibody drug conjugates. Invited. 65th Annual Meeting of the Italian Cancer Society. Turin, IT.
- 2025. Results From the Phase 1 Dose Escalation and Dose Expansion Study of Azenosertib, a WEE1 Inhibitor, in Patients With Advanced Solid Tumors. Poster. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, US.
- 2025. Zanidatamab in patients with advanced HER2-positive salivary gland cancer: A pooled analysis of early-phase studies. Poster. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, US.
- 2025. Novel frontiers in early drug development. Invited. Italian Summit on Precision Medicine. Rome, IT.
- 2025. Novel antibody drug conjugates and beyond. Invited. Italian Summit on Precision Medicine. Rome, IT.
- 2024. Phase 1/2 Dose Escalation Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in ER+ Metastatic Breast Cancer. Poster. ESMO Annual Meeting. Barcelona, ES.
- 2024. Implementing precision oncology: from genomics to ADCs. Invited. ESMO Targeted Anticancer Therapies Congress 2024. Paris, FR.
- 2023. Mini Oral Abstract: Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 (DP-02) study. Conference. ESMO Congress Annual Meeting. Madrid, ES.
- 2023. Poster Presentation: FONTANA: A Phase 1/2a study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours. Conference. ESMO Congress Annual Meeting. Madrid, ES.
- 2023. Implementing Decision Support for Precision Oncology. Invited. Nordic Precision Cancer Medicine Symposium. Oslo, NO.
- 2023. Oral Abstract: Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. Conference. 2023 ASCO Annual Meeting. Chicago, US.
- 2023. Poster Presentation: Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study. Conference. ASCO Annual Meeting. Chicago, US.
- 2023. Poster Presentation: Antitumor activity of TROP2 Antibody Drug Conjugate Datopotamab Deruxtecan in Chemotherapy-Resistant Breast Cancer Models. Conference. ESMO Breast. Berlin, DE.
- 2023. Poster Presentation: Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis. Conference. ASCO Gastrointestinal Cancers Symposium. San Francisco, US.
- 2022. Educational Session: A peek in to the future of precision medicine; Advances targeting HER family. Conference. ESMO Asia, SG.
- 2022. CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors. Conference. 34th EORTC-NCI-AACR Annual Symposium. Barcelona, ES.
- 2022. STING Agonists Early Phase Study. Conference. 34th EORTC-NCI-AACR Annual Symposium. Barcelona, ES.
- 2022. Oral Abstract: Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study. Conference. ASCO Annual Meeting. Chicago, US.
- 2022. Poster Presentation: First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors. Conference. ASCO Annual Meeting. Chicago, US.
- 2022. Poster Presentation: A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02). Conference. ASCO Gastrointestinal Cancers Symposium. Virtual, US.
- 2021. Optimizing ADC Development and Patient and Treatment Selection. Invited. World ADC Conference. San Diego, US.
- 2021. Poster Presentation: Anti-tumor Activity of ATR inhibitor BAY 1895344 in Patient-Derived Xenograft (PDX) Models with DNA Damage Response (DDR) Pathway Alterations. Conference. Bayer Healthcare, US.
- 2021. Panel Question and Answer Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Conference. ASCO Annual Meeting. Chicago, US.
- 2021. Oral Abstract: MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. Conference. ASCO Annual Meeting, US.
- 2021. Panel Question and Answer Rapid Abstract Session: Esophageal and Gastric Cancer Previous. Conference. ASCO Annual Meeting. Chicago, US.
- 2021. Poster Session: TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC). Conference. ASCO Annual Meeting. Chicago, US.
- 2021. Poster Presentation: Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. Conference. ASCO Gastrointestinal Cancers Symposium, US.
- 2020. Panel: Challenges in Applications in Precision Oncology Research and Routine Biomarker-Driven Care. Conference. AMIA Annual Symposium (Virtual), US.
- 2020. Poster Presentation: A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF‑06804103) in patients with HER2-positive solid tumors. Conference. ASCO Annual Meeting. Chicago, US.
- 2019. Panel: Decision Support for Genomically-Informed Cancer Therapy. Conference. Panel: Decision Support for Genomically-Informed Cancer Therapy. Washington, US.
- 2019. Personalizing Cancer Care. Invited. Rome, IT.
- 2019. Poster discussion: A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification. Conference. ESMO Congress Annual Meeting. Barcelona, ES.
- 2019. Poster discussion: Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumors. Conference. ESMO Congress Annual Meeting. Barcelona, ES.
- 2019. Precision Medicene Informatics: Translating Research into Practice Around the World. Conference. MEDINFO 17th World Congress of Medical and Healthy Informatics 2019. Lyon, FR.
- 2019. Precision Oncology Decision Support: What are the Next Steps?. Conference. Workshop on Methods in Oncology Phase 1 Trials and Translational Research. Tokyo, JP.
- 2019. Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations. Conference. WIN Symposium 2019. Paris, FR.
- 2019. Interactive Case-Based Session: The development of a molecular tumor board for gynecologic oncology. Conference. ASCO Annual Meeting. Chicago, US.
- 2019. CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study. Conference. ASCO Genitourinary Cancers Symposium. San Francisco, US.
- 2018. Moderator, Plenary Session 1: Should we be conducting more genomics driven, multi-arm clinical trials?. Conference. 30th EORTC-NCI-AACR Symposium on Molecular targets and Cancer Therapeutics. Dublin, IE.
- 2018. Precision medicine decision support. Conference. University of Chicago Center Beijing and Hepatobiliary Surgery and Nutrition (HBSN) Journal Publishing Company. Beijing, CN.
- 2018. Oral presentation: Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Conference. ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, ES.
- 2018. Future of Targeted Therapy. Conference. International Hepatobiliary Cancer Summit, CN.
- 2018. Personalized Medicine in Breast Cancer. Conference. Personalized Medicine in Breast Cancer, CZ.
- 2017. Phase I trial of novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. Conference. Phase I trial of novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. Chicago, US.
- 2016. Genomically informed breast cancer therapy. Conference. GAP, China Sister Institute Pathology Conference. Shanghai, CN.
- 2016. Surgical management of in situ carcinomas of the breast. Conference. GAP, China Sister Institute Pathology Conference. Shanghai, CN.
- 2016. Personalizing breast cancer therapy. Conference. WIN Symposium. Paris, FR.
- 2016. Implementing genomically informed therapy. Invited. Berlin, DE.
- 2016. Surgery of breast Cancer in Plenary Updates: Breast. Conference. GAP 2016 Conference "Challenging Cancer". Sao Paulo, BR.
- 2015. Written and Oral Research Presentations That Audiences Remember. Conference. AACR/ASCO Methods in Clinical Cancer Research Workshop. Vail, US.
- 2015. Prevalence of incidental actionable germline mutations in 1000 advanced cancer patients on a prospective somatic genomic profiling program. Conference. ASCO Annual Meeting. Chicago, US.
- 2015. Oral Presentation, Abstract, Prevalence of incidental actionable germline mutations in 1000 advanced cancer patients on a prospective somatic genomic profiling program. Conference. ASCO Annual Meeting. Chicago, US.
- 2015. Case-Based Clinical Topics: Somatic Mutations. Conference. ASCO Annual Meeting. Chicago, US.
- 2014. Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials. Conference. EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, ES.
- 2014. Personalized therapy in the real world. Conference. ACMI Symposium. Scottsdale, US.
- 2013. Findings of NSF-sponsored workshop on research challenges. Conference. AMIA Annual Meeting. Washington, US.
- 2013. Panel on international Perspectives on the Digital Infrastructure for the Learning Health System: Informatics Infrastructure for Routine Personalized Medicine. Conference. AMIA Annual Meeting. Washington, US.
- 2013. Informatics infrastructure for routine personalized medicine. Conference. Seattle, US.
- 2012. Somatic Mutation Analysis for Biomarker Discovery and Personalized Cancer Therapy. Conference. Philadelphia, US.
- 2012. Highlights 2012 in the Surgical Treatment of Breast Cancer. Conference. Videoconference, AR.
- 2012. Consortium Collaborations for Personalized Cancer Therapy. Conference. Coronado, US.
- 2012. Cancer Gene Profile of Metastatic Breast Cancer. Conference. Chicago, US.
- 2011. Surgical Management after Neoadjuvant Therapy. Conference, CO.
- 2011. Advances in Regional Management. Conference, CO.
- 2011. Breast Cancer Management in BRCA Carriers. Conference, CO.
- 2010. Prophylactic Mastectomy in High Risk Patients. Conference, CL.
- 2010. Update on Genetics of Breast Cancer. Conference, CO.
- 2010. Chemoprophylaxis, Yes or No? Whom?. Conference, CL.
- 2010. Clinical Decisions Based on Molecular Examinations. Conference, CO.
- 2010. Advances in Surgical Management of Breast Cancer. Conference, CO.
- 2010. Molecular Markers and Individualized Treatment for Breast Cancer. Conference, CO.
- 2010. Updates in Surgical Management of Breast Cancer. Conference, AE.
- 2010. Indications for Genetic Risk Assessment and Prophylactic Surgery in High Risk Patients. Conference, AE.
- 2010. Limitations of Current Surgical Treatment for DCIS. Invited, TW.
- 2010. What Does Local Recurrence Imply in a Mastectomy?. Conference. Cancer de Mama, BR.
- 2010. How to choose the best oncoplastic approach. Conference, BR.
- 2010. The Future of Breast Cancer Surgery. Invited, BR.
- 2010. What is the Best Surgical Approach to the Patient with Early Breast Cancer?. Conference. Cancer de Mama, BR.
- 2010. Breast Conservation Surgery and Sentinel Node Biopsy. Invited, GT.
- 2009. Surgical Management and Staging Post-Neoadjuvant. Conference. 3rd Congress of Oncology 2009 Solca Ecuador. Manta, EC.
- 2009. Conservative Surgical Treatment. Conference. 3rd Congress of Oncology 2009 Solca Ecuador. Manta, EC.
- 2009. A Multidisciplinary Approach to Breast Conservation. Conference. Dubai, AE.
- 2009. Breast Surgery: Advances and Controversies. Conference. Monterrey, MX.
- 2009. Advances in Breast Cancer Treatment. Conference. Monterrey, MX.
- 2009. Targeting mTOR for Cancer Therapy. Conference. Scientific Meeting on Translational Research. Tel Aviv, IL.
- 2009. Advances in Breast Surgery. Conference. Istanbul, TR.
- 2008. The PI3K-mTOR pathways as novel therapeutic targets for breast cancer. Conference. 7th International Symposium on Translational Research in Oncology. Huntington Beach, US.
- 2007. Skin sparing mastectomy: Technical and oncologic concerns. Conference. Cartagena, CO.
- 2007. Prophylactic mastectomy. Conference. Cartagena, CO.
- 2007. Breast conservation after preoperative chemotherapy. Conference. Cartagena, CO.
- 2007. Genetic Breast Cancer. Conference. VIII Argentine Congress of Mastologia 2007. Buenos Aires, AR.
- 2007. Prophylactic Mastectomy, current indications. Conference. VIII Argentine Congress of Mastologia 2007. Buenos Aires, AR.
- 2007. Translational research from an informatics perspective. Conference. MedInfo 2007. Brisbane, AU.
- 2007. Currency of online breast cancer information. Conference. MedInfo 2007. Brisbane, AU.
- 2005. Principles of Molecular Therapeutics. Conference. Istanbul, TR.
- 2005. Breast Conserving Therapy. Conference. Istanbul, TR.
- 2005. Breast Conserving Surgery for locally advanced Breast Cancer. Conference. Istanbul, TR.
- 2004. Skin preservation Mastectomy. Conference. American College of Surgeons VIII Latin American Congress and XXVII Inter-Chapter Mexican Meeting. Mexico City, MX.
- 2004. Sentinel Lymph Node Biopsy in Breast Cancer. Conference. American College of Surgeons VIII Latin American Congress and XXVII Inter-Chapter Mexican Meeting. Mexico City, MX.
- 2004. Conservative Surgery in Breast Cancer. Conference. American College of Surgeons VIII Latin American Congress and XXVII Inter-Chapter Mexican Meeting. Mexico City, MX.
- 2004. Sentinel Lymph Node In the Neoadjuvant Era; Pitfalls and Promises. Conference. The First International Symposium - Breast Cancer: Frontiers in Neoadjuvant Therapy. Hashemite, JO.
- 2004. Therapy of Breast Cancer: State-Of-The-Art, Prophylactic Mastectomy and Reconstruction. Conference. Lima, PE.
- 2004. Prophylactic Mastectomy and Reconstruction. Conference. Lima, PE.
- 2004. Locoregional Recurrence After Neoadjuvant Therapy; Evidence-Based Discussion. Conference. The First International Symposium - Breast Cancer: Frontiers in Neoadjuvant Therapy. Hashemite, JO.
Formal Peers
- 2025. Navigating the NCI's Early Therapeutics Clinical Trials Network, US.
- 2018. Developmental Therapeutics in Triple Negative Breast Cancer (TNBC). Invited. Hershey, PA, US.
- 2018. Liquid Biopsies/ctDNA. Invited. Toronto, CA.
- 2016. Decision support for genomically informed therapy. Invited. Rockville, MD, US.
- 2014. Connecting Cancer Variants to Clinical Phenotypes. Invited. Sonoma, CA, US.
- 2014. From Clinical to Basic Research. Invited. Lima, PE.
- 2014. Molecular Biology of Breast Cancer. Invited. Lima, PE.
- 2014. Tools for personalized therapy: Strengths and limitations. Invited. Tucson, AZ, US.
- 2013. Personalizing Investigational Cancer Therapeutics. Invited. Gilbert, AZ, US.
- 2013. Personalizing Breast Cancer Care: What have we achieved?. Invited. Toronto, CA.
- 2013. Targeting Pi3K/mTOR Signaling. Invited. Chicago, IL, US.
- 2012. Personalized Cancer Therapy: Opportunities and Challenges. Invited. Boston, MA, US.
- 2010. Surgery Issues after Preoperative Therapy. Invited. Boston, MA, US.
- 2010. Managing the Extra-Axillary Sentinel Node and Positive Internal Mammary Node and Positive Internal Mammary Nodes. Invited. Boston, MA, US.
- 2010. Personalizing Breast Cancer Therapy for Different breast phenotypes. Invited. Philadelphia, PA, US.
- 2010. Targeting mTOR for Breast Cancer Therapy. Invited. Philadelphia, PA, US.
- 2007. Controversies in Sentinel Node Biopsy. Invited. Shijiazhuang, CN.
- 2007. Principles of Molecular Therapeutics. Invited. Shijiazhuang, CN.
- 2006. The Role of Neoadjuvant Chemotherapy and Breast Surgery. Invited. Williamsburg, VA, US.
- 2006. Controversies in Breast Conservation. Invited. Williamsburg, VA, US.
- 2003. Targeting Translation Inhibition for Cancer Therapy. Invited. Seoul.
- 1998. Molecular Diagnosis of Cancer. Invited. Ann Arbor, MI, US.
- 1997. Regulation of Translation in Early Xenopus Development. Invited. Ann Arbor, MI, US.
- 1996. Translational Regulation in the Xenopus. Invited. Bethesda, MD, US.
- 1996. Masking of Maternal mRNA in Xenopus Laevis. Invited. Bethesda, MD, US.
Grant & Contract Support
| Date: | 2023 - 2025 |
| Title: | Optimizing TROP2-targeted antibody-drug conjugate therapy in metastatic breast cancer |
| Funding Source: | METAVivor Research and Support Inc |
| Role: | PI |
| ID: | FP00020415 |
| Date: | 2022 - 2029 |
| Title: | Identifying biomarkers of response to AZD8205 and potential combination partners |
| Funding Source: | AstraZeneca |
| Role: | PI |
| ID: | 14668 |
| Date: | 2022 - 2027 |
| Title: | Phase II Trial of Alpelisib with iNOS Inhibitor and Nab-paclitaxel in Patients with HER2 negative Metastatic or Locally Advanced Metaplastic Breast Cancer |
| Funding Source: | Houston Methodist Research Institute |
| Role: | Co-I |
| ID: | 1U01CA268813 |
| Date: | 2021 - 2024 |
| Title: | Delineating the Evolution and Ecology of Chemoresistance in Breast Cancer with Single Cell Genomics |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA236864 |
| Date: | 2021 - 2024 |
| Title: | Improving anti-tumor responses to immunotherapy using the combination biomarker ARID1A + CXCL 13" |
| Funding Source: | Kleberg Foundation |
| Role: | Co-I |
| ID: | AWD00006017 |
| Date: | 2021 - 2026 |
| Title: | Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA255074-01 |
| Date: | 2021 - 2026 |
| Title: | RNase H2 is a novel therapeutic target in triple negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA251206-01A1 |
| Date: | 2021 - 2026 |
| Title: | Developing novel bispecific antibodies for cancer treatment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA262288-01 |
| Date: | 2021 - 2024 |
| Title: | STRATEGIC ALLIANCE: MDACC/Blueprint CDK2 Inhibitor Research Plan |
| Funding Source: | Blueprint Medicines |
| Role: | Co-I |
| ID: | 13053 |
| Date: | 2021 - 2023 |
| Title: | Targeting ROR1 Overexpressing Tumors with NBE-002 |
| Funding Source: | Boehringer Ingelheim |
| Role: | PI |
| ID: | AWD00005909 |
| Date: | 2021 - 2024 |
| Title: | REFLECT: Recurrent Features Leveraged for Combination Thearapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01 CA248220 |
| Date: | 2021 - 2023 |
| Title: | Nanoparticle Delivery of miRNA-based Therapeutics to Overcome Clinical Challenges in Triple Negative Breast Cancer |
| Funding Source: | Methodist Hospital Research Institute |
| Role: | Co-I |
| ID: | 1 R01 CA253865-01A1 |
| Date: | 2020 - 2023 |
| Title: | Informatics for Functional Integration of Heterogeneous Cancer Genome and Transcriptome Sequencing Data |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U01CA247760 |
| Date: | 2020 - 2025 |
| Title: | Novel Targeted Therapeutics for Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA244344-01A1 |
| Date: | 2020 - 2024 |
| Title: | Texas EXperimental Cancer Therapeutics Network - TEX CTN |
| Funding Source: | NIH/NCI |
| Role: | Multi-PI |
| ID: | UM1CA186688 |
| Date: | 2020 - 2025 |
| Title: | Repare STRATEGIC Alliance Agreement: Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC) |
| Funding Source: | Repare Therapeutics |
| Role: | PI |
| ID: | 58202 |
| Date: | 2019 - 2020 |
| Title: | Optimal combination therapies for HER2-positive breast cancer |
| Funding Source: | PUMA Biotechnology |
| Role: | PI |
| Date: | 2019 - 2021 |
| Title: | Neratinib Combinations for Cholangiocarcinoma |
| Funding Source: | PUMA Biotechnology |
| Role: | PI |
| ID: | 57909 |
| Date: | 2019 - 2021 |
| Title: | Developing an RNA-based Strategy for Actionable Target Assessment to Personalize Cancer Therapies |
| Funding Source: | Tang Prize Foundation |
| Role: | PI |
| ID: | RCTS 57510 |
| Date: | 2019 - 2021 |
| Title: | Optimizing ADC targeted Therapy – Phase 1 |
| Funding Source: | Klus Pharma, Inc |
| Role: | PI |
| ID: | RCTS# 00056715 |
| Date: | 2019 - 2024 |
| Title: | Cancer Center Support Grant (Core) |
| Funding Source: | NIH/NCI |
| Role: | Co-Leader, Targeted Therapy Program to Developmental Therapeutics Program |
| ID: | P30 CA016672 |
| Date: | 2019 - 2024 |
| Title: | Center for Clinical and Translational Sciences (CCTS)/MD Anderson Translational Informatics |
| Funding Source: | NIH/NCATS |
| Role: | Co-I |
| ID: | TR003167 |
| Date: | 2018 - 2023 |
| Title: | Dissecting BRCA complexes in replication fork protection |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP180813 |
| Date: | 2018 - 2023 |
| Title: | EXTernal beam radiation to eliminate nominal metastatic disease (EXTEND): A randomized phase II basket trial to assess local control for oligo metastatic disease |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP180140 |
| Date: | 2018 - 2023 |
| Title: | Characterizing cancer genome instability and translational impact using new sequencing technologies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP180248 |
| Date: | 2017 - 2019 |
| Title: | University of Texas PDX Development and Trial Center – Identification and testing of novel druggable, systems-biology based targets in PDX by using algorithms such as VIPER5 and SynGEN to prioritize single agent and combination therapies |
| Funding Source: | NIH/NCI |
| Role: | Project PI |
| ID: | U54 CA224065-S1 |
| Date: | 2017 - 2023 |
| Title: | University of Texas PDX Development and Trial Center |
| Funding Source: | NIH/NCI |
| Role: | Multi-PI |
| ID: | U54 CA224065 |
| Date: | 2017 - 2022 |
| Title: | Inhibition of brain metastasis by blocking MAPK12 driver kinase functions |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R01 CA208213-4 |
| Date: | 2017 - 2020 |
| Title: | Dual inhibition of MDM2 and MDMX for p53-dependent breast cancer treatment |
| Funding Source: | Aileron Therapeutics |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Targeting Oxidative Phosphorylation for Triple Negative Breast Cancer Therapy |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Multi-PI |
| ID: | Women’s Cancer Moonshot Research |
| Date: | 2016 - 2020 |
| Title: | Investigating mutational evolution and intratumor heterogeneity in TNBC |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| ID: | RSG-16-092-01-TBG |
| Date: | 2015 - 2020 |
| Title: | Preclinical Evaluation Of Neratinib in Tumor Cell Lines, and Patient Derived Xenograft (PDX) Models |
| Funding Source: | PUMA Biotechnology |
| Role: | PI |
| ID: | 51154 |
| Date: | 2015 - 2020 |
| Title: | Precision Oncology Decision Support Core |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator-MDACC |
| ID: | RP150535 |
| Date: | 2015 - 2019 |
| Title: | Optimizing patient selection for probody-mediated anti-cancer therapy |
| Funding Source: | CytomX |
| Role: | PI |
| Date: | 2015 - 2016 |
| Title: | MLN1117 in combination with MLN0128 for the treatment of triple negative breast cancer (“TNBC”) |
| Funding Source: | Millennium Pharmaceuticals, Inc |
| Role: | PI |
| ID: | 00000986-RN00 |
| Date: | 2014 - 2016 |
| Title: | Informatics to enable routine personalized cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | Multi-PI |
| ID: | U01CA180964 |
| Date: | 2014 - 2017 |
| Title: | Developing a novel oxidative phosphorylation inhibitor in pancreatic cancer |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-I |
| Date: | 2014 - 2020 |
| Title: | Southwest Early Clinical Trials Consortium |
| Funding Source: | NIH/NCI |
| Role: | Corresponding-PI, Multi-PI |
| ID: | 1UM1CA186688-01 |
| Date: | 2014 - 2019 |
| Title: | UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1 U10 CA180858 |
| Date: | 2013 - 2016 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | Institutional Support |
| Role: | Co-Program Leader |
| Date: | 2013 - 2016 |
| Title: | Informatics to enable routine personalized cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | Multi-PI |
| ID: | 1U01CA180964 |
| Date: | 2012 - 2016 |
| Title: | Molecular predictors of post-mastectomy breast cancer loco-regional recurrence |
| Funding Source: | NIH/NCI |
| Role: | Multi-PI |
| ID: | R21CA161633 |
| Date: | 2012 - 2016 |
| Title: | Molecular predictors of post-mastectomy breast cancer loco-regional recurrence |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R21CA161633-01A1 |
| Date: | 2012 - 2016 |
| Title: | Development of a targeted therapy: a treatment that is able to suppress breast cancer initiating cells |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP120727 |
| Date: | 2012 - 2017 |
| Title: | Single-Cell Sequencing of Breast Tumors to Investigate Genome Evolution |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA169244 |
| Date: | 2012 - 2017 |
| Title: | Center for Clinical and Translational Sciences (CCTS)/MD Anderson Translational Informatics |
| Funding Source: | NIH/NCATS |
| Role: | Lead of Translational Informatics |
| ID: | UL1-TR000371 |
| Date: | 2012 - 2020 |
| Title: | Characterization of chemotherapy and hormonal therapy-resistant tumors to optimize personalized breast cancer therapy |
| Funding Source: | AstraZeneca Alliance |
| Role: | PI |
| ID: | 12104532 |
| Date: | 2012 - 2016 |
| Title: | Cancer Prevention Agent Development Program: Early Phase Clinical Research |
| Funding Source: | NIH/NCRR |
| Role: | Co-I |
| ID: | N01CN05014-69 |
| Date: | 2011 - 2014 |
| Title: | Phase II Trial of Akt Inhibitor MK-2206 in Patients with Advanced Breast Cancer who Have Tumors with a PIK3CA Mutation and/or PTEN Loss |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2011 - 2015 |
| Title: | Personalized Therapy of Residual Breast Cancer after Neoadjuvant Treatment |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| Date: | 2011 - 2014 |
| Title: | Determinants of Efficacy to the Akt Inhibitor Perifosine in Metastatic Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA158676- 01A1 |
| Date: | 2010 - 2015 |
| Title: | Optimizing Akt/mTOR targeted breast cancer therapy |
| Funding Source: | Susan G. Komen Scholar Grant |
| Role: | PI |
| Date: | 2010 - 2013 |
| Title: | Multistage Delivery of a PI3K/mTOR inhibitor Nanococktail to Breast Tumors |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Principal Investigator-MDACC |
| Date: | 2010 - 2014 |
| Title: | Nested Nanotherapeutics for Drug Synergy Enhancement in Breast Cancer Therapy |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-Mentor |
| ID: | BC098059 |
| Date: | 2010 - 2013 |
| Title: | Calabresi Scholar, Evaluation of the Phase 0 concept |
| Funding Source: | NIH/NCI |
| Role: | Co-Mentor |
| Date: | 2010 - 2011 |
| Title: | Anti-tumor Efficacy of PI3K Pathway Inhibitors in Novel Breast Cancer Models of Intrinsic and Acquired Rapamycin Resistance |
| Funding Source: | Stand Up For Cancer Dream Team (Cantley, Mills, Sawyers) Animal Model Pilot Project |
| Role: | PI |
| Date: | 2010 - 2011 |
| Title: | Targeting PI3K in Women’s Cancers |
| Funding Source: | Stand Up For Cancer Dream Team (Cantley, Mills, Sawyers) PI3K Activity Pilot Project |
| Role: | PI |
| Date: | 2010 - 2011 |
| Title: | Noninvasive Assessment of PIK3CA Mutation Status in Circulating Free DNA in Women’s Cancers |
| Funding Source: | Stand Up For Cancer Dream Team (Cantley, Mills, Sawyers) Biomarkers Pilot Project |
| Role: | PI |
| Date: | 2010 - 2011 |
| Title: | Changes in PI3K Pathway Mutations and PTEN Levels from Primary to Metastatic Breast Cancer |
| Funding Source: | Stand Up For Cancer Dream Team (Cantley, Mills, Sawyers) Biomarker Pilot Project |
| Role: | Co-PI |
| Date: | 2010 - 2012 |
| Title: | Helping consumers find accurate breast cancer information online |
| Funding Source: | Sub Contract UT Health Science Center |
| Role: | PI |
| Date: | 2010 - 2011 |
| Title: | Identifying Salivary Biomarkers for Breast Cancer Detection |
| Funding Source: | University of Texas Dental Branch |
| Role: | Principal Investigator-MDACC |
| ID: | 07-2007-071 |
| Date: | 2010 - 2011 |
| Title: | Stearoyl-CoA Desaturase as a novel mediator of breast cancer growth |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Date: | 2009 - 2013 |
| Title: | Targeting PI3K in Women’s Cancer |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-I |
| Date: | 2009 - 2012 |
| Title: | Biomarker Assessment for PI3K/mTOR-Targeted Breast Cancer Therapy |
| Funding Source: | Society of Surgical Oncology |
| Role: | PI |
| Date: | 2009 - 2011 |
| Title: | Biomarker Assessment for Personalized Breast Cancer Therapy |
| Funding Source: | Kleberg Foundation |
| Role: | PI |
| Date: | 2009 - 2010 |
| Title: | Near Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping |
| Funding Source: | UTHSC |
| Role: | Clinical Study Chair |
| ID: | 5R01CA2679-15 |
| Date: | 2009 - 2012 |
| Title: | Effects of Biospecimen Integrity, Intratumoral Heterogeneity, and Analytical variance on microarray-based pharmaogenomi |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2009 - 2014 |
| Title: | Towards individualized breast cancer therapy: Leveraging molecular medicine with multi-stage vector technology |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Principal Investigator-MDACC |
| Date: | 2009 - 2012 |
| Title: | Chemotherapy Resistance in Hispanic and African-American patients |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-Mentor |
| Date: | 2008 - 2011 |
| Title: | UTMDACC SPORE in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Director MDACC Career Development Program |
| ID: | 5P50CA116199 05 |
| Date: | 2008 - 2010 |
| Title: | Activation of the AKT and mammalian target of rapamycin (mTOR) signaling pathway in breast cancer by serum levels C-peptide and Insulin Growth Factor-1 |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2008 - 2009 |
| Title: | Identifying Salivary Biomarkers for Breast Cancer Detection |
| Funding Source: | University of Texas Dental Branch at Houston |
| Role: | Principal Investigator-MDACC |
| Date: | 2007 - 2008 |
| Title: | Markers of Response to New Drugs that inhibit the mTOR/eIF4E Signaling Pathway |
| Funding Source: | Texas Federation of Business and Professional Women |
| Role: | PI |
| ID: | 1 ID#25648 01 |
| Date: | 2006 - 2011 |
| Title: | Leveraging preclinical and clinical studies to facilitate biomarker discovery |
| Funding Source: | Center for Clinical and Translational Sciences |
| Role: | Co-I |
| ID: | 1 UL1 RR0241148 |
| Date: | 2006 - 2011 |
| Title: | The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1K23 CA121994-01 |
| Date: | 2006 - 2007 |
| Title: | Targeting Translation Initiation Factor 4E for Breast Cancer Therapy |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | PI |
| Date: | 2005 - 2007 |
| Title: | Breast Cancer SPORE - Regulation of Breast Cancer Biology by S6 Kinase 1 Isoforms |
| Funding Source: | MDACC Developmental Grant |
| Role: | PI |
| Date: | 2005 - 2010 |
| Title: | Targeting mTOR for Cancer Therapy |
| Funding Source: | NIH/NCI/R01 |
| Role: | PI |
| ID: | CA112199-01 |
| Date: | 2004 - 2005 |
| Title: | GSK3b as a Modulator of Paclitaxel Sensitivity |
| Funding Source: | Goodwin Funds Pilot Project |
| Role: | PI |
| Date: | 2004 - 2005 |
| Title: | Alterations in the Translational Profile as Markers of Response to PI3K/AKT Inhibitors |
| Funding Source: | Eli Lilly |
| Role: | PI |
| Date: | 2003 - 2004 |
| Title: | Validation of quality criteria for health information on the World Wide Web |
| Funding Source: | Robert Wood Johnson Foundation |
| Role: | Co-I |
| Date: | 2003 - 2004 |
| Title: | Targeting the Serine-Threonine Kinase mTOR for Breast Cancer Therapy |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2003 - 2003 |
| Title: | A Randomized, Double Blind, Study of Exploratory Pharmacogenomics and Pharmacodynamic Effects of Oral CCI-779 Administered to Women with Operable Breast Cancer Prior to Lumpectomy |
| Funding Source: | Wyeth-Ayerst Research Laboratories |
| Role: | PI |
| Date: | 2002 - 2003 |
| Title: | Characterization of Estrogen Receptor Negative Breast Cancer Related Markers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2 U10 CA045809 14 |
| Date: | 2002 - 2004 |
| Title: | Pilot study of biomarker modulation with a COX-2 inhibitor using ductal lavage in women at high risk for Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R03 CA 97557-01 |
| Date: | 2001 - 2004 |
| Title: | Growth and Translational Regulation by eIF4E Overexpression in Breast Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2001 - 2002 |
| Title: | An Investigation of the Utility of NMP66 in Breast Cancer Detection |
| Funding Source: | The University of Texas MD Anderson Cancer Center & Matritech, Inc |
| Role: | PI |
| ID: | LS01-314 |
| Date: | 2001 - 2006 |
| Title: | Role of Nuclear Tyrosine Kinase Rak in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1K08-CA91895-01 |
| Date: | 2001 - 2004 |
| Title: | Genomic Evaluation of In Vivo and In Vitro Pharmacology of Preventive Agents in Li Fraumeni Syndrome |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | N01-CN-05023-09 |
| Date: | 1994 - 2023 |
| Title: | Training of Academic Surgical Oncologists |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | T32 CA009599 |
| Title: | Scaling Clinical Decision Support for Routine Precision Medicine |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R18HS026329 |
Selected Publications
Peer-Reviewed Articles
- Johnson, A, Shen, Y, Zheng, X, Su, F, Zeng, J, Uzunparmak, B, Breuer, E, Holla, V, Kahle, M, Kim, S, Vu, T, Mills Shaw, KR, Ileana Dumbrava, EE, Yap, TA, Rodon Ahnert, J, Routbort, MJ, Patel, KP, Kulkarni, S, Hansel, DE, Bryan, J, Korkut, A, Chen, K, Meric-Bernstam, F. The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology. Nature Reviews Clinical Oncology 23(3):213-229, 2026. e-Pub 2026. PMID: 41492079.
- Schmidt, ST, Baysal, M, Fu, S, Hong, DS, Piha-Paul, SA, Naing, A, Rodon Ahnert, J, Yap, TA, Dumbrava, EE, Beck, J, Meric-Bernstam, F, Tsimberidou, AM. Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology. Signal Transduction and Targeted Therapy 11(1), 2026. e-Pub 2026. PMID: 41730847.
- Piha-Paul, SA, Tseng, C, Thompson, E, Stafford, RJ, Le, H, Kang, L, Fu, S, Tsimberidou, AM, Blumenschein, GR, Rodon Ahnert, J, Slopis, JM, Hong, DS, Naing, A, Meric-Bernstam, F, Ng, CS, Westin, SN, Sood, AK. Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies. Oncologist 31(3), 2026. e-Pub 2026. PMID: 41389341.
- Kang, I, Forschmiedt, JK, Loch, MM, Lew, DL, Barlow, WE, Gralow, J, Meric-Bernstam, F, Albain, KS, Hayes, DF, Lin, NU, Perez, EA, Goldstein, LJ, Rastogi, P, Schott, AF, Baehner, R, Sharma, P, Tripathy, D, Pusztai, L, Hortobagyi, GN, Kalinsky, K, Henry, NL. Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women A Secondary Analysis of the RxPONDER Randomized Clinical Trial. JAMA Oncology 12(2):159-166, 2026. e-Pub 2026. PMID: 41379459.
- Lim, JU, Lin, Y, Kang, L, Le, H, Tang, T, Champiat, S, Dumbrava, EE, Le, X, Naing, A, Piha-Paul, SA, Rodon Ahnert, J, Tsimberidou, AM, Yap, TA, Fu, S, Meric-Bernstam, F, Hong, DS. Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson. npj Precision Oncology 10(1), 2026. e-Pub 2026. PMID: 41530472.
- Luo, L, Wang, Y, Bui, T, Jiang, XT, Chen, MK, Rao, X, Mohammadhosseinpour, S, Li, M, Kim, S, Kim, RY, Kamaliasl, S, Ulizio, CW, Tsavachidis, S, Navarro Yepes, J, Kettner, NM, Wingate, H, Meric-Bernstam, F, Hunt, KK, Wang, J, Faia, K, Keyomarsi, K. CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. Nature communications 17(1), 2026. e-Pub 2026. PMID: 41571637.
- Wang, X, Haro-Silerio, JI, Beaudry, FE, Borgida, A, Abbas-Aghababazadeh, F, Sahebi, NB, Wang, M, Fox, DA, Nuh, M, Hsiang, M, Bhamidipati, D, Kang, H, Cox, V, Ludmir, EB, Koay, EJ, Kwong, L, Quentin, K, Chatterjee, D, Chun, YS, Cao, HT, Meric-Bernstam, F, Hu, I, Dodd, A, Hamza, O, Hildebrand, M, Bucur, R, Hirschfield, GM, Vogel, A, O'Kane, GM, Gallinger, S, Haibe-Kains, B, Notta, F, Sapisochin, G, Knox, J, Javle, M, Lee, SS, Grant, RC. Clinicogenomic Characterization of Primary Sclerosing Cholangitis–Associated Biliary Tract Cancers. Clinical Cancer Research 32(2):363-374, 2026. e-Pub 2026. PMID: 41252561.
- Meric-Bernstam, F, Rha, SY, Hamilton, E, Kang, YK, Hanna, D, Iqbal, S, Lee, KW, Lee, J, Beeram, M, Oh, DY, Chaves, J, Goodwin, RA, Ajani, JA, Yang, L, Oza, R, Elimova, E. Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40341383.
- Piha-Paul, SA, Tseng, C, Tran, HT, Fu, SC, Dumbrava, EE, Yap, TA, Naing, A, Lim, J, Murphy, MB, Ramirez, DL, Soliman, PT, Sood, AK, Meric-Bernstam, F. Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations. ESMO Open 10(12), 2025. e-Pub 2025. PMID: 41223631.
- Azhar, M, Soto, F, Su, A, Gonzalez, NV, Medina, KB, Madrigal, AL, Duran, CC, Reyna, CR, Chan, C, Shroff, G, Bassett Jr, R, Pasyar, S, Zhang, D, Shannon, VR, Altan, M, Mitchell, MP, Meric-Bernstam, F, Mouabbi, JA, Murthy, RK, Faiz, S, Bashoura, L, Lim, B, Sheshadri, A. Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer. Breast Cancer Research 27(1), 2025. e-Pub 2025. PMID: 41194091.
- Kushnarev, V, Stupichev, D, Davitavyan, S, Kriukov, K, Shanthappa, BU, Butusova, A, Menshikova, S, Belozerova, A, Shvyrkova, A, Tkachuk, A, Khatenkova, O, Balabanian, L, Postovalova, E, Lennerz, JK, Meric-Bernstam, F, Bagaev, A. RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation. Scientific reports 15(1), 2025. e-Pub 2025. PMID: 40753302.
- Kettner, NM, Bui, T, Navarro-Yepes, J, Ghotbaldini, S, Quintela, B, Luo, CK, Lam, N, Rao, X, Singareeka Raghavendra, A, Wang, Y, Azizian, NG, Kris Eckols, T, Kasembeli, MM, Evans, KW, Yi, M, Wingate, H, Wang, J, Sahin, AA, Meric-Bernstam, F, Hunt, KK, Damodaran, S, Tweardy, D, Tripathy, D, Keyomarsi, K. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 40715551.
- Ozirmak Lermi, N, Molina Ayala, M, Hernandez, S, Lu, W, Khan, KB, Serrano, A, Lubo Julio, IC, Hamana Zorrilla, L, Tomczak, K, Barnes, S, Dou, J, Liang, Q, Zhang, S, Zhang, Q, Zhang, J, Xu, M, Woodman, SE, Wang, W, Virani, S, Sun, B, Subramanya, S, Song, X, Shaw, KR, Prabhakaran, S, Piubelli, ML, Mohammad, MM, Meric-Bernstam, F, Mendoza, MT, Mallampati, S, Little, L, Lang, W, Knafl, M, Khanduri, I, Gite, S, Arrechedera, C, Raso, G, Tang, X, Sanchez Espiridion, B, Weissferdt, A, Heymach, JV, Zhang, J, Sepesi, B, Cascone, T, Tsao, A, Altan, M, Mehran, RJ, Gibbons, DL, Wistuba, II, Haymaker, CL, Chen, K. Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples. Nature communications 16(1), 2025. e-Pub 2025. PMID: 41006245.
- Wanis, K, Dong, W, Shen, Y, Meric-Bernstam, F, Adesoye, T, Kuerer, HM, Caudle, AS, Tamirisa, N, DeSnyder, SM, Sun, SX, Bedrosian, I, Singh, P, Cox, SE, Hunt, KK, Hwang, RF. Predicting pathologic ≥N2 disease in women with breast cancer. npj Breast Cancer 11(1), 2025. e-Pub 2025. PMID: 40404657.
- Sledge, GW, Xiu, J, Mahtani, R, Sandoval-Leon, A, Meric-Bernstam, F, Ribeiro, JR, Kulkarni, NN, Rampa, DR, Lee, J, Ueno, NT, Oberley, MJ, Radovich, M, Spetzler, D. Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling. npj Breast Cancer 12(1), 2025. e-Pub 2025. PMID: 41422323.
- Msaouel, P, Tannir, NM, Meric-Bernstam, F, King, JM, Voss, MH, Cheng, JP, Thomas, SS, Lim, ZD, Karki, M, He, R, Genovese, G, Sheth, RA, Ingram, D, Shamsutdinova, D, Wani, K, Wang, W, Lazar, A, Knipper-Davis, D, Berlinski, A, Soares, T, Stupichev, D, Kryukov, K, Davitavyan, S, Novokreshchenova, A, Lebedev, D, Kurpe, S, Kravets, A, Belousov, D, Hensley, M, Bagaev, A, Paradiso, F, Kushnarev, V. Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling. Cell Reports Medicine 6(11), 2025. e-Pub 2025. PMID: 41172996.
- Wotman, MT, Khalaf, A, Wang, K, Meric-Bernstam, F, Gillison, M, Akhave, NS, Kerrigan, KC, Ferrarotto, R. Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck. JNCCN Journal of the National Comprehensive Cancer Network 24(2), 2025. e-Pub 2025. PMID: 41213241.
- Swanton, C, Madison, RW, Tambaoan, CB, Meric-Bernstam, F, Sweeney, CJ, Kurzrock, R, Burris, H, Spigel, D, Tukachinsky, H, Hughes, JD, Malato, J, Yoo, B, Szado, T, Schwab, C, Pasquina, LW, Gasco, A, Schulze, K, Friedman, C. Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab. Molecular oncology 19(11):3060-3078, 2025. e-Pub 2025. PMID: 40434907.
- Gouda, M, Janku, F, Yuan, Y, Drusbosky, L, Chen, A, Zheng, X, Patel, KP, Hamilton, SR, Routbort, MJ, Tricoli, JV, Williams, PM, Iafrate, AJ, Sklar, J, Coffey, B, Little, R, Arteaga, CL, O'Dwyer, PJ, Flaherty, KT, Harris, LN, Meric-Bernstam, F. Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Clinical Cancer Research 31(20):4299-4310, 2025. e-Pub 2025. PMID: 40388547.
- Varadarajan, K, Cruz Pico, CX, Evans, KW, Raso, G, Rizvi, YQ, Zheng, X, Chachad, D, DiPeri, TP, Wang, B, Scott, S, Zhao, M, Akcakanat, A, Wengner, AM, Yap, TA, Meric-Bernstam, F. Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations. Molecular cancer therapeutics 24(9):1402-1414, 2025. e-Pub 2025. PMID: 40300249.
- Khatri, U, Dayal, N, Owusu, KB, Hunjan, MK, Pandey, S, Harper, HA, McMahan, C, Elzey, BD, Shen, T, Hu, X, Evans, KW, El-Sheikh, A, Jo, Sj, Holtsberg, FW, Aman, MJ, Meric-Bernstam, F, Woo, S, Sintim, HO, Wu, J. Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy. RSC Medicinal Chemistry 16(8):3541-3550, 2025. e-Pub 2025. PMID: 40496186.
- Derbala, M, Hajjar, J, Stephen, B, Gurses, S, Kwiatkowski, E, Budde, P, Zucht, HD, Bräutigam, M, Lindemann, AS, Abhari, BA, Gouda, M, Castillo, L, Zarifa, A, How, JA, Rodriguez, E, Moyers, JT, Hong, DS, Fu, S, Meric-Bernstam, F, Naing, A. Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open 10(8), 2025. e-Pub 2025. PMID: 40768895.
- Janku, F, Jegede, O, Puhalla, S, Konstantinopoulos, PA, Meric-Bernstam, F, Zwiebel, J, Gray, R, Wang, V, McShane, LM, Rubinstein, L, Patton, DR, Williams, PM, Hamilton, SR, Takebe, N, Ghani, S, Tricoli, JV, Conley, BA, Arteaga, CL, Harris, LN, O'Dwyer, PJ, Chen, A, Flaherty, KT. PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40865033.
- Meric-Bernstam, F, Raghav, KS, Sweeney, CJ, Swanton, C, Spigel, D, Bose, R, Burris, H, Friedman, C, Espenschied, CR, Grindheim, J, Malato, J, Schulze, K, Price, R, Kurzrock, R. ctDNA Analysis in ERBB2-Amplified Colorectal Cancer. Clinical Cancer Research 31(14):2935-2944, 2025. e-Pub 2025. PMID: 40512191.
- Chen, MK, Yamaguchi, H, Gao, Y, Xia, W, Chang, J, Hsiao, YC, Shegute, TW, Lin, ZS, Wu, CS, Wang, YH, Litton, J, Ding, Q, Wei, Y, Chu, Y, Meric-Bernstam, F, Piwnica-Worms, H, Arun, BK, Ahnert, JR, Liu, J, Yao, J, Chang, W, Wang, HL, Tapia, C, Albarracin, C, Keyomarsi, K, Wang, SC, Wang, Y, Hortobagyi, GN, Lin, C, Yang, L, Yu, D, Hung, M. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. Journal of Clinical Investigation 135(14), 2025. e-Pub 2025. PMID: 40460005.
- Al Baghdadi, T, Rothe, M, Mangat, PK, Garrett-Mayer, E, Crysler, OV, Mileham, KF, Farrington, LC, Adesunloye, B, Dublis, SA, Astsaturov, I, Calfa, C, Bleeker, J, Khalil, M, Thota, R, Cannon, TL, Alese, OB, Gold, PJ, Hafez, N, Baron, AD, Meric-Bernstam, F, Hobbs, EA, Marr, A, Rueter, J, Tawfik, B, Hinshaw, DC, Gregory, A, Grantham, GN, Halabi, S, Schilsky, RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 41100773.
- Wanis, K, Mitchell, MP, Giordano, SH, Litton, J, Shaitelman, SF, Tamirisa, N, Bedrosian, I, Dong, W, Shen, Y, Hunt, KK, Singh, P, Sun, SX, Caudle, AS, Kuerer, HM, Meric-Bernstam, F, Hwang, RF, Adesoye, T. Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer 131(11), 2025. e-Pub 2025. PMID: 40433858.
- Westphalen, CB, Boscolo Bielo, L, Aftimos, P, Beltran, H, Benary, M, Chakravarty, D, Collienne, M, Dienstmann, R, El Helali, A, Gainor, J, Horak, P, Le Tourneau, C, Marchiò, C, Massard, C, Meric-Bernstam, F, Pauli, C, Pruneri, G, Roitberg, F, Russnes, HE, Solit, DB, Starling, N, Subbiah, V, Tamborero, D, Tarazona, N, Turnbull, C, van de Haar, J, Andre, F, Mateo, J, Curigliano, G. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Annals of Oncology 36(6):614-625, 2025. e-Pub 2025. PMID: 40194904.
- Jacomina, LE, Swanson, DM, Mitchell, MP, Woodward, W, Smith, B, Hoffman, K, Goodman, C, Garber, HR, Sun, SX, Yap, TA, Meric-Bernstam, F, Arzu, I, Bloom, ES, Schlembach, PJ, Strom, EA, Stauder, MC, Shaitelman, SF. Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics 122(2):278-291, 2025. e-Pub 2025. PMID: 39549757.
- Ronaghy, A, Crimini, E, Holla, V, Mills Shaw, KR, Doefler, AM, Campbell, E, Yang, RK, Iorgulescu, JB, Patel, KP, McPherson, DD, Ning, J, Meric-Bernstam, F, Karp, DD. Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET. ESMO Open 10(6), 2025. e-Pub 2025. PMID: 40460677.
- Abdou, Y, Barlow, WE, Gralow, J, Meric-Bernstam, F, Albain, KS, Hayes, DF, Lin, NU, Perez, EA, Goldstein, LJ, Chia, S, Dhesy-Thind, S, Rastogi, P, Alba, E, Delaloge, S, Schott, AF, Shak, S, Sharma, P, Lew, DL, Miao, J, Unger, JM, Tripathy, D, Hortobagyi, GN, Pusztai, L, Kalinsky, K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. Journal of the National Cancer Institute 117(5):889-897, 2025. e-Pub 2025. PMID: 39656951.
- Gouda, MA, Voss, MH, Tawbi, H, Gordon, MS, Tykodi, SS, Lam, ET, Vaishampayan, U, Tannir, NM, Chaves, J, Nikolinakos, P, Fan, AC, Lee, RJ, McDermott, DF, Shapiro, GI, Gandhi, L, Bhatia, S, Katragadda, V, Meric-Bernstam, F. A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open 10(5), 2025. e-Pub 2025. PMID: 40359708.
- Oaknin, A, Lee, JY, Makker, V, Oh, DY, Banerjee, S, Gonzalez-Martin, A, Jung, KH, Lugowska, I, Manso, L, Manzano, A, Melichar, B, Siena, S, Stroiakovski, D, Fielding, A, Puvvada, S, Smith, A, Meric-Bernstam, F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy 42(5):2015-2018, 2025. e-Pub 2025. PMID: 40048102.
- Goyal, L, DiToro, DF, Hollebecque, A, Bridgewater, J, Shimura, M, Kano, A, Okamura, S, Silhavy, JL, Wacheck, V, Halim, AB, Meric-Bernstam, F. Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling. Annals of Oncology 36(4):414-425, 2025. e-Pub 2025. PMID: 39672383.
- Gouda, MA, Gonugunta, A, Ileana Dumbrava, EE, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Pohlmann, PR, Damodaran, S, Murthy, RK, Valero, V, Mouabbi, JA, Tripathy, D, Sahin, AA, Chen, H, Meric-Bernstam, F. Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clinical Cancer Research 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
- Ahmed, J, Knisely, A, Torrado, C, Stephen, B, Yang, Y, Song, J, Alshawa, A, Zarifa, A, Jhingran, A, Koay, EJ, Morris, VK, Javle, M, Wolff, RA, Meric-Bernstam, F, Pant, S, Rodon Ahnert, J, Naing, A. A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40139261.
- Alhalabi, O, Gouda, MA, Milton, D, Momin, HA, Yilmaz, B, Stephen, B, Ejezie, CL, Moyers, JT, Gurses, S, How, JA, Fu, S, Rodon Ahnert, J, Hong, DS, Piha-Paul, SA, Subbiah, V, Elena Dumbrava, E, Karp, DD, Janku, F, Meric-Bernstam, F, Tannir, NM, Naing, A. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma. Cancer medicine 14(4), 2025. e-Pub 2025. PMID: 39945382.
- Gouda, MA, Zarifa, A, Yang, Y, Stephen, B, Gurses, S, Sprenger, A, Tian, Y, Derbala, M, Glitza, IC, Meric-Bernstam, F, Patel, SP. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma. Journal of Immunotherapy and Precision Oncology 8(1):82-88, 2025. e-Pub 2025. PMID: 39816915.
- Piha-Paul, SA, Tseng, C, Tran, HT, Naing, A, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Yap, TA, Raghav, KS, Damodaran, S, Le, X, Soliman, PT, Lim, J, Meric-Bernstam, F. Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open 10(2), 2025. e-Pub 2025. PMID: 39908697.
- Ahmed, J, Janku, F, Karp, DD, Piha-Paul, SA, Tsimberidou, AM, Yap, TA, Stephen, B, Yang, Y, Gurses, S, Liu, Q, Song, J, Meric-Bernstam, F, Naing, A. A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers. Cancer 131(3), 2025. e-Pub 2025. PMID: 39853679.
- Ahmed, J, Stephen, B, Khawaja, MR, Yang, Y, Salih, I, Barrientos Toro, E, Raso, G, Karp, DD, Piha-Paul, SA, Sood, AK, Ng, CS, Johnson, A, Soliman, PT, Meric-Bernstam, F, Lu, KH, Naing, A. A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecologic oncology 193:73-80, 2025. e-Pub 2025. PMID: 39787747.
- Meric-Bernstam, F, Yuca, E, Evans, KW, Zhao, M, Maejima, T, Karibe, T, Raso, G, Tang, X, Zheng, X, Rizvi, YQ, Akcakanat, A, Scott, S, Wang, B, Byers, LA, Tripathy, D, Okajima, D, Damodaran, S. Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clinical Cancer Research 31(3):573-587, 2025. e-Pub 2025. PMID: 39585341.
- DiPeri, TP, Evans, KW, Scott, S, Zheng, X, Varadarajan, K, Kwong, L, Kahle, M, Cao, HS, Tzeng, CW, Vu, T, Kim, S, Su, F, Raso, G, Rizvi, YQ, Zhao, M, Wang, H, Lee, SS, Yap, TA, Rodon Ahnert, J, Javle, M, Meric-Bernstam, F. Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clinical Cancer Research 31(2):387-402, 2025. e-Pub 2025. PMID: 39513959.
- Powles, T, Bhatia, A, Burtness, B, Kogawa, T, Nishina, T, Nakayama, I, Fountzilas, C, Castillo, DR, McKean, M, Meric-Bernstam, F, Colombo, N, Smithy, JW, Fayette, J, Chandra, S, Sternberg, DW, Jin, F, Sullivan, K, Yueh, S, Clinthorne, G, Aguilo, AE, Kudchadkar, RR, Hayashi, H. HERTHENA-PanTumor01. Future Oncology 21(25):3283-3292, 2025. e-Pub 2025. PMID: 41088723.
- Xavier, CB, Andersen, C, Lim, J, Slade, JH, Bean, S, Kang, L, Le, H, Tsimberidou, AM, Naing, A, Hong, DS, Ileana Dumbrava, EE, Rodon Ahnert, J, Pohlmann, PR, Piha-Paul, SA, Champiat, S, Yap, TA, Tang, T, Meric-Bernstam, F, Fu, S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials. Cancer Research Communications 5(9):1631-1641, 2025. e-Pub 2025. PMID: 40862547.
- Meric-Bernstam, F, Gutierrez, M, Sanz-Garcia, E, Villa, D, Zhang, J, Friedmann, J, Yan, F, Socinski, MA, Sarantopoulos, J, Raez, LE, Chu, QC, Chénard-Poirier, M, Chatterjee, M, Ren, H, Liu, Q, Levine, DA, Jhaveri, K. Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Research Communications 5(9):1664-1673, 2025. e-Pub 2025. PMID: 40762544.
- Meric-Bernstam, F, Hollebecque, A, Furuse, J, Oh, DY, Bridgewater, J, Anderson, B, Hangai, N, Wacheck, V, Goyal, L. Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer. Future Oncology 21(2):139-150, 2025. e-Pub 2025. PMID: 39466121.
- Kim, D, Chung, H, Liu, W, Jeong, KJ, Ozmen, TY, Ozmen, F, Rames, MJ, Kim, S, Guo, X, Jameson, NM, de Jong, PR, Yea, S, Harford, L, Li, J, Mathews, C, Doroshow, DB, Charles, VJ, Kim, D, Fischer, K, Samatar, AA, Jubb, A, Bunker, KD, Blackwell, KL, Simpkins, F, Meric-Bernstam, F, Mills, GB, Harismendy, O, Ma, J, Lackner, MR. Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 39755818.
- Reddy, TP, Puri, A, Guzman-Rojas, L, Thomas, C, Qian, W, Zhou, J, Zhao, H, Mahboubi, B, Oo, A, Cho, YJ, Kim, B, Thaiparambil, J, Rosato, RR, Martinez, KO, Chervo, MF, Ayerbe, C, Giese, N, Wink, D, Lockett, S, Wong, ST, Chang, J, Krishnamurthy, S, Yam, C, Moulder, S, Piwnica-Worms, H, Meric-Bernstam, F, Chang, J. NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39737957.
- Piha-Paul, SA, Tseng, C, Leung, CH, Yuan, Y, Karp, DD, Subbiah, V, Hong, DS, Fu, S, Naing, A, Rodon Ahnert, J, Javle, M, Ajani, JA, Raghav, KS, Somaiah, N, Mills, GB, Tsimberidou, AM, Zheng, X, Chen, K, Meric-Bernstam, F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39085400.
- Wang, X, Zhao, L, Song, X, Wu, X, Krishnamurthy, S, Semba, T, Shao, SH, Knafl, M, Coffer, LW, Alexander, A, Vines, A, Bopparaju, S, Woodward, W, Chu, RA, Zhang, J, Yam, C, Loo, LW, Nasrazadani, A, Huong, LP, Woodman, SE, Futreal, A, Zhang, S, Zhang, Q, Xu, M, Wistuba, II, Wang, W, Virani, S, Sun, B, Subramanya, S, Song, X, Song, P, Shaw, KR, Prabhakaran, S, Marques-Piubelli, ML, Mohammad, MM, Meric-Bernstam, F, Mendoza, MT, Mallampati, S, Lu, W, Little, L, Lang, W, Kinyua, W, Khanduri, I, Jiang, M, Jacob, J, Jackson, S, Gite, S, Garcia-Prieto, C, Arrechedera, C, Tripathy, D. Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39558017.
- Holla, V, Kahle, M, Kim, SH, Ronaghy, A, Yang, RK, Patel, KP, Routbort, MJ, Overman, MJ, Ileana Dumbrava, EE, Mills Shaw, KR, Karp, DD, Meric-Bernstam, F. Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 39576951.
- Oaknin, A, Lee, JY, Makker, V, Oh, DY, Banerjee, S, Gonzalez-Martin, A, Jung, KH, Lugowska, I, Manso, L, Manzano, A, Melichar, B, Siena, S, Stroiakovski, D, Fielding, A, Puvvada, S, Smith, AN, Meric-Bernstam, F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status. Advances in Therapy 41(11):4125-4139, 2024. e-Pub 2024. PMID: 39261417.
- Grivas, PD, Garralda, E, Meric-Bernstam, F, Mellinghoff, IK, Goyal, L, Harding, JJ, Dees, EC, Bahleda, R, Azad, N, Karippot, A, Kurzrock, R, Tabernero, J, Kononen, J, Ng, M, Mehta, R, Uboha, NA, Bigot, F, Boni, V, Bowyer, S, Breder, V, Cervantes, A, Chan, N, Cleary, JM, Dhawan, M, Eefsen, RL, Ewing, J, Graham, DM, Guren, T, Kim, JW, Koynov, KD, Oh, DY, Redman, R, Yen, CJ, Spetzler, D, Roubaudi-Fraschini, MC, Nicolas-Metral, V, Ait-Sarkouh, R, Zanna, C, Ennaji, A, Pokorska-Bocci, A, Flaherty, KT. Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clinical Cancer Research 30(20):4572-4583, 2024. e-Pub 2024. PMID: 38771739.
- Curigliano, G, Jimenez, MM, Shimizu, T, Keam, B, Meric-Bernstam, F, Rutten, A, Glaspy, JA, Schuler, PJ, Parikh, NS, Ising, M, Hassounah, N, Wu, J, Leyk, M, Chen, X, Burks, H, Chaudhury, A, Otero, J, Cabanas, EG. A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies. ESMO Open 9(8), 2024. e-Pub 2024. PMID: 39088985.
- Son, J, Zhang, Y, Lin, Y, Mirallas, O, Ballesteros, PA, Nardo, M, Clark, N, Hillman, RT, Campbell, E, Holla, V, Johnson, A, Biter, A, Yuan, Y, Cobb, LP, Gershenson, DM, Jazaeri, AA, Lu, KH, Soliman, PT, Westin, SN, Euscher, ED, Lawson, BC, Yang, RK, Meric-Bernstam, F, Hong, DS. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clinical Cancer Research 30(14):2986-2995, 2024. e-Pub 2024. PMID: 38687597.
- Mosele, MF, Westphalen, CB, Stenzinger, A, Barlesi, F, Bayle, A, Bieche, I, Bonastre, J, Castro, E, Dienstmann, R, Krämer, A, Czarnecka, AM, Meric-Bernstam, F, Michiels, S, Miller, R, Normanno, N, Reis-Filho, JS, Remon, J, Robson, M, Rouleau, E, Scarpa, A, Serrano, C, Mateo, J, Andre, F. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024. Annals of Oncology 35(7):588-606, 2024. e-Pub 2024. PMID: 38834388.
- Bardia, A, Krop, IE, Kogawa, T, Juric, D, Tolcher, AW, Hamilton, E, Mukohara, T, Lisberg, AE, Shimizu, T, Spira, AI, Tsurutani, J, Damodaran, S, Papadopoulos, KP, Greenberg, J, Kobayashi, F, Zebger-Gong, H, Wong, R, Kawasaki, Y, Nakamura, T, Meric-Bernstam, F. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer. Journal of Clinical Oncology 42(19):2281-2294, 2024. e-Pub 2024. PMID: 38652877.
- Schuetze, S, Rothe, M, Mangat, PK, Garrett-Mayer, E, Meric-Bernstam, F, Calfa, C, Farrington, LC, Livingston, MB, Wentzel, K, Behl, D, Kier, Y, Marr, A, Von Mehren, M, Press, JZ, Thota, R, Grantham, GN, Gregory, A, Hinshaw, DC, Halabi, S, Schilsky, RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 39013131.
- White, BS, Woo, XY, Koc, S, Sheridan, T, Neuhauser, S, Wang, S, Evrard, YA, Chen, L, Pour, AF, Landua, J, Mashl, RJ, Davies, S, Fang, B, Rosa, MG, Evans, KW, Bailey, MH, Chen, Y, Xiao, M, Rubinstein, JC, Sanderson, BJ, Lloyd, M, Domanskyi, S, Dobrolecki, LE, Fujita, M, Fujimoto, J, Xiao, G, Fields, RC, Mudd, JL, Xu, X, Hollingshead, MG, Jiwani, S, Acevedo, S, Davis-Dusenbery, BN, Robinson, PN, Moscow, JA, Doroshow, JH, Mitsiades, N, Kaochar, S, Pan, CX, Carvajal-Carmona, L, Welm, AL, Welm, BE, Govindan, R, Li, S, Davies, MA, Roth, JA, Meric-Bernstam, F, Xie, Y, Herlyn, M, Ding, L. A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Research 84(13):2060-2072, 2024. e-Pub 2024. PMID: 39082680.
- Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA. Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther 23(7):924-938, 2024. e-Pub 2024. PMID: 38641411.
- Gouda, MA, Shunyakova, J, Naing, A, Ileana Dumbrava, EE, Hong, DS, Yuan, Y, Yang, P, Myers, AL, Liang, Y, Peng, J, Karp, DD, Tsimberidou, AM, Rodon Ahnert, J, Yap, TA, Piha-Paul, SA, Meric-Bernstam, F, Fu, S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open 9(6), 2024. e-Pub 2024. PMID: 38914452.
- Raso, G, Barrientos Toro, E, Evans, KW, Rizvi, YQ, Segura Lazcano, R, Akcakanat, A, Sini, P, Trapani, F, Madlener, EJ, Waldmeier, L, Lazar, A, Meric-Bernstam, F. Heterogeneous Profile of ROR1 Protein Expression across Tumor Types. Cancers 16(10), 2024. e-Pub 2024. PMID: 38791952.
- Moffat, GT, Hu, ZI, Meric-Bernstam, F, Kong, EK, Pavlick, D, Ross, JS, Murugesan, K, Kwong, L, De Armas, AD, Korkut, A, Javle, M, Knox, J. KRAS Allelic Variants in Biliary Tract Cancers. JAMA Network Open 7(5), 2024. e-Pub 2024. PMID: 38709532.
- Pilie PG, Giuliani V, Wang WL, McGrail DJ, Bristow CA, Ngoi NYL, Kyewalabye K, Wani KM, Le H, Campbell E, Sánchez NS, Yang D, Gheeya JS, Goswamy RV, Holla V, Shaw KR, Meric-Bernstam F, Liu CY, Ma X, Feng N, Machado AA, Bardenhagen JP, Vellano CP, Marszalek JR, Rajendra E, Piscitello D, Johnson TI, Likhatcheva M, Elinati E, Majithiya J, Neves J, Grinkevich V, Ranzani M, Roy-Luzarraga M, Boursier M, Armstrong L, Geo L, Lillo G, Tse WY, Lazar AJ, Kopetz SE, Geck Do MK, Lively S, Johnson MG, Robinson HMR, Smith GCM, Carroll CL, Di Francesco ME, Jones P, Heffernan TP, Yap TA. Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types. Clin Cancer Res 30(10):2121-2139, 2024. e-Pub 2024. PMID: 38416404.
- Meric-Bernstam F, Hollebecque A, Furuse J, Oh DY, Bridgewater JA, Shimura M, Anderson B, Hangai N, Wacheck V, Goyal L. Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clin Cancer Res 30(8):1466-1477, 2024. e-Pub 2024. PMID: 38329716.
- Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist 29(4):e514-e525, 2024. e-Pub 2024. PMID: 38297981.
- Higgins T, Kantor O, Harrison B, Giordano J, McGrath M, Burstein HJ, Schnitt SJ, Rahman T, Vora H, Garrido-Castro A, Tolaney SM, Meric-Bernstam F, King TA, Mittendorf EA. Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer. Ann Surg Oncol, 2024. e-Pub 2024. PMID: 38161200.
- Nelson BE, Roszik J, Ahmed J, Barretto CMN, Nardo M, Campbell E, Johnson AM, Piha-Paul SA, Oliva ICG, Weathers SP, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer 23(1):64, 2024. e-Pub 2024. PMID: 38532456.
- Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, Cabanillas M, Hu M, Castellanos LE, Amini B, Meric-Bernstam F, Shen T, Wu J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol 8(1):62, 2024. e-Pub 2024. PMID: 38438731.
- Goldberg J, Qiao N, Guerriero JL, Gross B, Meneksedag Y, Lu YF, Philips AV, Rahman T, Meric-Bernstam F, Roszik J, Chen K, Jeselsohn R, Tolaney SM, Peoples GE, Alatrash G, Mittendorf EA. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer. Cancer Res Commun 4(2):496-504, 2024. e-Pub 2024. PMID: 38335301.
- Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer, 2024. e-Pub 2024. PMID: 37864520.
- Coleman N, Stephen B, Fu S, Karp D, Subbiah V, Ahnert JR, Piha-Paul SA, Wright J, Fessahaye SN, Ouyang F, Yilmaz B, Meric-Bernstam F, Naing A. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med 13(3):e6877, 2024. e-Pub 2024. PMID: 38400671.
- Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol 7(1):7-17, 2024. e-Pub 2024. PMID: 38327755.
- Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer Res Commun, 2024. e-Pub 2024. PMID: 38126764.
- Woodfin AA, Yam C, Teshome M, Kuerer HM, Hunt KK, Meric-Bernstam F, Schaverien M, Barcenas CH, Sun SX. Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Ann Surg Oncol, 2024. e-Pub 2024. PMID: 37973647.
- DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol, 2024. e-Pub 2024. PMID: 37972659.
- Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol:101200JCO2302005, 2024. e-Pub 2024. PMID: 37870536.
- DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov 14(5):828-845, 2024. e-Pub 2024. PMID: 38358339.
- Wu Y, Chen S, Yang X, Sato K, Lal P, Wang Y, Shinkle AT, Wendl MC, Primeau TM, Zhao Y, Gould A, Sun H, Mudd JL, Hoog J, Mashl RJ, Wyczalkowski MA, Mo CK, Liu R, Herndon JM, Davies SR, Liu D, Ding X, Evrard YA, Welm BE, Lum D, Koh MY, Welm AL, Chuang JH, Moscow JA, Meric-Bernstam F, Govindan R, Li S, Hsieh J, Fields RC, Lim KH, Ma CX, Zhang H, Ding L, Chen F. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res 83(24):4161-4178, 2023. e-Pub 2023. PMID: 38098449.
- Surana, R, Gonzalez, GN, Rogers, JE, Hong, DS, Yap, TA, Rodon Ahnert, J, Naing, A, Wolff, RA, Smaglo, BG, Meric-Bernstam, F, Subbiah, V, Pant, S. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. Journal of Gastrointestinal Cancer 54(4):1308-1315, 2023. e-Pub 2023. PMID: 37119430.
- Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH. The New NCI Precision Medicine Trials. Clin Cancer Res, 2023. e-Pub 2023. PMID: 37531248.
- Phadnis S, Wang X, Daw NC, Herzog CE, Subbiah IM, Zaky W, Gouda MA, Morani AC, Amini B, Harrison DJ, Piha-Paul SA, Meric-Bernstam F, Gorlick R, Schwartz CL, Subbiah V. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open 8(6):101609, 2023. e-Pub 2023. PMID: 37879233.
- Farley C, Bassett R, Meric-Bernstam F, Bedrosian I, Caudle A, DeSnyder S, Hunt K, Kuerer H, Singh P, Sun S, Tamirisa N, Teshome M, Hwang RF. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?. Ann Surg Oncol 30(13):8327-8334, 2023. e-Pub 2023. PMID: 37670121.
- Saridogan T, Akcakanat A, Zhao M, Evans KW, Yuca E, Scott S, Kirby BP, Zheng X, Ha MJ, Chen H, Ng PKS, DiPeri TP, Mills GB, Rodon Ahnert J, Damodaran S, Meric-Bernstam F. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep 13(1):20223, 2023. e-Pub 2023. PMID: 37980453.
- DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Ileana Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res, 2023. e-Pub 2023. PMID: 37279095.
- Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol, 2023. e-Pub 2023. PMID: 37619847.
- Meric-Bernstam F, Calvo E, Lee KS, Moreno V, Park YH, Rha SY, Chalasani P, Zhong W, Zhou L, Pirie-Shepherd S, Leung ACF, Curigliano G. Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study. Mol Cancer Ther 22(10):1191-1203, 2023. e-Pub 2023. PMID: 37420274.
- Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Res 83(19):3264-3283, 2023. e-Pub 2023. PMID: 37384539.
- Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, Johnson ML, Meric-Bernstam F, Tolcher AW, Yamamoto N, Greenberg J, Kawasaki Y, Zebger-Gong H, Kobayashi F, Phillips P, Lisberg AE, Heist RS. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. J Clin Oncol:JCO2300059, 2023. e-Pub 2023. PMID: 37327461.
- Gouda MA, Hu MI, Cabanillas ME, Wu J, Meric-Bernstam F, Subbiah V. Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors. Ann Oncol 34(10):946-948, 2023. e-Pub 2023. PMID: 37473872.
- Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing A. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer 129(17):2685-2693, 2023. e-Pub 2023. PMID: 37129197.
- Repetto M, Crimini E, Belli C, Boscolo Bielo L, Ascione L, Meric-Bernstam F, Drilon A, Curigliano G. A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data. Eur J Cancer 190:112958, 2023. e-Pub 2023. PMID: 37451181.
- Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, Yang F, Akcakanat A, Roberto Estecio M, Tripathy D, Dumbrava EE, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ Breast Cancer 9(1):66, 2023. e-Pub 2023. PMID: 37567892.
- DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther 22(8):976-984, 2023. e-Pub 2023. PMID: 37339271.
- Chelariu-Raicu A, Piha-Paul SA, Chavez-MacGregor M, Johnson J, Sawaya R, McAleer MF, Nguyen A, Hartnett A, Tsimberidou AM, Meric-Bernstam F, Dumbrava EE. Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation. J Immunother Precis Oncol 6(3):158-161, 2023. e-Pub 2023. PMID: 37637237.
- Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer 11(8), 2023. e-Pub 2023. PMID: 37604642.
- Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol, 2023. e-Pub 2023. PMID: 37314501.
- Nze C, Msaouel P, Derbala MH, Stephen B, Abonofal A, Meric-Bernstam F, Tannir NM, Naing A. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568622.
- Johnson A, Ng PK, Kahle M, Castillo J, Amador B, Wang Y, Zeng J, Holla V, Vu T, Su F, Kim SH, Conway T, Jiang X, Chen K, Shaw KRM, Yap TA, Rodon J, Mills GB, Meric-Bernstam F. Actionability classification of variants of unknown significance correlates with functional effect. NPJ Precis Oncol 7(1):67, 2023. e-Pub 2023. PMID: 37454202.
- Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
- Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
- Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med 29(6):1400-1411, 2023. e-Pub 2023. PMID: 37277454.
- Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
- Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, Zheng X, Aldesoky AI, Alhanafy AM, Shehata MA, Wang J, Kopetz S, Meric-Bernstam F, Wistuba II, Luthra R, Janku F. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. Oncologist, 2023. e-Pub 2023. PMID: 36200910.
- Hunt KK, Suman VJ, Wingate HF, Leitch AM, Unzeitig G, Boughey JC, Meric-Bernstam F, Ellis MJ, Olson JA. ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer. Ann Surg Oncol 30(4):2119-2120, 2023. e-Pub 2023. PMID: 36745260.
- Hunt KK, Suman VJ, Wingate HF, Leitch AM, Unzeitig G, Boughey JC, Meric-Bernstam F, Ellis MJ, Olson J. Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. Ann Surg Oncol 30(4):2111-2118, 2023. e-Pub 2023. PMID: 36653664.
- Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol, 2023. e-Pub 2023. PMID: 34789422.
- Meric-Bernstam F, Ford JM, O'Dwyer PJ, Shapiro GI, McShane LM, Freidlin B, O'Cearbhaill RE, George S, Glade Bender J, Lyman GH, Tricoli JV, Patton D, Hamilton SR, Gray RJ, Hawkins DS, Ramineni B, Flaherty KT, Grivas P, Yap TA, Berlin J, Doroshow JH, Harris LN, Moscow JA. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clin Cancer Res, 2023. e-Pub 2023. PMID: 36662819.
- Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol:JCO2200830, 2023. e-Pub 2023. PMID: 36469840.
- Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
- Harding JJ, Piha-Paul SA, Shah RH, Murphy JJ, Cleary JM, Shapiro GI, Quinn DI, Braña I, Moreno V, Borad M, Loi S, Spanggaard I, Park H, Ford JM, Arnedos M, Stemmer SM, de la Fouchardiere C, Fountzilas C, Zhang J, DiPrimeo D, Savin C, Duygu Selcuklu S, Berger MF, Eli LD, Meric-Bernstam F, Jhaveri K, Solit DB, Abou-Alfa GK. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun 14(1):630, 2023. e-Pub 2023. PMID: 36746967.
- Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
- Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA, Investigators FS. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med 388(3):228-239, 2023. e-Pub 2023. PMID: 36652354.
- Leighton J, Hu M, Sei E, Meric-Bernstam F, Navin NE. Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing. Cell Genom 3(1):100215, 2023. e-Pub 2023. PMID: 36777188.
- Rohatgi, N, Rothe, M, Mangat, PK, Garrett-Mayer, E, Meric-Bernstam, F, Pisick, E, Alese, OB, Reynolds, CM, Thota, R, Vaccaro, G, Von Mehren, M, Arend, RC, Chiu, VK, Duvivier, HL, Gold, PJ, Hack, K, Marr, A, Winer, A, Grantham, GN, Hinshaw, DC, Gregory, A, Halabi, S, Schilsky, RL. Nivolumab Plus Ipilimumab in Patients with Solid Tumors with ATM Mutations. JCO Precision Oncology 7, 2023. e-Pub 2023. PMID: 38039429.
- Meric-Bernstam, F, Rothe, M, Mangat, PK, Garrett-Mayer, E, Gutierrez, R, Ahn, E, Cannon, TL, Powell, SF, Krauss, JC, Reynolds, CM, Von Mehren, M, Behl, D, Calfa, C, Duvivier, HL, Kaplan, HG, Livingston, MB, Sharma, MR, Urba, WJ, Grantham, GN, Hinshaw, DC, Gregory, A, Halabi, S, Schilsky, RL. Cobimetinib Plus Vemurafenib in Patients with Solid Tumors with BRAF Mutations. JCO Precision Oncology 7, 2023. e-Pub 2023. PMID: 38096472.
- Moyers JT, Carmagnani Pestana R, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap T, Karp D, Rodon J, Livingston JA, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res, 2023. e-Pub 2023. PMID: 36288393.
- Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
- Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, Friedman CF, Spigel DR, Szado T, Schulze K, Price R, Malato J, Lo AA, Levy J, Wang Y, Yu W, Meric-Bernstam F. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol:JCO2202636, 2023. e-Pub 2023. PMID: 37793085.
- Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Müller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S. Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study. Clin Cancer Res, 2023. e-Pub 2023. PMID: 36282874.
- Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76-82, 2023. e-Pub 2023. PMID: 36423446.
- Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol 23(12):1558-1570, 2022. e-Pub 2022. PMID: 36400106.
- Bose S, Barroso M, Chheda MG, Clevers H, Elez E, Kaochar S, Kopetz SE, Li XN, Meric-Bernstam F, Meyer CA, Mou H, Naegle KM, Pera MF, Perova Z, Politi KA, Raphael BJ, Robson P, Sears RC, Tabernero J, Tuveson DA, Welm AL, Welm BE, Willey CD, Salnikow K, Chuang JH, Shen X. A path to translation: How 3D patient tumor avatars enable next generation precision oncology. Cancer Cell, 2022. e-Pub 2022. PMID: 36270276.
- Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan NL, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. NPJ Breast Cancer 8(1):119, 2022. e-Pub 2022. PMID: 36344517.
- Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol 6(1):78, 2022. e-Pub 2022. PMID: 36302890.
- Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
- Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. European Journal of Cancer 174:S10, 2022. e-Pub 2022.
- Meric-Bernstam, F, Eder, JP, Vandross, A, Gara, M, Gayle, S, Pearson, P, DeCillis, A, Tolcher, AW. CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors. European Journal of Cancer 174:S7-S8, 2022. e-Pub 2022.
- Yap, TA, Ngoi, NY, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Fu, S, Hong, DS, Naing, A, Pant, S, Piha-Paul, SA, Subbiah, V, Tsimberidou, AM, Dufner, D, Rhudy, J, Gore, SD, Ivy, SP, Yuan, Y, Westin, SN, Mills, GB, Meric-Bernstam, F. NCI10329. European Journal of Cancer 174:S7, 2022. e-Pub 2022.
- Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol 6:e2200306, 2022. e-Pub 2022. PMID: 36315917.
- Barber FD, Campbell E, Yamamura Y, Patterson CJ, Hartnett AC, Kinahan H, Miller VA, Brink AL, Poullard A, Urschel GE, Brantley A, Cepeda IG, Goswami P, Charles S, Philip S, Bresser S, Musekiwa-Adjei S, Perez N, Le H, Phillips P, Subbiah V, Meric-Bernstam F, Dumbrava EE. Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience. J Adv Pract Oncol 13(7):664-672, 2022. e-Pub 2022. PMID: 36199491.
- Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep 12(1):14367, 2022. e-Pub 2022. PMID: 35999229.
- Huang L, Wang J, Fang B, Meric-Bernstam F, Roth JA, Ha MJ. CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep 12(1):12984, 2022. e-Pub 2022. PMID: 35906256.
- How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35954359.
- Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol 6:e2100512, 2022. e-Pub 2022. PMID: 35834760.
- Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol 6:e2100547, 2022. e-Pub 2022. PMID: 35862868.
- Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H, Consortium P, Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B, Dean DA, Chuang JH. PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer 4(2):zcac014, 2022. e-Pub 2022. PMID: 35475145.
- LeNoue-Newton ML, Chen SC, Stricker T, Hyman DM, Blauvelt N, Bedard PL, Meric-Bernstam F, Punglia RS, Schrag D, Lepisto EM, Andre F, Smyth L, Dogan S, Yu C, Wathoo C, Levy M, Eli LD, Xu F, Mann G, Lalani AS, Ye F, Micheel CM, Arnedos M. Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE. Clin Cancer Res 28(10):2118-2130, 2022. e-Pub 2022. PMID: 35190802.
- Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, GAMS VD, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial. Clin Cancer Res 28(10):2020-2029, 2022. e-Pub 2022. PMID: 35165101.
- Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, Garber JE, Meric-Bernstam F. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Netw Open 5(5):e2213070, 2022. e-Pub 2022. PMID: 35594047.
- Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. e-Pub 2022. PMID: 35618285.
- Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, Voss MH, Owonikoko TK, Carthon B, Srinivasan R, Bendell JC, Jenkins Y, Whiting SH, Orford K, Bennett MK, Bauer TM. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clin Cancer Res 28(8):1540-1548, 2022. e-Pub 2022. PMID: 35140121.
- Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, Lovly CM, Perlmutter J, Gray SW, Hwang J, Lieu C, André F, Azad N, Borad M, Tafe L, Messersmith H, Robson M, Meric-Bernstam F. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 40(11):1231-1258, 2022. e-Pub 2022. PMID: 35175857.
- Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep 40:100974, 2022. e-Pub 2022. PMID: 35434236.
- Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CR. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res, 2022. e-Pub 2022. PMID: 35443062.
- Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs, 2022. e-Pub 2022. PMID: 34562230.
- Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A, Swanton C. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discov, 2022. e-Pub 2022. PMID: 34876409.
- Li J, Lu H, Ng PK, Pantazi A, Ip CKM, Jeong KJ, Amador B, Tran R, Tsang YH, Yang L, Song X, Dogruluk T, Ren X, Hadjipanayis A, Bristow CA, Lee S, Kucherlapati M, Parfenov M, Tang J, Seth S, Mahadeshwar HS, Mojumdar K, Zeng D, Zhang J, Protopopov A, Seidman JG, Creighton CJ, Lu Y, Sahni N, Shaw KR, Meric-Bernstam F, Futreal A, Chin L, Scott KL, Kucherlapati R, Mills GB, Liang H. A functional genomic approach to actionable gene fusions for precision oncology. Sci Adv 8(6):eabm2382, 2022. e-Pub 2022. PMID: 35138907.
- Thein, KZ, Fu, S, Janku, F, Tsimberidou, AM, Piha-Paul, SA, Karp, DD, Shah, JJ, Milton, D, Gong, J, Sulovic, S, McQuinn, L, Stephen, B, Colen, R, Carter, B, Meric-Bernstam, F, Naing, A. Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors. Journal of Immunotherapy and Precision Oncology 5(1):10-12, 2022. e-Pub 2022. PMID: 35663832.
- Sousa LG, Wang K, Torman D, Binks BJ, Rubin ML, Andersen CR, Lewis WE, Rivera MJ, Kaya D, El-Naggar AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Rodon J, Meric-Bernstam F, Lee JJ, Ferrarotto R. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer, 2022. e-Pub 2022. PMID: 34661906.
- DiPeri TP, Demirhan M, Karp DD, Fu S, Hong DS, Subbiah V, Lim J, Ballester LY, Tayar JH, Suarez-Almazor ME, Javle M, Meric-Bernstam F. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol 5(1):26-30, 2022. e-Pub 2022. PMID: 35663835.
- Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang ML, Fang B. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv, 2022. e-Pub 2022. PMID: 34861697.
- Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, Gouda MA, Raina A, Madwani K, Holley VR, Call SG, Dustin DJ, Lanman RB, Meric-Bernstam F, Raymond VM, Kwong LN, Janku F. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol 6:e2100197, 2022. e-Pub 2022. PMID: 35171660.
- Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma. Hepatology, 2022. e-Pub 2022. PMID: 34510503.
- Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res, 2022. e-Pub 2022. PMID: 34716197.
- Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discov, 2022. e-Pub 2022. PMID: 34551969.
- Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs, 2022. e-Pub 2022. PMID: 34559346.
- Gouda MA, Polivka J, Huang HJ, Treskova I, Pivovarcikova K, Fikrle T, Woznica V, Dustin DJ, Call SG, Meric-Bernstam F, Pesta M, Janku F. Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma. ESMO Open 7(1):100357, 2022. e-Pub 2022. PMID: 34942440.
- Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 6:e2100267, 2022. e-Pub 2022. PMID: 35108036.
- Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer, 2022. e-Pub 2022. PMID: 34362693.
- Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep 12(1):1248, 2022. e-Pub 2022. PMID: 35075200.
- Yao S, Janku F, Koenig K, Tsimberidou AM, Piha-Paul SA, Shi N, Stewart J, Johnston A, Bomalaski J, Meric-Bernstam F, Fu S. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Med 11(2):340-347, 2022. e-Pub 2022. PMID: 34841717.
- Zeng J, Cruz-Pico CX, Saridogan T, Shufean MA, Kahle M, Yang D, Shaw K, Meric-Bernstam F. Natural Language Processing-Assisted Literature Retrieval and Analysis for Combination Therapy in Cancer. JCO Clin Cancer Inform 6:e2100109, 2022. e-Pub 2022. PMID: 34990212.
- Alhalabi O, Altameemi L, Campbell MT, Meric-Bernstam F. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer. Cancer J 28(6):417-422, 2022. e-Pub 2022. PMID: 36383903.
- Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol 10(1):59, 2021. e-Pub 2021. PMID: 34965890.
- Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 385(25):2336-2347, 2021. e-Pub 2021. PMID: 34914339.
- Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, Johnson A, Yap TA, Rodon J, Shaw K, Meric-Bernstam F. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol 5(1):99, 2021. e-Pub 2021. PMID: 34853384.
- Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Di Francesco ME, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple negative breast cancer. Cancer Res, 2021. e-Pub 2021. PMID: 34518211.
- Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol, 2021. e-Pub 2021. PMID: 34247335.
- Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53. Clin Cancer Res, 2021. e-Pub 2021. PMID: 34301750.
- Dumbrava EI, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230, 2021. e-Pub 2021. PMID: 34479035.
- Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol 28(10):5477-5485, 2021. e-Pub 2021. PMID: 34247335.
- Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs 39(5):1357-1365, 2021. e-Pub 2021. PMID: 33909232.
- Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, Shah MH, Ringel MD, Hofmann MC. RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers (Basel) 13(19), 2021. e-Pub 2021. PMID: 34638434.
- Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, Dunphy M, Le MH, Molineaux C, Orford K, Parlati F, Whiting SH, Bennett MK, Tannir NM, Meric-Bernstam F. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clin Cancer Res, 2021. e-Pub 2021. PMID: 34285061.
- Moore KN, Hong DS, Patel MR, Pant S, Ulahannan SV, Jones S, Meric-Bernstam F, Wang JS, Aljumaily R, Hamilton EP, Wittchen ES, Wang X, Lin AB, Bendell JC. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol 16(5):569-589, 2021. e-Pub 2021. PMID: 34559360.
- Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22(9):1290-1300, 2021. e-Pub 2021. PMID: 34339623.
- Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, Consortium NCI, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun 12(1):5086, 2021. e-Pub 2021. PMID: 34429404.
- Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther 38(8):4581-4591, 2021. e-Pub 2021. PMID: 34241781.
- Al-Zubidi, NS, Gombos, DS, Hong, DS, Subbiah, V, Fu, S, Rodon Ahnert, J, Piha-Paul, SA, Tsimberidou, AM, Karp, DD, Meric-Bernstam, F, Naing, A. Overview of Ocular Side Effects of Selinexor. Oncologist 26(7):619-623, 2021. e-Pub 2021. PMID: 33728727.
- Shariati M, Evans KW, Zheng X, Bristow CA, Ng PK, Rizvi YQ, Tapia C, Yang F, Carugo A, Heffernan TP, Peoples MD, Tripathy D, Meric-Bernstam F. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Oncogene 40(26):4425-4439, 2021. e-Pub 2021. PMID: 34108622.
- Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist 26(7):588-596, 2021. e-Pub 2021. PMID: 33783054.
- Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist 26(7):558-e1098, 2021. e-Pub 2021. PMID: 33491277.
- Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol 32(6):817-819, 2021. e-Pub 2021. PMID: 33617938.
- Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res, 2021. e-Pub 2021. PMID: 33637626.
- Akcakanat A, Zheng X, Cruz Pico CX, Kim TB, Chen K, Korkut A, Sahin A, Holla V, Tarco E, Singh G, Damodaran S, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res, 2021. e-Pub 2021. PMID: 33782032.
- Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res, 2021. e-Pub 2021. PMID: 33771853.
- DiPeri TP, Javle MM, Meric-Bernstam F. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol:1-4, 2021. e-Pub 2021. PMID: 33641586.
- Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer 7(1):44, 2021. e-Pub 2021. PMID: 33863913.
- Minussi DC, Nicholson MD, Ye H, Davis A, Wang K, Baker T, Tarabichi M, Sei E, Du H, Rabbani M, Peng C, Hu M, Bai S, Lin YW, Schalck A, Multani A, Ma J, McDonald TO, Casasent A, Barrera A, Chen H, Lim B, Arun B, Meric-Bernstam F, Van Loo P, Michor F, Navin NE. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature 592(7853):302-308, 2021. e-Pub 2021. PMID: 33762732.
- Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol, 2021. e-Pub 2021. PMID: 33011748.
- Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open 6(2):100079, 2021. e-Pub 2021. PMID: 33721621.
- Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol 5(1):21, 2021. e-Pub 2021. PMID: 33742104.
- Hajjar J, Mendoza T, Zhang L, Fu S, Piha-Paul SA, Hong DS, Janku F, Karp DD, Ballhausen A, Gong J, Zarifa A, Peterson CB, Meric-Bernstam F, Jenq R, Naing A. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep 11(1):5847, 2021. e-Pub 2021. PMID: 33712647.
- Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res 23(1):29, 2021. e-Pub 2021. PMID: 33663585.
- Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res, 2021. e-Pub 2021. PMID: 33323389.
- Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clin Cancer Res, 2021. e-Pub 2021. PMID: 33414137.
- Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang H, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. Clin Cancer Res, 2021. e-Pub 2021. PMID: 33115815.
- Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, Hu M, Cabanillas M, Behrang A, Meric-Bernstam F, Vo PTT, Mooers BHM, Wu J. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol, 2021. e-Pub 2021. PMID: 33161056.
- Janku F, Sakamuri D, Kato S, Huang HJ, Call SG, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinner RG, Tsimberidou AM, Hong DS, Meric-Bernstam F. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer, 2021. e-Pub 2021. PMID: 33119140.
- Xu, M, Tapia, C, Hajjar, J, Sabir, SH, Colen, R, Nagarajan, P, Aung, PP, Gong, J, Rodon Ahnert, J, Fu, S, Stephen, B, Roy Chowdhuri, S, Le, H, Yang, V, Zarifa, A, Abdelsalam, ME, Jhingran, A, Javle, M, Pant, S, Carter, B, Milton, D, Sun, R, Karp, DD, Koay, EJ, Yang, Y, Wistuba, II, Hwu, P, Meric-Bernstam, F, Naing, A. Implementation of a novel web-based lesion selection tool to improve acquisition of tumor biopsy specimens. Journal of Immunotherapy and Precision Oncology 4(2):45-52, 2021. e-Pub 2021. PMID: 35663531.
- Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discov, 2021. e-Pub 2021. PMID: 32988960.
- Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, Consortium P, Consortium E. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53(1):86-99, 2021. e-Pub 2021. PMID: 33414553.
- Chen AP, Kummar S, Moore N, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Sims D, O'Sullivan Coyne G, Rosenberger CL, Simpson M, Raghav KPS, Meric-Bernstam F, Leong S, Waqar S, Foster JC, Konaté MM, Das B, Karlovich C, Lih CJ, Polley E, Simon R, Li MC, Piekarz R, Doroshow JH. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 33928209.
- Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 14:3037-3049, 2021. e-Pub 2021. PMID: 33994796.
- Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep 10(1):22087, 2020. e-Pub 2020. PMID: 33328484.
- Naing A, Hajjar J, Gulley JL, Atkins MB, Ciliberto G, Meric-Bernstam F, Hwu P. Strategies for improving the management of immune-related adverse events. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33310772.
- Singh P, Scoggins ME, Sahin AA, Hwang RF, Kuerer HM, Caudle AS, Mittendorf EA, Thompson AM, Bedrosian I, Teshome M, DeSnyder SM, Meric-Bernstam F, Hunt KK. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open 1(2), 2020. e-Pub 2020. PMID: 34017965.
- Seligson ND, Warner JL, Dalton WS, Martin D, Miller RS, Patt D, Kehl KL, Palchuk MB, Alterovitz G, Wiley LK, Huang M, Shen F, Wang Y, Nguyen KA, Wong AF, Meric-Bernstam F, Bernstam EV, Chen JL. Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity. J Am Med Inform Assoc 27(11):1808-1812, 2020. e-Pub 2020. PMID: 32885823.
- Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res 26(21):5579-5587, 2020. e-Pub 2020. PMID: 33055173.
- Subbiah V, Erwin WD, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac HA, Meric-Bernstam F, Hong DS, Pant S, Le DB, Santos E, Gonzalez JF, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase 1 Study of P-cadherin-Targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res, 2020. e-Pub 2020. PMID: 32816889.
- Araya A, Zeng J, Johnson A, Shufean MA, Rodon J, Meric-Bernstam F, Bernstam EV. Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort. Int J Med Inform 143:104261, 2020. e-Pub 2020. PMID: 32889387.
- Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6), 2020. e-Pub 2020. PMID: 33229506.
- Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA, Team N. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst 112(10):1021-1029, 2020. e-Pub 2020. PMID: 31922567.
- Oaknin A, Friedman CF, Roman LD, D'Souza A, Brana I, Bidard FC, Goldman J, Alvarez EA, Boni V, ElNaggar AC, Passalacqua R, Do KTM, Santin AD, Keyvanjah K, Xu F, Eli LD, Lalani AS, Bryce RP, Hyman DM, Meric-Bernstam F, Solit DB, Monk BJ. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecol Oncol, 2020. e-Pub 2020. PMID: 32723675.
- Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. J Thorac Oncol, 2020. e-Pub 2020. PMID: 32540409.
- Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5), 2020. e-Pub 2020. PMID: 33097651.
- Bahleda R, Meric-Bernstam F, Goyal L, Tran B, He Y, Yamamiya I, Benhadji KA, Matos I, Arkenau HT. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol, 2020. e-Pub 2020. PMID: 32622884.
- Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 383(13):1207-1217, 2020. e-Pub 2020. PMID: 32955176.
- Pawlik TM, Tyler DS, Sumer B, Meric-Bernstam F, Okereke IC, Beane JD, Dedhia PH, Ejaz A, McMasters KM, Tanabe KK. COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission. Ann Surg Oncol 27(8):2591-2599, 2020. e-Pub 2020. PMID: 32472408.
- Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN. Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer. Int J Cancer 147(2):413-422, 2020. e-Pub 2020. PMID: 31714586.
- Hong DS, Parikh A, Shapiro GI, Varga A, Naing A, Meric-Bernstam F, Ö A, Reyderman L, Binder TA, Ren M, Liu M, Dayal S, Siu AY, Sachdev P, Xu L, Bhagawati-Prasad V, Tchakov I, Ooi CE, Bao X, Marabelle A. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32554609.
- Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discov 10(5):657-663, 2020. e-Pub 2020. PMID: 32029534.
- Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res 26(8):1924-1931, 2020. e-Pub 2020. PMID: 31852833.
- Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol 38(11):1209-1221, 2020. e-Pub 2020. PMID: 32083997.
- Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hasset MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, André F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM, GENIE Consortium AP. Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discov 10(4):526-535, 2020. e-Pub 2020. PMID: 31924700.
- Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Dumbrava EI, Janku F, Meric-Bernstam F. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget 11(11):969-981, 2020. e-Pub 2020. PMID: 32215185.
- Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 37(3):420, 2020. e-Pub 2020. PMID: 32183953.
- Krishnamurthy S, Sabir S, Ban K, Wu Y, Sheth R, Tam A, Meric-Bernstam F, Shaw K, Mills G, Bassett R, Hamilton S, Hicks M, Gupta S. Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin-Stained Sections of Core-Needle Biopsy Specimens. JAMA Netw Open 3(3):e200476, 2020. e-Pub 2020. PMID: 32134465.
- Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 31(3):412-421, 2020. e-Pub 2020. PMID: 32067683.
- Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
- Makawita S, Meric-Bernstam F. Antibody-Drug Conjugates: Patient and Treatment Selection. Am Soc Clin Oncol Educ Book 40:1-10, 2020. e-Pub 2020. PMID: 32213087.
- Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sørensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg LS, Gonzàlez-Farré X, Cervantes A, Bidard FC, Gorelick AN, Lanman RB, Nagy RJ, Ulaner GA, Chandarlapaty S, Jhaveri K, Gavrila EI, Zimel C, Selcuklu SD, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli LD, Dujka M, Lalani AS, Bryce R, Baselga J, Taylor BS, Solit DB, Meric-Bernstam F, Hyman DM. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discov 10(2):198-213, 2020. e-Pub 2020. PMID: 31806627.
- Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA, Team N. THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN. JNatl Cancer Inst, 2020. e-Pub 2020. PMID: 31922567.
- Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, Andre F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM. Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. Cancer Discov, 2020. e-Pub 2020. PMID: 31924700.
- Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 9:7, 2020. e-Pub 2020. PMID: 32337094.
- Cao J, Hu J, Liu S, Meric-Bernstam F, Abdel-Wahab R, Xu J, Li Q, Yan M, Feng Y, Lin J, Zhao S, Wang J, Kwong LN, Hu J, Carapeto F, Borad MJ, Wang K, Javle M, Zhao H. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 32923885.
- Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang B. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res 10(12):4464-4475, 2020. e-Pub 2020. PMID: 33415011.
- Ulaner GA, Saura C, Piha-Paul SA, Mayer I, Quinn D, Jhaveri K, Stone B, Shahin S, Mann G, Dujka M, Bryce R, Meric-Bernstam F, Solit DB, Hyman DM. Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clin Cancer Res 25(24):7381-7387, 2019. e-Pub 2019. PMID: 31548342.
- Creasy CA, Forget MA, Singh G, Tapia C, Xu M, Stephen B, Sabir S, Meric-Bernstam F, Haymaker C, Bernatchez C, Naing A. Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. Eur J Immunol 49(12):2245-2251, 2019. e-Pub 2019. PMID: 31532833.
- Piha-Paul SA, Taylor MH, Spitz D, Schwartzberg L, Beck JT, Bauer TM, Meric-Bernstam F, Purkayastha D, Karpiak L, Szpakowski S, Braiteh F. Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. Oncotarget 10(60):6526-6535, 2019. e-Pub 2019. PMID: 31741715.
- Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res 25(20):6107-6118, 2019. e-Pub 2019. PMID: 31363003.
- Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 36(4):444-457.e7, 2019. e-Pub 2019. PMID: 31588020.
- Kim SB, Meric-Bernstam F, Kalyan A, Babich A, Liu R, Tanigawa T, Sommer A, Osada M, Reetz F, Laurent D, Wittemer-Rump S, Berlin J. First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Target Oncol 14(5):591-601, 2019. e-Pub 2019. PMID: 31502117.
- Lluch A, González-Angulo AM, Casadevall D, Eterovic AK, Martínez de Dueñas E, Zheng X, Á G, Liu S, Pérez R, Chen K, Chacón JI, Mills GB, Antolín S, Blancas I, López-Serra P, Carrasco E, Caballero R, Prat A, Rojo F, Gonzalez-Perez A, Meric-Bernstam F, Albanell J. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. Eur J Cancer 120:54-64, 2019. e-Pub 2019. PMID: 31491604.
- Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol 92:32-38, 2019. e-Pub 2019. PMID: 31351155.
- Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
- Zeng J, Johnson A, Shufean MA, Kahle M, Yang D, Woodman SE, Vu T, Moorthy S, Holla V, Meric-Bernstam F. Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. JCO Clin Cancer Inform 3:1-12, 2019. e-Pub 2019. PMID: 31550176.
- Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget 10(49):5011-5019, 2019. e-Pub 2019. PMID: 31489111.
- Mandelker D, Donoghue M, Talukdar S, Bandlamudi C, Srinivasan P, Vivek M, Jezdic S, Hanson H, Snape K, Kulkarni A, Hawkes L, Douillard JY, Wallace SE, Rial-Sebbag E, Meric-Bernstam F, George A, Chubb D, Loveday C, Ladanyi M, Berger MF, Taylor BS, Turnbull C. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol 30(8):1221-1231, 2019. e-Pub 2019. PMID: 31050713.
- Avila M, Meric-Bernstam F. Next-generation sequencing for the general cancer patient. Clin Adv Hematol Oncol 17(8):447-454, 2019. e-Pub 2019. PMID: 31449513.
- Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 2019. e-Pub 2019. PMID: 31277699.
- Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
- Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol 20(7):835-851, 2019. e-Pub 2019. PMID: 31160797.
- Zeng J, Shufean MA, Khotskaya Y, Yang D, Kahle M, Johnson A, Holla V, Sánchez N, Mills Shaw KR, Bernstam EV, Meric-Bernstam F. OCTANE: Oncology Clinical Trial Annotation Engine. JCO Clin Cancer Inform 3:1-11, 2019. e-Pub 2019. PMID: 31265323.
- Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer 125(12):2002-2010, 2019. e-Pub 2019. PMID: 30854646.
- Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Mol Cancer Ther 18(6):1149-1157, 2019. e-Pub 2019. PMID: 31015311.
- Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR, Ishii N, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin Chessex A, Zanna C, Flaherty KT, Baselga J. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clin Cancer Res 25(9):2699-2707, 2019. e-Pub 2019. PMID: 30745300.
- Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther 18(5):991-1000, 2019. e-Pub 2019. PMID: 30926639.
- Wang F, Zhang S, Kim TB, Lin YY, Iqbal R, Wang Z, Mohanty V, Sircar K, Karam JA, Wendl MC, Meric-Bernstam F, Weinstein JN, Ding L, Mills GB, Chen K. Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. Nat Methods 16(5):401-404, 2019. e-Pub 2019. PMID: 30988467.
- Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2019. PMID: 30442682.
- Zhang G, Wang Y, Chen B, Guo L, Cao L, Ren C, Wen L, Li K, Jia M, Li C, Mok H, Chen X, Wei G, Lin J, Zhang Z, Hou T, Han-Zhang H, Liu C, Liu H, Liu J, Balch CM, Meric-Bernstam F, Liao N. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. Ann Transl Med 7(8):179, 2019. e-Pub 2019. PMID: 31168460.
- Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 20(4):518-530, 2019. e-Pub 2019. PMID: 30857956.
- You YN, Borras E, Chang K, Price BA, Mork M, Chang GJ, Rodriguez-Bigas MA, Bednarski BK, Meric-Bernstam F, Vilar E. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine. Dis Colon Rectum 62(4):429-437, 2019. e-Pub 2019. PMID: 30730459.
- George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res 21(3):e10348, 2019. e-Pub 2019. PMID: 30869638.
- Tevis SE, Bassett R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol 26(3):815-820, 2019. e-Pub 2019. PMID: 30556120.
- Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC. Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study. Ann Oncol 30(2):325-331, 2019. e-Pub 2019. PMID: 30624546.
- Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. Cancer 125(3):463-472, 2019. e-Pub 2019. PMID: 30383888.
- Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist 24(2):219-228, 2019. e-Pub 2019. PMID: 30108156.
- Fathiamini S, Johnson AM, Zeng J, Holla V, Sanchez NS, Meric-Bernstam F, Bernstam EV, Cohen T. Rapamycin - mTOR + BRAF =? Using Relational Similarity to Find Therapeutically Relevant Drug-Gene Relationships in Unstructured Text. J Biomed Inform 90:103094, 2019. e-Pub 2019. PMID: 30615938.
- Zhao M, Zhuo ML, Zheng X, Su X, Meric-Bernstam F. FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells. Oncotarget 10(1):30-44, 2019. e-Pub 2019. PMID: 30713601.
- Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol, 2019. e-Pub 2019. PMID: 30193295.
- Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K. Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clin Cancer Res 24(24):6594-6610, 2018. e-Pub 2018. PMID: 30181387.
- Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst 110(12):1409-1417, 2018. e-Pub 2018. PMID: 29718453.
- George GC, Buford A, Hess K, Piha-Paul SA, Zinner R, Subbiah V, Hinojosa C, Cleeland CS, Meric-Bernstam F, Bernstam EV, Hong DS. Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clin Cancer Inform 2:1-14, 2018. e-Pub 2018. PMID: 30652565.
- Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
- Akcakanat A, Meric-Bernstam F. MK-2206 window of opportunity study in breast cancer. Ann Transl Med 6(Suppl 1):S57, 2018. e-Pub 2018. PMID: 30613632.
- Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, Prieto VG, Nelson K, Curry JL. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol 45(10):786-790, 2018. e-Pub 2018. PMID: 30021048.
- Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol:JCO1800328, 2018. e-Pub 2018. PMID: 30339520.
- Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget 9(70):33258-33270, 2018. e-Pub 2018. PMID: 30279957.
- Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget 9(69):33232-33243, 2018. e-Pub 2018. PMID: 30237864.
- Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Reply to J.J. Tao et al. J Clin Oncol 36(23):JCO2018786392, 2018. e-Pub 2018. PMID: 29856693.
- Ileana Dumbrava E, Meric-Bernstam F, Yap TA. Challenges with biomarkers in cancer drug discovery and development. Expert Opin Drug Discov 13(8):1-6, 2018. e-Pub 2018. PMID: 29792354.
- Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs 36(4):601-607, 2018. e-Pub 2018. PMID: 29075985.
- Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36(4):638-646, 2018. e-Pub 2018. PMID: 29159766.
- Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res 24(14):3263-3272, 2018. e-Pub 2018. PMID: 29643063.
- Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther 17(7):1595-1601, 2018. e-Pub 2018. PMID: 29654067.
- Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24(12):2719-2731, 2018. e-Pub 2018. PMID: 29420224.
- Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F. Targeted Methylation Sequencing of Plasma Cell-free DNA for Cancer Detection and Classification. Ann Oncol 29(6):1445-1453, 2018. e-Pub 2018. PMID: 29635542.
- Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer 120:137-141, 2018. e-Pub 2018. PMID: 29748008.
- Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs 36(3):416-423, 2018. e-Pub 2018. PMID: 29047029.
- Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 118(11):1419-1424, 2018. e-Pub 2018. PMID: 29695765.
- Slosberg ED, Kang BP, Peguero J, Taylor M, Bauer TM, Berry DA, Braiteh F, Spira A, Meric-Bernstam F, Stein S, Piha-Paul SA, Salvado A. Signature program: a platform of basket trials. Oncotarget 9(30):21383-21395, 2018. e-Pub 2018. PMID: 29765547.
- Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9(28):19891-19899, 2018. e-Pub 2018. PMID: 29731991.
- Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Hucthagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ, Research Network CGA, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell 173(2):355-370.e14, 2018. e-Pub 2018. PMID: 29625052.
- Dumbrava EI, Meric-Bernstam F. Personalized cancer therapy: leveraging a knowledge base for clinical decision-making. Cold Spring Harb Mol Case Stud 4(2), 2018. e-Pub 2018. PMID: 29212833.
- Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer 118(6):763-769, 2018. e-Pub 2018. PMID: 29462132.
- Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33(3):401-416.e8, 2018. e-Pub 2018. PMID: 29533782.
- Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, Soewito S, Minussi DC, Moreno D, Kong K, Dogruluk T, Lu H, Gao J, Tokheim C, Zhou DC, Johnson AM, Zeng J, Ip CKM, Ju Z, Wester M, Yu S, Li Y, Vellano CP, Schultz N, Karchin R, Ding L, Lu Y, Cheung LWT, Chen K, Shaw KR, Meric-Bernstam F, Scott KL, Yi S, Sahni N, Liang H, Mills GB. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33(3):450-462.e10, 2018. e-Pub 2018. PMID: 29533785.
- Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. Physician interpretation of genomic test results and treatment selection. Cancer 124(5):966-972, 2018. e-Pub 2018. PMID: 29165790.
- Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2018. PMID: 29180604.
- Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378(8):731-739, 2018. e-Pub 2018. PMID: 29466156.
- Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol 36(6):536-542, 2018. e-Pub 2018. PMID: 29320312.
- Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554(7691):189-194, 2018. e-Pub 2018. PMID: 29420467.
- Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov 8(2):164-173, 2018. e-Pub 2018. PMID: 29196463.
- Casasent AK, Schalck A, Gao R, Sei E, Long A, Pangburn W, Casasent T, Meric-Bernstam F, Edgerton ME, Navin NE. Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing. Cell 172(1-2):205-217.e12, 2018. e-Pub 2018. PMID: 29307488.
- Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res 24(1):181-188, 2018. e-Pub 2018. PMID: 29051321.
- Fujii T, Matsuda N, Kono M, Harano K, Chen H, Luthra R, Roy-Chowdhuri S, Sahin AA, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT. Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. Eur J Cancer 89:64-71, 2018. e-Pub 2018. PMID: 29232568.
- Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 4:34, 2018. e-Pub 2018. PMID: 30345349.
- Kono M, Fujii T, Matsuda N, Harano K, Chen H, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT. Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. J Cancer 9(19):3640-3646, 2018. e-Pub 2018. PMID: 30310523.
- Wang Z, Ng KS, Chen T, Kim TB, Wang F, Shaw K, Scott KL, Meric-Bernstam F, Mills GB, Chen K. Cancer driver mutation prediction through Bayesian integration of multi-omic data. PLoS One 13(5):e0196939, 2018. e-Pub 2018. PMID: 29738578.
- Eckhardt BL, Gagliardi M, Iles L, Evans K, Ivan C, Liu X, Liu CG, Souza G, Rao A, Meric-Bernstam F, Ueno NT, Bartholomeusz GA. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. PLoS One 13(5):e0195932, 2018. e-Pub 2018. PMID: 29768500.
- Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
- Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. A population of heterogeneous breast cancer patient derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild type tumors. Clin Cancer Res 23(21):6468-6477, 2017. e-Pub 2017. PMID: 29093017.
- Kurnit KC, Bailey AM, Zeng J, Johnson AM, Shufean MA, Brusco L, Litzenburger BC, Sánchez NS, Khotskaya YB, Holla V, Simpson A, Mills GB, Mendelsohn J, Bernstam E, Shaw K, Meric-Bernstam F. "Personalized cancer therapy": A publicly available precision oncology resource. Cancer Res 77(21):e123-e126, 2017. e-Pub 2017. PMID: 29092956.
- Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
- Woo SU, Sangai T, Akcakanat A, Chen H, Wei C, Meric-Bernstam F. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis 6(10):e385, 2017. e-Pub 2017. PMID: 28991258.
- Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah V. Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst 109(10), 2017. e-Pub 2017. PMID: 29117359.
- Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8(50):87163-87173, 2017. e-Pub 2017. PMID: 29152071.
- Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res 23(18):5648-5656, 2017. e-Pub 2017. PMID: 28536309.
- Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res 19(1):93, 2017. e-Pub 2017. PMID: 28810913.
- Gao R, Kim C, Sei E, Foukakis T, Crosetto N, Chan LK, Srinivasan M, Zhang H, Meric-Bernstam F, Navin N. Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. Nat Commun 8(1):228, 2017. e-Pub 2017. PMID: 28794488.
- Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, Razak ARA, Hong DS. Use of expansion cohorts in phase 1 trials and probability of success in phase 2 for 381 anticancer drugs. Clin Cancer Res 23(15):4020-4026, 2017. e-Pub 2017. PMID: 28377482.
- Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA. Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma. Clin Cancer Res 23(15):4027-4034, 2017. e-Pub 2017. PMID: 28377484.
- Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res 23(14):3657-3666, 2017. e-Pub 2017. PMID: 28096270.
- Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8(26):41806-41814, 2017. e-Pub 2017. PMID: 28415679.
- Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24):39254-39267, 2017. e-Pub 2017. PMID: 28424409.
- Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat 163(2):263-272, 2017. e-Pub 2017. PMID: 28243898.
- Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol 28(5):1070-1077, 2017. e-Pub 2017. PMID: 28453704.
- Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017. e-Pub 2017. PMID: 28430579.
- Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509-515, 2017. e-Pub 2017. PMID: 27893038.
- Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High Prevalence of Mutant KRAS in Circulating Exosome-derived DNA from Early Stage Pancreatic Cancer Patients. Ann Oncol 28(4):741-747, 2017. e-Pub 2017. PMID: 28104621.
- Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8), 2017. e-Pub 2017. PMID: 28422758.
- Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clin Cancer Res 23(6):1407-1413, 2017. e-Pub 2017. PMID: 27852698.
- Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 28(3):642-650, 2017. e-Pub 2017. PMID: 27993791.
- FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol 24(3):652-659, 2017. e-Pub 2017. PMID: 27822630.
- Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs 35(1):59-67, 2017. e-Pub 2017. PMID: 27687047.
- Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
- Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35, 2017. e-Pub 2017. PMID: 28428884.
- Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-discharge survival outcomes of patients with advanced cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology 92(1):14-20, 2017. e-Pub 2017. PMID: 27802448.
- Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for molecular profiling and advanced cancer therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol 2017, 2017. e-Pub 2017. PMID: 29082359.
- Daniels M, Wathoo C, Brusco L, Lu KH, Shaw K, Ileana Dumbrava EE, Arun B, Strong L, Litton JK, Eterovic K, Aytac U, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Active disclosure of secondary germline findings to deceased research participants’ personal representatives: Process and outcomes. JCO Precis Oncol 1(1):1-5, 2017. e-Pub 2017.
- Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey A, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Boraddus R, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F. Clinical use of precision oncology decision support. JCO Precis Oncol 1(1):1-12, 2017. e-Pub 2017.
- Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
- Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev 35(4):547-573, 2016. e-Pub 2016. PMID: 28025748.
- Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med 5(12):3437-3444, 2016. e-Pub 2016. PMID: 27882721.
- Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget 7(47):76362-76373, 2016. e-Pub 2016. PMID: 27806348.
- Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE, Buchholz TA, Chavez-Macgregor M, Hunt KK, Meric-Bernstam F, Woodward WA. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys 96(3):637-44, 2016. e-Pub 2016. PMID: 27681760.
- Shen C, Meric-Bernstam F, Su X, Mendelsohn J, Giordano S. Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel. Oncotarget 7(44):71686-71695, 2016. e-Pub 2016. PMID: 27634896.
- Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
- Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep 6:35448, 2016. e-Pub 2016. PMID: 27748430.
- Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin AA, Welm A, Oesterreich S, Sikora MJ, Brown RE, Mills GB. High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype. Clin Cancer Res 22(20):5068-5078, 2016. e-Pub 2016. PMID: 27172895.
- Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget 7(41):67521-67531, 2016. e-Pub 2016. PMID: 27589687.
- Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, Tsai PC, Casasent A, Waters J, Zhang H, Meric-Bernstam F, Michor F, Navin NE. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet 48(10):1119-30, 2016. e-Pub 2016. PMID: 27526321.
- Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget 7(39):64421-64430, 2016. e-Pub 2016. PMID: 27486883.
- Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget 7(34):54627-54631, 2016. e-Pub 2016. PMID: 27421137.
- Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast 28:191-8, 2016. e-Pub 2016. PMID: 27336726.
- Xu J, Lee HJ, Zeng J, Wu Y, Zhang Y, Huang LC, Johnson A, Holla V, Bailey AM, Cohen T, Meric-Bernstam F, Bernstam EV, Xu H. Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov. J Am Med Inform Assoc 23(4):750-7, 2016. e-Pub 2016. PMID: 27013523.
- Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol 78(1):167-71, 2016. e-Pub 2016. PMID: 27286994.
- Fathiamini S, Johnson AM, Zeng J, Araya A, Holla V, Bailey AM, Litzenburger BC, Sanchez NS, Khotskaya Y, Xu H, Meric-Bernstam F, Bernstam EV, Cohen T. Automated identification of molecular effects of drugs (AIMED). J Am Med Inform Assoc 23(4):758-65, 2016. e-Pub 2016. PMID: 27107438.
- Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget 7(23):35132-43, 2016. e-Pub 2016. PMID: 27147567.
- Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
- Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
- Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27(5):795-800, 2016. e-Pub 2016. PMID: 26787237.
- Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol 77(5):973-7, 2016. e-Pub 2016. PMID: 27014780.
- Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin SY. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res 22(7):1699-712, 2016. e-Pub 2016. PMID: 26546619.
- Rogith D, Yusuf RA, Hovick SR, Fellman BM, Peterson SK, Burton-Chase AM, Li Y, Bernstam EV, Meric-Bernstam F. Patient knowledge and information-seeking about personalized cancer therapy. Int J Med Inform 88:52-7, 2016. e-Pub 2016. PMID: 26878762.
- Subbiah V, Hong DS, Meric-Bernstam F. Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. Proc Natl Acad Sci U S A 113(11):E1419-20, 2016. e-Pub 2016. PMID: 26917690.
- Bedrosian I, Xing Y, Abdel Rahman S, Allen L, Le-Petross H, Whitman GJ, Meric-Bernstam F, Hunt KK, Babiera GV, Cormier JN. A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer. Ann Surg Oncol 23(1):23-9, 2016. e-Pub 2016. PMID: 26156655.
- Chen T, Wang Z, Zhou W, Chong Z, Meric-Bernstam F, Mills GB, Chen K. Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics 17 Suppl 2:394, 2016. e-Pub 2016. PMID: 27356755.
- Kim J, de Sampaio PC, Lundy DM, Peng Q, Evans KW, Sugimoto H, Gagea M, Kienast Y, Amaral NSD, Rocha RM, Eikesdal HP, Lonning PE, Meric-Bernstam F, LeBleu VS. Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight 1(21):e90733, 2016. e-Pub 2016.
- Subbiah V, Holmes O, Gowen K, Spritz D, Amini B, Wang WL, Schrock AB, Meric-Bernstam F, Zinner R, Piha-Paul S, Zarzour M, Elvin JA, Erlich RL, Stockman DL, Vergilio JA, Suh JH, Stephens PJ, Miller V, Ross JS, Ali SM. Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology 91(6):348-353, 2016. e-Pub 2016. PMID: 27764830.
- Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience 3(5-6):164-72, 2016. e-Pub 2016. PMID: 27489863.
- Johnson A, Zeng J, Bailey AM, Holla V, Litzenburger B, Lara-Guerra H, Mills GB, Mendelsohn J, Shaw KR, Meric-Bernstam F. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today 20(12):1433-8, 2015. e-Pub 2015. PMID: 26148707.
- Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 2015. e-Pub 2015. PMID: 26486734.
- Zhou W, Chen T, Chong Z, Rohrdanz MA, Melott JM, Wakefield C, Zeng J, Weinstein JN, Meric-Bernstam F, Mills GB, Chen K. TransVar: a multilevel variant annotator for precision genomics. Nat Methods 12(11):1002-3, 2015. e-Pub 2015. PMID: 26513549.
- Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer 15(5):325-31, 2015. e-Pub 2015. PMID: 25913905.
- Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6(29):26886-94, 2015. e-Pub 2015. PMID: 26330075.
- Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-62, 2015. e-Pub 2015. PMID: 26014291.
- Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, Li Y, Do KA, Janku F, Meric-Bernstam F. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget 6(23):19500-13, 2015. e-Pub 2015. PMID: 25944619.
- Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget, 2015. e-Pub 2015. PMID: 26015395.
- Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
- Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 21(11):2644-51, 2015. e-Pub 2015. PMID: 25695693.
- Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer 22(3):431-41, 2015. e-Pub 2015. PMID: 25900182.
- Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. e-Pub 2015. PMID: 25980577.
- Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 2015. e-Pub 2015. PMID: 25973541.
- Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J 21(3):260-7, 2015. e-Pub 2015. PMID: 25789811.
- Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol 26(5):1012-8, 2015. e-Pub 2015. PMID: 25669829.
- Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clin Breast Cancer 15(2):153-60, 2015. e-Pub 2015. PMID: 25454687.
- Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE, Lu X, Lu H, Meric-Bernstam F, Mills GB, Palmer G, Perrier ND, Scott KL, Shaw KR, Waguespack SG, Williams MD, Yelensky R, Cote GJ. RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab 100(3):jc20144153, 2015. e-Pub 2015. PMID: 25546157.
- Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Karina Eterovic A. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
- Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst 107(3), 2015. e-Pub 2015. PMID: 25688104.
- Janku F, Gounder M, Murthy R, Rudin C, Helgason T, Hong D, Benjamin R, Meyer L, Zinner R, Meric-Bernstam F, Masters T, Valley Discoveries CSTB. P1.09Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer. Ann Oncol 26 Suppl 2:ii18, 2015. e-Pub 2015. PMID: 25795828.
- Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 6(5):2604-14, 2015. e-Pub 2015. PMID: 25605252.
- Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF V600: clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2015. PMID: 25148578.
- Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clin Genitourin Cancer 13(1):e19-26, 2015. e-Pub 2015. PMID: 25087088.
- Yusuf RA, Rogith D, Hovick SR, Peterson SK, Burton-Chase AM, Fellman BM, Li Y, McKinney C, Bernstam EV, Meric-Bernstam F. Attitudes toward molecular testing for personalized cancer therapy. Cancer 121(2):243-50, 2015. e-Pub 2015. PMID: 25209923.
- Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O. Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discov 5(1):64-71, 2015. e-Pub 2015. PMID: 25324352.
- Boland GM, Meric-Bernstam F. The role of surgeons in building a personalized medicine program. J Surg Oncol 111(1):3-8, 2015. e-Pub 2015. PMID: 24964977.
- McGuire KP, Hwang ES, Cantor A, Golshan M, Meric-Bernstam F, Horton JK, Nanda R, Amos KD, Forero A, Hudis CA, Meszoely I, De Los Santos JF. Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017. Ann Surg Oncol 22(1):75-81, 2015. e-Pub 2015. PMID: 25059792.
- Zhou W, Zhao H, Chong Z, Mark RJ, Eterovic AK, Meric-Bernstam F, Chen K. ClinSeK: a targeted variant characterization framework for clinical sequencing. Genome Med 7(1):34, 2015. e-Pub 2015. PMID: 25918555.
- Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 15:713, 2015. e-Pub 2015. PMID: 26474549.
- Malhotra A, Wang Y, Waters J, Chen K, Meric-Bernstam F, Hall IM, Navin NE. Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations. Genome Med 7(1):6, 2015. e-Pub 2015. PMID: 25729435.
- Chen G, Zhao J, Cohen T, Tao C, Sun J, Xu H, Bernstam EV, Lawson A, Zeng J, Johnson AM, Holla V, Bailey AM, Lara-Guerra H, Litzenburger B, Meric-Bernstam F, Jim Zheng W. Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature. Database (Oxford) 2015, 2015. e-Pub 2015. PMID: 25858285.
- McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS One 10(9):e0136851, 2015. e-Pub 2015. PMID: 26325287.
- Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clin Cancer Res 20(24):6336-45, 2014. e-Pub 2014. PMID: 25326232.
- de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clin Breast Cancer 14(6):468-74, 2014. e-Pub 2014. PMID: 25065564.
- Tang C, Hess KR, Fontes Jardim DL, De Melo-Gagliato D, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul SA, Subbiah V, Wheler JJ, Zinner RG, Kurzrock R, Ellis LM, Meric-Bernstam F, Hong D. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res, 2014. e-Pub 2014. PMID: 25316815.
- Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Mol Cancer Ther 13(12):3175-84, 2014. e-Pub 2014. PMID: 25253784.
- Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D, Esteva FJ. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget 5(20):9864-76, 2014. e-Pub 2014. PMID: 25296969.
- Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget 5(19):9049-64, 2014. e-Pub 2014. PMID: 24979294.
- Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 18(5):266-70, 2014. e-Pub 2014. PMID: 25205085.
- Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
- Rogith D, Yusuf RA, Hovick SR, Peterson SK, Burton-Chase AM, Li Y, Meric-Bernstam F, Bernstam EV. Attitudes regarding privacy of genomic information in personalized cancer therapy. J Am Med Inform Assoc 21(e2):e320-5, 2014. e-Pub 2014. PMID: 24737606.
- Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget 5(18):8544-57, 2014. e-Pub 2014. PMID: 25261369.
- Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, Navin NE. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512(7513):155-60, 2014. e-Pub 2014. PMID: 25079324.
- Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res 20(14):3870-83, 2014. e-Pub 2014. PMID: 24895461.
- Muranen T, Meric-Bernstam F, Mills GB. Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors. Cancer Cell 26(1):7-9, 2014. e-Pub 2014. PMID: 25026206.
- Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M. Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway. Mol Ther 22(7):1310-9, 2014. e-Pub 2014. PMID: 24569835.
- Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget 5(11):3607-10, 2014. e-Pub 2014. PMID: 25003820.
- Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 25(6):1122-7, 2014. e-Pub 2014. PMID: 24669015.
- Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5(9):2349-54, 2014. e-Pub 2014. PMID: 24811890.
- Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 13(5):1382-9, 2014. e-Pub 2014. PMID: 24608573.
- Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 25(5):1004-11, 2014. e-Pub 2014. PMID: 24562447.
- Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer. Clin Cancer Res 20(7):1757-67, 2014. e-Pub 2014. PMID: 24398047.
- Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361-70, 2014. e-Pub 2014. PMID: 24764583.
- Zhou W, Chen T, Zhao H, Eterovic AK, Meric-Bernstam F, Mills GB, Chen K. Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics, 2014. e-Pub 2014. PMID: 24389657.
- Bailey AM, Mao Y, Zeng J, Holla V, Johnson A, Brusco L, Chen K, Mendelsohn J, Routbort MJ, Mills GB, Meric-Bernstam F. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med 17(92):101-14, 2014. e-Pub 2014. PMID: 24534473.
- Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 23(2):316-23, 2014. e-Pub 2014. PMID: 24296856.
- Caudle AS, Yi M, Hoffman KE, Mittendorf EA, Babiera GV, Hwang RF, Meric-Bernstam F, Sahin AA, Hunt KK. Impact of Identification of Internal Mammary Sentinel Lymph Node Metastasis in Breast Cancer Patients. Ann Surg Oncol 21(1):60-5, 2014. e-Pub 2014. PMID: 24046126.
- Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS One 9(2):e89388, 2014. e-Pub 2014. PMID: 24586741.
- Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB. A pan-cancer proteomic perspective on the Cancer Genome Atlas. Nat Commun 5:3887, 2014. e-Pub 2014. PMID: 24871328.
- Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9(12):e115383, 2014. e-Pub 2014. PMID: 25536104.
- Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol 7:52, 2014. e-Pub 2014. PMID: 25085632.
- Meric-Bernstam F, Rasmussen JC, Krishnamurthy S, Tan IC, Zhu B, Wagner JL, Babiera GV, Mittendorf EA, Sevick-Muraca EM. Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents. Biomed Opt Express 5(1):183-96, 2013. e-Pub 2013. PMID: 24466486.
- Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK, Group investigators ACOSO. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 14(13):1317-25, 2013. e-Pub 2013. PMID: 24239210.
- Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM. Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma in Situ Treated with Mastectomy: Is Further Therapy Warranted?. Ann Surg Oncol 20(13):4103-12, 2013. e-Pub 2013. PMID: 23975313.
- Hassan B, Bernstam E, Hines OJ, Simeone DM, Weber SM, Geller DA, Evers BM, Meric-Bernstam F. Career track of Society of University Surgeons Resident Research Award recipients. J Surg Res 185(1):92-6, 2013. e-Pub 2013. PMID: 23751805.
- Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clin Cancer Res 19(19):5474-5484, 2013. e-Pub 2013. PMID: 24089446.
- Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clin Cancer Res 19(19):5533-5540, 2013. e-Pub 2013. PMID: 23948975.
- Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR Signaling Pathway. Surg Oncol Clin N Am 22(4):641-64, 2013. e-Pub 2013. PMID: 24012393.
- Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol 24(10):2522-6, 2013. e-Pub 2013. PMID: 23925999.
- Yao JC, Meric-Bernstam F, Lee JJ, Eckhardt SG. Accelerated approval and breakthrough therapy designation: oncology drug development on speed?. Clin Cancer Res 19(16):4305-8, 2013. e-Pub 2013. PMID: 23833307.
- Chae YK, Hu MI, Katz RL, Chavez-Macgregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 31(23):e398-400, 2013. e-Pub 2013. PMID: 23796991.
- Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, Zhang J, Thompson EJ, Network T, Meric-Bernstam F, Medeiros LJ, Weinstein JN, Su X. Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq. J Virol 87(16):8916-26, 2013. e-Pub 2013. PMID: 23740984.
- Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 2013. e-Pub 2013. PMID: 23562929.
- Blanco E, Sangai T, Hsiao A, Ferrati S, Bai L, Liu X, Meric-Bernstam F, Ferrari M. Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett 334(2):245-52, 2013. e-Pub 2013. PMID: 22858582.
- Lang JE, Tereffe W, Mitchell MP, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Hortobagyi GN, Babiera GV. Primary Tumor Extirpation in Breast Cancer Patients who Present with Stage IV Disease Is Associated with Improved Survival. Ann Surg Oncol 20(6):1893-9, 2013. e-Pub 2013. PMID: 23306905.
- De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. Cancer 119(10):1776-83, 2013. e-Pub 2013. PMID: 23436342.
- Yi M, Cormier JN, Xing Y, Giordano SH, Chai C, Meric-Bernstam F, Vlastos G, Kuerer HM, Mirza NQ, Buchholz TA, Hunt KK. Other Primary Malignancies in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy. Ann Surg Oncol 20(5):1514-21, 2013. e-Pub 2013. PMID: 23224829.
- Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. Building a Personalized Medicine Infrastructure at a Major Cancer Center. J Clin Oncol 31(15):1849-57, 2013. e-Pub 2013. PMID: 23589548.
- Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol 24(4):909-16, 2013. e-Pub 2013. PMID: 23139263.
- Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res 73(5):1449-53, 2013. e-Pub 2013. PMID: 23436795.
- Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg 257(2):173-9, 2013. e-Pub 2013. PMID: 23291658.
- Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 2013. e-Pub 2013. PMID: 22736407.
- Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 137(1):319-27, 2013. e-Pub 2013. PMID: 23208590.
- Yi M, Kuerer HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I, Meric-Bernstam F, Wagner JL, Hunt KK. Impact of the American College of Surgeons Oncology Group Z0011 Criteria Applied to a Contemporary Patient Population. J Am Coll Surg 216(1):105-13, 2013. e-Pub 2013. PMID: 23122536.
- Farhangfar CJ, Meric-Bernstam F, Mendelsohn J, Mills GB, Lucio-Eterovic AK. The impact of tumor heterogeneity on patient treatment decisions. Clin Chem 59(1):38-40, 2013. e-Pub 2013. PMID: 23143327.
- Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated Breast Cancers. Breast J 19(1):87-91, 2013. e-Pub 2013. PMID: 23231005.
- Takiar V, Strom EA, Baumann DP, Meric-Bernstam F, Alvarez RH, Gonzalez-Angulo AM. Locoregional Interaction of Ixabepilone (Ixempra) After Breast Cancer Radiation. Oncologist 18(3):265-70, 2013. e-Pub 2013. PMID: 23404814.
- Skinner HD, Strom EA, Motwani SB, Woodward WA, Green MC, Babiera G, Booser DJ, Meric-Bernstam F, Buchholz TA. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol 8:13, 2013. e-Pub 2013. PMID: 23311297.
- Mao Y, Chen H, Liang H, Meric-Bernstam F, Mills GB, Chen K. CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. PLoS One 8(10):e77945, 2013. e-Pub 2013. PMID: 24205039.
- Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I, Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer 118(24):6287-96, 2012. e-Pub 2012. PMID: 22648744.
- Lynch SP, Lei X, Chavez-Macgregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063-9, 2012. e-Pub 2012. PMID: 22776706.
- Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Ann Surg Oncol 19(12):3777-84, 2012. e-Pub 2012. PMID: 22622473.
- Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer 118(20):4936-43, 2012. e-Pub 2012. PMID: 22511276.
- Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer. Clin Cancer Res 18(20):5816-28, 2012. e-Pub 2012. PMID: 22932669.
- Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo AM. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 14(5):R138, 2012. e-Pub 2012. PMID: 23102376.
- Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Ann Surg Oncol 19(10):3144-51, 2012. e-Pub 2012. PMID: 22847123.
- Su X, Zhang L, Zhang J, Meric-Bernstam F, Weinstein JN. PurityEst: estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics 28(17):2265-6, 2012. e-Pub 2012. PMID: 22743227.
- Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 9(9):542-8, 2012. e-Pub 2012. PMID: 22850751.
- Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID: 22392043.
- Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-93, 2012. e-Pub 2012. PMID: 21953213.
- Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 2012. e-Pub 2012. PMID: 22621334.
- Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151(5):710-6, 2012. e-Pub 2012. PMID: 22285778.
- Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res 14(3):R82, 2012. e-Pub 2012. PMID: 22621306.
- Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
- Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, Bedrosian I, Crosby MA, Baumann DP, Ross MI, Feig BW, Krishnamurthy S, Hernandez M, Babiera GV. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol 19(4):1137-44, 2012. e-Pub 2012. PMID: 21979111.
- Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2012. PMID: 21837669.
- Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. e-Pub 2012. PMID: 22009639.
- Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18(6):1777-89, 2012. e-Pub 2012. PMID: 22422409.
- Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202-11, 2012. e-Pub 2012. PMID: 21800293.
- Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 19(3):901-7, 2012. e-Pub 2012. PMID: 21861223.
- Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol 30(6):600-7, 2012. e-Pub 2012. PMID: 22253459.
- Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 18(4):1109-19, 2012. e-Pub 2012. PMID: 22235097.
- Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 2012. e-Pub 2012. PMID: 21913181.
- Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Hwang RF. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 255(1):109-15, 2012. e-Pub 2012. PMID: 22167004.
- Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst 103(24):1871-83, 2011. e-Pub 2011. PMID: 22034635.
- Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 2011. e-Pub 2011. PMID: 21830012.
- Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17(20):6582-91, 2011. e-Pub 2011. PMID: 21831956.
- Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 29(28):3739-46, 2011. e-Pub 2011. PMID: 21900106.
- Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11(5):325-31, 2011. e-Pub 2011. PMID: 21764391.
- Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 18(11):3164-73, 2011. e-Pub 2011. PMID: 21947595.
- Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 20(3):341-56, 2011. e-Pub 2011. PMID: 21907925.
- Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
- Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 2011. e-Pub 2011. PMID: 21606433.
- Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645-52, 2011. e-Pub 2011. PMID: 21632501.
- Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg 254(1):119-24, 2011. e-Pub 2011. PMID: 21494124.
- Feldman S, Krishnamurthy S, Gillanders W, Gittleman M, Beitsch PD, Young PR, Streck CJ, Whitworth PW, Levine EA, Boolbol S, Han LK, Hermann R, Hoon DS, Giuliano AE, Meric-Bernstam F, Group US. A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer 117(12):2599-607, 2011. e-Pub 2011. PMID: 21226034.
- Langsner RJ, Middleton LP, Sun J, Meric-Bernstam F, Hunt KK, Drezek RA, Yu TK. Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue. Biomed Opt Express 2(6):1514-23, 2011. e-Pub 2011. PMID: 21698015.
- Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6):1093-101, 2011. e-Pub 2011. PMID: 21490305.
- Yi M, Kronowitz SJ, Meric-Bernstam F, Feig BW, Symmans WF, Lucci A, Ross MI, Babiera GV, Kuerer HM, Hunt KK. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer 117(5):916-24, 2011. e-Pub 2011. PMID: 20945319.
- Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 253(3):572-9, 2011. e-Pub 2011. PMID: 21209588.
- Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 2011. e-Pub 2011. PMID: 21233401.
- Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 17(2):210-2, 2011. e-Pub 2011. PMID: 21294809.
- Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-47, 2011. e-Pub 2011. PMID: 20740500.
- Singh G, Akcakanat A, Sharma C, Luyimbazi D, Naff KA, Meric-Bernstam F. The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer 63(2):264-71, 2011. e-Pub 2011. PMID: 21294052.
- Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer 10(6):477-82, 2010. e-Pub 2010. PMID: 21147692.
- Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated Tumor Cells in Biologic Subtypes of Stage I-III Breast Cancer Patients. Ann Surg Oncol 17(12):3252-8, 2010. e-Pub 2010. PMID: 20559739.
- Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 6(4):129-51, 2010. e-Pub 2010. PMID: 21691416.
- McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis. Clin Breast Cancer 10:S59-65, 2010. e-Pub 2010. PMID: 21115423.
- Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. Ann Surg Oncol, 2010. e-Pub 2010. PMID: 21061075.
- Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899-908, 2010. e-Pub 2010. PMID: 20443145.
- Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 17(Suppl 3):343-51, 2010. e-Pub 2010. PMID: 20853057.
- Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. Mol Cancer Ther 9(10):2770-84, 2010. e-Pub 2010. PMID: 20876744.
- Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer?. Ann Surg Oncol 17(Suppl 3):280-5, 2010. e-Pub 2010. PMID: 20853047.
- Woodward WA, Truong PT, Yu TK, Tereffe W, Oh J, Perkins G, Strom E, Meric-Bernstam F, Gonzalez-Angulo AM, Speers C, Ragaz J, Buchholz TA. Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat 123(2):597-605, 2010. e-Pub 2010. PMID: 20306128.
- Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 3(8):1026-34, 2010. e-Pub 2010. PMID: 20647335.
- Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 116(12):2884-9, 2010. e-Pub 2010. PMID: 20564395.
- Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC, Ching CD, Gilcrease MZ. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116(12):2878-83, 2010. e-Pub 2010. PMID: 20564394.
- Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A Phase I Study to Assess the Feasibility and Oncologic Safety of Axillary Reverse Mapping in Breast Cancer Patients. Cancer 116(11):2543-8, 2010. e-Pub 2010. PMID: 20336790.
- Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. J Clin Oncol 28(11):1821-8, 2010. e-Pub 2010. PMID: 20231683.
- Fearmonti RM, Gayed IW, Kim E, Bedrosian I, Hunt KK, Meric-Bernstam F, Feig B, Ghonimi E, Warneke C, Babiera GV. Intra-Individual Comparison of Lymphatic Drainage Patterns Using Subareolar and Peritumoral Isotope Injection for Breast Cancer. Ann Surg Oncol 17(1):220-7, 2010. e-Pub 2010. PMID: 19680729.
- Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-14, 2010. e-Pub 2010. PMID: 19241157.
- Rosbach KJ, Shin D, Muldoon TJ, Quraishi MA, Middleton LP, Hunt KK, Meric-Bernstam F, Yu TK, Richards-Kortum RR, Yang W. High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study. Biomed Opt Express 1(3):911-922, 2010. e-Pub 2010. PMID: 21258518.
- Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381-8, 2009. e-Pub 2009. PMID: 19920100.
- Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700-6, 2009. e-Pub 2009. PMID: 19884543.
- Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953-8, 2009. e-Pub 2009. PMID: 19596702.
- Boughey JC, Goravanchi F, Parris RN, Kee SS, Kowalski AM, Frenzel JC, Bedrosian I, Meric-Bernstam F, Hunt KK, Ames FC, Kuerer HM, Lucci A. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg 198(5):720-5, 2009. e-Pub 2009. PMID: 19427625.
- Fearmonti RM, Batista LI, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Eva Singletary S, Babiera GV. False Negative Rate of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Breast Cancers May be Higher in Cases with Large Additive Tumor Burden. Breast J 15(6):645-8, 2009. e-Pub 2009. PMID: 19735388.
- Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients. Ann Surg, 2009. e-Pub 2009. PMID: 19730235.
- Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117(1):61-8, 2009. e-Pub 2009. PMID: 18663571.
- Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg 198(3):387-91, 2009. e-Pub 2009. PMID: 19362281.
- Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297-302, 2009. e-Pub 2009. PMID: 19487376.
- Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20(6):1013-9, 2009. e-Pub 2009. PMID: 19237480.
- Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol 16(6):1606-11, 2009. e-Pub 2009. PMID: 19280264.
- Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther, 2009. e-Pub 2009. PMID: 19417153.
- Litton JK, Westin SK, Ready K, Sun CC, Peterson S, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu K, Hortobagyi GN, Arun BK. Perception of screening and risk-reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. e-Pub 2009. PMID: 19280625.
- Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304-14, 2009. e-Pub 2009. PMID: 19345329.
- Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera GV, Ames FC, Feig BW, Ross MI, Singletary SE, Hunt KK, Bedrosian I. A prospective study comparing touch imprint cytology, frozen section analysis and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 115(7):1361-2, 2009. e-Pub 2009. PMID: 19195040.
- Yim EK, Dai H, Li K, Mills GB, Meric-Bernstam F, Lin SY. Essential Role of Rak in PTEN Protein Stability and Tumor Suppression. Cancer Cell 15:304-314, 2009. e-Pub 2009.
- Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Hsu L, Meric-Bernstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PI3KCA mutations and prognosis in breast cancer. Clin Can Res 15(7):2472-8, 2009. e-Pub 2009. PMID: 19276248.
- Beadle BM, Woodward WA, Middleton LP, Tereffe W, Strom EA, Litton JK, Meric-Bernstam F, Theriault RL, Buchholz TA, Perkins GH. The impact of pregnancy on breast cancer outcomes in women
- Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu TK, Meric-Bernstam F, Litton JK, Buchholz TA. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73(3):734-44, 2009. e-Pub 2009. PMID: 18707822.
- Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 115(5):962-71, 2009. e-Pub 2009. PMID: 19172584.
- Kim D, Akcakanat A, Singh G, Sharma C, Meric-Bernstam F. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors 27(1):12-21, 2009. e-Pub 2009. PMID: 19085255.
- Arun B, Vogel K, Lopez A, Hernandez M, Atchley D, Broglio K, Amos CI, Meric-Bernstam F, Kuerer HM, Hortobagyi GN, Albarracin C. High Prevalence of Pre-invasive lesions adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prev Res (Phila Pa) 2(2):122-7, 2009. e-Pub 2009. PMID: 19174581.
- Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 113(3):501-7, 2009. e-Pub 2009. PMID: 18327638.
- Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin CT, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. J Clin Oncol 27(2):220-6, 2009. e-Pub 2009. PMID: 19047281.
- Dong J, Akcakanat A, Stivers DN, Zhang J, Kim D, Meric-Bernstam F. RNA-Binding Specificity of Y-Box Protein 1. RNA Biol 6(1):59-64, 2009. e-Pub 2009. PMID: 19098458.
- Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer 8(1):75, 2009. e-Pub 2009. PMID: 19778445.
- Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, Babiera GV, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early stage breast cancer patients. Ann Surg Oncol 15(12):3369-77, 2008. e-Pub 2008. PMID: 18815841.
- Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study. J Clin Oncol 26(26):4311-8, 2008. e-Pub 2008. PMID: 18779618.
- Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Can Ther 7(7):1872-8, 2008. e-Pub 2008. PMID: 18644990.
- Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF, Hunt KK. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 196(1):81-7, 2008. e-Pub 2008. PMID: 18436181.
- Buchholz TA, Woodward WA, Duan Z, Fang S, Oh JL, Tereffe W, Strom EA, Perkins GH, Yu TK, Hunt KK, Meric-Bernstam F, Hortobagyi GN, Giordano SH. Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 71(4):1022-7, 2008. e-Pub 2008. PMID: 18234447.
- Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, Wang LE. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged less than 55 years. Breast Cancer Res Treat 110(2):357-66, 2008. e-Pub 2008. PMID: 17851762.
- Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. Cancer 113(1):30-7, 2008. e-Pub 2008. PMID: 18457326.
- Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F. Comparison of Akt / mTOR signaling in Primary Breast Tumors and Matched Distant Metastases. Cancer 112(11):2352-2358, 2008. e-Pub 2008. PMID: 18386830.
- Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Gonzalez-Angulo AM. Prognostic significance of HER2 Status in Women with Inflammatory Breast Cancer. Cancer 112(9):1905-11, 2008. e-Pub 2008. PMID: 18300243.
- Jeruss JS, Newman LA, Ayers GD, Cristofanilli M, Broglio KR, Meric-Bernstam F, Yi M, Waljee JF, Ross MI, Hunt KK. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer 122(12):2646-54, 2008. e-Pub 2008. PMID: 18442039.
- Batista LI, Lu KH, Beahm EK, Arun BK, Bodurka DC, Meric-Bernstam F. Coordinated Prophylactic Surgical Management for Women with Hereditary Breast-Ovarian Cancer Syndrome. BMC Cancer 8:101, 2008. e-Pub 2008. PMID: 18410690.
- Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor Activity of Rapamycin and Octreotide as Single Agents or in Combination in Neuroendocrine Tumors. Endocr Relat Cancer 15(1):257-266, 2008. e-Pub 2008. PMID: 18310292.
- Bernstam EV, Walji MF, Sagaram S, Sagaram D, Johnson CW, Meric-Bernstam F. Commonly cited Web site quality criteria are not effective at identifying inaccurate online information about breast cancer. Cancer 112(6):1206-13, 2008. e-Pub 2008. PMID: 18266210.
- Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13(1):6-15, 2008. e-Pub 2008. PMID: 18245008.
- Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Yang W, Albarracin C, Meric F, Hortobagyi G, Theriault R. Development of new cancers in patients with DCIS: The M. D. Anderson experience. Ann Surg Oncol 15(1):244-9, 2008. e-Pub 2008. PMID: 18043978.
- Garg AK, Oh JL, Oswald MJ, Huang E, Strom EA, Perkins GH, Woodward WA, Yu TK, Tereffe W, Meric-Bernstam F, Hahn K, Buchholz TA. Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy. Int J Radiat Oncol Biol Phys 69(5):1478-83, 2007. e-Pub 2007. PMID: 17855016.
- Boughey JC, Cormier JN, Xing Y, Hunt KK, Meric-Bernstam F, Babiera GV, Ross MI, Kuerer HM, Singletary SE, Bedrosian I. Decision Analysis to Assess the Efficacy of Routine Sentinel Lymphadenectomy in Patients Undergoing Prophylactic Mastectomy. Cancer 110(11):2542-50, 2007. e-Pub 2007. PMID: 17932905.
- Meric-Bernstam F, Walji M, Sagaram S, Sagaram D, Bernstam E. Currency of online breast cancer information. MedInfo 12(Pt 2):973-6, 2007. e-Pub 2007. PMID: 17911860.
- Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, Perkins GH, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Akins JS, Hunt KK. Long-Term Outcomes in patients with mucinous, medullary, tubular and invasive ductal carcinomas after lumpectomy. Am J Surg 194(4):527-31, 2007. e-Pub 2007. PMID: 17826073.
- Akcakanat A, Singh G, Hung MC, Meric-Bernstam F. Rapamycin Regulates the Phosphorylation of Rictor. Biochem Biophys Res Commun 362(2):330-3, 2007. e-Pub 2007. PMID: 17707343.
- Williams SA, Ehlers RA, Hunt KK, Yi M, Kuerer HM, Singletary SE, Ross MI, Feig BW, Symmans WF, Meric-Bernstam F. Metastases to the Breast from Non-breast solid neoplasms: Presentation and Determinants of Survival. Cancer 110(4):731-7, 2007. e-Pub 2007. PMID: 17582626.
- Gonzalez-Angulo AM, Hennessey BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Singletary SE, Buzdar AU, Hortobagyi GN. Trends for inflammatory breast cancer: Is survival improving?. Oncologist 12(8):904-12, 2007. e-Pub 2007. PMID: 17766649.
- Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, Babiera GV, Tereffe W, Liu DD, Hunt KK. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 110(4):723-30, 2007. e-Pub 2007. PMID: 17587208.
- Mazouni C, Peintinger F, Kau SW, Andre F, Gonzalez-Angulo A, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25(19):2650-5, 2007. e-Pub 2007. PMID: 17602071.
- Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy following preoperative chemotherapy in breast cancer patients with documented axillary metastasis. Cancer 109(7):1255-63, 2007. e-Pub 2007.
- Cabioglu N, Hunt KK, Sahin AA, Kuerer HM, Babiera GV, Singletary SE, Whitman GJ, Ross ML, Ames FC, Feig BW, Buchholz TA, Meric-Bernstam F. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol 14(4):1458-71, 2007. e-Pub 2007. PMID: 17260108.
- Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107(12):2745-51, 2006. e-Pub 2006. PMID: 17109443.
- Lu J, Wei Q, Bondy ML, Li D, Brewster A, Shete S, Yu TK, Sahin A, Meric-Bernstam F, Hunt KK, Singletary SE, Ross MI, Wang LE. Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women
- Jeruss JS, Hunt KK, Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, Ross MI, Cormier JN. Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?. Cancer 107(10):2328-36, 2006. e-Pub 2006. PMID: 17039501.
- Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 13(11):1443-9, 2006. e-Pub 2006. PMID: 17028770.
- Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, Shete S, Sahin A, Meric-Bernstam F, Wang LE. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107(9):2245-53, 2006. e-Pub 2006. PMID: 17063466.
- Rosenkranz KM, Bedrosian I, Feng L, Hunt KK, Hartman K, Lucci A, Meric-Bernstam F, Kuerer HM, Singletary ES, Hwang R, Feig B, Ross M, Ames F, Babiera GV. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg 192(4):541-4, 2006. e-Pub 2006. PMID: 16978971.
- Vo TN, Meric-Bernstam F, Yi M, Buchholz TA, Ames FC, Kuerer HM, Bedrosian I, Hunt KK. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 192(4):552-5, 2006. e-Pub 2006. PMID: 16978974.
- Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, Giordano SH, Babiera GV, Ames FC, Hunt KK. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 203(4):475-80, 2006. e-Pub 2006. PMID: 17000390.
- Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 66(2):352-7, 2006. e-Pub 2006. PMID: 16887286.
- Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 244(3):464-70, 2006. e-Pub 2006. PMID: 16926572.
- Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 66(1):76-82, 2006. e-Pub 2006. PMID: 16765534.
- Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7):1440-7, 2006. e-Pub 2006. PMID: 16955504.
- Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 10(2):145-57, 2006. e-Pub 2006. PMID: 16872911.
- Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 107(6):1248-1254, 2006. e-Pub 2006. PMID: 16862596.
- Kawase K, Gayed IW, Hunt KK, Kuerer HM, Akins J, Yi M, Grimes L, Babiera GV, Ross MI, Feig BW, Ames FC, Singletary SE, Buchholz TA, Symmans WF, Meric-Bernstam F. Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg 203(1):64-72, 2006. e-Pub 2006. PMID: 16798488.
- Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK, Ross MI, Gwyn KM, Feig BW, Ames FC, Hortobagyi GN. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 13(6):776-82, 2006. e-Pub 2006. PMID: 16614878.
- Esquivel A, Meric-Bernstam F, Bernstam EV. Accuracy and self correction of information received from an internet breast cancer list: content analysis. BMJ 332(7547):939-42, 2006. e-Pub 2006. PMID: 16513686.
- Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7):1037-44, 2006. e-Pub 2006. PMID: 16505422.
- Lambert LA, Ayers GD, Hwang RF, Hunt KK, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Ames FC, Feig B, Lucci A, Krishnamurthy S, Meric-Bernstam F. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 13(3):310-20, 2006. e-Pub 2006. PMID: 16463073.
- Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243(2):257-64, 2006. e-Pub 2006. PMID: 16432360.
- Andtbacka RH, Babiera G, Singletary SE, Hunt KK, Meric-Bernstam F, Feig BW, Ames FC, Ross MI, Dejesus Y, Kuerer HM. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 243(1):96-101, 2006. e-Pub 2006. PMID: 16371742.
- Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42-50, 2006. e-Pub 2006. PMID: 16333852.
- Al-Refaie W, Kuerer HM, Khuwaja A, Perry A, Hunt KK, Feig B, Ames F, Ross M, Singletary SE, Meric-Bernstam F, Babiera GV. Determinants of mastectomy in breast conservation therapy candidates. Am J Surg 190(4):602-5, 2005. e-Pub 2005. PMID: 16164931.
- Schechter NR, Strom EA, Perkins GH, Arzu I, McNeese MD, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Babiera G, Hunt KK, Hortobagyi GN, Buchholz TA. Immediate breast reconstruction can impact postmastectomy irradiation. Am J Clin Oncol 28(5):485-94, 2005. e-Pub 2005. PMID: 16199989.
- Khakpour N, Hunt KK, Kuerer HM, Yi M, Meric-Bernstam F, Ross MI, Lucci A. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. Am J Surg 190(4):598-601, 2005. e-Pub 2005. PMID: 16164930.
- Walji M, Sagaram S, Meric-Bernstam F, Johnson CW, Bernstam EV. Searching for cancer-related information online: unintended retrieval of complementary and alternative medicine information. Int J Med Inform 74(7-8):685-93, 2005. e-Pub 2005. PMID: 16027034.
- Raut CP, Hunt KK, Akins JS, Daley MD, Ross MI, Singletary SE, Marshall GD, Jr, Meric-Bernstam F, Babiera G, Feig BW, Ames FC, Kuerer HM. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer 104(4):692-9, 2005. e-Pub 2005. PMID: 15981283.
- Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer 104(3):479-90, 2005. e-Pub 2005. PMID: 15968686.
- Bernstam EV, Sagaram S, Walji M, Johnson CW, Meric-Bernstam F. Usability of quality measures for online health information: Can commonly used technical quality criteria be reliably assessed?. Int J Med Inform 74(7-8):675-83, 2005. e-Pub 2005. PMID: 16043090.
- Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, Babiera GV, Ames FC, Sahin AA, Meric-Bernstam F. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer 104(1):20-9, 2005. e-Pub 2005. PMID: 15912514.
- Kawase K, Dimaio DJ, Tucker SL, Buchholz TA, Ross MI, Feig BW, Kuerer HM, Meric-Bernstam F, Babiera G, Ames FC, Singletary SE, Hunt KK. Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol 12(5):391-7, 2005. e-Pub 2005. PMID: 15915373.
- Shahar KH, Buchholz TA, Delpassand E, Sahin AA, Ross MI, Ames FC, Kuerer HM, Feig BW, Meric-Bernstam F, Babiera GV, Singletary SE, Akins JS, Mirza NQ, Hunt KK. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer 103(7):1323-9, 2005. e-Pub 2005. PMID: 15726547.
- Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, Ames FC, Kuerer HM. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200(4):516-26, 2005. e-Pub 2005. PMID: 15804465.
- Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 65(5):1961-72, 2005. e-Pub 2005. PMID: 15753396.
- Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Babiera G, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy. Cancer 103(4):689-95, 2005. e-Pub 2005. PMID: 15641036.
- Babiera GV, Delpassand ES, Breslin TM, Ross MI, Ames FC, Singletary SE, Kuerer HM, Feig BW, Meric-Bernstam F, Hunt KK. Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy. Clin Nucl Med 30(1):11-5, 2005. e-Pub 2005. PMID: 15604959.
- Bernstam EV, Shelton DM, Walji M, Meric-Bernstam F. Instruments to assess the quality of health information on the World Wide Web: what can our patients actually use?. Int J Med Inform 74(1):13-9, 2005. e-Pub 2005. PMID: 15626632.
- Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-86, 2004. e-Pub 2004. PMID: 15389473.
- Tseng JF, Kronowitz SJ, Sun CC, Perry AC, Hunt KK, Babiera GV, Newman LA, Singletary SE, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer 101(7):1514-23, 2004. e-Pub 2004. PMID: 15378473.
- Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo Aldaz C, Hortobagyi GN, Pusztai L. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat 87(3):205-14, 2004. e-Pub 2004. PMID: 15528963.
- Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10(20):7031-42, 2004. e-Pub 2004. PMID: 15501983.
- Shen J, Valero V, Buchholz TA, Singletary SE, Ames FC, Ross MI, Cristofanilli M, Babiera GV, Meric-Bernstam F, Feig B, Hunt KK, Kuerer HM. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 11(9):854-60, 2004. e-Pub 2004. PMID: 15313733.
- Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM, Meric-Bernstam F, Feig B, Ross MI, Ames FC, Babiera GV. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer 101(6):1330-7, 2004. e-Pub 2004. PMID: 15316905.
- Cabioglu N, Krishnamurthy S, Kuerer HM, Hunt KK, Singletary SE, Meric-Bernstam F, Ross MI, Feig BW, Ames FC, Babiera GV. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge. Cancer 101(3):508-17, 2004. e-Pub 2004. PMID: 15274063.
- Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. Expression of c-kit proto-oncogene product in breast tissue. Breast J 10(4):323-7, 2004. e-Pub 2004. PMID: 15239791.
- Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22(12):2303-12, 2004. e-Pub 2004. PMID: 15197191.
- Walji M, Sagaram S, Sagaram D, Meric-Bernstam F, Johnson C, Mirza NQ, Bernstam EV. Efficacy of quality criteria to identify potentially harmful information: a cross-sectional survey of complementary and alternative medicine web sites. J Med Internet Res 6(2):e21, 2004. e-Pub 2004. PMID: 15249270.
- Yen TW, Hunt KK, Mirza NQ, Thomas ES, Singletary SE, Babiera GV, Meric-Bernstam F, Buchholz TA, Feig BW, Ross MI, Ames FC, Theriault RL, Kuerer HM. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 100(5):942-9, 2004. e-Pub 2004. PMID: 14983489.
- Pawlik TM, Perry A, Strom EA, Babiera GV, Buchholz TA, Singletary E, Perkins GH, Ross MI, Schecter NR, Meric-Bernstam F, Ames FC, Hunt KK, Kuerer HM. Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer 100(3):490-8, 2004. e-Pub 2004. PMID: 14745864.
- Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10(3):1013-23, 2004. e-Pub 2004. PMID: 14871980.
- Sagaram S, Walji M, Meric-Bernstam F, Johnson C, Bernstam E. Inter-observer agreement for quality measures applied to online health information. Medinfo 11(Pt 2):1308-12, 2004. e-Pub 2004. PMID: 15361026.
- Walji M, Sagaram S, Meric-Bernstam F, Johnson C, Bernstam E. Cancer-related complementary and alternative medicine online: factors affecting information retrieval. Medinfo 11(Pt 2):1318-22, 2004. e-Pub 2004. PMID: 15361028.
- Bedrosian I, Bedi D, Kuerer HM, Fornage BD, Harker L, Ross MI, Ames FC, Krishnamurthy S, Edeiken-Monroe BS, Meric F, Feig BW, Akins J, Singletary SE, Mirza NQ, Hunt KK. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol 10(9):1025-30, 2003. e-Pub 2003. PMID: 14597440.
- Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, Buzdar AU, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 57(2):336-44, 2003. e-Pub 2003. PMID: 12957243.
- Chagpar A, Yen T, Sahin A, Hunt KK, Whitman GJ, Ames FC, Ross MI, Meric-Bernstam F, Babiera GV, Singletary SE, Kuerer HM. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg 186(4):371-7, 2003. e-Pub 2003. PMID: 14553853.
- Chagpar A, Meric-Bernstam F, Hunt KK, Ross MI, Cristofanilli M, Singletary SE, Buchholz TA, Ames FC, Marcy S, Babiera GV, Feig BW, Hortobagyi GN, Kuerer HM. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol 10(6):628-34, 2003. e-Pub 2003. PMID: 12839847.
- Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, Kuerer HM, Singletary SE, Babiera G, Meric F, Akins JS, Neely J, Ross MI. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 10(3):248-54, 2003. e-Pub 2003. PMID: 12679309.
- Cabioglu N, Hunt KK, Singletary SE, Stephens TW, Marcy S, Meric F, Ross MI, Babiera GV, Ames FC, Kuerer HM. Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg 196(3):354-64, 2003. e-Pub 2003. PMID: 12648684.
- Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Cancer Genet Cytogenet 141(2):148-53, 2003. e-Pub 2003. PMID: 12606133.
- Diaz LK, Hunt K, Ames F, Meric F, Kuerer H, Babiera G, Ross M, Singletary E, Middleton LP, Symmans WF, Krishnamurthy S, Sahin A, Sneige N, Gilcrease MZ. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol 27(3):385-9, 2003. e-Pub 2003. PMID: 12604895.
- Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer 97(4):926-33, 2003. e-Pub 2003. PMID: 12569592.
- Vlastos G, Mirza NQ, Meric F, Hunt KK, Mirza AN, Newman LA, Ames FC, Kuerer HM, Ross MI, Feig B, Babiera G, Buchholz TA, Hortobagyi GN, Singletary SE. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol 9(9):912-9, 2002. e-Pub 2002. PMID: 12417515.
- Huang E, Buchholz TA, Meric F, Krishnamurthy S, Mirza NQ, Ames FC, Feig BW, Kuerer HM, Ross MI, Singletary SE, McNeese MD, Strom EA, Hunt KK. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer 95(10):2059-67, 2002. e-Pub 2002. PMID: 12412158.
- Solorzano CC, Middleton LP, Hunt KK, Mirza N, Meric F, Kuerer HM, Ross MI, Ames FC, Feig BW, Pollock RE, Singletary SE, Babiera G. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg 184(4):364-8, 2002. e-Pub 2002. PMID: 12383904.
- Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, Plager C, Papadopoulos NE, Burgess MA, Pollock RE, Feig BW. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 95(5):1120-6, 2002. e-Pub 2002. PMID: 12209699.
- Meric F, Buchholz TA, Mirza NQ, Vlastos G, Ames FC, Ross MI, Pollock RE, Singletary SE, Feig BW, Kuerer HM, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 9(6):543-9, 2002. e-Pub 2002. PMID: 12095969.
- Mirza NQ, Vlastos G, Meric F, Buchholz TA, Esnaola N, Singletary SE, Kuerer HM, Newman LA, Ames FC, Ross MI, Feig BW, Pollock RE, McNeese M, Strom E, Hunt KK. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol 9(3):256-65, 2002. e-Pub 2002. PMID: 11923132.
- Meric F, Bernstam EV, Mirza NQ, Hunt KK, Ames FC, Ross MI, Kuerer HM, Pollock RE, Musen MA, Singletary SE. Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ 324(7337):577-81, 2002. e-Pub 2002. PMID: 11884322.
- Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 8(2):361-7, 2002. e-Pub 2002. PMID: 11839650.
- Solorzano CC, Ross MI, Delpassand E, Mirza N, Akins JS, Kuerer HM, Meric F, Ames FC, Newman L, Feig B, Singletary SE, Hunt KK. Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. Ann Surg Oncol 8(10):821-7, 2001. e-Pub 2001. PMID: 11776497.
- Vlastos G, Mirza NQ, Meric F, Hunt KK, Kuerer HM, Ames FC, Ross MI, Buchholz TA, Hortobagyi GN, Singletary SE. Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer 92(5):1092-100, 2001. e-Pub 2001. PMID: 11571720.
- Laronga C, Meric F, Truong MT, Mayfield C, Mansfield P. A treatment algorithm for pneumothoraces complicating central venous catheter insertion. Am J Surg 180(6):523-6; discussion 526-7, 2000. e-Pub 2000. PMID: 11182411.
- Meric F, Liao Y, Lee WP, Pollock RE, Hung MC. Adenovirus 5 early region 1A does not induce expression of the ewing sarcoma fusion product EWS-FLI1 in breast and ovarian cancer cell lines. Clin Cancer Res 6(10):3832-6, 2000. e-Pub 2000. PMID: 11051226.
- Meric F, Milas M, Hunt KK, Hess KR, Pisters PW, Hildebrandt G, Patel SR, Benjamin RS, Plager C, Papadopolous NE, Burgess MA, Pollock RE, Feig BW. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol 18(19):3378-83, 2000. e-Pub 2000. PMID: 11013278.
- Mirza NQ, Vlastos G, Meric F, Sahin AA, Singletary SE, Newman LA, Kuerer HM, Ames FC, Ross MI, Feig BW, Pollock RE, Buchholz TA, McNeese MD, Strom EA, Hortobagyi GN, Hunt KK. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol 7(9):656-64, 2000. e-Pub 2000. PMID: 11034242.
- Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, Ellis LM. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 7(7):490-5, 2000. e-Pub 2000. PMID: 10947016.
- Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, Pollock RE, Newman LA, Feig BW, Strom EA, Buchholz TA, McNeese MD, Hortobagyi GN, Singletary SE. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol 7(6):435-40, 2000. e-Pub 2000. PMID: 10894139.
- Strouboulis J, Damjanovski S, Vermaak D, Meric F, Wolffe AP. Transcriptional repression by XPc1, a new Polycomb homolog in Xenopus laevis embryos, is independent of histone deacetylase. Mol Cell Biol 19(6):3958-68, 1999. e-Pub 1999. PMID: 10330136.
- Meric F, Teitelbaum DH, Geiger JD, Harmon CM, Groner JI. Latex sensitization in general pediatric surgical patients: a call for increased screening of patients. J Pediatr Surg 33(7):1108-11; discussion 1111-2, 1998. e-Pub 1998. PMID: 9694104.
- Meric F, Matsumoto K, Wolffe AP. Regulated unmasking of in vivo synthesized maternal mRNA at oocyte maturation. A role for the chaperone nucleoplasmin. J Biol Chem 272(19):12840-6, 1997. e-Pub 1997. PMID: 9139745.
- Meric F, Searfoss AM, Wormington M, Wolffe AP. Masking and unmasking maternal mRNA. The role of polyadenylation, transcription, splicing, and nuclear history. J Biol Chem 271(48):30804-10, 1996. e-Pub 1996. PMID: 8940061.
- Matsumoto K, Meric F, Wolffe AP. Translational repression dependent on the interaction of the Xenopus Y-box protein FRGY2 with mRNA. Role of the cold shock domain, tail domain, and selective RNA sequence recognition. J Biol Chem 271(37):22706-12, 1996. e-Pub 1996. PMID: 8798444.
- Steimle CN, Meric F, Hirschl RB, Bozynski M, Coran AG, Bartlett RH. Effect of extracorporeal life support on survival when applied to all patients with congenital diaphragmatic hernia. J Pediatr Surg 29(8):997-1001, 1994. e-Pub 1994. PMID: 7965537.
- Meric F, Hirschl RB, Mahboubi S, Womer RB, Goldwein J, Ross AJ, rd, Schnaufer L. Prevention of radiation enteritis in children, using a pelvic mesh sling. J Pediatr Surg 29(7):917-21, 1994. e-Pub 1994. PMID: 7931970.
- Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 16(5):459-64, 1990. e-Pub 1990. PMID: 2239937.
Invited Articles
- Meric-Bernstam F. The need for Molecular Tumour Boards. Nature Medicine, 2025. e-Pub 2025.
- Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Enhancing Antitumour Efficacy with Immunotherapy Combinations. Lancet, 2021. e-Pub 2021. PMID: 33285141.
- Kreisberg JF, Ideker T, Meric-Bernstam F, Mills G. Prospecting whole cancer genomes. Nature Cancer:273–275, 2020. e-Pub 2020.
- Akcakanat A, Hong DS, Meric-Bernstam F. Targeting translation initiation in breast cancer. Translation 29(2):e28968, 2014. e-Pub 2014. PMID: 26779407.
- Wagner JL, Meric-Bernstam F. Reply to Letter: "Waiting Time for Breast Cancer Treatment". Ann Surg 259(3):e50, 2014. e-Pub 2014. PMID: 24169189.
- Feldman S, Meric-Bernstam F. ASBrS and ASO: a new partnership begins. Ann Surg Oncol 17(Suppl 3):195-6, 2010. e-Pub 2010. PMID: 20853032.
- Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: A therapeutic opportunity in breast cancer. Clin Cancer Res 16(6):1695-700, 2010. e-Pub 2010. PMID: 20215559.
- Meric-Bernstam F. Translation Initiation Factor 4E (eIF4E): Prognostic Marker and Potential Therapeutic Target. Ann Surg Oncol 15(11):2996-7, 2008. e-Pub 2008. PMID: 18712446.
- Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12(21):6326-30, 2006. e-Pub 2006. PMID: 17085641.
- Stoeltzing O, Meric-Bernstam F, Ellis LM. Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cell 10(2):89-91, 2006. e-Pub 2006. PMID: 16904605.
- Meric-Bernstam F, Esteva FJ. Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy. Clin Breast Cancer 6(4):357-60, 2005. e-Pub 2005. PMID: 16277888.
- Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Semin Oncol 31(6(S16)):10-7; discussion 33, 2004. e-Pub 2004. PMID: 15799239.
- Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric F, Schechter NR, Sahin AA, Middleton LP, Buchholz TA. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys 59:1074-9, 2004. e-Pub 2004. PMID: 15234041.
- Meric-Bernstam F. Breast conservation in breast cancer: surgical and adjuvant considerations. Curr Opin Obstet Gynecol 16(1):31-6, 2004. e-Pub 2004. PMID: 15128005.
- Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB. Molecular therapeutics: promise and challenges. Semin Oncol 31(1(S3)):39-53, 2004. e-Pub 2004. PMID: 15052542.
- Chen AM, Meric-Bernstam F, Hunt KK, Buchholz TA. Neoadjuvant chemotherapy to permit breast conservation for patients with locally advanced breast cancer. Am J Oncol Rev 3:692-696, 2004. e-Pub 2004.
- Meric-Bernstam F, Bernstam EV. Breast Cancer on the World Wide Web. Breast Diseases: A Year Book Quarterly 14:20-23, 2003. e-Pub 2003.
- Meric-Bernstam F. Impact of positive surgical margins and ipsilateral breast tumor recurrence on disease-specific survival after breast-conserving therapy. Am J Oncol Rev 8:428-433, 2003. e-Pub 2003.
Review Articles
- Adesoye, T, Ileana Dumbrava, EE, Raghav, KS, Sahin, AA, Chen, H, Lee, SS, Javle, M, Pant, S, Alhalabi, O, Le, X, Valero, V, Pohlmann, PR, Meric-Bernstam, F. Advances in Targeting HER2 across Cancer Subtypes. Clinical Cancer Research 32(2):260-290, 2026. e-Pub 2026. PMID: 41283902.
- Sahin, AA, Chen, H, Xiao, H, Damodaran, S, Meric-Bernstam, F. Emerging molecular Therapeutic targets in breast Cancer. Human Pathology 162, 2025. e-Pub 2025. PMID: 40759284.
- Shah, NM, Meric-Bernstam, F. The present and future of precision oncology and tumor-agnostic therapeutic approaches. Oncologist 30(6), 2025. e-Pub 2025. PMID: 40536268.
- Meric-Bernstam, F, Bardia, A, Bossi, P, Bianchini, G, Gatlin, F, Lalla, RV, Melosky, B, Niikura, N, Yap, TA, Kim, SS, Rajagopalan, R, Fairhurst, RM, Graff, SL, Rugo, H. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 30(3), 2025. PMID: 40139260.
- Newhook TE, Tsai S, Meric-Bernstam F. Precision Oncology in Hepatopancreatobiliary Cancer Surgery. Surg Oncol Clin N Am 33(2):343-367, 2024. e-Pub 2024. PMID: 38401914.
- Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 125:102720, 2024. e-Pub 2024. PMID: 38502995.
- Nelson BE, Meric-Bernstam F. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors. Annu Rev Med, 2024. e-Pub 2024. PMID: 37758237.
- Tsimberidou AM, Kahle M, Vo HH, Baysal MA, Johnson A, Meric-Bernstam F. Molecular tumour boards - current and future considerations for precision oncology. Nat Rev Clin Oncol, 2023. e-Pub 2023. PMID: 37845306.
- Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. e-Pub 2023. PMID: 37072571.
- Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X. Antibody-drug conjugates in lung cancer: dawn of a new era?. NPJ Precis Oncol 7(1):5, 2023. e-Pub 2023. PMID: 36631624.
- Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):8701, 2022. e-Pub 2022. PMID: 35610322.
- Bernstam EV, Shireman PK, Meric-Bernstam F, N Zozus M, Jiang X, Brimhall BB, Windham AK, Schmidt S, Visweswaran S, Ye Y, Goodrum H, Ling Y, Berapatre S, Becich MJ. Artificial intelligence in clinical and translational science: Successes, challenges and opportunities. Clin Transl Sci, 2022. e-Pub 2022. PMID: 34706145.
- Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol, 2020. e-Pub 2020. PMID: 32853681.
- Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs 28(11):977-988, 2019. e-Pub 2019. PMID: 31594388.
- Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol 35:69-76, 2018. e-Pub 2018. PMID: 29843069.
- DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer 124(13):2704-2713, 2018. e-Pub 2018. PMID: 29682723.
- Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol 15(5):273-291, 2018. e-Pub 2018. PMID: 29508857.
- Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther, 2017. e-Pub 2017. PMID: 28174090.
- Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud 3(1):a001115, 2017. e-Pub 2017. PMID: 28050598.
- Bupathi M, Kaseb A, Meric-Bernstam F, Naing A. Hepatocellular carcinoma: Where there is unmet need. Mol Oncol 9(8):1501-9, 2015. e-Pub 2015. PMID: 26160430.
- Blanco E, Hsiao A, Ruiz-Esparza GU, Landry MG, Meric-Bernstam F, Ferrari M. Molecular-targeted nanotherapies in cancer: enabling treatment specificity. Mol Oncol 5(6):492-503, 2011. e-Pub 2011. PMID: 22071376.
- Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci 102(7):1247-52, 2011. e-Pub 2011. PMID: 21447010.
- Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 11(4):373-82, 2010. e-Pub 2010. PMID: 20171141.
- Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27(13):2278-87, 2009. e-Pub 2009. PMID: 19332717.
- Chagpar A, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, Ross MI, Ames FC, Singletary SE, Buchholz TA, Valero V, Hunt KK. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 103(8):1581-6, 2005. e-Pub 2005. PMID: 15747375.
- Singletary SE, Walsh G, Vauthey JN, Curley S, Sawaya R, Weber KL, Meric F, Hortobagyi GN. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8(3):241-51, 2003. e-Pub 2003. PMID: 12773746.
- Meric F Hunt KK. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther 1(11):971-9, 2002. e-Pub 2002. PMID: 12481419.
- Meric F, Hung MC, Hortobagyi GN, Hunt KK. HER2/neu in the management of invasive breast cancer. J Am Coll Surg 194(4):488-501, 2002. e-Pub 2002. PMID: 11949754.
- Singletary SE, Fornage BD, Sneige N, Ross MI, Simmons R, Giuliano A, Hansen N, Kuerer HM, Newman LA, Ames FC, Babiera G, Meric F, Hunt KK, Edeiken B, Mirza AN. Radiofrequency ablation of early-stage invasive breast tumors: an overview. Cancer J 8(2):177-80, 2002. e-Pub 2002. PMID: 11999950.
- Liu DC, Rodriguez JA, Meric F, Geiger JL. Laparoscopic excision of a rare type II choledochal cyst: case report and review of the literature. J Pediatr Surg 35(7):1117-9, 2000. e-Pub 2000. PMID: 10917310.
- Wolffe AP, Meric F. Coupling transcription to translation: a novel site for the regulation of eukaryotic gene expression. Int J Biochem Cell Biol 28(3):247-57, 1996. e-Pub 1996. PMID: 8920634.
Other Articles
- Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Naing A Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. J Clin Oncol 40(16_suppl), 2022.
- Meric-Bernstam F Are there patients who should not receive pre-operative therapy?. 2008 Breast Cancer Symposium Educational Summary, 2008.
- Meric-Bernstam F Clinical Trials Using Neoadjuvant Targeted Therapies - SSO Symposium CME. Targeted Therapy in the Surgical Patient with Breast Cancer - SSO Monograph:4-6, 2008.
- Mills GB, Meric-Bernstam F The Developing Diversity of Targeted Therapy in Oncology. Signal Transduction Inhibition: Current Knowledge, Pathways and Experience in Cancer Therapy:1-13, 2004.
Editorials
- Yap TA, Johnson A, Meric-Bernstam F. Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. JAMA Oncol 7(4):507-509, 2021. PMID: 33630035.
- Basho RK, Meric-Bernstam F. Next-Generation Sequencing: How Close Are We to Clinical Application?. Breast Diseases: A Year Book Quarterly 25(4):296-299, 2014.
- Meric-Bernstam F. HER2 studies look promising. Cancer 117(6):1109, 2011. PMID: 21381005.
- Meric-Bernstam F. Intraoperative Margin Analysis in Breast-Conserving Surgery. Breast Diseases: A Year Book Quarterly 19(1):25-6, 2008.
- Meric-Bernstam F. Heterogenic Loss of BRCA in Breast Cancer: The "Two-Hit" Hypothesis Takes a Hit. Ann Surg Oncol 14(9):2422-3, 2007. PMID: 17406948.
- Beahm EK, Walton RL, Meric-Bernstam F. Postmastectomy breast reconstruction using microvascular breast-sharing technique. Plast Reconstr Surg 118:1317-1319, 2006.
- Meric-Bernstam F. Serum proteomics for BRCA1-associated breast cancer. Ann Surg Oncol 11(10):883-4, 2004. PMID: 15383421.
Abstracts
- Bedard PL, S-A I, Elimova E, Rha SY, Goodwin RA, Ferrario C, K-W L, Martynova A, Meric-Bernstam F, Kabos P, Beeram M, Hamilton EP, Cobleigh M, Samuel Nached T, Sharma K, D-Y O. Zanidatamab (Zani) + chemotherapy (Chemo) for patients (Pts) with HER2-expressing metastatic breast cancer (mBC): Final results of a phase I trial. ESMO Breast Cancer Congress, 2025. e-Pub 2025.
- Baird RD, W-P C, Schmid P, Dongen MV, Jung KH, Naito Y, Shimoi T, Lau PKH, Meric-Bernstam F, D-Y O, Rubovszky G, Van Gorp T, Aftimos P, Lugowska I, Sanai E, Dubois VFS, MillerN, Varga A, Luheshi N, Kim GM. Puxitatug samrotecan (P-Sam, AZD8205) in patients (pts) with HR+/HER2– breast cancer (BC): A first-in-human phase I/IIa dose escalation and expansion study. ESMO Breast Cancer Congress, 2025. e-Pub 2025.
- Hamilton EP, Han H, Abuhadra N, Kalinsky K, McAndrew NP, Spira A, Chan N, Kelley K, Parajuli R, O'Shaughnessy J, Starks D, Wulf G, Weise AM, Chaudhry A, Wang JS, Richardson DL, Meric-Bernstam F, Burger R, Bradshaw C, Giordano A. Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC. ESMO Breast Cancer Congres, 2025. e-Pub 2025.
- Mouabbi AJ, Sakr Y, Singareeka Raghavendra A, Abualkhair OA, Barcenas CH, Damodaran S, Layman RM, Tripathy D, Pohlmann PR, Meric-Bernstam F. Real-world effectiveness of trastuzumab deruxtecan (T-DXd) in endocrine therapy (ET)-refractory metastatic invasive lobular carcinoma (mILC) with HER2-low wild type (HER2wt) versus HER2-low mutant (HER2m). ESMO Breast Cancer Congress, 2025. e-Pub 2025.
- Nguyen TQA, McGrail DJ, Dai H, Cifci A, Du Y, Meric-Bernstam F, S-Y L. Targeting RNase H2: a dual mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in triple-negative breast cancer. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Srour SA, Tannir N, Jazaeri A, Campbell MT, Nieto Y, Haymaker C, Yuan Y, Salih I, Yang Y, Doppler V, Garibal J, Escande M, Yang M, Kushner J, Koo J, Gurses SA, Hong DS, Fu S, Meric-Bernstam F, Naing A. Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Akhave N, Holder A, Davies M, Pacha O, Weiser R, Meric-Bernstam F, Naing A. Phase 2 study of Ivonescimab in patients with cutaneous squamous cell carcinoma. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Mouabbi JA, Hammell A, SuryawanshiS, Middleton L, Bassett R, Zaayman T, Geoffrey L, Meric-Bernstam F. REPLOT Trial: Phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4/6 inhibition. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Torrado C, Tomczak K, Dumbrava EE, Sun B, Ngoi N, Arrechedera C, Para ER, Rodon Anhert J, Piha-Paul SA, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, Hong DS, Meric-Bernstam F, Msaouel P, Haymaker CL, Yap TA. Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial. AACR Annual Meeting, 2025. e-Pub 2025.
- Jeong J, Ma J, Abed M, Chung H, Kim D, Molden N, Rajendran D, Shim C, Jandial DD, LacknerMR, Simpkins F, Meric-Bernstam F, Randall LM, Harismendy O. Cell-free DNA molecular response predicts clinical efficacy in HGSOC patients treated with azenosertib. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- George GC, Lee H, Piha-Paul SA, Dumbrava E, Tsimberidou A, Fu S, Appleton G, Noor L, Rodon J, Yap TA, Meric-Bernstam F, Hong DS. Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Alkassis S, Lipsyc-Sharf M, Hegarty-Traverso C, Mercer J, Yilma B, Fragkogianni S, Yuan Y, Meric-Bernstam F, Rugo H, O'Shaughnessy J, Rimawi M, Schiff R, Elashoff D, Glaspy J, McDermott M, Cummings A, Chao C, Bardia A. Genomic and transcriptomic mediators of resistance to antibody-drug conjugates (ADCs) in metastatic breast cancer (MBC): A comprehensive multi-center study. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Gouda MA, Xavier CB, Torrado C, Shah PA, Rai K, Vokes N, Alhalabi O, Bedford MT, Gao J, Majd NK, Li J, Javle M, Meric-Bernstam F, Rodon J. Pan-cancer prevalence of unusual MTAP alterations: data from the AACR GENIE databas. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Lei JT, Dobrolecki LE, Huang C, Srinivasan RR, Vasaikar SV, Lewis AN, Sallas C, Zhao N, Cao J, Landua JD, Moon CI, Liao Y, Hilsenbeck SG, Osborne CK, Rimawi MF, Ellis MJ, Petrosyan V, Wen B, Li K, Saltzman AB, Jain A, Malovannaya A, Wulf GM, Marangoni E, Li S, Kraushaar DC, Wang T, Damodaran S, Zheng X, Meric-Bernstam F, Echeverria GV, Anurag M, Chen X, Welm BE, Welm AL, Zhang B Lewis MT. Patient-derived xenografts allow deconvolution and prediction of chemotherapy responses. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Braganca Xavier C, Andersen C, Lim JT, Slade JH, Bean SA, Kang L, Le H, Tsimberidou A, Naing A, Hong D, Dumbrava E, Rodon J, Pohlmann P, Piha-Paul S, Champiat S, Yap TA, T-Y T, Meric-Bernstam F, Fu S. Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Mileham KF, Adesunloye B, Colocci N, Chen MD, Meric-Bernstam F, Pisick E, Marr AS, Benyounes A, Alese OB, Gregory A, Hinshaw DC, Grantham GN, Halabi S, Schilsky RL. Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Ngoi NYL, Rodon J, Dumbrava EE, Garmezy B, Hong DS, Piha-Paul S, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, T-Y T, Clemente H, Rhudy J, Valladolid C, Salguero C, Velez NA, Tran HT, Meric-Bernstam F, Yap TAA. TalaCom: Phase Ib investigator-initiated trial combining talazoparib and axitinib in patients with DNA damage response mutated cancers or BRCA1/2 wildtype ovarian cancer incorporating prospective intrapatient dose titration. ESMO Targeted Anticancer Therapies (TAT) Congress, 2025. e-Pub 2025.
- Stephen B, Kwiatkowski E, Anderson MR, Derbala MH, Salih I, Castillo L, Yang Y, Gurses SA, Lim JT, Klekers AR, Le H, Kang L, Xu M, Ahmed J, Tan HN, Champiat S, T-Y T, Dumbrava EE, Fu S, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap T, Yuan Y, Hong DS, Meric-Bernstam F, Bhosale P, Naing A. Impact of liver metastases and systemic biomarkers on immunotherapy response and survival outcomes in patients with solid tumors. AACR IO, 2025. e-Pub 2025.
- Meric-Bernstam F, Alhalbi O, Lisberg A, Drakaki A, Garmezy B, Kogawa T, Spira AI, Salkeni MA, Gao X, Tolcher AW, Bhave MA, Doroshow DB, Hoffman-Censits J, Klauss G, Kaga Y, Kakurai Y, Kojima T. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. ASCO Genitourinary Cancers Symposium, 2025. e-Pub 2025.
- Trueman S, Wu L, Girgis S, Vaidya K, Meric-Bernstam F, Harding J, Pant S, Zhao Y, Garfin P, Iannone R, Zhou H, Ma J. Zanidatamab dose optimization in patients with HER2-positive biliary tract cancer (BTC). ASCO Gastrointestinal Cancers Symposium, 2025. e-Pub 2025.
- Lee C-K, Seo DH, Fox D, Haro-Silerio J, Chung T, Kim CG, Bhamidipati D, Meric-Bernstam F, Pant S, Javle M, Lee S. Impact of HER2-positivity on prognosis and targeted therapeutic outcomes in advanced biliary tract cancer. ASCO Gastrointestinal Cancers Symposium, 2025. e-Pub 2025.
- Meza K, Villegas De Leon A, Pant S, Tang T-Y, Meric-Bernstam F, Hu Z, Javle M, Lee S. Tumor vascularity as a predictor of FGFR inhibitor response in FGFR2-fused intrahepatic cholangiocarcinoma. ASCO Gastrointestinal Cancers Symposium, 2025. e-Pub 2025.
- Iwase T, Damodaran S, Marx A, Meric-Bernstam F, Tripathy D, Barcenas C, Lee J, Ueno N. Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cance. ASCO Annual Meeting, 2024. e-Pub 2024.
- Gouda M, Lin H, Kang L, Le H, Dumbrava E, Fu S, Karp D, Tsimberidou A, Naing A, Piha-Paul S, Pohlmann P, Rodon Ahnert J, Yap T, Meric-Bernstam F, Hong D. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. ASCO Annual Meeting, 2024. e-Pub 2024.
- Mouabbi J, Meric-Bernstam F, Nasrazadani A, Nelson B, Salem B, Kushnarev V, Tkachuk A, Sotova M, Polyakova M, Baranov O, Turova P, Chernyshov K, Kotlov N, Brown J, Clayton P, Sarachakov A, Postovalova E, Bagaev A, Tripathy D, Layman R. The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast. ASCO Annual Meeting, 2024. e-Pub 2024.
- Knisely A, Rafei H, Basar R, Banerjee P, Metwalli Z, Lito K, Fellman B, Yuan Y, Wolff R, Morelli MP, Meyer L, Wang X, Westin S, Meric-Bernstam F, Shpall E, Lu K, Rezvani K, Jazaeri A. Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer. ASCO Annual Meeting, 2024. e-Pub 2024.
- Sands J, Lisberg A, Bardia A, Shimizu T, M-J A, Paz-Ares L, Meric-Bernstam F, Kitazono S, Krop I, Girard N, Pons Tostivint E, Heist R, Cornelissen R, Pistilli B, Lee K, Howarth P, Gu W, Fairhurst R, Khan S, Okamoto I. Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO Annual Meeting 42(16_suppl), 2024. e-Pub 2024.
- George G, Piha-Paul S, Dumbrava E, Subbiah V, Fu S, Tsimberidou A, Pant S, Appleton G, Noor L, Yap T, Rodon Ahnert J, Meric-Bernstam F, Cleeland C, Mendoza T, Hong D. Patient-reported symptom interference with activity- and mood-related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade. ASCO Annual Meeting, 2024. e-Pub 2024.
- Chan J, Rothe M, Mangat P, Garrett-Mayer E, Cannon T, Ahn E, Swiecicki P, Hobbs E, Nazemzadeh R, Bell M, Hosein P, Meric-Bernstam F, Hinshaw D, Gregory A, Grantham G, Halabi S, Schilsky R. Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. ASCO Annual Meeting, 2024. e-Pub 2024.
- D-Y O, Lugowska I, Stroyakovskiy D, Jung KH, Dumas O, Penkov K, Dechaphunkul A, Oaknin A, Kim ST, Starling N, Chewaskulyong B, Charonpongsuntown C, Doroshow D, S-Y H, Y-P H, Jung L, Kuptsova-Clarkson N, Michelini F, Puvvada S, Meric-Bernstam F. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). ASCO Annual Meeting, 2024. e-Pub 2024.
- Mirallas O, Lin R, Alvarez-Ballesteros P, Campbell E, Le H, Dumbrava E, Yap T, Hong D, Meric-Bernstam F, Thall P, Rodon Ahnert J, Martin Cullell B. Total toxicity burden as a practical tool to quantify the overall severity of multiple adverse events in clinical trials. ASCO Annual Meeting, 2024. e-Pub 2024.
- Torrado Martin C, Brink A, Gouda M, Kang L, Osburn J, Patterson C, Charles S, Poullard A, Urschel G, Dumbrava E, Karp D, Naing A, Piha-Paul S, Pohlmann P, Rodon Ahnert J, Tsimberidou A, Yap T, Hong D, Meric-Bernstam F, Fu S. Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center. ASCO Annual Meeting, 2024. e-Pub 2024.
- Gouda M, Shunyakova J, Naing A, Dumbrava E, Hong D, Yuan Y, Yang P, Myers A, Liang Y, Ping J, Karp D, Tsimberidou A, Rodon Ahnert J, Yap T, Piha-Paul S, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ASCO Annual Meeting, 2024. e-Pub 2024.
- Torrado Martin C, Rai K, Moawad M, Dumbrava E, Fu S, Hong D, Karp D, Meric-Bernstam F, Naing A, Pohlmann P, Rodon Ahnert J, Tsimberidou A, Yap T, Said R, Pelosof L, Piha-Paul S. A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449). ASCO Annual Meeting, 2024. e-Pub 2024.
- Winer I, Barve M, Shah S, Sharma M, Marsolais C, Demeule M, Daigle K, Douglas L, Meric-Bernstam F. Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC). ASCO Annual Meeting, 2024. e-Pub 2024.
- Spira A, Lee E, O'Cearbhaill R, LoRusso P, Falchook G, Patel M, Richardson D, Covino N, Lu W, Marreddy P, Farrington D, Wheler J, Slosberg E, Subbiah V, Meric-Bernstam F. A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. ASCO Annual Meeting, 2024. e-Pub 2024.
- Sands J, Tolaney S, Ueno N, Spira A, Yamamoto N, Janjigian Y, Naito Y, Damodaran S, Meric-Bernstam F, Modi S, Enzinger P, Mohapatra A, Iko Y, He S, Nakajima K, Shitara K. A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors. ASCO Annual Meeting, 2024. e-Pub 2024.
- Patnaik A, Azad N, Borad M, Bullock A, Call J, Davis SL, Fakih M, Goodwin, R, Lakhani N, Pelster M, Perez C, Pourhosseini P, Wang T, Demers B, Meric-Bernstam F. An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001). ASCO Annual Meeting, 2024. e-Pub 2024.
- Tsimberidou A, Fu S, Hong D, Piha-Paul S, Naing A, Rodon Ahnert J, Yap T, Karp D, Dumbrava E, Heymach J, Ajani J, Cartwright C, Beck J, Andersen C, Kahle M, Vining D, Ross J, Chao C, Berry D, Meric-Bernstam F. Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center. ASCO Annual Meeting, 2024. e-Pub 2024.
- Dumbrava EE, Kennon AM, Murthy RK, Montazari EJ, Tawbi H, Li J, Lang F, Sanchez G, Wang J, Glitza IC, O'Brien BJ, Beckham T, Swanson T, Tom MC, Vu UM, Darko TT, Cai T, Shah K, Meric-Bernstam F, Rodon J. A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB). AACR Annual Meeting 84(suppl 7), 2024. e-Pub 2024.
- Meric-Bernstam F, Perez CA, Lakhani N, Pelster M, Call J, McGoldrick S, Wang T, Demers B, Patnaik A. An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress). Cancer Res 84(suppl 7), 2024. e-Pub 2024.
- Kurzrock R, Childress M, Li W, Muse A, Malato J, Wang Y, Liu M, Aleshin A, Wang RSP, Thierauf J, Sweeney CJ, Hainsworth J, Szado T, Young A, Schulze K, Spigel D, Meric-Bernstam F, Swanton C, Burris III HA. Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab + pertuzumab. Cancer Res 84(suppl 7), 2024. e-Pub 2024.
- Dumbrava EE, Montazari EJ, Vu UM, Cai T, Altan M, Ibrahim NK, Yeboa DN, Li J, Lang FF, Sanchez G, Glitza IC, O'Brien BJ, Murthy RK, Wang J, Darko TT, Velazquez D, Shah K, Meric-Bernstam F, Tawbi H, Rodon J. Phase II study of pembrolizumab in combination with lenvatinib in patients with triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and other tumor types and brain metastases. Cancer Res 84(suppl 7), 2024. e-Pub 2024.
- Yap T, Dumbrava E, Rodon Ahnert J, Tsimberidou A, Hong D, Piha-Paul S, Karp D, Fu S, Naing A, Pohlmann P, Rhudy J, Berenji-Jalaei S, Cole A, Valladolid C, Dufner D, Bockorny B, Bullock A, Fein D, Buchbinder E, Choudhury A, Haddox C, Lee E, Wulf G, Ivy P, Said R, Shapiro G, Meric-Bernstam F. NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations. Cancer Res 84(suppl 7), 2024. e-Pub 2024.
- Shah PA, Kumar Saw A, Padron W, Zhao M, Akcakanat A, Evans K, Meric-Bernstam F, Javle M, Rodon J, Rai K. MTAP loss alters the epigenetic landscape and demonstrates superior therapeutic sensitivity to concomitant PRMT5 and PARP inhibition in cholangiocarcinoma. Cancer Res 84(suppl 7), 2024. e-Pub 2024.
- Tedeschi A, Peng DH, Schischlik F, Herdeis L, Schaff O, Santoro V, Gerlach D, Savarese F, Lipp J, Haslinger C, Rocchetti F, Popow J, Huber HJ, Wilding B, Treu M, Fuchs J, Broeker J, Wunber T, Gmachl M, Rumpel K, Rees M, Ron M, Roth J, Williams M, Deckard C, Ramamoorthy V, Daniele JR, Ajani JA, Meric-Bernstam F, Kopetz S, Kim M, Gibbons DL, Vellano CP, Marszalek JR, Heffernan TP, McConnell D, Pearson M, Kraut N, Rudolph D. KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications. Cancer Res 84(suppl 7), 2024. e-Pub 2024.
- Uzunparmak B, Su F, Johnson AM, Nomie K, Fowler N, Kontselidze L, Bagaev A, Butusova A, Dumbrava EE, Rodon-Ahnert J, Fu S, Hong DS, Yap TA, Naing A, Piha-Paul SA, Karp DD, Pohlmann PR, Tsimberidou AM, Patel KP, Meric-Bernstam F. Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors. Cancer Res 84(suppl 7), 2024. e-Pub 2024.
- Fox D, Haro-Silerio J, Bhamidipati D, Meric-Bernstam F, Pant S, Ross J, Hu Z, Koay E, Ludmir E, Tran Cao H, C-W T, Shin Chun Y, J-N V, Newhook T, Metwalli Z, Habibollahi P, Cox V, Kang H, Javle M, Lee S. Characterizing outcomes of ERBB2-amplified biliary tract cancer. J Clin Oncol 42(suppl 3), 2024. e-Pub 2024.
- Bhamidipati D, Haro-Silerio J, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Pant S, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Johnson A, Lee M, Raghav K, Morris V, Overman M, Kopetz S, Meric-Bernstam F, Yap T, Dasari A. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. J Clin Oncol 42(suppl 3), 2024. e-Pub 2024.
- Rosen EY, Sharma M, Berz D, Caswell-Jin J, Fulgar G, Densel M, Chiang G, Sperry S, Warner D, Meric-Bernstam F. Poster Session: Phase 1/2 Dose Expansion Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in Patients with ER+ Metastatic Breast Cancer. Proceedings of the 2023 San Antonio Breast Cancer Symposium (SABCS), 2023. e-Pub 2023.
- Piha-Paul S, Xu B, Fan Y, Yuan Y, Lavasani S, Mortimer J, Goel S, Tsimberidou A, Ibrahim N, Abouharb S, Barcenas C, Iheme A, Karp D, Rodon Ahnert J, Dumbrava E, Fan J, Peng P, Sun C, Wang H, Hennessy K, Fu X, Xu R, Ni S, Wu F, Meric-Bernstam F. Oral Presentation: The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC. Proceedings of the 2023 San Antonio Breast Cancer Symposium (SABCS), 2023. e-Pub 2023.
- Valero V, Mouabbi J, Alonzo H, Pohlmann P, Iheme A, Hassan A, Murthy R, Huang X, Qiao W, Patel M, Rauch G, Checka C, Symmans WF, Hunt K, Tripathy D, Meric-Bernstam F. Poster Spotlight: Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer. Proceedings of the 2023 San Antonio Breast Cancer Symposium (SABCS), 2023. e-Pub 2023.
- Navarro-Yepes J, Kettner N, Rao X, Bui T, Bishop C, Wingate H, Singareeka Raghavendra A, Wang Y, Wang J, Sahin A, Meric-Bernstam F, Hunt K, Damodaran S, Tripathy D, Keyomarsi K. Poster Session: Abemaciclib is effective in palbociclib resistant estrogen receptor positive breast cancers. Proceedings of the 2023 San Antonio Breast Cancer Symposium (SABCS), 2023. e-Pub 2023.
- Damodaran S, Iwase T, Marx A, Willey J, Meric-Bernstam F, Tripathy D, Barcenas C, Lee J, Ueno N. Poster Session: Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer. Proceedings of the 2023 San Antonio Breast Cancer Symposium (SABCS), 2023. e-Pub 2023.
- Varkaris A, Jhaveri K, Cabanas EG, Sanz L, Kim J, Perez CA, Hamilton E, Spira AI, Wisinski K, Guerrero A, Henry J, Rodon Ahnert J, Tan G, Li X, Hummel D, Hunter T, Timm A, Samadani R, Puente-Poushnejad E, Kwak E, Mar BG, Schram AM. Poster Session: First-in-human global study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer. Proceedings of the 2023 San Antonio Breast Cancer Symposium (SABCS), 2023. e-Pub 2023.
- Ahmed J, Knisely A, Stephen B, Yang Y, Song J, Alshawa A, Zarifa A, Morris V, Javle M, Wolff R, Meric-Bernstam F, Pant S, Rodon J, Naing A. Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies. J Immunother Cancer 11(Suppl 1), 2023. e-Pub 2023.
- Kushnarev V, Stupichev D, Kryukov K, Davitavyan S, Johnson M, Uddajjara Shanthappa B, Xiang Z, Nomie K, Postovalova E, Bagaev A, Fowler N, Meric-Bernstam F. Correlating RNA-seq detection and IHC staining of potential antibody-drug conjugate (ADC) targets: HER3, HER2, TROP2, Nectin4, and aFLR. J Immunother Cancer 11(Suppl 1), 2023. e-Pub 2023.
- Makker V, J-Y L, D-Y O, Oaknin A, Puvvada SD, Cecchi F, McEwen R, Michelini F, Meric-Bernstam F. DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma. Ann Oncol 34(Suppl 2):S239-S240, 2023. e-Pub 2023.
- Sen S, Spira AI, Sommerhalder D, Meric-Bernstam F, Subbiah V, Berlin JD, Parikh A, Cecchini M, Sanborn RE, Chablani PV, Peoples GE, Schürpf T, Dillon LA, Clifton GT, Eder JP, Tolcher AW. A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. Ann Oncol 34(Suppl 2):S649-S650, 2023. e-Pub 2023.
- Khalil MF, Rothe M, Mangat PK, Garrett-Mayer E, Mileham KF, Ahn ER, Duvivier HL, Farrington LC, Akce M, Behl D, Gold PJ, Chiu VK, Vijayvergia N, Calfa C, Gaba A, Meric-Bernstam F, Schuetze SM, Gregory A, Halabi S, Schilsky RL. Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Ann Oncol 34(Suppl 2):S265-S266, 2023. e-Pub 2023.
- Meric-Bernstam F, Song M, Westin SN, Au-Yeung G, Mitchell P, Myers C, Gymnopoulos M, Fraenkel PG, Nawinne M, Brier T, Mileshkin L. FONTANA: A Phase 1/2a study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours. Ann Oncol 34(Suppl 2):S541, 2023. e-Pub 2023.
- Yap TA, Piha-Paul SA, Karp D, Dumbrava EE, Hong DS, Fu S, Subbiah V, Tsimberidou AM, Rodon J, Rhudy J, Valladolid C, Yuan Y, Jana B, Spiliopoulou P, Randall L, Poklepovic A, Sehgal K, Shapiro GI, Said R, Meric-Bernstam F. NCI10221: Phase II Multicenter Biomarker Driven Combination Trial of Copanlisib and Nivolumab in Patients with Molecularly-selected Advanced Solid Tumors (BaCoN). Ann Oncol 34(Suppl 2):S487-S488, 2023. e-Pub 2023.
- Meric-Bernstam F, Makker V, Oaknin A, D-Y O, Banerjee S, Gonzalez Martin A, Jung K, Lugowska I, Manso Sanchez L, Manzano Fernandez A Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, J-Y L. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 (DP-02) study. Ann Oncol 34(Suppl 2):S1273-S1274, 2023. e-Pub 2023.
- Li B, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, De Miguel Luken MJ, Kalra M, D-Y O, Park OJ, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Kalil Machado K, Saura Manich C. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Ann Oncol 34(Suppl 2):S459-S460, 2023. e-Pub 2023.
- Son J, Zhang Y, Nardo M, Mirallas O, Hillman R, Lin H, Campbell E, Holla V, Johnson A, Clark N, Alvarez-Ballesteros P, Yuan Y, Cobb L, Gershenson D, Jazaeri A, Soliman P, Weston S, Meric-Bernstam, Hong D. Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Meric-Bernstam F, Makker V, Oaknin A, Do-Youn O, Banerjee S, Gonzalez Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Anoka C, Ma Y, Puvvada S, J-Y L. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Meric-Bernstam F, Hollebecque A, Furuse J, D-Y O, Bridgewater JA, Shimura M, Anderson B, Hangai N, Vacheck V, Goyal L. Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Liu J, Fu S, Richardson G, Vranjes Z, Meniawy T, Shannon C, Hamilton E, Blank S, Mathews C, j A, Ruseva R, Shi Q, Harismendy O, Ptaszynski A, Westin S, Meric-Bernstam F, Thaker P. Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Janjigian Y, Oaknin A, Lang J, Ciombor K, Ray-Coquard I, Oza A, Yonemori K, R-H X, Zhao J, Gajavelli S, Filant J, Hovey T, Meric-Bernstam F. TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Gouda M, Ahmed J, Nelson B, Nardo M, Roszik J, Cabanillas M, Hu M, Busaidy N, Sherman S, Dadu R, Naing A, Karp D, Rodon Ahnert J, Hong D, Elamin Y, Blumenschein G, Heymach J, Meric-Bernstam F, Subbiah V. Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- George GC, Piha-Paul SA, Fu S, Rodon Ahnert J, Yap TA, Subbiah V, Dumbrava E, Tsimberidou A, Pant S, Appleton G, Noor L, Meric-Bernstam F, Cleeland CS, Mendoza TR, Hong DS. Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Rosen E, Sharma M, Berz D, Caswell-Jin J, Spira A, Fulgar G, Densel M, Rana N, Sperry S, Warner D, Meric-Bernstam F. Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Rodriguez Rivera I, Hafez N, Tolcher A, LoRusso P, Wilks S, Tripathy D, Gara M, Pearson P, DeCillis A, Meric-Bernstam F. CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Mouabbi J, Meric-Bernstam F, Khorkova S, Turova P, Kotlov N, Chernyshov K, Kushnarev V, Love A, Clayton P, Nomie K, Fowler N, Tripathy D. Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Meric-Bernstam F, Shah S, Sharma M, Metcalfe A, Roy G, Douglas L, Marsolais C, Winer I. Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study. J Clin Oncol 41(Suppl 16), 2023. e-Pub 2023.
- Nelson B, Roszik J, Noia Barreto CM, Nardo M, Ahmed J, Campbell E, Johnson A, Piha-Paul S, Glitza I, S-P W, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Mouabbi, Meric-Bernstam F, Turova P, Chernyshov K, Kushnarev V, Kotlov N, Brown J, Clayton P, Nomie K, Flowler N, Tripathy D, Damodaran S. Genomic characterization of the GATA3 mutational landscape in breast cancer. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
- Davidson T, Le H, Campbell E, Ozenne C, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Meric-Bernstam F, Subbiah V. Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center. ASCO Annual Meeting 41(suppl 16), 2023. e-Pub 2023.
- Meric-Bernstam F, Janjigian Y, Lang J, Ciombor KK, Ray-Coquard I, Oza A, Yonemori K, Xu R, Zhao JL, Gajavelli S, Filant J, Hovey T, Oaknin A. TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Shpektor D, Dargahi D, Samiotakis A, Wienke S, Livernnois A, Yablonovitch A, Yalamanchili G, Gartner E, Meric-Bernstam F. ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Lee HM, Sorokin A, Kanikarla Marie P, Chowdhury S, Singh A, Anderson A, Alshenaifi JY, Meric-Bernstam F, Rai K, Kopetz S. Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Landua JD, Mashl RJ, Davies SR, Fang B, Raso MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein J, Foroughi Pour A, Dobrolecki LE, Fujita M, Fujimoto J, Xiao G, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, Consortium P, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, C-x P, Jr CM, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bolt CJ, Dean DA II, Chuang JH. A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Han J, Mahendra M, Gandhi P, Daniele JR, Carrillo CC, Bivona BJ, Feng N, Heymach JV, Meric-Bernstam F, Oguchi K, Mizuarai S, Heffernan TP, Vellano CP, Marszalek JR. TAS2940 inhibits intracranial tumor growth and prolongs survival in HER2-aberrant and EGFR-amplified patient-derived xenograft models. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Varadarajan K, Pico CXC, Evans K, Raso MG, Rizvi Y, Zheng X, Diperi TP, Wang, Scott S, Zhao M, Akcakanat A, Wengner AM, Yap TA, Meric-Bernstam F. Antitumor activity of the ATR inhibitor Elimusertib in patient-derived xenograft models with DNA damage response pathway alterations. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Reddy TP, Puri A, Guzman-Rojas L, Thomas C, Qian W, Zhou J, Zhao H, Li X, Mahboubi B, Oo A, Young-Jae C, Kim B, Thaiparambil J, Chervo MF, Rosato R, Ayerbe C, Giese N, Moulder S, Piwnica-Worms H, Meric-Bernstam F, Chang JC. NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Pilie PG, McGrail, W-L W, Ngoi N, Kyewalabye K, Wani K, Le H, Campbell E, Holla V, Shaw KR, Meric-Bernstam F, Lazar AJ, Giuliani V, Heffernan T, Yap TA. Ataxia-telangiectasia mutated loss of function displays variant and tissue specific differences across tumor types. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Ngoi NY, Lin HY, Dumbrava E, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Uzunparmak B, Haymaker C, Raso G, Zhu C, Masciari S, Wang L, Kirby B, Lin H, Gorur A, A-M C, Kennon A, Ding Q, Palmieri A, Urschel GE, Yuan Y, Feng G, Rizvi Y, Hussain A, Subbiah V, Yap TA, Rodon-Ahnert J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Ahou T, Akhave N, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Kim SY, Goldberg S, Ni Y, Resuli B, Landi L, S-C T, Nishino M, Owen D, Blakely C, Mountzios G, Shu CA, Bestvina C, Garassino M, Marrone K, Gray J, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil P, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC. Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Holla V, Ronaghy A, Yang RK, Patel KP, Routbort MJ, Overman MJ, Dumbrava EE, Shaw KR, Karp DD, Meric-Bernstam F. Genomic alterations in DNA mismatch repair (dMMR). Proceedings of the 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Meric-Bernstam F, Hollebecque A, Furuse J, D-Y O, Bridgewater JA, Shimura M, Anderson B, Hangai N, Vacheck V, Goyal L. Management of Futibatinib-Associated Adverse Events in Patients With Advanced Cancers: Results of a Pooled Analysis. Proceedings of the 2023 NCODA Spring Forum, 2023. e-Pub 2023.
- Meric-Bernstam F, Hollebecque A, Furuse J, D-Y O, Bridgewater JA, Shimura M, Anderson B, Hangai N, Vacheck V, Goyal L. Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis. J Clin Oncol: Proceedings of the 2023 ASCO Gastrointestinal Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
- Juric D, Jhaveri K, Beeram M, Hamilton E, Chau V, Hanley MP, Liu S, Smyth LM, Meric-Bernstam F. A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress). Proceedings of the 2022 San Antonio Breast Cancer Symposium (SABCS), 2022. e-Pub 2022.
- Kang I, Forschmiedt JK, Loch MM, Barlow WE, Lew DL, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Miao J, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status. Proceedings of the 2022 San Antonio Breast Cancer Symposium (SABCS), 2022. e-Pub 2022.
- Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K. Race and clinical outcomes in the RxPONDER trial (SWOG S1007). Proceedings of the 2022 San Antonio Breast Cancer Symposium (SABCS), 2022. e-Pub 2022.
- Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan NL, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older estrogen receptor positive / human epidermal growth factor receptor-2 negative breast cancers. Proceedings of the 2022 San Antonio Breast Cancer Symposium (SABCS), 2022. e-Pub 2022.
- Reddy T, Puri A, Guzman L, Qian W, Zhou J, Rosato R, Zhao H, Thomas C, Li X, Mahboubi B, Oo A, Y-J C, Kim B, Thaiparambil J, Ayerbe C, Giese N, Moulder S, Piwnica-Worms H, Meric-Bernstam F, Chang J. NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer. Proceedings of the 2022 San Antonio Breast Cancer Symposium (SABCS), 2022. e-Pub 2022.
- Bardia A, Krop I, Meric-Bernstam, Tolcher AW, Mukohara T, Lisberg A, Shimizu T, Ep H, Spira AI, Papadopoulos KP, Greenberg J, Gu W, Kobayashi F, Zebger-Gong H, Kawasaki Y, Wong R, Kogawa T. Datopotamab Deruxtecan (Dato-DXd) in advanced triple-negative breast cancer (TNBC): Updated results from the Phase 1 TROPION-PanTumor01 Study. Proceedings of the 2022 San Antonio Breast Cancer Symposium (SABCS), 2022. e-Pub 2022.
- Loch MM, Forschmiedt JK, Kang IM, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Barlow WE, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status. Proceedings of the 2022 San Antonio Breast Cancer Symposium (SABCS), 2022. e-Pub 2022.
- Yap TA, Ngoi N, Dumbrava EE, Karp DD, Rodon Ahnert J, Fu S, Hong DS, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Dufner D, Rhudy J, Gore S, Ivy SP, Yuan Y, Westin SN, Mills GB, Meric-Bernstam F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly(ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. Proceedings of the 34th Annual 34th EORTC-NCI-AACR Symposium, 2022. e-Pub 2022.
- Ngoi NY, Lin H, Ileana Dumbrava EE, Fu S, Karp D, Naing A, Pant S, Rodon J, Piha-Paul SA, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials. Annals of Oncology: Abstract Book of the ESMO Congress 2022, 2022. e-Pub 2022.
- Friedman C, Swanton C, Spigel D, Bose R, Burris H, Yu W, Wang Y, Malato J, Price R, Darbonne W, Szado T, Schulze K, Sweeney C, Hainsworth J, Meric-Bernstam F, Kurzrock R. MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors. Annals of Oncology: Abstract Book of the ESMO Congress 2022, 2022. e-Pub 2022.
- Harding JJ, Piha-Paul SA, Shah RH, Cleary JM, Quinn DI, Brana I, Moreno V, Borad MJ, Loi S, Spanggaard I, Ford JM, DiPrimeo D, Berger MF, DeFazio Eli L, Meric-Bernstam F, Solit DB, Abou-Alfa GK. Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Ngoi N, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Campbell E, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Coleman N, DiPeri TP, Nguyen D, Naing A, Piha-Paul SA, Tsimberidou AM, Zheng X, Johnson A, Wang W, Shaw KR, Dumbrava EE, Fu S, Rodon J, Rodon Ahnert J, Hong DS, Subbiah V, Yap TA, Luthra R, Patel KP, Meric-Bernstam F. Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Petruzzelli M, Postel-Vinay S, Garralda E, Powderly JD, Johnson ML, Alvarez EC, Kyriakopoulos C, Villaneueva R, Meric-Bernstam F, Santa-Maria CA, Opyrchal M, Stone J, Goldberg F, McMorn S, Sarvotham T, Milner A, Angell H, Collins T, Massard C, Siu LL. Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Meric-Bernstam F, D-Y O, Naito Y, Shimizu T, Chung V, Park H, Gaillard S, Wang F, Cooper ZA, Kinneer K, Rebelatto M, l K, Luheshi N, Miller N, Varga A, Mileshkin L. First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Piha-Paul SA, Xu B, Singh Raghav KP, Meric-Bernstam F, Janku F, Dumbrava EE, Fu S, Karp DD, Rodon Ahnert J, Conley AP, Mott F, Ajani JA, Hong DS, Fan Y, Peng P, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, Abrams TA, Kelley RK, Cassier PA, Furuse J, H-J K, H-M C, L-T C, Komatsu Y, Masuda K, Ahn DH, Li K, Benhadji KA, Wacheck V, Bridgewater JA. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Naing A. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Kalinskuy K, Tolcher AW, Wang S, Meric-Bernstam F, Winkler R, Li M, Sun X, Pan W, Paudyal B, Liang Z, Lu M, Yang D, Zhai Y. Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER⁺) breast cancer or advanced solid tumors. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, More JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Rodon Ahnert J, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Dumbrava EE, Burton EM, Subudhi SK, Milton DR, Aparicio A, Yap TA, Naing A, Gettys Corn P, Pilie PG, Zurita AJ, Wang J, Navroze Amaria R, McQuade JL, Glitza IC, Lazar AJ, Meric-Bernstam F, Logothetis C, Davies MA, Hwu P, Tawbi HA. Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Nelson BE, Andersen C, Yuan Y, Hong DS, Naing A, Karp DD, Yap TA, Rodon Ahnert J, Campbell E, Tsimberidou AM, Dumbrava EE, Fu S, Piha-Paul SA, Pant S, Blumenschein GR, Altan M, Tawbi HA, Tannir NM, Meric-Bernstam F, Subbiah V. Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. J Clin Oncol 40(16_suppl), 2022. e-Pub 2022.
- Hurvitz SA, Chaves J, Brufsky A, Montero AJ, Fang B, Yeung K, Patel MR, Parajuli R, Omidpanah A, Gartner E, Fong A, Randolph S, Meric-Bernstam F. Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)‑expressing cancers, including breast cancer: A phase 1b/2, multicenter, open‑label, dose‑finding and cohort‑expansion study (ZWI‑ZW25‑204). Cancer Research: 2021 San Antonio Breast Cancer Symposium; December 7-10, 2021; San Antonio, Texas 82(4_Supplement), 2022. e-Pub 2022.
- Saridogan T, Akcakanat A, Zhao M, Evans KW, Yuca E, Scott S, Kirby BP, Zheng X, Damodaran S, Meric-Bernstam F. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations. Cancer Research: 2021 San Antonio Breast Cancer Symposium; December 7-10, 2021; San Antonio, Texas 82(4_Supplement), 2022. e-Pub 2022.
- Bedard PL, S-A I, Elimova E, Rha SY, Goodwin R, Ferrario C, K-W L, Hanna D, Meric-Bernstam F, Mayordomo J, Beeram M, Hamilton E, Chaves J, Cobleigh M, Mwatha T, Woolery J, D-Y O. Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. Cancer Research: 2021 San Antonio Breast Cancer Symposium; December 7-10, 2021; San Antonio, Texas 82(4_Supplement), 2022. e-Pub 2022.
- Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, J-Y P, Bermejo B, Ramos-Vasquez M, Jung KH, J-M F, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Pusztai L, Hortobagyi G. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER). Cancer Research: 2021 San Antonio Breast Cancer Symposium; December 7-10, 2021; San Antonio, Texas 82(4_Supplement), 2022. e-Pub 2022.
- Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg AE, Kogawa T, Papadopoulos KP, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F. GS1-05 Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study. Cancer Research: 2021 San Antonio Breast Cancer Symposium; December 7-10, 2021; San Antonio, Texas 82(4_Supplement), 2022. e-Pub 2022.
- Chalasani P, Tolcher A, Meric-Bernstam F, Mamdani H, Jong PR, Anderes K, Samatar AA, Sergeeva M, Gazdoiu M, Viana MR, Pultar P, Voliotis D, Donate F. Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3. Annals of Oncology: Abstract Book of the ESMO Congress 2021(32):suppl_5, 2021. e-Pub 2021.
- Moyers J, Nguyen D, Hong DS, Dumbrava E, Fu S, Karp D, Naing A, SPant, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap T. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. Annals of Oncology: Abstract Book of the ESMO Congress 2021 32(suppl_5), 2021. e-Pub 2021.
- Burton E, Dumbrava EE, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. Annals of Oncology: Abstract Book of the ESMO Congress 2021(32):suppl_5, 2021. e-Pub 2021.
- Gouda MA, Overman MJ, Huang HJ, Thomas J, Dasari NA, Meric-Bernstam F, Kopetz S, Janku F. Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer. Annals of Oncology: Abstract Book of the ESMO Congress 2021 32(suppl_5), 2021. e-Pub 2021.
- Hollebecque A, Bridgewater JA, Meric-Bernstam F, Goyal L, Arkenau H, Yamamiya I, Yamashita F, Li K, Wacheck V, Doi T. Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA). Annals of Oncology: Abstract Book of the ESMO Congress 2021 32(suppl_5), 2021. e-Pub 2021.
- Garon EB, Johnson ML, Lisberg AE, Spira A, Yamamoto N, Heist RS, Sands JM, Yoh K, Meric-Bernstam F, Kitazono S, Greenberg J, Kobayashi F, Kawasaki Y, Jukofsky L, Nakamura K, Shimizu T. Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study. Annals of Oncology: Abstract Book of the ESMO Congress 2021(32):suppl_5, 2021. e-Pub 2021.
- Gouda MA, Polivka J, Huang H, Treskova I, Pivovarcikova K, Meric-Bernstam F, Pesta M, Janku F. BRAFV600 mutation in circulating tumor DNA can predict outcomes in early-stage melanoma. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Curigliano G, Jimenez MM, Shimizu T, Keam B, Meric-Bernstam F, Rutten A, Glaspy J, Parikh NS, Ising M, Hassounah N, Wu J, Xu K, Choudhry S, Garralda E. Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors. Cancer Res 87(13_Supplement), 2021. e-Pub 2021.
- Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Westin S, Xing Y, Ileana Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Rodon J, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Li D, Ha MJ, Evrard YA, Chen H, McShane LM, Grover J, Wang J, Fang B, DiPeri T, Lewis MT, Rubinstein L, Roth JA, Chuang JH, Doroshow JH, Moscow JA, Meric-Bernstam F. A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in NCI PDXNet centers. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Johnson A, Ng PK, Kahle M, Castillo J, Amador B, Holla V, Vu T, Huang L, Su F, Kim S, Zeng J, Shufean MA, Conway T, Shaw KR, Yap TA, Rodon J, Meric-Bernstam F. Patient-specific, tiered, variant-level actionability correlates with functional effect in growth survival assay. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- DiPeri TP, Evans KW, Tzeng CD, Kwong L, Kahle MP, Zheng X, Li D, Tran Cao HS, Vu T, Kim S, Su F, Kirby B, Wathoo C, Raso G, Rizvi Y, Wang H, Janku F, Shaw K, Yap T, Javle M, Rodon J, Meric-Bernstam F. The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Koc S, Lloyd M, Neuhauser S, Noodbakhsh J, Srivastava A, Woo XY, Jeon R, Grover J, Seepo S, Frech C, DiGiovanna J, Evard YA, Wallace T, Moscow J, Doroshow JH, Mitsuade N, Kaochar S, Pan C, Chen MS, Carvarjal-Carmona L, Welm A, Welm B, Lewis MT, Ramaswamy G, Ding L, Li S, Herlyn M, Davies M, Roth J, Meric-Bernstam F, Robinson P, Bult CJ, Davis-Dusenbery B, Dennis A Dean II, Chuang JH. Advancing PDX research through model, data, and bioinformatics with the PDXNet Portal. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Alhalabi O, Naing A, Groisberg R, Hahn A, Zhang S, Berkey SC, Tsimberidou AM, Rodon J, Yap TA, Pant S, Shah AY, Zurita-Saavedra A, Tannir N, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Hainsworth J, Friedman CF, Kurzrock R, Spigel DR, Burris H, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Shames D, Schulze K, Patel A, Swanton C. Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Coleman N, Abbot C, Somaiah N, Piha-Paul S, Pant S, Rodon J, Call S, Boyle S, Meric-Bernstam F, Janku F. Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST). Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, Abrams TA, Kelley RK, Cassier P, Furuse J, Klümpen H, Chang H, Chen L, Komatsu Y, Masuda K, Ahn D, He Y, Soni N, Benhadji KA, Bridgewater JA. Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. Cancer Res 81(13_Supplement), 2021. e-Pub 2021.
- Yap TA, Ashok A, Stoll J, Schwarzbach AE, Blackwell KL, Li T, Kang H, Garber JE, Meric-Bernstam F. Rate of incidental germline findings detected by tumor-normal matched sequencing in cancer types lacking hereditary cancer testing guidelines. J Clin Oncol 39(15_suppl), 2021. e-Pub 2021.
- Damodaran S, Murthy RK, Nusrat M, Saigal B, Trager SC, Tripathy D, Meric-Bernstam F. Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with PIK3CA mutation or PTEN mutation. Cancer Res 81(4_spuulement), 2021. e-Pub 2021.
- Yang F, Rizvi Y, Yuca E, Zhao M, Evans K, Zheng X, Sahin A, Meric-Bernstam F. Loss of Trop2 protein in metaplastic carcinoma of breast by IHC. Cancer Res 81(4_Supplement), 2021. e-Pub 2021.
- Meric-Bernstam F, Hamilton EP, Beeram M, Hanna DL, El-Khoueiry AB, Kang Y, Lee KW, Lee J, Rha SY, Chaves JM, Oh D, Goodwin RA, Ajani JA, Gray T, Woolery J, Elimova E. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. J Clin Oncol 39(3_suppl), 2021. e-Pub 2021.
- Gouda M, Huang H, Piha-Paul S, Call SG, D Karp D, Fu S, Naing A, Subbiah V, Pant S, A Tsimberidou M, D Hong S, Rodon J, Meric-Bernstam F. Circulating Tumor DNA Dynamics Predict Outcomes of Systemic Therapy in Patients with Advanced Cancers. European Journal of Cancer 138(Supplement 2, S3), 2020. e-Pub 2020.
- Cruz Pico CX, Evans KW, Chen K, Zheng X, Akcakanat A, Zhao M, Tapia C, Scott SM, Yuca E, Meric-Bernstam F. Overcoming PARP inhibitor resistance with molecularly guided rational combinations in triple-negative breast cancer patient-derived xenograft models. Cancer Res 80(16_Supplement), 2020. e-Pub 2020.
- Shen Y, Pico CC, Mohanty V, Johnson A, Zeng J, Shaw KM, Chen K, Meric-Bernstam F. Utility of Assessing HER2 RNA expression for precision medicine. Cancer Res 80(16_Supplement), 2020. e-Pub 2020.
- Boni V, Howard A Burris III, Liu JF, Spira AI, Arkenau H, Fidler MJ, Rosen LS, Sweis RF, Uboha NV, Sanborn RE, O'Neil B, Harding JJ, LoRusso P, Weise AM, Garcia-Corbacho J, Victoria I, Frye JW, Li R, Stroh M, Meric-Bernstam F. CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). J Clin Oncol 38(15_suppl), 2020. e-Pub 2020.
- Murthy R, Sheth R, Subbiah V, Janku F, Naing A, Rodon J, Yap TA, Diab A, Patel SP, Tam A, Gupta S, Meric-Bernstam F. Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center. J Clin Oncol 38(15_suppl), 2020. e-Pub 2020.
- Avila M, Wathoo C, Zeng J, Andersen C, Yuan Y, Yap TA, Ahnert JR, Meric-Bernstam F. Variety of clinical trial enrollment by actionable tumor suppressor genotype. J Clin Oncol 38(15_suppl), 2020. e-Pub 2020.
- Pairawan S, Hess K, Janku F, Sánchez N, Shaw K, Eng C, Damodaran S, Javle M, Kaseb A, Hong D, Subbiah V, Fu S, Fogelman D, Raymond V, Lanman R, Meric-Bernstam F. Cell-Free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. CCR, 2019. e-Pub 2019. PMID: 31852833.
- Yang P, Javle M, Pang F, Zhao W, Abdel-Wahab R, Chen X, Meric-Bernstam F, Chen H, Borad M, Liu Y, Zou C, Mu S, Xing Y, Wang K, Peng C, Che X. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr 8(Suppl 6), 2019. e-Pub 2019. PMID: 31929987.
- Moss TJ, Ahnert JR, Oakley HD, Kahle M, Karp DD, Pant S, Jacob J, Raymond VM, Lanman RB, Kwong L, Routbort M, Soni N, Huang J, Javle MM, Meric-Bernstam F. Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. Journal of Clinical Oncology 37(no. 15_suppl), 2019. e-Pub 2019.
- Matos I, Goyal L, Cleary J, Voss M, Oh D, Meric-Bernstam F, Ng C, Iyer G, Ishii N, Hu Y, Chessex AV, Pokorska-Bocci A, Nicolas V, Kirpicheva Y, Zanna C, Flaherty K, Tabernero J, Hyman D. Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Ann Oncol 30(Suppl 4; Abstr SO-003), 2019. e-Pub 2019.
- Harding J, Cleary J, Shapiro G, Brana I, Moreno V, Quinn D, Borad M, Loi S, Spanggaard I, Stemmer S, Dujka M, Cutler R, Xu F, Eli L, Macia S, Lalani A, Bryce R, Meric-Bernstam F, Solit D, Hyman D, Piha-Paul S. Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial. Ann Oncol 30(Suppl 4; Abstr O-005), 2019. e-Pub 2019.
- Meric-Bernstam F, Boni V, Spira AI, Sanborn RE, H-T A, Sweis R, Burris H, Li R, Yalamanchili S, Will M, Liu JF, Harding JJ, Gautam P. Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the Probody drug conjugate CX-2009 in patients with advanced solid tumors. Cancer Res 79(Suppl 13; Abstr LB-185), 2019. e-Pub 2019.
- Owusu-Brackett N, Scott S, Yuca E, Evans KW, Tapia C, Meric-Bernstam F. Efficacy of adjuvant 5-Fluorouracil in residual HER2-negative breast cancer following neoadjuvant chemotherapy. Cancer Res 79(Suppl 4; Abstr P1-13-04), 2019. e-Pub 2019.
- Zhao M, M-L Z, Zheng X, Su X, Meric-Bernstam. FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells. Cancer Res 79(Suppl 4; Abstr P6-20-12), 2019. e-Pub 2019.
- Liao N, Zhang G, Wang Y, Guo L, Cao L, Zhang Z, Balch CM, Meric-Bernstam. Genomic profiling of 304 treatment-naïve Chinese breast cancer patients: A comparison of Chinese and TCGA cohorts. Cancer Res 79(Suppl 4; Abstr P4-04-08), 2019. e-Pub 2019.
- Shariati M, Paez-Arango N, Bristow CA, Evans KW, Peoples MD, Carugo A, Heffernan TP, Meric-Bernstam. Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer. Cancer Res 79(Suppl 4; Abstr P6-18-13), 2019. e-Pub 2019.
- Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Tapia C, Illeana-Dumbrava E, Janku F, Meric-Bernstam F. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Cancer Res 79(Suppl 4; Abstr P6-21-04), 2019. e-Pub 2019.
- Pairawan SS, Yuca E, Evans K, Annis A, Narasimhan N, Sutton D, Carvajal LA, J-G R, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Illeana-Dumbrava EE, Aivado M, Meric-Bernstam. The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models. Cancer Res 79(Suppl 4; Abstr P6-20-11), 2019. e-Pub 2019.
- Damodaran S, Meric-Bernstam F, Hess KR, Litton JK, Raymond V, Lanman R, Ueno NT, Hamilton S, Wistuba II, Valero V, Moulder SL, Tripathy D. INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC). Cancer Res 79(Suppl 4; Abstr OT1-03-94), 2019. e-Pub 2019.
- Meric-Bernstam F, Shukla N, Peled N, Landman Y, Onitilo A, Montez S, Ku NC, Hyman DM, Drilon A, Hong DS. Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers. Cancer Res 79(Suppl 4; Abstr P6-20-02), 2019. e-Pub 2019.
- Smyth LM, Piha-Paul SA, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga C, de la Fuente M, Brufksy AM, Mau-Sorensen M, Arnedos M, Moreno V, J-H S, Schwartzberg L, Gonzalez-Farre X, Cervantes A, Mann G, Shahin S, Jr CR, Eli LD, Xu F, Bagulho T, Lalani AS, Bryce R, Solit DB, Hyman DM, Meric-Bernstam F, Baselga J. Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial. Cancer Res 79(Suppl 4; Abstr PD3-06), 2019. e-Pub 2019.
- Pairawan S, Evans K, Kopetz S, Akcakanat A, Zhao M, Tapia C, Busaidy N, Dumbrava E, Meric-Bernstam F. The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models. Proceedings of the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, Massachusetts Boston (MA): AACR, 2019, 2019. e-Pub 2019.
- Meric-Bernstam F, Chaves J, Oh D, Lee J, Kang Y, Hamilton E, Mayordomo J, Cobleigh M, Vaklavas C, Elimova E, Ajani J, Rodon J, Rowse G, Gray T, Lai R, Hanna D. Safety and efficacy of ZW25, a HER2‑targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer. Proceedings of the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, Massachusetts Boston (MA): AACR, 2019, 2019. e-Pub 2019.
- Zhao M, Scott S, Evans K, Yuca E, Saridogan T, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani A, Piha-Paul S, Meric-Bernstam F. Combinatorial therapies of neratinib for HER2-amplified cancer. Proceedings of the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, Massachusetts Boston (MA): AACR, 2019, 2019. e-Pub 2019.
- Shariati M, Bristow C, Carugo A, Heffernan T, Zheng X, Peoples M, Tripathy D, Meric-Bernstam F. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Proceedings of the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, Massachusetts Boston (MA): AACR, 2019, 2019. e-Pub 2019.
- Evans K, Moulder S, Yuca E, Scott S, Arango N, Shariati M, Vellano C, Saridogan T, Zheng X, Gonzalez-Angulo A, Zhao M, Su X, Tapia C, Chen K, Akcakanat A, Perou C, Lim B, Tripathy D, Yap T, Francesco M, Draetta G, Jones P, Marszalek J, Meric-Bernstam F. Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer. Proceedings of the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, Massachusetts Boston (MA): AACR, 2019, 2019. e-Pub 2019.
- Sen S, Pestana R, Hess KR, Hong DS, Janku F, Naing A, Falchook GS, Conley AP, Patel S, Meric-Bernstam F, Subbiah V. Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical benefit, and survival in sarcoma patients on phase 1 trials. J Clin Oncol 37(Suppl, Abstr 11018), 2019. e-Pub 2019.
- Naing A, Dumbrava EEI, Murthy R, Meric-Bernstam F, Fox A, Krige D, Carter J, Champion B, Cockl P, Koetz B, McElwaine-John H. A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE). J Clin Oncol 37(Suppl, Abstr TPS2668), 2019. e-Pub 2019.
- Idris T, Barghash M, Kotrotsou A, Huang HJ, Subbiah V, Kaseb AO, Piha-Paul SA, Hong DS, Meric-Bernstam F, Javle MM, Janku F, Colen RR. CT-based radiogenomic signature to identify isocitrate dehydrogenase (IDH)1/2 mutations in advanced intrahepatic cholangiocarcinoma. J Clin Oncol 37(Suppl, Abstr 4081), 2019. e-Pub 2019.
- De Bono JS, Tan DSP, Caldwell R, Terbuch A, Goh BC, Heong V, Haris NM, Bashir S, Hong DS, Meric-Bernstam F, Bordia S, Liu L, Wilkinson G, Hreiki J, Wengner A, Fischer K, Boix O, Lagkadinou E, Plummer E, Yap TA. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. J Clin Oncol 37(Suppl, Abstr 3007), 2019. e-Pub 2019.
- Meric-Bernstam F, Sandhu SK, Hamid O, Spreafico A, Kasper S, Dummer R, Shimizu T, Steegis N, Lewis N, Talluto CC, Dolan S, Bean A, Brown R, Trujillo D, Nair N, Luke JJ. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. J Clin Oncol 37(Suppl, Abstr 2507), 2019. e-Pub 2019.
- Iafrate AJ, Borger DR, Vivancos A, Voss M, Cleary J, Meric-Bernstam F, Tabernero J, Flaherty K, Ishii N, Brichory F, Tanaka H, Pokorska-Bocci A, Baselga J, Nuciforo P. Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347. Cancer Res 79(Suppl 13; Abstr 4881):1254, 2019. e-Pub 2019.
- Hegde A, Huang L, Liu S, Hess K, Cabanillas M, Hu M, Busaidy N, Sherman S, Simon G, Blumenschein G, Papadimitrakopoulou VA, Hong DS, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors in RET dependent cancers. Cancer Res 79(Suppl 13; Abstr 4997), 2019. e-Pub 2019.
- Sen S, Pestana RC, Hess K, Hong DS, Subbiah IM, Conley A, Falchook GS, Benjamin RS, Patel S, Meric-Bernstam F, Subbiah V. Outcomes of geriatric sarcoma patients enrolled in phase 1 clinical trials. Cancer Res 79(Suppl 13; Abstr 3997), 2019. e-Pub 2019.
- Smyth L, Zhou QC, Yu C, Lepisto E, Arnedos M, Hasset M, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel C, Wathoo C, Horlings H, Hudecek J, Gao JJ, Schultz N, Zarski A, Lee J, Sheffler-Collins S, Park BH, Sawyers C, Andre F, Levy M, Meric-Bernstam F, Bedard P, Lasonos A, Schrag D, Hyman D, Consortium G. Use of AACR Project GENIE, a clinicogenomic registry, to defıne the natural history of AKT1E17KMutant ER+/HER2-metastatic breast cancer (MBC). Proceedings of the American Association for Cancer Research 60(Abstr 3463):892, 2019. e-Pub 2019.
- LeNoue-Newton M, S-C C, Stricker T, Hyman D, Bedard P, Meric-Bernstam F, Punglia RS, Schrag D, Lepisto E, Andre F, Smyth L, Dogan S, Yu C, Wathoo C, Levy M, Mann G, Lalani AS, Micheel C, Arnedos M. Natural history and clinical characteristics of ERBB2 mutant hormone receptor-positive breast cancers: Results from the AACR Project GENIE Registry. Proceedings of the American Association for Cancer Research 60(Abstr 1724):442, 2019. e-Pub 2019.
- Won HH, Selcuklu SD, Piha-Paul SA, Saura C, Rodon J, Mayer IA, Loi S, Shapiro GI, Lu J, Brufsky A, Zimel C, Melcer M, Scaltriti M, Eli LD, Cutler RE, Lalani AS, Bryce RP, Arteaga C, Meric-Bernstam F. Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT 'Basket' trial. Cancer Res 79(Suppl 13; Abstr 929):240, 2019. e-Pub 2019.
- Moss T, Rodon J, Oakley H, Kahle M, Karp D, Pant S, Jacob J, Raymond V, Lanman R, Kwong L, Routbort M, Soni N, Huang J, Javle M, Meric-Bernstam F. Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. J Clin Oncol 37(Suppl, Abstr 3056), 2019. e-Pub 2019.
- Meric-Bernstam F, H-T A, Tran B, Bahleda R, Kelley RK, Hierro C, Ahn DH, Zhu AX, Javle M, He H, Huang J, Goyal L. TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in pretreated patients with cholangiocarcinoma. Proceedings of the Cholangiocarcinoma Foundation Annual Conference, 2019. e-Pub 2019.
- Meric-Bernstam F, Beeram M, Hanna D, Ajani J, Bendell J, Murphy MB, El-Khoueiry A, Lenz HJ, Pant S, Patnaik A, Press MF, Raghav K, Hausman D, Thimmarayappa J, Hamilton E. Single-agent activity of ZW25, a HER2 targeted bispecific antibody, in HER2-expressing gastroesophageal and other cancers. Proceedings of the Cholangiocarcinoma Foundation Annual Conference, 2019. e-Pub 2019.
- Hegde A, Jayaprakash P, Sumner E, Nguyen D, Zain H, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava E, Yap T, Subbiah V, Bhosale P, Higgins J, Williams ET, Wilson TF, Meric-Bernstam F, Curran M, Hong D. A phase 1 dose escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies. J Immunotherap Cancer 7(Suppl 1, Abstr P348), 2019. e-Pub 2019.
- O'Sullivan Coyne G, Yap T, Moore N, Mittra A, Takebe N, Juwara L, Khan S, Dumbrava E, Streicher H, Piekarz R, Sharon E, Meric-Bernstam F, Parchment R, Navas T, Fung K, Mitchell J, Fino K, Montez S, Doyle A, Rubinstein L, Doroshow J, Chen A. Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. Proceedings of the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, Massachusetts Boston (MA): AACR, 2019, 2019. e-Pub 2019.
- Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Dumbrava EI, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Proceedings of the 14th Annual Academic Surgical Congress, February 5-7, Houston, Texas(Abstr 24.07), 2019. e-Pub 2019.
- Meric-Bernstam F, Goyal L, Tran B, Matos I, H-T A, He H, Huang J, Bahleda R. TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study. Cancer Res 79(Suppl 13; Abstr CT238), 2019. e-Pub 2019.
- Kurnit KC, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gerhenson DM, Mills GB, Westin SN. Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations. Cancer Res 79(Suppl 13; Abstr CT020), 2019. e-Pub 2019.
- Shariati M, Meric-Bernstam F. Combined inhibition of DDR1with CDK4/6 induced synergistic effect in ER-positive, HER2-negative breast cancer having PIK3CA/AKT1 mutations. Proceedings of the American Association for Cancer Research 60(Abstr 396):101, 2019. e-Pub 2019.
- Meric-Bernstam F, Lee RJ, Carthon BC, Iliopoulos O, Mier JW, Patel MR, Tannir NM, Owonikoko T, Haas N, Voss MH, Harding JJ, Srinivasan R, Shapiro G, Telli MI, Munster PN, Carvajal RD, Jenkins Y, Whiting SH, Bendell J, Bauer TM. CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study. J Clin Oncol 37(Suppl 7S, Abstr 549), 2019. e-Pub 2019.
- Eckhardt BL, Torres AM, Woodward WA, Krishnamurthy S, Meric-Bernstam F, Ueno NT. EphA2: An emerging target in triple-negative breast cancer. Cancer Res Suppl; 4; Abstr P3-07-04, 2018. e-Pub 2018.
- Lam M, Pereira AA, Loree JM, Advani SM, Overman MJ, Bailey A, Johnson A, Holla V, Sanchez NS, Khotskaya Y, Meric-Bernstam F, Kopetz S, Pant S. Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting. J Cln Oncol 36(Suppl, Abstr 3522), 2018. e-Pub 2018.
- Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F, Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Ahnert JR, Tawbi HA, Welsh JW, Meric-Bernstam F, Hong DS. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. J Clin Oncol 36(Suppl 4S, Abstr 12052), 2018. e-Pub 2018.
- Wyant T, Tuck D, Y-J B, Ma A, Sosman J, Daud A, Powderly J, Garcia-Corbacho J, Patel M, Lee J, K-P K, Brody J, Rha SY, Hamilton E, Martin MG, Aix SP, Ramchandren R, M-J A, Spicer J, Pacey S, Falchook G, Meric-Bernstam F. Pharmacodynamic effects of CA170, a first-in-class. J Immunother Cancer 6(Suppl 1, Abstr P139), 2018. e-Pub 2018.
- Nusrat M, Oh J, Z-Q J, Fogelman DR, Kee BK, Menter D, Raghav KPS, Morris VK, Wu J, Meric-Bernstam F, Morris J, Overman MJ, Kopetz S. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. J Clin Oncol 36(Suppl, Abstr 3549), 2018. e-Pub 2018.
- Tran B, Meric-Bernstam F, H-T A, Bahleda R, Kelley RK, Hierro C, Ahn D, Zhu A, Javle M, Winkler R, He H, Huang J, Goyal L. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s. Ann Oncol 29(Suppl 9; Abstr 1550), 2018. e-Pub 2018.
- Robichaux JP, Elamin YY, Tan Z, Vailati Negrao M, Routbort M, Roeck B, Li S, Liu S, Chen T, Rodon Ahnert J, Diao L, Nilsson MB, Zhang S, Yang Z, Wang J, Meric-Bernstam F, K-K W, Heymach JV. Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing. Cancer Res 78(Suppl 13, Abstr 4772), 2018. e-Pub 2018.
- Subbiah V, Erwin W, Mawlawi O, Gonzalez-Lepera C, Tokura M, Kurman M, Liu H, Hong DS, Meric-Bernstam F, Pant S, Johansen M, Madden T, Santos E, Ravizzini G. Phase 1 study of FF-21101(90Y), a radioimmunotherapeutic (RIT) targeting P-cadherin, in advanced solid tumors. Cancer Res 78(Suppl 13, Abstr CT128), 2018. e-Pub 2018.
- Pant S, Subbiah V, Rodon J, Janku F, Hong DS, Karp D, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Schwartz B, Meric-Bernstam F, Yap T. Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. Cancer Res 78(Suppl 13, Abstr CT024), 2018. e-Pub 2018.
- Mehrvarz Sarshekeh A, Loree J, Pereira AA, Raghav KP, Lam M, Advani SM, Davis JS, Dasari A, Morris VK II, Menter D, Eng C, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The rate of novel actionable mutations in standard of care NGS panel testing in gastrointestinal malignancies. J Clin Oncol 36(Suppl 4S, Abstr 640), 2018. e-Pub 2018.
- Ku P, Kyrish K, Terrell JA, Liebig Akay C, Bedrosian I, Black DM, Caudle AS, Checka C, Feig BW, Hunt K, Hwang RF, Kuerer HM, Lucci A, Meric-Bernstam F, Refinetti AP, Reyna C, Ross MI, Teshome M, Thompson AM, DeSnyder SM. Opioid prescriptions after breast cancer surgery: Perception and reality 36(Suppl, Abstr e18799), 2018. e-Pub 2018.
- Xing Y, Guo Y, Ning Chang JC, Patel TA, Kheder E, Meric-Bernstam F, Y-CT S. Off-label use of everolimus and associated factors in non-elderly cancer patients with private insurance in the United States. J Clin Oncol 36(Suppl, Abstr e18718), 2018. e-Pub 2018.
- Bauer TM, Gounder MM, Weise AM, Schwartz GK, Rd C, Kumar P, Zernovak O, Beck A, Doyle J, Mendell-Harary J, Kochan JP, Chen S, LoRusso P, Tap WD, Somaiah N, Hyman DM, Meric-Bernstam F, Hong DS. A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma(WD/DD LPS), solid tumors (ST) and lymphomas (L). J Clin Oncol 36(Suppl, Abstr 11514), 2018. e-Pub 2018.
- Groisberg R, Hess KR, Hong DS, Heymach J, Naing A, Piha-Paul SA, Janku F, Javel MM, I-N HM, Conley AP, Meric-Bernstam F, Subbiah V. Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials. J Clin Oncol 36(Suppl, Abstr 2590), 2018. e-Pub 2018.
- Yap TA, Burris HA, Kummar S, Falchook GS, Pachynski RK, LoRusso P, Tykodi SS, Gibney GT, Gainor JF, Rahma OE, Seiwert TY, Meric-Bernstam F, Blum Murphy MA, Keating Litton J, Diament Hooper EM, Hirsch HA, Harvey C, Clancy M, McClure T, Callahan MK. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. J Clin Oncol 36(Suppl, Abstr 3000), 2018. e-Pub 2018.
- Sanchez NS, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Kahle M, Kaseb AO, Javle MM, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Rael Shaw K, Meric-Bernstam. Identification of actionable genomic alterations utilizing cfDNA. J Clin Oncol 36(Suppl, Abstr 12110), 2018. e-Pub 2018.
- Meric-Bernstam F, Beeram M, Mayordomo JI, Hanna K. Single agent activity of ZW25, a HER2‑targeted bispecific antibody, in heavily pretreated HER2‑expressing cancers. J Clin Oncol 36(Suppl, Abstr 2500), 2018. e-Pub 2018.
- Kamiya-Matsuoka C, Metrus NR, Shaw KR, Penas-Prado M, S-PS W, Loghin ME, Alfaro-Munoz K, Yuan Y, O'Brien BJ, Harrison RA, Yung WKA, Meric-Bernstam F, De Groot JF. The natural course of hypermutator gliomas. J Clin Oncol 36(Suppl, Abstr 2014), 2018. e-Pub 2018.
- Subbiah V, Cascone T, Hess KR, Subbiah IM, Nelson S, Morikawa N, Nilsson MB, Bhatt T, Ali S, William WN, Raymond VM, Lanman RB, Carbone DP, Saiga R, Owonikoko K, Simon GR, Meric-Bernstam F, Doebele RC, Heymach J. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. J Clin Oncol 36(Suppl, Abstr 9035), 2018. e-Pub 2018.
- Kheder E, Xing Y, Hess KR, Janku F, Shaw KR, Huang L, Patel K, Meric-Bernstam F, Subbiah V. Non-V600 BRAF mutations in advanced malignancies: Prevalence and survival impact. J Clin Oncol 36(Suppl, Abstr 12100), 2018. e-Pub 2018.
- Tannir NM, Fan AC, Lee RJ, Carthon BC, Iliopoulos O, Mier JW, Patel MR, Meric-Bernstam F, DeMichele A, Voss MH, Harding JJ, r S, Shapiro G, Telli ML, Munster PN, Carvajal RD, Jenkins Y, Whiting SH, Bendell JC, Bauer TM. Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). J Clin Oncol 36(Suppl 6S, Abstr 603), 2018. e-Pub 2018.
- Hong DS, Parikh A, Shapiro G, Varga A, Naing A, Meric-Bernstam F, Reyderman L, Bao X, Binder TA, Ren M, Siu A, Xu L, Liu M, Dayal S, Bhagawati-Prasad V, Tchakov I, Owa T, Ooi C, Marabelle A. Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor in patients with advanced solid tumors: clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression. J Clin Oncol 36(Suppl 4S, Abstr 640), 2018. e-Pub 2018.
- Pant S, Spira AI, Cho BC, Goel S, Hoimes CJ, Alva AS, Balaraman R, Bauer TM, Lowry PA, Ramaekers RC, Siegel RD, Verner TL, Tannier NM, Faltaos D, Potvin D, Neuteboom STC, Christensen J, Chao RC, Kyriakopoulos. Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT) 36(Suppl, Abstr 4568), 2018. e-Pub 2018.
- Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Meric-Bernstam F. Efficacy of PI3Kβ inhibitor AZD8186 in PTEN-deficient triple-negative breast cancer. Cancer Res 78(Suppl 13, Abstr 5802), 2018. e-Pub 2018.
- Wang F, Zhang S, Chen Y, Hart T, Shaw K, Meric-Bernstam F, Mills G, Chen K. ARDE: Detecting selectively expressed cancer driver mutations through integration of exome and transcriptome sequencing data. Cancer Res 78(Suppl 13, Abstr 2346), 2018. e-Pub 2018.
- Groisberg R, Rosznik J, Meric-Bernstam F, Subbiah V. Comprehensive evaluation of antibody-drug conjugate targets for drug development across tumor types: Analysis from TCGA. Cancer Res 78(Suppl 13, Abstr 2343), 2018. e-Pub 2018.
- Di Francesco ME, Marszalek JR, McAfoos T, Carroll CL, Kang Z, Liu G, Theroff JP, Bardenhager JP, Bandi ML, Molina JR, Gera S, Protopopova M, Sun Y, Geck Do MK, Feng N, Gay JP, Muller F, Konopleva M, Meric-Bernstam F, Toniatti C, Heffernan TP, Draetta GF, Jones P. Discovery and development of IACS-010759, a novel inhibitor of Complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors. Cancer Res 78(suupl 13, Abstr 1655), 2018. e-Pub 2018.
- Sen S, Hess KR, Roszik J, Shaw KR, Heymach J, Huang L, Schwartz GK, Meric-Bernstam F, Subbiah V. Characterization of KEAP1-NRF2 genomic alterations across diverse tumor types: Co-occurring alterations, survival outcomes, and implications for targeting cancer metabolism. J Clin Oncol 36(Suppl, Abstr 2558), 2018. e-Pub 2018.
- Piha-Paul SA, Fu S, Hong DS, Janku F, Karp DD, Naing A, Pant S, Ahnert JR, Subbiah V, Tsimberidou AM, Yap TA, Meric-Bernstam F. Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. J Clin Oncol 36(Suppl, Abstr TPS2611), 2018. e-Pub 2018.
- Janku F, Jegede O, Puhalla SL, Konstantiopoulos P, Meric-Bernstam F, Mitchell EP, Zwiebel JA, McShane LM, Li S, Rubinstein LV, Doyle LA, Patton D, Conley BA, O'Dwyer PJ, Harris LN, Arteaga C, Williams PM, Hamilton SR, Chen AP, Flaherty KT. NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. Ann Oncol 29(Suppl 8; Abstr 418PD), 2018. e-Pub 2018.
- Sarshekeh AM, Loree JM, Manyam GC, Pereira AAL, Raghav KPS, Lam M, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The characteristics of ARID1A mutations in colorectal cancer. J Clin Oncol 36(Suppl, Abstr 3595), 2018. e-Pub 2018.
- Kalinsky K, Harding JJ, DeMichele A, Infante JR, Gogineni K, Owonikoko TK, Isakoff S, Iliopoulos O, Patel MR, Munster P, Telli ML, Jenkins Y, Fiji GP, Whiting SH, Meric-Bernstam. Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer. Cancer Res 78(Suppl 4; Abstr PD3-13), 2018. e-Pub 2018.
- Hamilton E, Meric-Bermsta F, Infante J, Murthy R, Patnaik A, Piha-Paul SA, Tolcher A, Royer N, Beeram M. Phase 1 dose escalation with ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-high breast cancer (BC). Cancer Res 78(Suppl 4; Abstr P5-20-06), 2018. e-Pub 2018.
- Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Dumbrava EI, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Proceedings of the AACR Targeting PI3K/mTOR Signaling, November 30-December 3, Boston, MA(Abstr B07), 2018. e-Pub 2018.
- Piha-Paul SA, Xiong WW, Moss T, Mostorino RM, Sedelmeier S, Hess K, Fu S, Hong D, Janku F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou AM, Yap T, Javle M, Tapia C, Shaw KR, Eterovic K, Mills GB, Meric-Bernstam F. Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer). Mol Cancer Therap 17(Suppl 1; Abstr A096), 2018. e-Pub 2018.
- Dumbrava EI, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Broaddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong DS, ahnert JR, Shaw K, Piha-Paul S, Meric-Bernstam F. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. Mol Cancer Therap 17(Suppl 1; Abstr A167), 2018. e-Pub 2018.
- Lim B, Park IA, Wang Y, Bollu L, Brown P, Baggerly K, Meric-Bernstam F, Ueno N. TNBC kinase prioritization for targeted therapy after chemotherapy resistance. Mol Cancer Therap 17(Suppl 1; Abstr LB-B22), 2018. e-Pub 2018.
- Kono M, Fujii T, Matsuda N, Harano K, Chen H, Wathoo C, Aron JY, Tripathy D, Meric-Bernstam F, Ueno NT. Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. Cancer Res 78(Suppl; 4; Abstr P1-16-04), 2018. e-Pub 2018.
- Kono M, Fujii T, Matsuda N, Chen H, Wathoo C, Aron JY, Tripathy D, Meric-Bernstam F, Ueno NT. Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. Cancer Res 78(Suppl 4; Abstr P1-16-04), 2018. e-Pub 2018.
- Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J. Phase I dose-finding study of MIW815 (ADU-S100),. J Immunother Cancer 6(Suppl 1, Abstr P309), 2018. e-Pub 2018.
- Wang Y, Loree JM, Yu C, Tschautscher M, Briggler AM, Overman MJ, Broaddus R, Meric-Bernstam F, Jones JC, Balcom J, Kipp B, Kopetz S, Grothey A. Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer. J Clin Oncol 36(Suppl, Abstr 3513), 2018. e-Pub 2018.
- Pairawan SS, Hess KR, Janku F, Sanchez NS, Eng C, Damodaran S, Javle MM, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer. J Clin Oncol 36(Suppl, Abstr 12022), 2018. e-Pub 2018.
- Sen S, Hong DS, Hess K, Meric-Bernstam F, Subbiah V. Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose. Mol Cancer Therap 17(Suppl 1; Abstr A199), 2018. e-Pub 2018.
- Reilley M, Ager C, Meng M, Tsimberidou A, Piha-Paul S, Yap T, Fu S, Naing A, Rodon J, Nguyen L, Bhosale P, Schmidt M, Baumann M, Meric-Bernstam F, Curran M, Hong D. Combination of subcutaneously administered TLR9. J Immunother Cancer 6(Suppl 1, Abstr P299), 2018. e-Pub 2018.
- Keene KS, King T, Hwang ES, Peng B, McGuire K, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic KA, Hudis C, Wolff A, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Molecular determinants of post-mastectomy breast cancer recurrence. Cancer Res 78(Suppl; 4; Abstr P3-04-01), 2018. e-Pub 2018.
- Cleary JM, Voss MH, Meric-Bernstam F, Hierro C, Heist RS, Ishii N, Kirpicheva Y, Nicholas-Metral V, Pokorska-Bocci A, Vaslin A, Venetz W, Zanna C, Flaherty K, Tabernero J, Baselga J. Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated biliary tract cancer (BTC). J Clin Oncol 36(Suppl 4S, Abstr 447), 2018. e-Pub 2018.
- Naing A, Autio KA, Falchook GS, Meric-Bernstam F, Litton JK, Ibrahim NK, Hung A, Oft M, Leveque J, Patel MR. Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy. Ann Oncol 29(Suppl 8; Abstr 1145P), 2018. e-Pub 2018.
- Meric-Bernstam F, Arkenau H, Tran B, Bahleda R, Kelley R, Hierro C, Ahn D, Zhu A, Javle M, Winkler R, He H, Huang J, Goyal L. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann Oncol 29(Suppl 5; Abstr O-001), 2018. e-Pub 2018.
- Alshawa A, Fujii T, Sbeih HA, Blechacz B, Bilen MA, Hess KR, Suarez-Almazor ME, Hong DS, Tsimberidou AM, Gong J, SStephen B, Subbiah V, Piha-Paul SA, fu S, Mendoza TR, Thirumurthi S, Meric-Bernstam F, Naing A, Miller E. Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment. J Clin Oncol 36(Suppl 5S), 2018. e-Pub 2018.
- Raghav KP, Loree JM, Morris J, Manuel S, Crosby S, Meric-Bernstam F, Menter D, Raymond V, Lanman RB, Talasaz A, Kopetz S. Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC). J Clin Oncol 36(Suppl 4S, Abstr 661), 2018. e-Pub 2018.
- Sen S, Hess KR, Hong DS, Naing A, Huang L, Meric-Bernstam F, Subbiah V. Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials. J Clin Oncol 36(Suppl, Abstr 3077), 2018. e-Pub 2018.
- Willauer AN, Loree JM, Pereira AA, Lam M, Raghav KP, Morris VK II, Menter D, Shaw KR, Boraddus R, Meric-Bernstam F, Wang Y, Overman MJ, Kopetz S. Clinical and molecular characterization of early-onset colorectal cancer patients with inflammatory bowel disease. J Clin Oncol 36(Suppl, Abstr 689), 2018. e-Pub 2018.
- Sheth R, Murthy R, Meric-Bernstam F, hong D, Patel S, Tam A. Image-guided intratumoral delivery of. J Immunother Cancer 6(Suppl 1, Abstr P619), 2018. e-Pub 2018.
- Creasy C, Haymaker C, M-A F, Singh G, Tapia C, Bernatchez C, Painter J, Meric-Bernstam F, Creasy C. Exposure to anti-PD-1 causes Functional Differences. J Immunother Cancer 6(Suppl 1, Abstr P542), 2018. e-Pub 2018.
- Wyant T, Y-L B, Sosman J, Daud A, Meric-Bernstam F, Garcia-Corbacho J, Patel M, Lee J, K-P K, Brody J, Rha SY, Martin MG, Aix SP, Hamilton E, Ramchandren R, M-J A, Spicer J, Pacey S, Falchook G, Wang H, Xu G, Adams L, Ma A, Ghararvi R tuck D, Powderly J. Phase 1 study of CA-170, a first-in-class, orally. J Immunother Cancer 6(Suppl 1, Abstr P341), 2018. e-Pub 2018.
- Sakamuri D, Kato S, Huang HJ, Naing A, Holley VR, Patel S, Piha-Paul SA, Tsimb eridou AM, Hong DS, Meric-Bernstam F, Janku F. Dose escalation study of vemurafenib with crizotinib or sorafenib in patient with BRAF-mutated advance cancers. Ann Oncol 28(Suppl 5; Abstr 404P), 2017. e-Pub 2017.
- Garcia-Corbacho J, Spira A, Boni V, Feliu J, Middleton M, Burris H, Yang Weaver A, Will M, Harding J, Meric-Bernstam F, Heinemann V. PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally avanced unresectable solid tumors. Ann Oncol 28(Suppl 5, Abstr 422TiP), 2017. e-Pub 2017.
- Meric-Bernstam F, Gordon M, Tykodi S, Lam E, Vaishampayan U, Chaves J, Nikolinakos P, Fan A, Lee R, McDermott D, Shapiro G, Gandhi L, Tawbi H, Bhatia S, Muigai L, Jenkins Y, Whiting S, Voss M. A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC). J Immunother Cancer 5(Suppl 2):86, 2017. e-Pub 2017.
- Bang YJ, Powderly J, Patel M, Kim KP, Lee J, Brody J, Garcia-Corbacho J, Rha SY, Meric-Bernstam F, Hamilton E, Aix SP, Ramchandren R, Sosman J, Ahn MJ, Snozl M, Falchook G, Martin MG, Wang H, Adams L, Caldwell C, Lazorchak A, Wyant T, Ma A, Tuck D, Daud A. Phase 1 trial of CA-170, a first-in-class, orally available, small molecule immune checkpoint inhibitor (ICI) dually targeting PD-L1 and VISTA, in patients with advanced solid tumors or lymphomas. J Immunother Cancer 5(Suppl 2):86, 2017. e-Pub 2017.
- Danysh BP, Busaidy N, Sinha D, Evans KW, Akcakanat A, Meric-Bernstam F, Cabanillas ME, Ringel MD, Shah MH, Hofmann M. BRAF mutant papillary thyroid cancer cells with concurrent mutations along the KRAS-RACI axis develop resistance to BRAF(V600E)-inhibitors and are associated with increases in EMT markers. Thyroid 27(Suppl 1), 2017. e-Pub 2017.
- Sen S, Roszik J, Meric-Bernstam F, Subbiah V. Hormone receptor (AR/ER/PR) expression as a prognostic marker and novel candidate for drug development across multiple tumor types. J Clin Oncol 35(Suppl, Abstr 2537), 2017. e-Pub 2017.
- Vallecillo LB, Chang JT, Chen K, Moss TJ, Shaw KR, Meric-Bernstam F, Eterovic AK, Mills GB, Mani S, Li X, Gilcrease M, Moulder S. Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival. J Clin Oncol 35(Suppl, Abstr 1090), 2017. e-Pub 2017.
- Groisberg R, Hong DS, Janku H, Jiang Y, Wei C, Karp DD, Tsimberidou AM, Naing A, Bhalla KN, Meric-Bernstam F, Subbiah V. SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients. J Clin Oncol 35(Suppl, Abstr 2588), 2017. e-Pub 2017.
- Groisberg R, Hong DS, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical next generation sequencing for precision oncology in rare cancers. J Clin Oncol 35(Suppl, Abstr 2582), 2017. e-Pub 2017.
- Ferrarotto R, Glisson B, Blumenschein G, Hong D, Piha-Paul S, Jain D, Alshawa A, Painter J, Hess K, Colen R, Bernatchez C, Lu C, Stephen B, Tapia C, Mendoza T, Meric-Bernstam F, Naing A. Efficacy of pembrolizumab in patients with cutaneous aquamous. J Immunother Cancer 5(Suppl 2, Abstr P425), 2017. e-Pub 2017.
- Habra MA, Campbell M, Jimenez C, Karp D, hong D, Subbiah V, Pant S, Painter J, Khan S, Bernatchez C, Stephen B, Alshawa A, Tapia C, Mendoza T, Colen R, Hess K, Meric-Bernstam F, a N. Efficacy of pembrolizumab (MK-3475) in patients with. J Immunother Cancer 5(Suppl 2, Abstr P424), 2017. e-Pub 2017.
- Creasy C, Haymaker C, M-A F, Singh G, Tapia C, Painter JM, Meric-Bernstam F, Bematchez C, Naing A. Impact of anti- PD1 on TIL phenotype and function. J Immunother Cancer 5(Suupl 2, Abstr P316), 2017. e-Pub 2017.
- Jassowicz A, Liu L, Huang H, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Toung J, Vijayaraghavan R, Zhang R, Kang H, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder S, Kopetz S, Amaria R, Meric-Bernstam F, Janku F. Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes. Ann Oncol 28(Suppl 5; Abstr 125P), 2017. e-Pub 2017.
- Meric-Bernstam F, Beeram M, Blum MA, Hausman DF, Infante JR, Patnaik A, Piha-Paul SA, Rasco DW, Rowse G, Thimmarayappa J, Tolcher AW, Hamilton EP. Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2‑expressing cancers. J Clin Oncol 35(Suppl, Abstr 1035), 2017. e-Pub 2017.
- Pant S, Wheler JJ, Fu S, Hong DS, Karp DD, Subbiah V, Tsimberidou AM, Holley VR, Brewster AM, Koenig KH, Ibrahim NK, Murthy RK, Meric-Bernstam F, Janku F. Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance. J Clin Oncol 35(Suppl, Abstr 2583), 2017. e-Pub 2017.
- Falchook GS, Infante JR, Meric-Bernstam F, Miller LL, Morison K, Vallner D, Sperry S, Goel V, Chiang GG, Webster K, Barton J, Patel MR. A phase 1 dose escalation study of eFT508, an inhibitor of mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK-1) and MNK-2 in patients with advanced solid tumors. J Clin Oncol 35(Suppl, Abstr 2579), 2017. e-Pub 2017.
- Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Meng X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, Mitra R, Wu S, Sood A, Coleman RL. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. J Clin Oncol 35(Suppl, Abstr TPS2604), 2017. e-Pub 2017.
- Naing A, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Colen RR, Carter BW, Evans E, A-H T, Karp DD, Subbiah V, Dev R, Hess KR, Ueno NT, Simon GR, Overman MJ, Coleman RL, Meric-Bernstam F. Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies. J Clin Oncol 35(Suppl, Abstr TPS2603), 2017. e-Pub 2017.
- Sen S, Piha-Paul SA, Kato S, Karp DD, Janku F, Fu S, Naing A, Pant S, Tsimberidou AM, Subbiah V, Kurzrock R, Meric-Bernstam F, Hong DS. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers. J Clin Oncol 35(Suppl, Abstr 2526), 2017. e-Pub 2017.
- Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Sweeney C, Yoo B, Beattie MS, Patel R, Schulze K, Lam ET. Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. J Clin Oncol 35(Suppl, Abstr 6086), 2017. e-Pub 2017.
- Varadhachary GR, Raghav KPS, Pant S, Janku F, Fu S, Hong DS, Piha-Paul SA, Colen RR, Subbiah V, Painter J, Tsimberidou AM, Stephen B, Karp DD, McQuinn L, Mendoza TR, Hess KR, Meric-Bernstam F, Naing A. Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary. J Clin Oncol 35(Suppl, Abstr TPS3103), 2017. e-Pub 2017.
- Moehrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eng C, Kopetz S, Skog J, Meric-Bernstam F, Janku F. Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers. J Clin Oncol 35(Suppl, Abstr 11551), 2017. e-Pub 2017.
- Hainsworth JD, Bose R, Sweeney C, Meric-Bernstam F, Hurwitz H, Swanton C, Burris HA, Kurzrock R, Yoo B, Beattie MS, Gupta R, Patel RD, Schulze K, Spigel DR. Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. J Clin Oncol 35(Suppl, Abstr 9073), 2017. e-Pub 2017.
- Loree JM, Miron B, Holla V, Overman MJ, Pereira AAL, Lam M, Morris VK, Raghav KPS, Routbort M, Shaw KR, Burck N, Sharivkin R, Edelheit O, Meric-Bernstam F, Vidne M, Tarcic G, Kopetz S. Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations. J Clin Oncol 35(Suppl, Abstr 3589), 2017. e-Pub 2017.
- Goyal L, H-T A, Tran B, J-C S, r B, Mak G, Zhu A, Javle M, Hiroshi H, Benedetti F, Huang J, Winkler R, Meric-Bernstam F. Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. Ann Oncol 28(Suppl 3; Abstr O-020), 2017. e-Pub 2017.
- Xing Y, Xu Y, Meric-Bernstam F, Chang JCN, Shjih Y-C T. Prescription trends of everolimus in non-elderly cancer patients with private insurance in the United States. J Clin Oncol 35(Suppl, Abstr e18016), 2017. e-Pub 2017.
- Livingston JA, Posey K, Subbiah V, Daw NC, Somalah N, Ravi V, Patel S, Benjamin RS, W-L W, Lazar A, Broaddus R, Meric-Bernstam F, Shaw KR, Roszik J, Conley AP. Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations. J Clin Oncol 35(Suppl, Abstr 11019), 2017. e-Pub 2017.
- Janku F, De Groot JF, Javle MM, Penas-Prado M, Shroff RT, Luthra R, Banks K, Lanman RB, Conley AP, Broaddus R, Davies MA, Kopetz S, Yung WKA, Heymach J, Fu S, Shaw KR, Meric-Bernstam F. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. J Clin Oncol 35(Suppl, Abstr 11609), 2017. e-Pub 2017.
- Albanell J, Gonzalez A, Gonzalez-Angulo AM, Eterovic AK, Martinez-De Duenas E, Zheng X, Guerrero A, Liu S, Perez-Carrion R, Chen K, Chacon JI, Mills GB, Novoa SA, Blancas I, Sanchez-Arago M, Carrasco EM, Caballero R, Rojo F, Meric-Bernstam F, Hernandez AL. Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study. J Clin Oncol 35(Suppl, Abstr 1017), 2017. e-Pub 2017.
- Dumbrava EEI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Routbort M, Piha-Paul SA, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. J Clin Oncol 35(Suppl, Abstr 1524), 2017. e-Pub 2017.
- Dumbrava EEI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Piha-Paul SA, Subbiah V, Hong DS, Woodman SE, Mendelsohn J, Yap TA, Mills GB, Chen K, Meric-Bernstam F. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. J Clin Oncol 35(Suppl, Abstr 11567), 2017. e-Pub 2017.
- Piha-Paul SA, Hierro C, Boni V, Moreno V, Hahn NM, Titting RL, Bauer TM, Aggarwal RR, Gourlay S, Smith P, Venetsanakos E, Meric-Bernstam F, Brameld K, Karr D, Tabernero J. A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations. J Clin Oncol 35(Suppl, Abstr TPS2616), 2017. e-Pub 2017.
- Slavin TP, Banks K, Chudova D, Oxnard GR, Jl O, Nagy RJ, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek M, Lilly MB, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. J Clin Oncol 35(Suppl, Abstr 1514), 2017. e-Pub 2017.
- Meric-Bernstam F, Saleh MN, Infante JR, Goel S, Falchook GS, Shapiro G, Chung KY, Conry RM, Hong DS, S-Z W, Steidl U, Walensky LD, Guerlavais V, Payton M, Annis DA, Aivado M, Patel MR. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J Clin Oncol 35(Suppl, Abstr 2505), 2017. e-Pub 2017.
- Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Gandhi L, Ishii N, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Purcea D, Vaslin A, Moulon C, Zanna C, Flaherty K, Tabernero J, Baselga J. Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors. J Clin Oncol 35(Suppl, Abstr 2500), 2017. e-Pub 2017.
- Jain A, Shroff RT, Zuo M, Weatherly J, Meric-Bernstam F, Isaacs R, Ali SM, Bekaii-Saab TS, Javle MM. Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC). J Clin Oncol 35(Suppl, Abstr 4086), 2017. e-Pub 2017.
- Payton M, Pinchasik D, Mehta A, Goel S, Zain JM, Sokol L, Jacobsen SE, Patel MR, Horwitz SM, Meric-Bernstam F, Shustov A, Weinstock D, Aivado M, Annis DA. Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma. Ann Oncol 28(Suppl 5; Abstr 1039TiP), 2017. e-Pub 2017.
- Piha-Paul SA, Xiong WW, Moss T, Mostorino RM, Sedelmeier S, Hess K, Fu S, Hong D, Janu F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou AM, Yap T, Javle M, Tapia C, Shaw KR, Eterovic K, Mills GB, Meric-Bernstam F. Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer). Proceedings of the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, Pennsylvania. Philadelphia (PA): AACR, 2017. e-Pub 2017.
- Dumbrava EI, Balajii K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Broaddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong DS, Ahnert JR, Shaw K, Piha-Paul S, Meric-Bernstam F. A167 / 167 - Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. Proceedings of the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, Pennsylvania. Philadelphia (PA): AACR, 2017. e-Pub 2017.
- Sen S, Hong DS, Hess K, Meric-Bernstam F, Subbiah V. A199 / 199 - Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose?. Proceedings of the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, Pennsylvania. Philadelphia (PA): AACR, 2017. e-Pub 2017.
- Powderly J, Patel MR, Lee JJ, Brody J, Meric-Bernstam F, Hamilton E, Aix SP, Garcvia-Corbacho J, Y-J B, M-J A, Rha SY, K-P K, Martin MG, Wang H, Laorchak A, Wyant T, Ma A, Agarwal S, Tuck D, Daud A. CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study. Ann Oncol 28(Suppl 5; Abstr 1141PD), 2017. e-Pub 2017.
- Lim B, Park IA, Wang Y, Bollu L, Brown P, Baggerly K, Meric-Bernstam F, Ueno N. LB-B22 / LB-22 - TNBC kinase prioritization for targeted therapy after chemotherapy resistance. Proceedings of the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, Pennsylvania. Philadelphia (PA): AACR, 2017. e-Pub 2017.
- Jassowicz A, Liu L, Huang H, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Toung J, Vijayaraghavan R, Zhang R, Kang H, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder S, Kopetz S, Amaria R, Meric-Bernstam F, Janku F. Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes. Ann Oncol 28(Suppl 5, Abstr 125P), 2017. e-Pub 2017.
- Sakamuri D, Kato S, Huang HJ, Naing A, Holley VR, Patel S, Piha-Paul SA, Tsimberidou AM, Hong DS, Meric-Bernstam F, Janku F. Dose escalation study of vemurafenib with crizotinib or sorfenib in patients with BRAF-mutated advance cancers. Ann Oncol 28(Suppl 5, Abstr 404P), 2017. e-Pub 2017.
- Beeram M, Hamilton E, Blum Murphy M, Hausman D, Infante JR, Korn R, Patnaik A, Piha-Paul SA, Rasco D, Rowse G, Thimmarayappa J, Tolcher A, Meric-Bernstam F. Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers. Ann Oncol 28(Suppl 5, Abstr 255P), 2017. e-Pub 2017.
- Tang C, Hess K, Sanders D, Davis S, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong D. Efficient clinical research infrastructure and trial performance: Assessment of a dedicated clinical trials unit within an academic cancer center. Eur J Cancer 68(Suppl 1):Abstr 180, 2016. e-Pub 2016.
- Meric-Bernstam M, Tannir N, Harding J, Voss M, Mier J, DeMichele A, Munster P, Patel M, Iliopoulos O, Owonikoko T, Whiting S, Orford M, Bennett M, Carvajal R, McKay R, Fan A, Telli M, Infante J. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). Eur J Cancer 68(Suppl 1):Abstr 26, 2016. e-Pub 2016.
- Fujii T, Colen R, Bilen M, Hess K, Jajjar J, Suarez-Almazor M, Alshawa A, Hong D, Stephen B, Janku F, Subbiah V, Kato S, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Sharma P, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis. Eur J Cancer 68(Suppl 1):Abstr 290, 2016. e-Pub 2016.
- George G, Buford A Hess K, Piha-Paul S, Zinner R, Subbiah V, Iwuanyanwu E, Cleeland C, Meric-Bernstam F, Bernstam E, Hong D. Cancer-related internet use in patients with advanced cancer in a phase I clinical trials clinic. Eur J Cancer 68(Suppl 1):Abstr 183, 2016. e-Pub 2016.
- Janku F, Vergilioo JA, Salhai B, Fanale M, Oki Y, Huang J, Westin J, Nahas M Mughal T, Miller V, Stephens P, Raina A, Garrido-Laguna I, Meric-Bernstam F, Ross J, Liang W. Comprehensive genomic profiling reveals recurrent XP01 mutations and other alterations in archival samples of patients with Hodgkin lymphoma. Eur J Cancer 68(Suppl 1):Abstr 106, 2016. e-Pub 2016.
- Meric-Bernstam F, Tannir NM, Mier JW, DeMichele A, Telli ML, Fan AC, Munster PN, Carvajal RD, Orford KW, Bennett MK, Iliopoulos O, Owonikoko TK, Patel MR, McKay R, Infante JR, Voss MH, Harding JJ. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). J Clin Oncol 34(Suppl):Abstr 4568, 2016. e-Pub 2016.
- Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Raghav PS, Shureiqui I, Wolff RA, Pate K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris V K, Vilar-Sanchez E, Manuel S, Dasari A. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). J Clin Oncol 34(Suppl):Abstr 3607, 2016. e-Pub 2016.
- Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spiegel DR Sweeney C, Burris HA, Bose R, Guo S, Bernaards C, Stanley Beattie M, Stein A, Brammer M, Kurzrock R. Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. J Clin Oncol 34(Suppl):Abstr LBA11511, 2016. e-Pub 2016.
- DeMichele A, Harding JJ, Telli ML, Munster PN, McKay R, Iliopoulos O, Orford KW, Bennett MK, Mier JW, Owonikoko TK, Patel MR, Carvajal RD, Meric-Bernstam F, Infante JR. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). J Clin Oncol 34(Suppl):Abstr 1011, 2016. e-Pub 2016.
- Piha-Paul SA, Hierro C, Funk JO, Gourlay S, Smith P, Venetsanakos E, Meric-Bernstam F, Tabernero J. A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations. J Clin Oncol 34(Suppl):Abstr TPS2602, 2016. e-Pub 2016.
- Dasari A, Overman MJ, Fogelman DR, Kee BK, Menter D, Pratap K, Raghav S, Morris VK, Oh J, Wu J, Jiang Z, Tian F, l A, Brimer M, Morris J, Meric-Bernstam F, Kopetz S. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC). J Clin Oncol 34(Suppl):Abstr 3563, 2016. e-Pub 2016.
- Jain A, Shroff RT, Kelley RK, Kaseb AO, Wang Y, Abdel-Wahab R, Ahn DH, Bocobo AG, Meric-Bernstam F, Isaacs R, Bekaii-Saab TS, Javle MM. FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy. J Clin Oncol 34(Suppl):Abstr 109, 2016. e-Pub 2016.
- Cascone T, Subbiah V, Hess KR, Nelson S, Nilsson MB, Subbiah IM, Ali SM, Carbone DP, Salgia R, Owonikoko TK, Meric-Bernstam F, Doebele RC, Haymach J. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. J Clin Oncol 34(Suppl):Abstr 9069, 2016. e-Pub 2016.
- Johnson A, Khotskaya Y, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger B, Sanchez N, Shufean MA, Piha-Paul SA, Subbiah V, Hong DS, Naing A, Routbort M, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F. Clinical utilization of precision oncology decision support for genomically-informed cancer therapy. J Clin Oncol 34(Suppl):Abst 302, 2016. e-Pub 2016.
- Cascone T, Hess KR, Piha-Paul SA, Hong DS, Subbiah IM, Bhatt T, Fu S, Naing A, Janku F, Karp DD, Meric-Bernstam F, Heymach J, Subbiah V. Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors. J Clin Oncol 34(Suppl):Abstr 9073, 2016. e-Pub 2016.
- Reilley M, Biley AM, Subbiah V, Janku F, Naing A, Falchook GS, Karp DD, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Lim JA, Bean SA, Bass A, Montez S, Vence LM, Sharma P, Allison JP, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Clin Oncol 34(Suppl):Abstr 3054, 2016. e-Pub 2016.
- Dembla V, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzgog CE, Karp DD, Meric-Bernstam F, Subbiah V. Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors. J Clin Oncol 34(Suppl):Abstr 11057, 2016. e-Pub 2016.
- Sen S, Rao A, Janku F, Hong DS, Tsimberdiou AM, Piha-Paul S, Heymach J, Byers LA, Meric-Bernstam F, Subbiah V. Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor. J Clin Oncol 34(Suppl):Abstr 2546, 2016. e-Pub 2016.
- Groisberg R, Hong DS, Janku F, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Conley AP, Herzog CE, Meric-Bernstam F, Subbiah V. Clinical next-generation sequencing in sarcomas. J Clin Oncol 34(Suppl):Abstr 11046, 2016. e-Pub 2016.
- Mitri ZI, Ueno NT, Yang W, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Piwnica-Worms H, Tripathy D, Symmans F, Moulder-Thompson S. Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):OT-03-03, 2016. e-Pub 2016.
- Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Ewer MS, Hunt KK. Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):P1-14, 2016. e-Pub 2016.
- Segura-Ibarra V, Wu S, Cara FE, Meric-Bernstam F, Ferrari M, Blanco E. Temporospatial delivery of chemotherapeutics from nanoparticles for synergy enhancement. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):P6-13-14, 2016. e-Pub 2016.
- Lesurf R, Griffith O, Griffith M, Watson MA, Hoog J, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer – Results from the ACOSOG Z1041 (Alliance) trial. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):PD6-02, 2016. e-Pub 2016.
- Janku F, Hong DS, Atkins JT, Karp DD, Tsimberidou AM, Piha-Paul SA, Subbiah V, Naing A, Fu S, Moulder SL, Tripathy D, Meric-Bernstam F, Wheler JJ. Everolimus, letrozole and trastuzumab in estrogen receptor and HER2-positive patients with metastatic breast cancer and other solid tumors: Evaluating synergy and overcoming resistance. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):P4-13-11, 2016. e-Pub 2016.
- Hyman DM, Piha-Paul SA, Rodón J, Saura C, Puzanov I, Shapiro GI, Loi S, Joensuu H, Hanrahan AJ, Modi S, Lalani AS, Xu F, Garza SJ, Cutler RE, Bryce R, Meric-Bernstam F, Baselga J, Solit DB. Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):PD5-05, 2016. e-Pub 2016.
- Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Wheler JJ, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder S. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):P3-14-02, 2016. e-Pub 2016.
- Ross MI, Bedrosian I, Black DM, Mittendorf EA, Caudle AS, Babiera GV, Hwang RF, Meric-Bernstam F, Grissom CB, Brulotte M, Andtbacka RHI. A phase I clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):P3-01-09, 2016. e-Pub 2016.
- De Los Santos J, Hyslop T, Alvarado M, Forero A, Golshan M, Hieken T, Horton J, Hudis C, McGuire K, Meric-Bernstam F, Nanda R, Zagar T, Hwang S. Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Res 76(4 Suppl):S3-06, 2016. e-Pub 2016.
- Davis AJ, Gao R, Sei E, P-C T, Casasent A, Zhang A, Shi X, Wang Y, Waters J, Meric-Bernstam F, Edgerton M, Navin N. Multi-cell phylogenetic inference of copy number evolution in breast cancer. Cancer Res 76(14):2371, 2016. e-Pub 2016.
- Madwani K, Huang HJ, Shelton DN, Fu S, Tsimberidou AM, Piha-Paul SA, Naing A, Hong DS, Karp DD, Andrews DL, Cabrillo G, Kopetz ES, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F, Janku F. Quantity of KRAS mutations in cell-free DNA is associated with survival of patients with advanced cancers. J Clin Oncol 76(14):493, 2016. e-Pub 2016.
- Khawaja MR, Khatua S, Karp D, Janku F, Hong D, Munoz J, Tsimberidou A, Zaky W, Sherman SI, Hwu P, Meric-Bernstam F, Subbiah V. A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a BRAF aberration. Cancer Res 76(14):CT052, 2016. e-Pub 2016.
- Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim NK, Murray JL III, Koenig KB, Hong DS, Subbiah V, Kurzrock R, Janku F, Moulder S. Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response?. Cancer Res 76(14):2273, 2016. e-Pub 2016.
- Fujii T, Vibat CR, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Hong DS, Huang HJ, Madwani K, Andrews DL, Hancock S, Naing A, Luthra R, Kee BK, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F, Janku F. Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers. Cancer Res 76(14):3146, 2016. e-Pub 2016.
- Mitri Z, Ueno NT, Yang W, Valero V, Litton JK, Murthy R, Lim B, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Gilcrease M, Piwnica-Worms H, Tripthy D, Symmans WF, Moulder-Thompson S. Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. Cancer Res 76(14):CT076, 2016. e-Pub 2016.
- Paez-Arango N, Evans K, Zhao M, Yuca E, ScOft S, Kim C, Naing A, Meric-Bernstam F. Nuclear export inhibitor selinexor (KPT-330) demonstrates anti-tumor efficacy alone and in combination with chemotherapy in multiple breast cancer models. Cancer Res 76(14):3075, 2016. e-Pub 2016.
- Capasso A, Dasari A, Lockhart AC, Stein M, Sanoff H, Lee J, Hansen A, Bekaii-Saab T, Rippke S, Yao J, Meric-Bernstam F, Eckhardt SG, Lieu CH. A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). Cancer Res 76(14):CT146, 2016. e-Pub 2016.
- Sarshekeh AM, Overman MJ, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Sanchez EV, Manuel S, Shureiqui I, Wolff RA, Patel K, Luthra R, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. J Clin Oncol 34(Suppl 4S):Abstr 565, 2016. e-Pub 2016.
- Hurwitz H, Hainsworth JD, Swanton C, Perez EA, Sweeney C, Burris HA, Spigel D, Meric-Bernstam F, Strickland DK, Leon L, Brammer M, Stanley Beattie M, Bose R. Targeted therapy for gastrointestinal (GI) tumors based on molecular profiles: Early results from MYPathway, an open-label phase Iia basket study in patients with advanced solid tumors. J Clin Oncol 34(Suppl 4S):Abstr 653, 2016. e-Pub 2016.
- Evans KW, yuca E, Scott SM, Paez NA, Zheng X, Chen K, Gonzales L, Tapia C, Tarco E, Black DM, Mills GB, Meric-Bernstam F. Patient-derived xenografts to test emerging therapies for triple negative breast cancer. Clin Cancer Res 22(16 Suppl; Abstr A39), 2016. e-Pub 2016.
- Subbiah V, Hong DS, Amini B, Piha-Paul S, Fernandez JG, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. Phase I dose escalation study fo the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer 14(12 (Suppl 2)):C50-C50, 2015. e-Pub 2015.
- Khawaja MR, Madhusudanannair V, Ng C, Nick A, Janku F, Piha-Paul S, Coleman R, Soliman P, Fu S, Hong D, Karp D, Subbiah V, Tsimberidou A, Meric-Bernstam F, Lu K, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers. Mol Cancer Ther 14(12 Suppl 2):C44-C44, 2015. e-Pub 2015.
- Meric-Bernstam, DeMichele A, Telli ML, Munster P, Orford KW, Owonikoko TK, Bennett MK, Patel MR, Infante JR, Harding JJ. Phase I study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors. Mol Cancer Ther 14(12 Suppl 2):Phase I study of CB-839, a first-in-class, orally administered s, 2015. e-Pub 2015.
- Bauer T, Hong D, Somaiah N, Cai C, Song S, Kumar P, Gajee R, Rosen M, Kochan J, Shen S, Hyman D, Masters T, Meric-Bernstam F, Tse A, LoRusso P, Weise A, Gounder M. A phase I dose escalation study of the MDM2 inhibitor DS-3032b in patients with advanced solid tumors and lymphomas. Mol Cancer Ther 14(12 (Suppl 2)):B27-B27, 2015. e-Pub 2015.
- Cascone T, Hess KR, Piha-Paul S, Hong DS, Roxas M, Subbiah IM, Fu S, Naing A, Janku F, Karp D, Sherman SI, Meric-Bernstam F, Heymach JV, Subbiah V. A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations. Mol Cancer Ther 14(12 Suppl 2):LB-C17-LB-C17, 2015. e-Pub 2015.
- Janku F, Huang HJ, Ramzanali NM, Hong DS, Karp DD, Cai X, Zhao Y, Salathia N, Waters J, Liu L, Klausner R, Meric-Bernstam F, J-B F. Novel, ultradeep next-generation sequencing of plasma cell-free DNA from patients with advanced cancers. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
- Huang HJ, Shelton DN, Fu S, Piha-Paul SA, Tsimberidou AM, Zinner RG, Wheler JJ, Naing A, Hong DS, Falckook GS, Kopetz S, Luthra R, Kee BK, Karlin-Neumann GA, Meric-Bernstam F, Janku F. Multiplex KRAS G12/G13 mutation testing of 16ng of unamplified cell-free DNA from plasma of patients with advanced cancers using Droplet Digital PCR. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
- Sakamuri D, Cuellar SLB, Glitza IC, Fu S, Wheler JJ, Falckook GS, Tsimberidou AM, Hong DS, Subbiah V, Fanale MA, Cabanillas ME, Meric-Bernstam F, Janku F. Phase 1 study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
- Blanco E, Wu S, Cara F, Segura-Ibarra V, Meric-Bernstam F, Ferrari M. Multistage delivery of RNA interfering nanotherapeutics targeting the PI3K/Akt/mTOR pathway. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
- Subbiah V, Murthy R, Hong DS, Brown RE, Prins R, Hosing C, McGuire M, Naing A, Fu S, Chou T, Lin Q, Guevarra RP, Conley A, Kaur I, Meric-Bernstam F, Bosch M. Clinical and immunopathological effects following image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
- Kato S, Naing A, Falchook G, Holley VR, Velez-Bravo VM, Patel S, Zinner RG, Piha-Paul SA, Tsimberidou AM, Hong DS, Kurzrock R, Meric-Bernstam F, Janku F. Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
- Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Tsimberidou AM, Hong DS, Naing A, Wheler JJ, Piha-Paul SA, Karp DD, Subbiah V, Zinner RG, Ramzanali N, Luthra R, Patel SP, Kopetz ES, Sablon E, Maertens G, Kurzrock R, Meric-Bernstam F. Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
- Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Ames FC, Ross MI, Feig BW, Kuerer HM, Hunt KK. Role of lymphovascular invasion and lobular histology in predicting the detection of isolated tumor cells in sentinel lymph nodes from early stage breast cancer patients. 2007 Breast Cancer Symposium, 2015. e-Pub 2015.
- Kato S, Janku F, Piha-Paul, SA, Naing A, Karp DD, Tsimberidou AM, Subbiah V, Zinner R, W-J H, Javle MM, Parkhurst KL, Ramzanali NM, Kurzrock R, Meric-Bernstam F, Chae YK, Kim K, Falchook GS. Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer. J Clin Oncol 33(Suppl, abstr 105), 2015. e-Pub 2015.
- Meric-Bernstam F. Targeting mTOR for breast cancer therapy. Proceedings of the AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; Sep 14-17, 2014; Philadelphia, PA. Philadelphia (PA): AACR 14(7 Suppl):Abstr nr IA22, 2015. e-Pub 2015.
- Janku F, Gounder M, Murthy R, Rudin C, Helgason T, Hong D, Benjamin R, Meyer L, Zinner R, Meric-Bernstam F. Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer. Ann Oncol 26(Suppl 2; Abstr P1.09), 2015. e-Pub 2015.
- Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu, KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. J Clin Oncol 33(Suppl, abstr 1510), 2015. e-Pub 2015.
- Shaw KR, Zeng J, Bailey AM, Johnson A, Litzenburger B, Holla V, Bernstam EV, Mills GB, Mendelsohn J, Routbort M, Meric-Bernstam F. Development of a public knowledgebase to facilitate decision support for clinical cancer genomics reporting and clinical trial enrollment. J Clin Oncol 33(Suppl, abstr 22163), 2015. e-Pub 2015.
- Moulder SL, Ueno NT, Yang WT, Ensor J, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun B, Mittendorf EA, Hunt K, Meric-Bernstam F, Thompson AM, Piwnica-Worms H, Tripathy D, Symmans WF. Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). J Clin Oncol 33(Suppl, abstr TPS1113), 2015. e-Pub 2015.
- Ross JS, Wang K, Javle MM, Catenacci DVT, Shroff RT, Ali SM, Elvin JA, Chmielecki, J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Meric-Bernstam F. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. J Clin Oncol 33(Suppl, abstr 4009), 2015. e-Pub 2015.
- Davies MA, Joon A, Bassett RL, Roszik J, Siroy A, Haydu LE, Chen K, tingo F, Baladandayuthapani V, Shaw KR, Meric-Bernstam F, Tetzlaff MT, Gershenwald JE, Woodman SE, Lazar AJF. Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients. J Clin Oncol 33(Suppl, abstr 9057), 2015. e-Pub 2015.
- Kopetz S, Litzenburger B, Kinjua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw, KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol 33(Suppl, abstr 3608), 2015. e-Pub 2015.
- Janku F, Vibat CRT, Falchook GS, Huang HJ, Hong, DS, Piha-Paul SA, Subbiah V, Ramzanali NM, Hancock S, Naing A, Karp DD, Nitti G, Cabrilo G, Luthra R, Patel SP, Overman MJ, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F. Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers. J Clin Oncol 33(Suppl, abstr 11048), 2015. e-Pub 2015.
- Wheler JJ, Yelensky R, Stephen B, Hong DS, Zinner R, Subbiah V, Fu S, Karp DD, Falchook GS, Naing A, Tsimberidou AM, Piha-Paul SA, Janku F, Li Y, Lee JJ, Miller VA, Meric-Bernstam F, Kurzrock R. Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. J Clin Oncol 33(Suppl, abstr 11019), 2015. e-Pub 2015.
- Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 33(Suppl, abstr 3511), 2015. e-Pub 2015.
- Basho RK, Gagliato DDM, Ueno NT, Alvarez RH, Wathoo C, Chen H, Wei C, Sahin AA, Roy-Chowdhuri S, Moulder SL, Chavez-Mac Gregor M, Litton JK, Valero V, Luthra R, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. J Clin Oncol 33(Suppl, abstr 1524), 2015. e-Pub 2015.
- Kato S, Jardim DLF, Johnson FM, Subbiah V, Piha-Paul SA, Tsimberidou AM, Falchook GS, Karp DD, Wheler JJ, Zinner R, Janku F, Fu S, Dandu L, Browne E, Meric-Bernstam F, Hong DS. Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer. J Clin Oncol 33(Suppl, abstr 2597), 2015. e-Pub 2015.
- Harding JJ, Telli ML, Munster PN, Le MH, Molineaux C, Bennett MK, Mittra E, Burris HA, Clark AS, Dunphy M, Meric-Bernstam F, Patel MR, DeMichele A, Infante JR. Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. J Clin Oncol 33(Suppl 15, abstr 2512), 2015. e-Pub 2015.
- Bendell JC, Eng C, Moore KN, Burris HA, Meric-Bernstam F, Jones SF, Piha-Paul SA, Infante JR, Subbiah V, Bauer TM, Golden L, Lin J, Martinez R, Wijayawardana S, Lin AK, Hong DS. Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus. J Clin Oncol 33(Suppl, abstr 3520), 2015. e-Pub 2015.
- Janku F, Huang HJ, Ramzanali NM, Hong DS, Karp DD, Fu S, Cai X, Zhao Y, Salathia N, Waters J, Liu L, Meric-Bernstam F, Mills GB, J-B F. Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers. J Clin Oncol 33(Suppl, abstr), 2015. e-Pub 2015.
- Lin SH, Mok I, Leos D, Pasia MG, Thall PF, Lin HY, Welliver MX, Villalona-Calero MA, Yao JC, Meric-Bernstam F, Komaki R, Chen HX, Blumenschein GR. NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer. J Clin Oncol 33(Suppl, abstr TPS7585), 2015. e-Pub 2015.
- Wagner M, Hess KR, Hong DS, Tang C, Naing A, Fu S, Janku F, Piha-Paul SA, Zinner R, Wheler JJ, Tsimberidou AM, Patel S, Somaiah N, Ravi V, Benjamin RS, Meric-Bernstam F, Vivek Subbiah V. Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. J Clin Oncol 33(Suppl, abstr 10558), 2015. e-Pub 2015.
- Piha-Paul SA, Goldstein JB, Hess KR, Fu S, Hong DS, Janku F, Karp DD, Naing A, Subbiah V, Tsimberidou AM, Wheler JJ, Zinner R, Mills GB, Meric-Bernstam F. Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer). J Clin Oncol 33(Suppl, abstr TPS2617), 2015. e-Pub 2015.
- Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Subbiah V, Tsimberidou AM, Kaseb AO, Oki Y, Zinner R, Patel S, Bravo VMV, Fanale MA, Meric-Bernstam F, Kurzrock R, Janku F. Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. J Clin Oncol 33(Suppl, abstr 2584), 2015. e-Pub 2015.
- Somaiah N, Beird H, Shaw KR, W-L W, Conley AP, Ravi V, Torres KE, Ingram D, Roland CL, Subbiah V, Feig BW, Lazar AJF, Benjamin RS, Patel S, Hwu P, Futreal A, Meric-Bernstam F, Hong DS. Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations. J Clin Oncol 33(Suppl, abstr 10550), 2015. e-Pub 2015.
- Meric-Bernstam F, Brusco L, Kopetz S, Davies M, Routbort MJ, Piha-Paul SA, Alvarez R, Khose S, DeGroot J, Ravi V, Janku F, Hong D, Li Y, Lutha R, Patel KP, Roaddus R, Shaw K, Mendelsohn J, Mills GB. Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials. Eur J Cancer 50(Suppl 6):3, 2014. e-Pub 2014.
- Janku F, Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul S, Tsimberidou AM, Zinner RG, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra RG, Patel SP, Kopetz ES, Sablon E, Maertens G, Kurzrock R, Meric-Bernstam F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla). Eur J Cancer 50(Suppl 6):56, 2014. e-Pub 2014.
- Janku F, Huang HJ, Ramzanali NM, Cai X, Klausner R, Meric-Bernstam, Fan JB. Novel, ultra-deep next-generation sequencing fro BRAF mutation testing using small amount of cell-free DNA from plasma of patients with advanced cancer. Eur J Cancer 50(Suppl 6):57, 2014. e-Pub 2014.
- Bugano D, Hess K, Siu LL, Meric-Bernstam F, Razak ARA, Hong DS. Impact of phase 1 expansion cohorts on probability of success in phase 2 and time-to-drug-approval: analysis of 385 new drugs in oncology. Eur J Cancer 50(Suppl 6):79, 2014. e-Pub 2014.
- Bilen MA, Patel A, Hess KR, Muloz J, Busaidy N, Wheler J, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor (TKI) therapy in phase I clinic trials. Cancer Res 74(19 (suppl)):2827, 2014. e-Pub 2014.
- Liu X, Hou M, Wheler J, Naing A, Hong D, Tsimberidou AM, Piha-Paul SA, Zinner R, Falchook G, Janku F, Ramondetta L, Schmeler K, Lu K, Kurzrock R, Fu S. Differential effect of PIK3CA mutations and PTEN loss in patients with advanced endometrial cancers on matched therapy. Cancer Res 74(19 (suppl)):2838, 2014. e-Pub 2014.
- Janku F, Falchook GS, Piha-Paul SA, Naing A, Holley VR, Hong DS, Subbiah V, Karp DD, Zinner RG, Fu S, Wheler JJ, Meric-Bernstam F, Stepanek VM, Luthra R, l L, Hassaine L, Kosco K, Erlander MG. Digital droplet PCR detection and monitoring of BRAF mutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease. Clin Cancer Res 74(19 (suppl)):LB-170, 2014. e-Pub 2014.
- Tang C, Jardim DF, De Melo Galgiato D, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Meric-Bernstam F, Hong DS. Analysis of 1115 patients tested for MET amplification and therapy response in the MD Anderson phase I clinic. Cancer Res 74(19 (suppl)):4424, 2014. e-Pub 2014.
- Subbiah IM, Varadhachary G, Tsimberidou AM, Wheler JJ, Subbiah V, Janku F, Chowdhury SR, Zinner R, Meric-Bernstam F, Hong DS. One size does not fit all: Fingerprinting advanced carcinoma of unknown primary through comprehensive profiling identifies aberrant activationof the PI3K and MAPK signaling cascades in concert with impaired cell cycle arrest. Cancer Res 74(19, suppl):4700, 2014. e-Pub 2014.
- Huang HJ, Claes B, Falchook GS, Holley VR, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner RG, Karp DD, FU S, Subbiah V, Hong DS, Wheler JJ, Stepanek VM, Cabrilo G, Luthra R, Bedikian AY, Kee BK, Eng C, Overman MJ, Kim KB, Ivens T, Sablon E, Maertens G, Kurzrock R, Meric-Bernstam F, Janku F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylia™). Cancer Res 74(19 (suppl)):5607, 2014. e-Pub 2014.
- Janku F, Legendre B, Richardson K, Falchook GS, Naing A, Holley VR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Zinner RG, Subbiah V, Tsimberidou AM, Karp DD, Stepanek VM, Cabrilo G, Luthra R, Meric-Bernstam F, Bedikian AY, Kee BK, Eng C, Overman MJ, Kim KB, Kruempel A, Pope J, Cubrich C, Wu G, Shi Y, Lewis M, Kurzrock R. BRAF and KRAS mutation treating in plasma cell-free DNA with ICE-COLD PCR in patients with advanced cancers. Cancer Res 74(19 (suppl)):5607, 2014. e-Pub 2014.
- Livingston JA, Hess KR, Fernandez JG, Naing A, Hong DS, Patel S, Anderson PM, Benjamin RS, Ludwig JA, Herzog CE, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Janku F, Rohren E, Meric-Bernstam F, Kurzrock R, Subbiah V. Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. J Clin Oncol 32(5s; abstr 10531), 2014. e-Pub 2014.
- Shaw K, Hamilton SR, Wolff RA, Meric-Bernstam F, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. J Clin Oncol 32(5s; abstr 3619), 2014. e-Pub 2014.
- Aldape K, Luthra R, Routbort M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 32(5s; abstr 3509), 2014. e-Pub 2014.
- Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett CR, Karp DD, Kurzrock R, Zinner R, Raghav KPS, Subbiah V, Meric-Bernstam F, Hong DS, Overman MJ. Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. J Clin Oncol 32(5s; abstr 3607), 2014. e-Pub 2014.
- Legendre BL, Richardson K, Falchook GS, Naing A, Holley VR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Zinner R, Subbiah V, Tsimberidou AM, Luthra R, Meric-Bernstam F, Bedikian AY, Eng C, Melnikova V, Lewis M, Kurzrock R, Janku F. BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. J Clin Oncol 32(Suppl; abstr e22147), 2014. e-Pub 2014.
- Eng C, Bendell JC, Kopetz S, Tarco E, Xiao L, Ying J, Wang X, Phillips J, Sportelli P, Meric-Bernstam F. Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory metastatic colorectal cancer (mCRC) patients. J Clin Oncol 32(5s; abstr 3606), 2014. e-Pub 2014.
- Hong DS, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, Zinner R, Fogelman DR, Mistry R, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 32(5s; abstr 3516), 2014. e-Pub 2014.
- Wheler JJ, Janku F, Atkins JT, Moulder SL, Zinner R, Lee JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Karp DD, Naing A, Fu S, Hong DS, Subbiah V, Stephens PJ, Yelensky R, Miller VA, Valero V, Kurzrock R, Meric-Bernstam F. PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. J Clin Oncol 32(5s; abstr 2606), 2014. e-Pub 2014.
- Tsimberidou AM, Ye Y, Wheler JJ, Gerald Steven Falchook GS, Hong DS, Naing A, Fu S, Kurzrock R, Piha-Paul SA, Janku F, Zinner R, Moulder SL, Subbiah V, Karp DD, Meric-Bernstam F, Hwu P, Kies MS, Miller VA, Broaddus R, Hess KR. Genomic profiling and precision medicine in 3,745 patients with advanced cancer. | 2014 ASCO Annual Meeting Abstracts. J Clin Oncol 32(Suppl; abstr e13521), 2014. e-Pub 2014.
- Subbiah V, Agarwal R, Janku F, Tsimberidou AM, Patel S, Benjamin RS, Ludwig JA, Anderson PM, Araujo DM, Ravi V, Conley AP, Somaiah N, W-L W, Naing A, Zinner R, Hong DS, Meric-Bernstam F. Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine. J Clin Oncol 32(5s; abstr 10595), 2014. e-Pub 2014.
- Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner R, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra R, Kee BK, Overman MJ, Kim K, Maertens GG, Kurzrock R, Funda Meric-Bernstam F, Janku F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). J Clin Oncol 32(Suppl; abstr e22139), 2014. e-Pub 2014.
- Janku F, Vibat CRT, Falchook GS, Piha-Paul SA, Naing A, Subbiah V, Holley VR, Wheler JJ, Meric-Bernstam F, Cabrilo G, Stepanek VMT, Luthra R, Leppin L, Hassaine L, Kosco K, Erlander M. Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. J Clin Oncol 32(Suppl; abstr e22175), 2014. e-Pub 2014.
- Boland GM, Piha-Paul SA, Subbiah V, Brusco L, Herbrich SM, Baggerly KA, Routbort M, Patel K, Luthra R, Naing A, Fu S, Falchook GS, Hong DS, Wheler JJ, Janku F, Shaw KR, Aldape KD, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next-generation sequencing to identify actionable alterations in a phase I program. J Clin Oncol 32(5s; abstr 11115), 2014. e-Pub 2014.
- M-M H, Bellido J, Naing A, Falchook GS, Hess KR, Zinner R, Wheler JJ, Subbiah V, Hong DS, Piha-Paul SA, Tsimberidou AM, Karp DD, Kurzrock R, Meric-Bernstam F, Fu S. A phase I trial of pazopanib and vorinostat: The role of TP53 mutations. J Clin Oncol 32(5s; abstr 2576), 2014. e-Pub 2014.
- Fu S, Nguyen E, Janku F, Subbiah V, Patel SP, Falchook GS, Zinner R, Tsimberidou AM, Hong DS, Piha-Paul SA, Wheler JJ, Shi N, Bomalaski JS, Hwu P, Meric-Bernstam F. Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin. J Clin Oncol 32(5s; abstr 2563), 2014. e-Pub 2014.
- Bupathi M, Falchook GS, Hong DS, Subbiah IM, Piha-Paul SA, Karp DD, Saigal B, Zinner R, Wheler JJ, Tsimberidou AM, Fu S, Sherman SI, Meric-Bernstam F, Subbiah V. A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. J Clin Oncol 32(5s; abstr TPS2639), 2014. e-Pub 2014.
- Subbiah IM, Varadhachary GR, Tsimberidou AM, Wheler JJ, Subbiah V, Falchook GS, Janku F, Zinner R, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine. J Clin Oncol 32(Suppl; abstr e22154), 2014. e-Pub 2014.
- Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Bravo VMV, Hong DS, Westin JR, Nunez C, Fayad L, Neelapu SS, Kwak LW, Shpall EJ, Wheler JJ, Barnes T, Liang WS, Salhia B, Meric-Bernstam F, Kurzrock R, mA F. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. J Clin Oncol 32(5s; abstr 8508), 2014. e-Pub 2014.
- Janku F, Falchook GS, Piha-Paul SA, Naing A, Tsimberdou AM, Holley VR, Karp DD, Zinner RG, Fu S, Wheler JJ, Hong DS, Meric-Bernstam F, Stepanek VM, Luthra R, Leppin L, Hassaine L, Kosco K, Poole JC, Erlander MG. Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by droplet digital PCR. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 12(11 Suppl):Abstract nr B175, 2013. e-Pub 2013.
- FitzSullivan E, Kuerer HM, Bassett RL, Mittendorf EA, Yi M, Hunt KK, Babiera G, Caudle AS, Black DM, Bedrosian I, Meric-Bernstam F, Hwang RF. Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. J Clin Oncol 31(Suppl):Abstr 53, 2013. e-Pub 2013.
- Myers AP, Broaddus R, Makker V, Konstantiopoulos PA, Drapkin R, Horowitz NS, Liu J, Hummelen PV, Meric-Bernstam F, Birrer MJ, Doyle A, Coleman RL, Aghajanian C, Mills GB, Cantley L, Matulonis UA, Westin SN. Phase II, two-stage, two-arm PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). J Clin Oncol 31(Suppl):Abstr 5524, 2013. e-Pub 2013.
- Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Plietenpol JA, Hortobagi GN, Symmans WF, Ueno NT. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. J Clin Oncol 31(Suppl):Abstr 1005, 2013. e-Pub 2013.
- Ewer M, Suman VJ, Buzdar A, McCall LM, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce M, Hunt K ACOSOG Z. Cardiac events (CE) among those receiving neoadjuvant anthracyclines (A) and taxanes with trastuzumab (T) for HER2+ breast cancer. J Clin Oncol 31(Suppl):Abstr 526, 2013. e-Pub 2013.
- Buzdar A, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce M, Hunt K ACOSOZ Z. Definitive analysis of randomized neoadjuvant trial company FEC followed by paclitaxel plus trastuzumab (FEC->P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T->FEC+T) in HER2+ operable breast cancer. J Clin Oncol 31(Suppl):Abstr 502, 2013. e-Pub 2013.
- Pusztai L, Mattair D, Ueno NT, Valero V, Moulder SL, Murray JL, Alvarez RH, Chavez-MacGregor M, Santiago L, Avritscher R, Sahin AA, Hortobagyi GN, Symmans WF, Meric-Bernstam F, Burton EM, Gonzalez-Angulo AM. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection 31(Suppl):Abstr 532, 2013. e-Pub 2013.
- Umovitz HB, Beck J, Schutz E, Singh G, Mitchell WM, Black DM, Babiera G, Bedrosian I, Kuerer HM, Mills GB, Meric-Bernstam F. Modulation of breast cancer cell-free DNA with surgical resection. J Clin Oncol 31(Suppl):Abstr 11060, 2013. e-Pub 2013.
- Yusuf RA, Rogith D, Hovick SRA, Peterson SK, Burton-Chase AM, Fellman B, Li Y, Urbauer DL, McKinney C, Bernstam EV, Meric-Bernstam F. Racial differences in attitudes toward molecular testing for personalized cancer therapy. J Clin Oncol 31(Suppl):Abstr 6566, 2013. e-Pub 2013.
- Beck J, Schutz E, Umovitz HB, Tabchy A, Mitchell WM, Mills GB, Meric-Bernstam F. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J Clin Oncol 31(Suppl):Abstr 11013, 2013. e-Pub 2013.
- Ravi V, Ali SM, Ramesh N, Meric-Bernstam F, Plalmer GA, Hwu P, Patel S, Futreal A. Targeted next generation sequencing of sarcomas for identification of therapeutic targets 31(Suppl):Abstr 10577, 2013. e-Pub 2013.
- Rogith D, Yusuf RA, Hovick SRA, Peterson SK, Burton-Chase AM, Li Y, Meric-Bernstam F, Bernstam EV. Attitudes rergarding privacy of genomic information in personalized cancer therapy. J Clin Oncol 31(Suppl):Abstr 9576, 2013. e-Pub 2013.
- Morris VK, Overman MJ, Eng C, Sanchez EV, Morelli M, Jiang Z, Luthra R, Maru DM, Meric-Bernstam F, Kopetz. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. J Clin Oncol 31(Suppl):Abstr 3632, 2013. e-Pub 2013.
- Janku F, Kurzrock R, Helgason T, Valero V, Esteva F, Wheler JJ, Karp DD, Meric-Bernstam F, Moulder SL. Genomic landscape in advanced metaplastic breast cancer and outcomes with mTOR targeted therapy. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR, Mol Cancer Ther 12(11 Suppl):Genomic landscape in advanced metaplastic breast cancer and outc, 2013. e-Pub 2013.
- M-M H, Liu X, Piha-Paul SA, Janku F, Wheler J, Naing A, Bodurka D, Schmeler K, Lu K, Zinner R, Hong D, Meric-Bernstam F, Kurzrock R, Fu S. Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 12(11 Suppl):Abstract nr B191, 2013. e-Pub 2013.
- Janku F, Angenendt P, Naing A, Falchook GS, Tsimberidou AM, Holley VR, fu S, Hong DS, Wheler JJ, Piha-Paul SA, Zinner RG, Karp DD, Subbiah V, Kim KB, Meric-Bernstam F, Diehl F, Kurzrock R. Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 11(11 Suppl):Abstract nr B26, 2013. e-Pub 2013.
- Huang HJ, Claes B, Falchook GS, Tsimberidou AM, Holley VR, Subbiah V, Zinner RG, Naing A, Karp DD, Piha-Paul SA, Wheler JJ, Fu S, Hong DS, Stepanek VM, Luthra R, Meric-Bernstam F, Ivens T, Sablon E, Maertens G, Kee BK, Kurzrock R, Scherer S, Jank F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 12(11 Suppl):Abstract nr A202, 2013. e-Pub 2013.
- Huang HJ, Claes B, Falchook GS, Devogelaere B, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberdou AM, Sepanek VM, Kim KB, Angelo LS, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Sablon E, Maertens G, Meric-Bernstam F, Kurzrock R, Scherer S, Janku F. BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 12(11 Suppl):Abstract nr C198, 2013. e-Pub 2013.
- Janku F, Legendre B, Richardson K, Falchook GS, Naing A, Holley VR, Hong DS, Zinner RG, Fu S, Tsimberidou AM, Subbiah V, Karp DD, Piha-Paul SA, Wheler JJ, Stepanek VM, Cabrilo G, Luthra R, Meric-Bernstam F, Kruempel A, Pope J, Cubrich C, Wu G, Shi Y, Lewis M, Kurzrock R. BRAF and KRAS mutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 12(11 Suppl):Abstract nr C203, 2013. e-Pub 2013.
- Sohn J, Liu S, Chen H, Meng X, Do KA, Mills G, Hortobagyi G, Meric-Bernstam F, Gonzalez-Angulo. Biomarker identification of residual triple negative breast cancer (TNBC) after standard neoadjuvant chemotherapy (NCT). AACR Annual Meeting 2012, Chicago, IL (#162), 2012. e-Pub 2012.
- Holder A, Gonzalez-Angulo A, Chen H, Akcakanat A, Do KA, Symmans F, Pusztai L, Mills G, Meric-Bernstam F. Increased Stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. AACR Annual Meeting 2012, Chicago, IL (#682), 2012. e-Pub 2012.
- Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy B, Hortobagyi G, Mills G, Gonzalez-Angulo A. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. AACR Annual Meeting 2012, Chicago, IL (#4904), 2012. e-Pub 2012.
- Akay C, Whitsell T, Albarracin C, Hunt KK, Bassett R, Mittendorf EA, Yi M, Sahin A, Krishnamurthy S, Kuerer H, Meric-Bernstam F, Babiera GV, Bedrosian I, Hwang RF. Intraoperative sentinel lymph node evaluation is accurate after neoadjuvant therapy for breast cancer. Ann Surg Oncol 19(Suppl 1):S86, 2012. e-Pub 2012.
- Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang R, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women and DCIS. Ann Surg Oncol 19(Suppl 1):S58, 2012. e-Pub 2012.
- Allen LR, Gadgil PV, Bassett R, Hunt KK, Mittendorf EA, Yi M, Babiera G, Kuerer HM, Ross MI, Bedrosian I, Meric-Bernstam F, Hwang RF. Nomogram to predict sentinel lymph node involvement in patients with clinically node-negative breast cancer receiving neoadjuvant chemotherapy. J Clin Oncol 30(suppl 27), 2012. e-Pub 2012.
- Raghav K, Hernandez-Aya LF, Lei X, Chavez-Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin AA, Do K, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. ASCO Annual Meeting (#1023), 2011. e-Pub 2011.
- Abbott D, Brouquet A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey J. Resection of Liver Metastases from Breast Cancer: Timing of Surgery and Estrogen Receptor Status Define Outcome. 64th SSO Annual Cancer Symposium, San Antonio, TX (#P135), 2011. e-Pub 2011.
- Wagner JL, Ross MI, Hunt KK, Meric-Bernstam F, Mittendorf EA, Strom EA, Bedrosian I. Treatment of Ipsilateral Supraclavicular Metastasis in Breast Cancer Patients. 64th SSO Annual Cancer Symposium, San Antonio, TX (# P102), 2011. e-Pub 2011.
- Veerapong J, Boughey J, Mittendorf E, Harrell R, Bassett R, Ross M, Yi M, Meric-Bernstam F, Babiera G, Kuerer H, Lucci A, Bedrosian I, Brodt J, Jakub J, Hunt K, Hwang R. A Validated Risk Assessment of Sentinel Lymph Node Involvement In Breast Cancer Patients. 64th SSO Annual Cancer Symposium, San Antonio, TX (# P66), 2011. e-Pub 2011.
- McAuliffe PF, Akcakanat A, Sharma C, Adkins F, Sangai T, Singh G, Gonzalez-Angulo AM, Meric-Bernstam F. Role of Dose and Schedule in Rapamycin-mediated Growth Inhibition in Breast Cancer. 64th SSO Annual Cancer Symposium, San Antonio, TX (# 29), 2011. e-Pub 2011.
- Akay C, Meric-Bernstam F, Grubbs LG, Hoffman KE, Babiera GV, Strom EA, Feig BW, Perkins GH, Bedrosian I, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Validation of a Prognostic Index Score for Local-Regional Recurrence after Mastectomy or Breast Conservation Therapy in Patients Treated with Neoadjuvant Chemotherapy. 64th SSO Annual Cancer Symposium, San Antonio, TX (# 34), 2011. e-Pub 2011.
- Abdel-Rahman S, Le-Petross H, Whitman GJ, Meric-Bernstam F, Babiera GV, Hunt KK, Hwang RF, Lucci A, Feig BW, Ross MI, Mittendorf EA, Kuerer HM, Bedrosian I. Prospective Study to Evaluate Surgical Impact and Cost of Routine Preoperative Breast MRI in Women with Invasive Lobular Carcinoma. 64th SSO Annual Cancer Symposium, San Antonio, TX (#33), 2011. e-Pub 2011.
- Adkins F, Kim W, Akcakanat A, Singh G, Hung M, Meric-Bernstam F. Differential Regulation Of Tumor Suppressor PDCD4 Expression By Rapamycin. 2011 Academic Surgical Congress, Huntington Beach, CA (ASC20110549), 2011. e-Pub 2011.
- Sangai T, Akcakanat A, Adkins F, McAuliffe P, Mills G, Gonzalez-Angulo AM, Meric-Bernstam F. Role of PTEN status on MK2206 sensitivity in breast cancer. AACR Targeting PI3K/mTOR Signaling in Cancer Workshop, San Francisco, CA (#2740), 2011. e-Pub 2011.
- Akcakanat A, Adkins F, Chen H, Do KA, Gonzalez-Angulo AM, Siwak DR, Singh G, Mills G, Meric-Bernstam F. Feedback loop activation of Akt is not a marker of rapamycin resistance. AACR Targeting PI3K/mTOR Signaling in Cancer Workshop, San Francisco, CA (#2729), 2011. e-Pub 2011.
- McAuliffe PF, Akcakanat A, Sharma C, Chen H, Singh G, Do KA, Gonzalez-Angulo AM, Mills GB, Meric-Bernstam F. Dose-dependent effects of rapamycin on the functional proteomic profile of rapamycin-resistant versus rapamycin-sensitive in vivo breast cancer models. AACR Targeting PI3K/mTOR Signaling in Cancer Workshop, San Francisco, CA (#2734), 2011. e-Pub 2011.
- Adkins FC, Meric-Bernstam F, Akcakanat A, Chen H, Sharma C, Singh G, Do KA, Gonzalez-Angulo AM, Mills GB, Hung MC. Development and characterization of a breast cancer cell line with acquired resistance to rapamycin. AACR Targeting PI3K/mTOR Signaling in Cancer Workshop, San Francisco, CA (#2715), 2011. e-Pub 2011.
- Abbott DE, Brouquet A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt K, Vauthey J. Resection of liver metastases from breast cancer: Effect of timing of surgery and estrogen receptor status on outcome. 2011 Gastrointestinal Cancers Symposium (#288), 2011. e-Pub 2011.
- Gonzalez-Angulo AM, Barlow WE, Gralow J, Meric-Bernstam F, Hayes DF, Moinpour C, Ramsey SD, Schott AF, Sparks DB, Albain KS, Hortobagyi GN. SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. ASCO Annual Meeting (#TPS104), 2011. e-Pub 2011.
- Elsayegh N, Bayraktar S, Gutierrez-Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton JK, Meric-Bernstam F, Hortobagyi GN, Arun B. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. ASCO Annual Meeting (#1512), 2011. e-Pub 2011.
- Chavez-MacGregor M, Lei X, Litton JK, Melhem A, Mittendorf EA, Meric-Bernstam F, Sahin A, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy. ASCO Annual Meeting (#1036), 2011. e-Pub 2011.
- Gonzalez-Angulo AM, Green MC, Murray JL, Palla SL, Koenig KH, Brewster AM, Valero V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, Flores PR, Dryden MJ, Symmans WF, Giordano SH, Pusztai L, Buzdar A, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). ASCO Annual Meeting (#1016), 2011. e-Pub 2011.
- Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar A, Valero V, Melhem A, Kuerer HM, Hortobagyi G, Sahin A, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. ASCO Annual Meeting (#532), 2011. e-Pub 2011.
- Meric-Bernstam F, Gutierrez-Barrera A, Litton JK, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun B. Mutation position in BRCA-associated breast cancers. ASCO Annual Meeting (#1542), 2010. e-Pub 2010.
- Buzdar A, Suman V, Meric-Bernstam F, Boughey JC, Leitch AM, Unzeitig GW, Ellis MJ, Ewer M, Hunt K. Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ASOSOGZ1041). ASCO Annual Meeting (#594), 2010. e-Pub 2010.
- Bernstam E V, Herskovic JR, Reeder P, Meric-Bernstam F. Oncology research using electronic medical record data. ASCO Annual Meeting (#e16501), 2010. e-Pub 2010.
- Jackson M, Brandt A, Gutierrez-Barrera A, Meric-Bernstam F, Litton JK, Lu KH, Hortobagyi GN. Effects of ethnicity on genotype-phenotype correlations in individuals with a BRCA1 or BRCA2 mutation. ASCO Annual Meeting (#6060), 2010. e-Pub 2010.
- Chavez-Mac Gregor M, Hubbard R, Meric-Bernstam F, Shinde SS, Litton JK, Woodward WA, Valero V, Hortobagyi GN, Symmans WF, Gonzalez-Angulo AM. Residual cancer burden (RCB) in breast cancer patients treated with taxane-and anthracycline-based neoadjuvant chemotherapy: The effect of race. ASCO Annual Meeting (#607), 2010. e-Pub 2010.
- Gonzalez-Angulo AM, Chen H, Timms K, Litton JK, Potter J, Lanchbury JS, Arun B, Hortobagyi GN, Do K, Meric-Bernstam F. Incidence and outcome of BRCA mutation carriers with triple receptor-negative breast cancer (TNBC). Breast Cancer Symposium (#160), 2010. e-Pub 2010.
- Woodward WA, Truong PT, T-K Y, Tereffe W, Oh JL, Perkins GH, Strom EA, Meric-Bernstam F, A-M G, Ragaz J, Buchholz TA. Clinical Data Do Not Support the Hypothesis That Irradiation Promotes Biologically Aggressive Local Recurrences through Stromal Activation. 32nd Annual San Antonio Breast Cancer Symposium, 2009. e-Pub 2009.
- Gainer SM, Lodhi AK, Krishnamurthy S, Jackson S, Hall CS, Andreopoulou E, Singh B, Bedrosian I, Meric-Bernstam F, Kuerer HM, Hunt KK, Cristofanilli M, Lucci A. Predictors of Persistent Micrometastatic Disease after Neoadjuvant Chemotherapy. 32nd Annual San Antonio Breast Cancer Symposium, 2009. e-Pub 2009.
- Krishnamurthy S, Tang S, Wang X, Sahin AA, Pantoja LM, Lucci A, Kuerer HM, Babiera G, Bedrosian I, Hunt KK, Meric-Bernstam F. Utility of a One-Step Nucleic Acid Amplification (OSNA) Assay for Comprehensive Examination of Axillary Lymph Nodes in Breast Cancer. 32nd Annual San Antonio Breast Cancer Symposium, 2009. e-Pub 2009.
- Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Pusztai L, Krishnamurthy S, Le-Petross HT, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt KK, Valero V, Kuerer HM. Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. 32nd Annual San Antonio Breast Cancer Symposium, 2009. e-Pub 2009.
- Caudle AS, Gonzalez-Angulo AM, Hunt KK, Kuerer HM, Pusztai L, S-WC K, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of Progression during Neoadjuvant Chemotherapy on Operative Management of Breast Cancer. 32nd Annual San Antonio Breast Cancer Symposium, 2009. e-Pub 2009.
- Litton JK, Westin SN, Ready K, Peterson SK, Meric-Bernstam F, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk-reduction surgeries in patients tested for a BRCA mutation. 2007 Breast Cancer Symposium, 2009. e-Pub 2009.
- Buzdar A, Ballman KV, Meric-Bernstam F, Boughey JC, Leitch AM, Unzeitig G, Unzeitig, etal M. Initial safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2 positive operable breast cancer (ACOSOG Z1041). ASCO Breast Cancer Symposium, 2009. e-Pub 2009.
- Gonzalez-Angulo AM, Dawood S, Woodward W, Meric-Bernstam F, Hunt K, Buzdar A, Hortobagyi G, Buchholz T. Adjuvant radiation therapy benefits breast cancer patients with 1 to 3 positive lymph nodes undergoing a modified radical mastectomy and systemic therapy. 2009 ASCO Annual Meeting, 2009. e-Pub 2009.
- Wagner JL, Warneke C, Bedrosian I, Mittendorf E, Babiera G, Kuerer H, Hunt K, Yang W, Sahin A, Meric-Bernstam F. Modest delays in primary surgical treatment are not associated with significant progression of tumor size in breast cancer patients. ASCO 2009 Annual Meeting (#622), 2009. e-Pub 2009.
- Ready K, Gutierrez-Barrera AM, Litton J, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi G, Arun B. Racial differences in the use of contralateral prophylactic mastectomy among women undergoing BRCA1/BRCA2 genetic testing. ASCO 2009 Annual Meeting, 2009. e-Pub 2009.
- Caudle AS, Gonzalez-Angulo AM, Kelly HK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. ASCO 2009 Annual Meeting; Accepted for Presentation, 2009. e-Pub 2009.
- Gonzalez-Angulo AM, Hennessy BT, Lluch A, Speers C, Børresen-Dale A, Symmans W, Alsner J, Overgaard J, Coombes KR, Meric-Bernstam F. A novel functional proteomic approach to define prognosis and to predict pathologic complete response in patients with breast cancer. Breast Cancer Symposium (#36), 2009. e-Pub 2009.
- Zhu Q, Zou C, Smith KD, McCutcheon I, Slopis J, Meric-Bernstam F, Bornmann W, Mills G, Lazar A, Pollock R, Lev D. Dual targeting of AKT and mTOR: A potential therapeutic approach for the malignant peripheral nerve sheath tumors. 2009 AACR Annual Meeting (#2819), 2009. e-Pub 2009.
- Dawood S, Gonzalez-Angulo AM, Woodward W, Meric-Bernstam F, Hunt K, Buzdar A, Hortobagyi G, Buchholz T. Value of adjuvant radiation therapy in breast cancer patients with one to three positive lymph nodes undergoing a modified radical mastectomy and systemic therapy. ASCO Annual Meeting (#507), 2009. e-Pub 2009.
- Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Meric-Bernstam F, Lu KH, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Breast Cancer Symposium (#7), 2009. e-Pub 2009.
- Yi M, Hunt KK, Arun BK, Bedrosian I, Gutierrez Barrera AM, Kuerer HM, Babiera G, Mittendorf EA, Meric-Bernstam F. Factors leading to the decision for contralateral prophylactic mastectomy in patients with breast cancer. ASCO Annual Meeting (#1528), 2009. e-Pub 2009.
- Chavez-Mac Gregor M, Litton J, Huiquin C, Meric-Bernstam F, Hudis CA, Wolff A, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo A. Race and pathologic complete response (pCR) in breast cancer patients receiving anthracyclin and taxane-based neoadjuvant chemotherapy. Breast Cancer Symposium (#229), 2009. e-Pub 2009.
- Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Breast Cancer Symposium (#220), 2009. e-Pub 2009.
- Symmans WF, Hatzis C, Holmes FA, Hunt KK, Cotrina J, Ferrer-Lozano J, Souchon EA, Valero V, Pusztai L, Meric-Bernstam F. Relationship between genomic prediction of chemosensitivity and pathologic nodal status after neoadjuvant chemotherapy. Breast Cancer Symposium (#27), 2009. e-Pub 2009.
- Lucci A, Krishnamurthy S, Mosalpuria K, Bedrosian I, Meric-Bernstam F, Reuben JM, Singh B, Woodward WA, Cristofanilli M. Association between acute severe renal toxicity (ASRT) and survival in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib. Genitourinary Cancers Symposium (#307), 2009. e-Pub 2009.
- Luyimbazi D, Akcakanat A, Zhang L, Zheng Y, Meric-Bernstam F. mTOR modulates cellular fat metabolism by regulating stearoyl-CoA desaturase 1 transcription. 31st Annual San Antonio Breast Cancer Symposium, 2008. e-Pub 2008.
- Yi M, Hunt KK, Meric-Bernstam F, Kronowitz SJ, Nayeemuddin K, Feig B, Hwang RF, Symmans WF, Lucci A, Ross MI, Ames FC, Bedrosian I, Singletary E, Kuerer HM. Local-regional and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. 31st Annual San Antonio Breast Cancer Symposium, 2008. e-Pub 2008.
- Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F. Rapamycin-regulated gene expression signature determines prognosis in breast cancer. 31st Annual San Antonio Breast Cancer Symposium, 2008. e-Pub 2008.
- Luyimbazi D, Akcakanat A, Zhang L, Zheng Y, Meric-Bernstam F. mTOR modulates cellular fat metabolism by regulating Stearoyl-CoA desaturase 1 Transcription. 31st Annual San Antonio Breast Cancer Symposium, 2008. e-Pub 2008.
- Yang WT, Lewis MT, Wong H, Hess K, Tsimelzon A, Karadag N, Cairo M, Meric-Bernstam F, Sahin A, Chang JC. Decreased TGF signaling and increased COX2 expression in high risk women with increased mammographic breast density. 31st Annual San Antonio Breast Cancer Symposium, 2008. e-Pub 2008.
- Rakkhit R, Broglio K, Peintinger F, Cardoso F, Hanrahan EO, Litton JK, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz TA, Valero V, Theriault RL, Piccart M, Ravdin P, Hortobagyi GN, Gonzalez-Angulo AM. Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. 31st Annual San Antonio Breast Cancer Symposium, 2008. e-Pub 2008.
- Yi M, Hunt KK, Meric-Bernstam F, Bedrosian I, Hwang RA, Kuerer HM, Lucci A, Ross MI, Akins J, Babiera GV. Sentinel Lymph Node Biopsy in Patients with Multicentric Invasive Breast Cancer. 2007 Breast Cancer Symposium, 2008. e-Pub 2008.
- Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Feig BW, Lucci A, Hunt KK. Ipsilateral breast tumor relapse after breast conservation therapy. 2008 ASCO Breast Cancer Symposium, 2008. e-Pub 2008.
- Mittendorf EA, Tucker SL, Meric-Bernstam F, Gonzalez-Angulo A, Yu T, Yang W, Symmans W, Ross MI, Hortobagyi GN, Hunt KK. Extent of estrogen receptor (ER) expression predicts pathologic complete response rates after administration of neoadjuvant chemotherapy. 2008 ASCO Breast Cancer Symposium, 2008. e-Pub 2008.
- Mittendorf EA, Esteva FJ, Wu Y, Meric-Bernstam F, Hunt KK, Buzdar A, Dawood S, Hortobagyi GN, Gonzalez-Angulo A. Determination of HER2 status in patients achieving less than a pathologic complete response following neoadjuvant therapy with combination chemotherapy plus trastuzumab. 2008 ASCO Breast Cancer Symposium, 2008. e-Pub 2008.
- Wagner JL, Boughey JC, Babiera GV, Kuerer HM, Meric-Bernstam F, Singletary SE, Hunt KK, Middleton LP, Bedrosian I. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. 2008 ASCO Breast Cancer Symposium, 2008. e-Pub 2008.
- Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo AM, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. 2008 Cold Spring Harbor Laboratory Translational Control Meeting, 2008. e-Pub 2008.
- Jiralerspong S, Barnet C, Giordano S, Meric-Bernstam F, Kau SW, Hung MC, Hortobagyi GN, Gonzalez-Angulo A. The effects of metformin on pathologic complete response (pCR) rates in diabetic breast cancer (BC) patients receiving neoadjuvant systemic therapy. 44th ASCO Annual Meeting, 2008. e-Pub 2008.
- Kong AL, Hunt KK, Yi M, Weatherspoon K, Bedrosian I, Tereffe W, Hwang R, Ross MI, Buchholz TA, Meric-Bernstam F. The impact of IMC nodal drainage on primary breast cancer outcome. 44th ASCO Annual Meeting, 2008. e-Pub 2008.
- Yang WT, Sahin A, Wong H, Tsimelzon A, Hess K, Karadag N, Cairo M, Meric-Bernstam F, Arun B, Chang JC. Molecular portraits of mammographic breast density in normal breast tissue. 44th ASCO Annual Meeting, 2008. e-Pub 2008.
- Luyimbazi D, Akcakanat A, Zhang L, Zheng Y, Meric-Bernstam F. Rapamycin inhibits Stearoyl CoA Desaturase 1 expression in Breast Cancer Cells. AACR Annual Meeting 2008, 2008. e-Pub 2008.
- Meric-Bernstam F, Rashid A, Crosby K, Phan AT, Chang DZ, Gupta S, Akcakanat A, Yao JC. Biomarker Analysis for the Phase II study of RAD001 (everolimus) and Depot Octreotide (Sandostatin LAR) in advanced low grade neuroendocrine carcinoma. AACR Annual Meeting 2008, 2008. e-Pub 2008.
- Mittendorf EA, Sahin A, Tucker SL, Meric-Bernstam F, Yi M, Ames FC, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are strong predictors of detecting isolated tumor cells in sentinel lymph nodes from early stage breast cancer patients. Ann Surg Oncol 15(S2):24, 2008. e-Pub 2008.
- Fearmonti R, Batista LI, Meric-Bernstam F, Hunt KK, Bedrosian I, Kuerer HM, Singletary SE, Babiera GV. Margin width correlates with residual disease at re-excision for ductal carcinoma in situ of the breast. Ann Surg Oncol 15(S2):73, 2008. e-Pub 2008.
- Mosalpuria K, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Cristofanilli M, Lucci A. Correlation of COX-2 expression with Stage I-III triple receptor negative breast cancer. Ann Surg Oncol 15(S2):79, 2008. e-Pub 2008.
- Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera G, Hwang RF, Feig BW, Kuerer HM, Lucci A, Ross MI, Hunt KK. Predictors of Contralateral Breast Cancer in Patients with Unilateral Breast Cancer. 9th ASBS Annual Meeting, 2008. e-Pub 2008.
- Lang JE, Tereffe W, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi G, Babiera GV. Use of neoadjuvant chemotherapy (NC) prior to resection of the primary tumor in stage IV breast cancer may predict for improved survival. 9th ASBS Annual Meeting, 2008. e-Pub 2008.
- Lucci A, Krishnamurthy S, Mosalpuria K, Bedrosian I, Meric-Bernstam F, Reuben JM, Singh B, Woodward WA, Cristofanilli M. Global evaluation of minimal residual disease in primary breast cancer patients. 2008 ASCO Annual Meeting(1020), 2008. e-Pub 2008.
- Gonzalez-Angulo AM, Hennessy BT, Ju Z, Meric-Bernstam F, Lajos P, Symmans WF, Coombes KR, Hortobagyi GN, Mills GB. Functional proteomic-based predictor of pathologic complete response to neoadjuvant chemotherapy with paclitaxel/FAC-FEC in breast cancer. 2008 ASCO Annual Meeting(11078), 2008. e-Pub 2008.
- Mittendorf EA, Tucker SL, Meric-Bernstam F, Gonzalez-Angulo A, Yu T, Yang W, Symmans W, Ross MI, Hortobagyi GN, Hunt KK. Relationship between extent of estrogen receptor (ER) expression and pathologic complete response rates after administration of neoadjuvant chemotherapy. Breast Cancer Symposium(230), 2008. e-Pub 2008.
- Dawood SS, Broglio K, Kau Shu-Wan S, Green M, Giordano S, Meric-Bernstam F, Buchholz T, Albarracin C, Yang W, Hortobagyi G, Gonzalez-Angulo A. Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes. Breast Cancer Symposium(87), 2008. e-Pub 2008.
- Lang JE, Tereffe W, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera GV. Response to Neoadjuvant Chemotherapy (NC) Prior to resection of the primary tumor in Stage IV Breast Cancer may help select for Improved survival. 9th ASBS Annual Meeting, 2008. e-Pub 2008.
- Ready KJ, Gutierrez-Barrera AM, Atchley D, Solomon KK, Amos C, Meric-Bernstam F, Lu KH, Hortobagyi GN, Arun B. Cancer risk management decisions of women with BRCA variants of uncertain significance. 2008 ASCO Annual Meeting(22021), 2008. e-Pub 2008.
- Soni A, Akcakanat A, Meric-Bernstam F. Eukaryotic Initiation Factor 4E (eIF4E) can be effectively downregulated using small interfering RNA (siRNA), inhibiting growth in breast cancer cells. American College of Surgeons 93rd Annual Clinical Congress, 2007. e-Pub 2007.
- Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos CI, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a Predictive Breast Cancer Risk Model. AMIA 2007 Symposium Proceedings, 2007. e-Pub 2007.
- Akcakanat A, Singh G, Meric-Bernstam F. Rapamycin inhibits the phosphorylation of rictor in breast cancer cells. 2007 Breast Cancer Symposium, 2007. e-Pub 2007.
- Yao JC, Phan A, Chang DZ, Wolff RA, Jacobs C, Mares JE, Gupta S, Meric-Bernstam F, Rashid A. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 25:18S, 2007. e-Pub 2007.
- Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF, Hunt KK. Role of Primary Tumor Characteristics in Predicting Positive Sentinel Lymph Nodes in Ductal Carcinoma in situ or Microinvasive Breast Cancer. 8th Annual American Society of Breast Surgeons Conference, 2007. e-Pub 2007.
- Akcakanat A, Sahin AA, Velasco M, Meric-Bernstam F. Comparison of the Akt/mTOR signaling in primary breast tumors and matched distant metastases. Breast Cancer Symposium(114), 2007. e-Pub 2007.
- Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans F, Meric-Bernstam F, Valero V, Hortobagyi G, Pusztai L. Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy. 2007 ASCO Annual Meeting(530), 2007. e-Pub 2007.
- Lang JE, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera GV. Impact on overall survival of primary tumor extirpation in breast cancer patients who present tage IV disease. J Clin Oncol 25:27S, 2007. e-Pub 2007.
- Boughey JC, Ross MI, Kuerer HM, Yi M, Akins JS, Giordano SH, Babiera GV, Ames FC, Lucci A, Singletary SE, Meric-Bernstam F, Bedrosian I, Hunt KK. Comparative Analysis of SLN Surgery in Male and Female Breast Cancer Patients. Am Soc Breast Surg, 2006. e-Pub 2006.
- Boughey JC, Middleton L, Harker L, Garrett B, Fornage B, Meric-Bernstam F, Hunt KK, Babiera GV, Dempsey P, Bedrosian I. Ultrasound and fine needle aspiration for preoperative nodal staging of patients with invasive lobular carcinoma of the breast. Am Soc Breast Surg, 2006. e-Pub 2006.
- Fearmonti G, Gayed IW, Kim E, Warneke C, Bedrosian I, Hunt KK, Ghonomi E, Meric-Bernstam F, Babiera GV. In vivo comparison of lymphatic drainage patterns of subareolar and peritumoral isotope injection for breast cancer. Soc Surg Oncol, 2006. e-Pub 2006.
- Lu J, Wei Q, Bondy ML, Li D, Brewster A, T-K Y, Sahin A, Meric-Bernstam F, Hunt KK, Singletary SE, Ross MI, L-E W. Polymorphisms and haplotypes of the NBS1 gene associated with risk of sporadic breast cancer in young women: A case-control study. AACR, 2006. e-Pub 2006.
- Al-Refaie WB, Cormier JN, Xing Y, Hunt KK, Fearmonti G, Ghandi R, Kuerer HM, Meric-Bernstam F, Bedrosian I, Lucci A. Initial biopsy procedure for breast cancer diagnosis influences number of surgical procedures and cost of care. J Clin Oncol 24(18S):27S, 2006. e-Pub 2006.
- Jeruss JS, Ayers GD, Cristofanilli M, Ross MI, Babiera GV, Meric-Bernstam F, Kuerer HM, Feig BW, Yi M, Hunt KK. Positive Sentinel Nodes after Neoadjuvant Chemotherapy: What Factors Predict Additional Disease in the Axilla?. J Clin Oncol 24(18S):28S, 2006. e-Pub 2006.
- Meric-Bernstam F, Walji M, Sagaram S, Sagaram CW, Johnson F, Bernstam EV. Conventional Cautions Regarding Online Information: Do They Predict Accuracy of Breast Cancer Websites?. J Clin Oncol 24(18S):322S, 2006. e-Pub 2006.
- Uyei AR, Broglio KR, Solomon TL, Vogel KJ, Amos CI, Lu K, Meric-Bernstam F, Strong L, Arun B. Clinical factors that affect breast cancer risk reduction decisions in high risk women tested for the BRCA1/2 genetic mutation. J Clin Oncol 24(18S):52S, 2006. e-Pub 2006.
- Yao JC, Phan AT, Chang DZ, Jacobs C, Mares JE, Rashid A, Meric-Bernstam F. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 24(18S):189S, 2006. e-Pub 2006.
- Boughey JC, Cormier JN, Xing Y, Meric-Bernstam F, Ross MI, Babiera GV, Ames FC, Hunt KK, Bedrosian I. Routine use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy: A decision analysis model. J Clin Oncol 24(18S):29S, 2006. e-Pub 2006.
- Rosenkranz KM, Hartman K, Ghonimi E, Kuerer HM, Singletary SE, Hunt KK, Meric-Bernstam F, Lucci A, Hwang R, Bedrosian I, Feig B, Ross M, Ames F, Babiera GV. Breast Cancer in the Very Elderly: Treatment Patterns in a Tertiary Cancer Center. Am Soc Breast, 2006. e-Pub 2006.
- Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Hwang R, Babiera GV, Lucci A, Feig B, Kuerer HM, Singletary SE, Ames FC, Hunt KK, Bedrosian I. Routine use of sentinel lymph node surgery in prophylactic mastectomy is not warranted. Ann Surg Oncol 13(2):p64, 2006. e-Pub 2006.
- Boughey JC, Peintinger F, Meric-Bernstam F, Perry A, Hunt KK, Babiera GV, Bedrosian KK, Buzdar AU, Pusztai L, Kuerer HM. Impact of Pre-Operative Versus Post-Operative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated on Randomized Clinical Trials for Breast Cancer. Am Surg Assoc, 2006. e-Pub 2006.
- Phan A, Chang D, Rashid A, Meric-Bernstam F, Yao J. RAD001 and depot octreotide in advanced low-grade carcinoid and pancreatic neuroendocrine tumors: Phase 2 study. Ann Oncol 17(Suppl 6; Abstr PD-001):vi28-vi31, 2006. e-Pub 2006.
- Strom EA, Motwani SB, Schchter N, Butler C, Langstein H, Lee G, Meric-Bernstam F, Ibrahim N, Buchholz TA. The Effect of Immediate Breast Reconstruction on Postmastectomy Irradiation. ASTRO, 2005. e-Pub 2005.
- Kawase K, Gayed IW, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Singletary SE, Akins J, Yi M, Feig BW, Ames FC, Hunt KK. Lymphatic Drainage Patterns from Breast Cancer: A Large Cancer Center Experience. Soc Nuc Med, 2005. e-Pub 2005.
- Khakpour N, Zager J, Yen T, Stephens T, Kuerer HM, Meric-Bernstam F, Singletary SE, Ross MI, Hunt KK, Babiera GV. The Role of Ultrasound in Surgical Management of Patients Diagnosed with Ductal Carcinoma in-situ of the Breast. Am Society of Breast Surg, 2005. e-Pub 2005.
- Al-Refaie WB, Kuerer HM, Khuwaja A, Perry A, Xia L, Hunt KK, Singletary SE, Meric-Bernstam F, Ross MI, Babiera GV. Determinants of Mastectomy in Breast Conservation Therapy Candidates. Am Society of Breast Surg, 2005. e-Pub 2005.
- Huo L, Wu Y, Meric-Bernstam F, Sahin AA. Morphologic Features of Ipsilateral Recurrent Breast Cancers in Patients Treated with Breast Conserving Therapy (BCT). United States & Canadian Academy of Pathology, 2005. e-Pub 2005.
- Mondesire WH, Zhang H, Dong J, Mills GB, Meric-Bernstam F. Rapamycin Enhances Paclitaxel-Induced Cytotoxicity in a GSK3β-Dependent Manner. Society of University Surgeons, 2005. e-Pub 2005.
- Gilcrease MZ, Zhou X, Hunt KK, Meric-Bernstam F, Welch K. ⓰⓸ Integrin-Induced EGFR Clustering in Breast Carcinoma. Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
- Meric-Bernstam F, Zhang H, Lotan R, Lotan D, Sahin A, Babiera GV, Kopelovich, Crowell JA, Strong LC. Feasibility of the Use of Primary Breast Epithelial Cell Cultures to Identify Genotype-Specific Preventive Agents. Proc Am Soc Clin Oncol, 2005. e-Pub 2005.
- Khakpour N, Lucci A, Yi M, Meric-Bernstam F, Kuerer H, Babiera GV, Feig B, Ross MI, Singletary SE, Ames F, Garg A, Buchholz T, Hunt KK. Sentinel Lymph Node Dissection Provides Similar Local-regional Control Compared to Axillary Dissection in Patients with Node Negative Breast Cancer. Proc Am Soc Clin Oncol, 2005. e-Pub 2005.
- Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, M-C H, Meric-Bernstam F. Role of GSK3B in Rapamycin-Mediated Cell Cycle Regulation. Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
- Bernstam EV, Herskovic JR, Meric-Bernstam F. Using Citation Analysis to Ease Information Overload in Oncology. Proc Am Soc Clin Oncol, 2005. e-Pub 2005.
- Adepoju L, Symmans WF, Babiera GV, Singletary SE, Sahin A, Buchholz TA, Hunt KK, Meric-Bernstam F, Ross MI, Ames FA, Kuerer HM. The Clinical Impact of Proliferative High-Risk Lesions Presenting Concurrently with Ductal Carcinoma In Situ (DCIS) in Patients (pts) Treated with Breast Conserving Therapy (BCT). Proc Am Soc Clin Oncol, 2005. e-Pub 2005.
- Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Bucana C, Hortogbagyi GN, Fidler IJ, Cristofanilli M. CXCR4/CCR7 in Advanced Breast Cancer: Differential Expression in Metastatic Disease Sites with Diagnostic and Therapeutic Implications. Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
- Hanrahan EO, Gonzalez-Angulo AM, Broglio K, Meric-Bernstam F, Cristofanilli M, Buccholz TA, Hortobagyi GN, Valero V. Outcome and Prognostic Factors Among Patients with Node-Negative Invasive Brest Carcinoma that is One Centimeter or Less in Size (Stage 1; T1a,b N0 M0): the University of Texas M D Anderson Cancer Center Experience. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 94(S1):S124, 2005. e-Pub 2005.
- Cabioglu N, Sahin AA, Guray M, Islam R, Morandi P, Meric-Bernstam F, Hortobagyi GN, Cristofanilli M. Increased Expression of CD44 in Visceral Metastases of Breast Cancer. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 94(S1):S190, 2005. e-Pub 2005.
- Guarneri V, Broglio KR, Kau S, Cristofanilli M, Buzdar AU, Valero V, buchholz TA, Meric-Bernstam F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Patients with Hormone Receptor-Positive Breast Cancer. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 94(S1):S190, 2005. e-Pub 2005.
- Murray JL, Kawano K, Efferson C, Babiera GV, Meric-Bernstam F, Ibrahim N, Kallinteris NL, Humphreys RE, Vanderhoff E. Enhanced HER2/neu Specific T-Cell Immunity In Vitro by HER2/neu Ii-Key Modified “agonist” class II Peptides in Breast Cancer Patients. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 94(S1):S198, 2005. e-Pub 2005.
- Huang E, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Comparison of Local-Regional Recurrence After Mastectomy of Breast Conservation Therapy for Patients Treated with Neoadjuvant Chemotherapy Stratified According to a Prognostic. Int J Rad Oncol Biol Phys 63(2):S25, 2005. e-Pub 2005.
- Garg AK, Oh JL, Huang E, Strom EA, Perkins GH, Gwyn K, Meric-Bernstam F, Buchholz TA. Postmastectomy Radiation Therapy in Stage II-III Breast Cancer Patients < 35 Years Old Treated with Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy. Int J Rad Oncol Biol Phys 63(2):S237, 2005. e-Pub 2005.
- Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA. The Effect of Immediate Breast Reconstruction on Postmastectomy Irradiation. Int J Rad Oncol Biol Phys 63(2):S51, 2005. e-Pub 2005.
- Uyei A, Erlichman J, Lu K, Meric-Bernstam F, Strong L, Arun B. Risk Reduction Choices of Women with Deleterious BRCA1 and BRCA2 Mutations at a Single Institution. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 94(S1):S25, 2005. e-Pub 2005.
- Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Ames FC, Kuerer HM, Ross MI, Singletary SE, Babiera GV, Feig BW, Hunt KK. Low Local-Regional Failure Rates in Selected Breast Cancer Patients with Tumor-Positive Sentinel Nodes Who Do Not Undergo Completion Axillary Dissection. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 94(S1):S35, 2005. e-Pub 2005.
- Rao R, Feng L, Kuerer HM, Singletary SE, Hunt KK, Feig BW, Ross MI, Meric-Bernstam F, Ames FC, Babiera GV. Optimal Timing of Surgical Intervention for the Primary Tumor in Stage IV Breast Cancer Improves Outcome. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 94(S1):S112, 2005. e-Pub 2005.
- Huang EH, Strom EA, Valero V, Perkins GH, Schecter NR, Hunt KK, Meric-Bernstam F, McNeese MD, Hortobagyi GN, Buchholz TA. Locoregional Treatment Outcomes for Patients with Ipsilateral Supraclavicular Metastases at Diagnosis of Breast Cancer. American Society of Therapeutic Radiology and Oncology, 2004. e-Pub 2004.
- Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, Ross MI, Babiera GV, Kuerer HM, Singletary SE, Hunt KK, Cormier JN. Cost-Effectiveness (CE) of Intraoperative Touch Imprint Cytology of Sentinel Lymph Nodes in Patients with Breast Cancer. Pharmaceutical Services and Outcomes Research Symposium, 2004. e-Pub 2004.
- Andtbacka RHI, Hunt KK, Singletary E, Babiera GV, Meric-Bernstam F, Ames F, Feig B, Ross M, Dejesus Y, Kuerer HM. The incidence, prophylaxis and treatment of deep venous thrombosis in patients undergoing breast cancer surgery. Am Soc Clin Oncol 23:31, 2004. e-Pub 2004.
- Shen J, Mirza NQ, Sahin A, Buchholz TA, Meric-Bernstam F, Kuerer HM, Ross MI, Ames FC, Feig BW, Singletary SE, Babiera GV, Hunt KK. Invasive Lobular Carcinoma: Clinicopathologic Factors that Impact Extent of Disease and Margin Status. Southern Surgical Association, 2004. e-Pub 2004.
- Rao R, Kuerer HM, Khuwaja A, Hunt KK, Singletary SE, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Babiera GV. Surgical Intervention for the Primary Tumor Improves Progression-Free survival in Patients Initially Presenting with Stage IV Breast Cancer. Society of Surgical Oncology, 2004. e-Pub 2004.
- Lambert LA, Hunt KK, Hwang RF, Ross MI, Ayers GD, Kuerer H, Singletary SE, Babiera GV, Ames FC, Feig B, Krishnamurthy S, Meric-Bernstam F. Validation of a Breast Cancer Nomogram for Predicting Additional Nodal Metastases After Positive Sentinel Node Biopsy. Society of Surgical Oncology, 2004. e-Pub 2004.
- Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM, Meric-Bernstam F, Feig B, Ross MI, Ames F, Babiera GV. Intramammary Lymph Node Metastasis is an Independent Predictor in Breast Cancer Outcomes. Am Soc Clin Oncol 23:30, 2004. e-Pub 2004.
- Xing Y, Savitri K, Meric-Bernstam F, Cantor SB, Ross MI, Babiera GV, Kuerer HM, Singletary SE, Hunt KK, Cormier JN. Is Intraoperative Touch Imprint Cytology of Sentinel Lymph Nodes in Patients with Breast Cancer Cost-Effective?. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 88(S1):S82, 2004. e-Pub 2004.
- Shen J, Mirza NQ, Babiera GV, Ross MI, Ames FC, Meric-Bernstam F, Feig B, Singletary SE, Kuerer HM, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in breast cancer patients with cytologically proven axillary metastases. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 88(S1):S81, 2004. e-Pub 2004.
- Shen J, Hunt KK, Meric-Bernstam F. Breast Conservation Therapy in T4 Locally Advanced Breast Cancer: Effective Local Control with Long-Term Survival. Ann Surg Oncol 11(2):S75, 2004. e-Pub 2004.
- Goldflam K, Gershenwald JE, Hunt KK, Singletary SE, Mirza N, Arun B, Babiera GV, Kuerer HM, Ross MI, Ames FC, Feig BW, Sahin AA, Meric-Bernstam F. Contralateral Prophylactic Mastectomy: Efficacy and Determinants of Significant Histologic Findings. Ann Surg Oncol 11(2):S94, 2004. e-Pub 2004.
- Tseng JF, Kronowitz SJ, Hunt KK, Sun CC, Babiera GV, Singletary E, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The Rate of Immediate Reconstruction Following Mastectomy for Breast Cancer Varies by Patient Race. Ann Surg Oncol 11(2):S92, 2004. e-Pub 2004.
- Yen TW, Mirza N, Hunt KK, Ross M, Babiera GV, Singletary SE, Meric-Bernstam F, Feig B, Ames F, Kuerer H. Predictors of Invasive Breast Cancer in Patients with an Initial Diagnosis of Ductal Carcinoma In Situ. Ann Surg Oncol 11(2):S93, 2004. e-Pub 2004.
- Kawase K, Hunt K, Kuerer H, Meric-Bernstam F, Mirza N, Feig B, Ames F, Babiera GV, Singletary SE, Ross M. Sentinel Lymph Node Biopsy Accurately Reflects Nodal Status Following Preoperative Chemotherapy for Breast Cancer. Ann Surg Oncol 11(2):S75, 2004. e-Pub 2004.
- Rouzier R, Anderson K, Hess KR, James S, Ayers M, Gold D, Ross JS, Wagner P, Meric-Bernstam F, Valero V, Symmans F, Perou CM, Hortobagyi GN, Pusztai L. Basal and Luminal Types of Breast Cancer Defined by Gene Expression Patterns Respond Differently to Neoadjuvant Chemotherapy. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 88(S1):S24, 2004. e-Pub 2004.
- Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of Systemic Recurrence and Disease-Specific Survival Following Ipsilateral Breast Tumor Recurrence. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 88(S1):S54, 2004. e-Pub 2004.
- Cabioglu N, Mirza N, Hunt KK, Buchholz TA, Singletary SE, Kuerer HM, Babiera GV, Ross MI, Ames FC, Feig BW, Sahin A, Meric-Bernstam F. Improving Local Control with Breast-Conserving Therapy: A 27-year Single Institution Experience. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 88(S1):S165, 2004. e-Pub 2004.
- Cabioglu N, Hunt KK, Mirza N, Shin AA, Singletary SE, Kuerer HM, Babiera GV, Ross MI, Ames FC, Feig BW, Meric-Bernstam F. Intraoperative Margin Assessment in Breast-Conserving Surgery. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 88(S1):S167, 2004. e-Pub 2004.
- Yen T, Hunt K, Mirza N, Thomas E, Meric F, Babiera G, Buchholz T, Singletary E, Feig B, Ross M, Theriault R, Ames F, Kuerer H. Physician Recommendations and Patient Utilization of Tamoxifen Following Surgery for Ductal Carcinoma In Situ at a National Comprehensive Cancer Center. Proceedings of the American Society of Breast Surgeons 4:P-34, 2003. e-Pub 2003.
- Chagpar A, Yen T, Sahin A, Hunt K, Whitman G, Ames F, Ross M, Meric F, Babiera G, Singletary ES, Kuerer HM. Intra-operative Margin Assessment Reduces Re-excision Rates in Breast Conservation Surgery for Ductal Carcinoma In Situ. Proceedings of the American Society of Breast Surgeons 5:O-8, 2003. e-Pub 2003.
- Shahar KH, Buchholz TA, Delpassand E, Sahin A, Ross MI, Ames F, Kuerer H, Feig BW, Meric-Bernstam F, Babiera GV, Singletary E, Akins J, Mirza N, Hunt KK. Lower and Central Tumor Location Correlates with Lymphoscintigraphy Drainage to the Internal Mammary Lymph Nodes in Breast Cancer. Western Surgical Association, 2003. e-Pub 2003.
- Lu K, Beahm E, Arun B, Bodurka-Bevers D, Sun C, Miller M, Hunt KK, Ames F, Strong L, Meric-Bernstam F. Coordinating Prophylactic Surgical Management for Women with Breast-Ovarian Cancer Syndrome. Cancer Epidemiology Biomarkers & Prevention 12(11):1352S, 2003. e-Pub 2003.
- Kawase K, DiMaio DJ, Tucker SL, Ross MI, Feig BW, Ames F, Kuerer H, Meric-Bernstam F, Singletary E, Babiera G, Buchholz T, Hunt KK. Paget’s Disease of the Breast: A Long-Term Follow-up Study. Proceedings of the 26th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 82(S1):S108, 2003. e-Pub 2003.
- Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig B, Hortobagyi GN, Sahin AA, Perkins GH, Schechter NR, Buchholz TA. Breast-Conserving Therapy After Neoadjuvant Chemotherapy: The M. D. Anderson Cancer Center Experience. Proceedings of the 26th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 82(S1):S7-8, 2003. e-Pub 2003.
- Chagpar A, Mirza AN, Buzdar AU, Dempsey P, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of Physical Examination (PE), Ultrasonography (US) and Mammography (M) in Prediciting Residual Pathological Tumor Size In Patients Treated With Neoadjuvant Chemotherapy (NAC) For Breast Cancer. Proceedings of the 26th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 82(S1):S52, 2003. e-Pub 2003.
- Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric-Bernstam F, Schechter NR, Sahin AA, Buchholz TA. Factors Predictive of Having Four Or More Positive Axillary Lymph Nodes in Patients With Involved Sentinel Lymph Nodes: Implications for Selection of Radiation Treatment Fields. Proceedings of the 26th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 82(S1):S182, 2003. e-Pub 2003.
- Sagaram S, Walji M, Bernstam EV, Meric F. Cancer-related Complementary and Alternative Medicine (CAM) on the Web. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting 22:552, 2003. e-Pub 2003.
- Cabioglu N, Krisnamurthy S, Kuerer HM, Hunt K, Singletary SE, Meric F, Feig B, Ross M, Ames F, Babiera GV. The role of Breast Conserving Surgery in Women with Breast Cancer Presenting with Nipple Discharge. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting 22:34, 2003. e-Pub 2003.
- Chagpar A, Meric F, Hunt K, Ross M, Cristofanilli M, Singletary SE, Buchholz TA, Ames F, Marcy S, Babiera G, Feig B, Hortobagyi G, Kuerer H. Chest Wall Recurrence Following Mastectomy Does Not Always Portend Dismal Prognosis. Ann Surg Oncol 10(1):S34, 2003. e-Pub 2003.
- Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. C-kit proto-oncogene product expression in breast tissue. Modern Pathology 15(1):229, 2002. e-Pub 2002.
- Frederick WA, Azizzadeh A, Harker LA, Mirza NQ, Hunt KK, Kuerer HM, Ames FC, Feig BW, Meric F, Ross MI, Singletary SE, Babiera GV. Metaplastic breast carcinoma: a single institution review. Proceedings of the 25th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 76(S1):S50, 2002. e-Pub 2002.
- Cabioglu N, Hunt KK, Singletary SE, Stephens TW, Marcy S, Meric F, Babiera GV, Ross MI, Ames FC, Kuerer HM. Utility of imaging techniques in surgical treatment and diagnosis of breast carcinoma in women presenting with nipple discharge. Proceedings of the 25th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 76(S1):S94, 2002. e-Pub 2002.
- Hortobagyi G, Mendelsohn J, Zhen F. Triple combination with ST1571 (Gleevec), Trastuzumab (Herceptin) and Cetuximab (IMC-C225): a treatment model for breast cancer through modulation of growth factor receptors and tyrosine kinases signaling. Proceedings of the American Association for Cancer Research, 2002. e-Pub 2002.
- Solorzano CC, Hunt KK, Middleton LP, Mirza NQ, Ross MI, Kuerer HM, Ames FC, Feig BW, Meric F, Singletary SE, Babiera G. Treatment and Outcome of Intracystic Papillary Carcinoma of the Breast: A Contemporary Series. Proceedings of the American Society of Breast Surgeons Third Annual Meeting, 2002. e-Pub 2002.
- Mirza A, Fornage B, Sneige N, Simmons R, Giuliano A, Hanson N, Ross M, Kuerer H, Newman L, Ames F, Babiera G, Meric F, Hunt, Edeiken B, Singletary SE. Radiofrequency ablation of early-stage invasive breast tumors; results of a multi-center study. Proceedings of the 25th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 76(S1):S116, 2002. e-Pub 2002.
- Bernstam EV, Kamvar SD, Meric F, Dugan JM, Chang JT, Chizek SC, Stave C, Troyanskaya OG, Fagan LM. Oncology Patient Interface to Medline. Proceedings of the 37th Annual American Society of Clinical Oncology Annual Meeting 20:244a, 2001. e-Pub 2001.
- Laronga C, Ross M, Alderfer J, Mirza N, Meric F, Kuerer H, Ames F, Delpassand E, Singletary E, Hunt K. Tumor Location and Nodal Drainage Patterns on Lymphoscintigraphy are Predictors of Axillary Sentinel Lymph Node Status. Proceedings of the 37th Annual American Society of Clinical Oncology Annual Meeting 20:40a, 2001. e-Pub 2001.
- Hunt K, Middleton L, Sahin A, Kuerer H, Ames F, Feig B, Newman L, Meric F, Alderfer J, Ross M. Serial sectioning and Immunohistochemical Staining for Cytokeratin Improves the Accuracy of Sentinel Lymph Node Biopsy for Breast Cancer. Proceedings of the 37th American Society of Clinical Oncology Annual Meeting 20:42b, 2001. e-Pub 2001.
- Meric F, Bernstam EV, Mirza NQ, Musen MA. Quality and accuracy of breast cancer information on the World Wide Web. Proceedings of the 24th Annual San Antonio Breast Cancer Symposium, 2001: Breast Cancer Research and Treatment 69(3):268, 2001. e-Pub 2001.
- Mirza NQ, Vlastos G, Meric F, Ames FC, Feig BW, Kuerer HM, Pollock RE, Ross MI, Singletary E, Bucholz TA, Buzdar AU, Hortobagyi GN, Hunt KK. Predictors of Systemic Recurrence Among Early Stage Breast Cancer Patients Treated with Breast Conserving Therapy. Proceedings of the 24th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 69(3):227, 2001. e-Pub 2001.
- Arun B, Zhang H, Mirza NQ, Hortobagyi GN, Hung MC, Meric F. Growth Inhibition of Breast Cancer Cells by Celecoxib. Proceedings of the 24th Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 69(3):234, 2001. e-Pub 2001.
- Meric F, Bernstam EV, Mirza NQ, Hunt KK, Ames FC, Ross MI, Kuerer HM, Pollock RE, Musen MA, Singletary SE. Breast Cancer on the World Wide Web: Determinants of Web Site Popularity. Proceedings of the 37th Annual American Society of Clinical Oncology Annual Meeting 20:38b, 2001. e-Pub 2001.
- Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, Pollock RE, Newman LA, Feig BW, Strom EA, Buchholz TA, McNeese MD, Hortobagyi GN, Singletary SE. Prognostic Implication of Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer. Proceedings of the Society of Surgical Oncology 53rd Annual Symposium, 2000. e-Pub 2000.
- Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, Ellis LM. Hepatic Surgery after Downstaging of Unresectable Disease with Hepatic Artery Infusion Therapy. Proceedings of the Society of Surgical Oncology 53rd Annual Symposium, 2000. e-Pub 2000.
- Dackiw APB, Meric F, Chang DW, Colchin M, Porter GA, Ross MI, Hunt KK, Pollock RE, Ames FC, Feig BW, Newman LA, Robb GL, Singletary SE. Incidence and Outcome of Contralateral Breast Cancer in Patients Status Post Unilateral Mastectomy with Unilateral Breast Reconstruction. Proceedings of the Society of Surgical Oncology 53rd Annual Symposium, 2000. e-Pub 2000.
- Mirza NQ, Vlastos G, Meric F, Buchholz TA, Singletary SE, Ames FC, Newman LA, Kuerer HM, Feig BW, Ross MI, Pollock RE, Hortobagyi GN, Hunt KK. Incidence and Survival Impact of Non-Breast Second Primary Malignancies (SPM) following Breast Conserving Therapy (BCT). Proceedings of the 23rd Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 64:103, 2000. e-Pub 2000.
- Wills DD, Meric F, Mirza NQ, Singletary SE, Ames FC, Kuerer H, Ross MI, Newman LA, Feig BW, Pollock RE, Hunt KK. Metastases to the Breast: Determinants of Survival. Proceedings of the 23rd San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment 64:93, 2000. e-Pub 2000.
- Meric F, Buchholz TA, Mirza NQ, Vlastos G, Singletary SE, Ross MI, Ames FC, Pollock RE, Feig BW, Kuerer H, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK. Long-term Complications Associated with Breast Conservation Surgery and Radiation Therapy. Proceedings of the 23rd San Antonio Breast Cancer Symposium: Breast Cancer and Treatment 64:102, 2000. e-Pub 2000.
- Meric F, Hess KR, Varma DGK, Hunt KK, Pisters PWT, Patel SR, Benjamin RS, Plager C, Papadopolous NEJ, Burgess MA, Pollock RE, Feig BW. Impact of Neoadjuvant Therapy on Local Control of Soft Tissue Sarcomas. Proceedings of the American Society of Clinical Oncology Annual Meeting 19:558a, 2000. e-Pub 2000.
- Meric F, Bernstam EV, Mirza NQ, and Musen MA. Quality and accuracy of breast cancer information on the World Wide Web. Proceedings of the 23rd Annual San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 64:103, 2000. e-Pub 2000.
- Laronga C, Meric F, Truong MT, Mayfield C, Mansfield P. Complicating Central Venous Catheter Insertion. Proceedings of the Annual Meeting of the Southwestern Surgical Congress, 2000. e-Pub 2000.
- Meric F, W-P L, Robinson D, H-J K, M-C H. Profiling of Tyrosine Kinases in Breast Cancer. Proceedings of the American Association for Cancer Research, 2000. e-Pub 2000.
- Vlastos G, Mirza NQ, Meric F, Hunt KK, Newman LA, Kuerer HM, Ames FA, Ross MI, Pollock RE, Buchholz TA, Hortobagyi GN, Singletary SE. Breast Conserving Therapy (BCT) in the Elderly: An Appropriate Treatment Choice. Proceedings of the 23rd San Antonio Breast Cancer Symposium: Breast Cancer Research and Treatment 64:103, 2000. e-Pub 2000.
- Meric F, Milas M, Hunt K, Hildebrandt G, Hess K, Pisters PWT, Papadopoulos N, Plager C, Burgess M, Patel S, Benjamin RS, Pollock RE, Feig BW. Impact of Neoadjuvant chemotherapy on postoperative morbidity in sarcomas. Proceedings of the 5th Annual Scientific Meeting of the Connective Tissue Oncology Society, 1999. e-Pub 1999.
- Meric F, Milas M, Hunt K, Hildebrandt G, Hess K, Pisters PWT, Patel S, Benjamin RS, Pollock RE, Feig BW. Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity in Sarcomas. Proceedings of the American Society of Clinical Oncology Annual Meeting 18:549, 1999. e-Pub 1999.
- Meric F, Mirza NQ, Vlastos G, Ames FC, Feig BW, Ross MI, Pollock RE, Buchholz TA, Strom EA, McNeese MD, Theriault R, Buzdar AU, Hortobagyi GN, Singletary SE, Hunt KK. Breast Conversation Surgery: Long-term results from a single institution. Proceedings of the 22nd San Antonio Breast Cancer Symposium: Breast Cancer and Treatment 57:51, 1999. e-Pub 1999.
- Mirza NQ, Vlastos G, Meric F, Singletary E, Reed L, Ames FC, Feig BW, Ross MI, Pollock RE, Buchholz TA, Strom EA, McNeese MD, Theriault R, Buzdar AU, Hortobagyi GN, Hunt KK. Time to Local-Regional Recurrence (LRR) Following Breast Conserving Therapy (BCT) Predicts Survival. Proceedings of the 22nd San Antonio Breast Cancer Symposium: Breast Cancer and Treatment 57:49, 1999. e-Pub 1999.
- Meric F, Wolffe AP. Transcription-coupled translational masking and unmasking in xenopus oocytes. Proceedings of the Cold Spring Harbor Laboratory Translational Control Meeting, 1996. e-Pub 1996.
- Matsumoto K, Meric F, Wolffe AP. Transcriptional and translational control in xenopus ooctyes. Proceedings of the FASEB Conference on Transcriptional Regulation during Cell Growth, Differentiation and Development, 1996. e-Pub 1996.
- Meric F, Wolffe AP. Translational masking is coupled to transcription in Xenopus Oocytes. Proceedings of the Annual Meeting of the RNA society, 1996. e-Pub 1996.
- Wolffe AP, Kass S, Landsberger N, Meric F, Y-B S, Wong J. Global controls of transcription and translation during early development. Proceedings of the Molecular Genetics of Development, 1996. e-Pub 1996.
Book Chapters
- Meric-Bernstam F. Incorporating precision medicine into Phase I clinical. In: Phase I Trials in Oncology. Springer, 2020.
- Carson III WE, Meric-Bernstam F, Pollock RE. Oncology. In: Schwartz's Principles of Surgery. Eleventh. McGraw-Hill, Chapter 10, 2019.
- Owusu-Brackett N, Shariati M, Meric-Bernstam F. Role of PI3k/AKT/mTOR in Cancer Signaling. In: Predictive Biomarkers in Oncology: Applications in Precision Medicine. Springer International Publishing AG (Springer Nature), 263-270, 2018.
- Owusu-Brackett N, Meric-Bernstam F. Ductal carcinoma in situ: risk factor or cancer. In: Atypical Breast Proliferative Lesions and Benign Breast Disease. Springer International Publishing, 37-49, 2018.
- Evans KW, Paez Arango N, Akcakanat A, Yuca E, and Meric-Bernstam F. Modeling breast cancer heterogeneity with patient-derived xenografts. In: Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier Inc, Chapter 4:243-256, 2017.
- Naing A, Mills GB, Meric-Bernstam F. P13K-mTor in Cancer and Cancer Therapy. In: Cancer Drug Discovery and Development. Springer, 151-180, 2016.
- Holder AM, Meric-Bernstam F. Toward Personalized Therapy for Cancer. In: Translational Cancer Therapeutics: Molecular Therapeutics. Wiley, 268 pp, 2015.
- Akay C, Meric-Bernstam F. Treatment of advanced breast cancer. In: Surgery: Core Principles and Practice. 2/e (Chapter 103). JP Medical Publishers, 2015.
- Meric-Bernstam F, Pollock RE. Oncology. In: Schwartz's Principles of Surgery. Tenth. McGraw-Hill, Inc, pp. 1069, 2014.
- McAuliffe PF, Strom E, Meric-Bernstam F. Feasibility of Breast Conservation Therapy. In: Advanced Therapy of Breast Disease 3rd Edition. People's Medical Publishing House, 877-894, 2012.
- Bernstam E, Meric-Bernstam F. Quality and accuracy of online health information. In: E-health: The advent of online cancer information systems. Hampton Press, 35-62, 2011.
- Meric-Bernstam F. Neoadjuvant Chemotherapy. In: Kuerer's Breast Surgical Oncology. McGraw-Hill, 885-894, 2010.
- Meric-Bernstam F, Pollock RE. Oncology. In: Schwartz's Principles of Surgery. Ninth. McGraw Hill, Inc, 235-69, 2009.
- Hunt KK, Meric-Bernstam F. Surgical Options For Breast Cancer. In: M. D. Anderson Cancer Care Series, Breast Cancer. Second. Springer Science & Business Media LLC, 197-234, 2008.
- Meric-Bernstam F. Molecular Underpinnings. In: Advanced Therapy in Surgical Oncology. BC Decker Inc, 6-24, 2008.
- Meric-Bernstam F, Symmans WF. Prognostic/Predictive Profiling in Breast Cancer. In: Advanced Therapy in Surgical Oncology. BC Decker Inc, 533-42, 2008.
- Meric-Bernstam, F, et al. Funda Meric-Bernstam, M.D. In: Legends and Legacies, Personal Journies of Women Physicians and Scientists at M.D. Anderson Cancer Center. Women Faculty Programs, Public Affairs and Scientific Publications, M.D. Anderson Cancer, 116-23, 2008.
- Meric-Bernstam F. M. D. Anderson Kanser Merkezi deneyimleri. In: Sentinel Lenf Nodu Biyopsisi. Istanbul Medikal Ltd. Sti, 169-82, 2007.
- Bernstam EV, Meric-Bernstam F. Reliability and evaluation of online health information. In: Web Mobile-Based Applications for Healthcare Management. Idea Group Press, 181-196, 2007.
- Andtbacka RH, Meric-Bernstam F, Robinson EK, Hunt KK. Noninvasive Breast Cancer. In: The M D Anderson Surgical Oncology Handbook. Fourth. Lippincott Williams and Wilkins, 1-22, 2006.
- Meric-Bernstam F, Pollock RE. Oncology. In: Schwartz's Manual of Surgery. Eighth. McGraw-Hill Inc, 183-215, 2006.
- Meric-Bernstam F, Pollock RE. Oncology. In: Principles of Surgery. Eighth. McGraw-Hill, Inc, 249-294, 2004.
- McAuliffe P, Strom EA, Meric-Bernstam F. Feasibility of Breast Conservation Surgery. In: Advanced Therapy of Breast Disease. BC Decker Inc, 509-521, 2004.
- Meric F, Robinson E, Hunt KK. Noninvasive Breast Cancer. In: The M. D. Anderson Surgical Oncology Handbook. Third. Lippincott Williams and Wilkins, 1-13, 2003.
- Meric F, Ross MI. Benign Breast Disease. In: Unbound Surgery. Unbound Medicine, 2002.
- Pusztai L, Symmans WF, Buchholz TA, Stec J, Ayers M, Clark E, Meric F, Stivers D, Hess K. Application of DNA Microarray Technology to Clinical Biopsies of Breast Cancer. In: Computational And Statistical Approaches To Genomics. Kulwer Academic Publishers, 257-276, 2002.
- Meric F, Ross MI. Breast Cancer. In: Unbound Surgery. Unbound Medicine, 2002.
- Meric F, Hunt KK. Surgical Options for Breast Cancer. In: M. D. Anderson Cancer Care Series, Breast Cancer. Springer-Verlag, 187-222, 2001.
Letters to the Editor
- Meric-Bernstam F, Shaw K, Mendelsohn J, Mills GB. Reply to M.P. Decatris et al. J Clin Oncol 34: 886, 2016.
- Wagner JL, Meric-Bernstam F. Waiting time for breast cancer treatment, 2013.
- Meric-Bernstam F. Axillary Reverse Mapping: Mapping and Preserving Arm Lymphatics May Be Important in Preventing Lymphedema during Sentinel Lymph Node Biopsy - Invited Commentary. Breast Diseases: A Year Book Quarterly, 2008.
- Meric-Bernstam, F. Axillary Reverse Mapping (ARM): A new concept to identify and enhance lymphatic preservation. Breast Diseases: A Year Book Quarterly, 2008.
- Lambert LA, Ayers GD, Meric-Bernstam F. Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases after a Positive Sentinel Node Biopsy. Ann Surg Oncol 14: 2422-3, 2007.
- Meric-Bernstam F. Molecular Clonality Relationships in Initial Carcinomas, Ipsilateral Breast Failures and Distant Metastases in patients treated with Breast Conserving Therapy: Evidence suggesting that some distant metastases are derived from ipsilateral breast failures and that metastases can metastasize (Goldstein NS, et al.). Breast Diseases: A Year Book Quarterly, 2006.
- Meric-Bernstam F. Patient selection for breast conservation after neoadjuvant chemotherapy: developing a prognostic index (Huang EH, et al). Am J Oncol Rev, 2006.
- Meric-Bernstam F. Defining negative margins in DCIS patients treated with Breast Conservation Therapy: The University of Chicago Experience (Sahoo S, et al.). Breast Diseases: A Year Book Quarterly, 2005.
- Raut CP, Daley D, Hunt KK, Akins J, Ross MI, Singletary SE, Marshall GD, Meric-Bernstam F, Babiera G, Feig BW, Ames FC, Kuerer HM. Anaphylactoid Reactions to Isosulfan Blue Dye during Breast Cancer Lymphatic Mapping in Patients Given Preoperative Prophylaxis. J Clin Oncol 22: 567-568, 2004.
- Meric-Bernstam F. Seroma Formation following Breast Cancer Surgery (Gonzalez EA, et al.). Breast Diseases: A Year Book Quarterly, 2004.
- Meric-Bernstam F. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma (Span PN, et al.). Breast Diseases: A Year Book Quarterly, 2003.
- Meric-Bernstam F. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy (McIntosh SA, et al.). Breast Diseases: A Year Book Quarterly, 2003.
- Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins G, McNeese M M, Strom E, Valero V, Hunt KK. Positive Surgical Margins and Ipsilateral Breast Tumor Recurrence Predict Systemic Recurrence and Disease-Specific Survival After Breast-Conserving Therapy. Cancer 98: 2523-2524, 2003.
- Meric-Bernstam F. Breast Cancer metastatic to the abdomen and pelvis: role of surgical resection (Eitan R, et al.). Breast Diseases: A Year Book Quarterly, 2003.
- Meric-Bernstam F. Use of an Artificial Neural Network to Quantitate Risk of Malignancy for Abnormal Mammograms (Orr RK). Breast Diseases: A Year Book Quarterly, 2002.
- Meric-Bernstam F. The Internet as a source of information on Breast Augmentation (Gordon JB, et al.). Breast Diseases: A Year Book Quarterly, 2001.
- Meric-Bernstam F. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer (Pierga JY, et al.). Breast Diseases: A Year Book Quarterly, 2001.
Patient Reviews
CV information above last modified March 24, 2026